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ABSTRACT
The antiphospholipid syndrome (APS) is characterised by the presence of pathogenic 
antiphospholipid antibodies (aPL) that bind phospholipid via the N-terminal domain I 
(D I) of the protein cofactor beta2-glycoprotein I (62GPI). This thesis aims to
investigate and identify the nature of this interaction at the molecular level.
In order to study DI, a system for expressing and purifying sufficient quantities of 
this protein was developed using Escherichia coii (E.coli) as the expression host. This 
was achieved primarily by synthesising a gene with all codons optimised for E.coli, 
tight regulation of expression and recovery of DI from the periplasm to facilitate 
folding. Recombinant purified DI bound clinically relevant human monoclonal and
polyclonal purified IgG aPL in both solid an fluid phase assays.
Hypotheses were generated that identified candidate epitopes for aPL binding as 
potentially involving residues D8, D9, E23, E26, E27, R39, G40, R43 and the D I-II 
interlinker region. In total, 15 mutants of DI targeting these areas were created and 
computer modelling employed to predict the likely structural effects of these 
mutations upon DI.
Expressed DI mutants were then tested in both solid and fluid phase assays for 
binding to polyclonal IgG derived from patients with APS and compared to wild-type 
DI. Some mutations, such as those targeting R39, caused loss of binding to aPL in 
the fluid phase whilst others caused enhanced binding over wild-type DI.
In conclusion, this thesis demonstrates that DI of fcGPI may be expressed using 
E.coli and binds clinically relevant IgG aPL. Detailed mutational studies support the 
concept that aPL bind discontinuous epitopes on DI involving regions D8 and D9, 
R39 to R43 and the D I-II interlinker which are in close proximity to each other in the 
tertiary structure. The ability to produce a mutant of DI with enhanced binding over 
wild-type holds therapeutic potential.
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CHAPTER 1 
INTRODUCTION
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OVERVIEW OF INTRODUCTION
The aim of this chapter is to review the clinical and scientific literature relating to the 
antiphospholipid syndrome (APS) which is relevant to the content of this thesis. 
Given that this is an autoimmune condition an overview of the immune response is 
provided, with emphasis placed on mechanisms that undergo dysregulation in APS. 
Factors governing the structure of proteins and nature of antibody-antigen  
interactions are also discussed. The clinical syndrome of APS is then described in 
detail and, given the close association with systemic lupus erythematosus (SLE), this 
condition is also described briefly.
This chapter then shifts focus, describing the characterisation of antiphospholipid 
antibodies (aPL) and exploring in depth the likely pathogenic mechanisms of APS 
described to date in the literature. The key aPL antigenic target of beta 2- 
glycoprotein I ( 6 2GPI) is then discussed in detail and current evidence citing 
candidate immunodominant domains of I32GPI is explored critically.
Finally, given that this thesis describes a novel method of expression of an important 
biological protein as outlined in Chapter 3, the production of recombinant proteins by 
various hosts is discussed, with particular emphasis placed on using prokaryotic 
expression platforms. This chapter concludes with a statem ent of aims that 
constitutes the scope of this thesis.
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1.1 THE IMMUNE SYSTEM: ANTIBODIES, ANTIGENS AND THE 
INTERPLAY OF PROTEINS
1.1.1 The Immune response -  innate and adaptive
The function of the immune response is to recognise a pathogen or other foreign 
material, neutralise the threat to host and eliminate it. This response may be broadly 
classified into two distinct types: innate and adaptive. The majority of micro 
organisms encountered daily in life are detected and destroyed within hours by 
mechanisms that are not antigen specific and do not require prolonged periods of 
induction. This early phase of the immune response is termed innate immunity and 
does not improve with each successive encounter. Only if this first line of defence is 
breached, does then an adaptive immune response ensue. Innate immunity also 
serves to keep the infection under some degree of control while the effector cells of 
the adaptive response are activated. The adaptive immune response is characterised 
by the two fundamental features of specificity and memory. In conjunction with this 
high degree of specificity, the adaptive immune response is also characterised by a 
high degree of diversity. These are key properties that are required in order to 
respond to many different foreign antigens whilst retaining the ability to recognise 
self from non-self. This highly specific response to a particular pathogen  
characteristically improves with each successive encounter and is triggered earlier. 
However, this response usually takes between four to seven days to mount.
1.1.1.1 Components of the innate immune system
The innate immune response is comprised of multiple barriers to infection. Surface 
epithelia may form a mechanical, chemical (e.g. fatty acids of skin, enzymes in tears 
and gut, low pH) and microbiological (e.g. normal flora of gut) barrier. Complement 
activation can proceed on the surface of some pathogens whilst sparing host cells 
even in the absence of specific antibodies. If  epithelial barriers have been breached, 
tissue macrophages may recognise opsonised pathogens and trap, engulf and 
destroy them potentially preventing an infection from becoming established 
(Janeway et al., 2004, Roitt et al., 2001).
1.1.1.2 Cellular components of the adaptive immune response
The most important principle in adaptive immunity is clonal selection of lymphocytes, 
which are the key effector cells. Each 'naive' lymphocyte bears a distinct receptor for 
a particular antigen. The lymphocytes that bear a receptor recognising self antigen
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are eliminated early in development. When antigen interacts with a receptor on the 
surface of a mature lymphocyte, that cell is activated and becomes a blast cell. This 
lymphoblast then undergoes clonal expansion, dividing and giving rise to a clone of 
identical progeny, whose receptors all bind identical antigen. These cells then 
differentiate into effector cells such as those that secrete antibody. Effector cells 
eliminate the infection thereby removing the initial stimulus and the immune 
response ceases. However some lymphocytes differentiate into memory cells rather 
than effector cells, allowing host to respond more rapidly and intensely to a 
subsequent challenge by the same antigen (Janeway et al., 2004). There are two 
types of antigen specific lymphocytes that have been distinguished and these are 
termed B lymphocytes and T  lymphocytes.
B lymphocytes comprise approximately 25%  of the lymphocyte population. Each is 
genetically programmed to encode for a specific receptor, a membrane bound 
antibody specific for a particular antigen. When this antigen is encountered, B cells 
under the influence of cytokines and B cell growth factors undergo clonal expansion 
and differentiate into plasma cells and memory B cells. The function of plasma cells 
is to produce large amounts of circulating antibody that is identical to the original 
receptor molecule on the surface of the B cell from which the plasma cell was 
derived, thus maintaining specificity for the original antigenic stimulus. These cells 
generally have a life-span of only a few days and are the major effector cells of the 
humoral immune response, though it is recognised that a small number of plasma 
cells may be long-lived and survive for many months (Manz et al., 1998). Memory B 
cells have a longer life-span and continue to express surface receptor identical to the 
parent B cell. Mature B lymphocytes may be distinguished by the presence of CD19 
and CD20 molecules on the surface, which are not present on the surface of plasma 
cells (Roitt et al., 2001, Morrow et al., 1999).
T  lymphocytes may be divided into two major types, helper (TH) cells and cytotoxic 
(Tc) cells. Th cells express CD4 on the surface and T c cells express CD8 . TH cells of 
the type-1 class (TH1) promote immune responses that are primarily cell mediated or 
inflammatory. This process is mediated to a large extent via the production of 
specific cytokines: interleukin (IL )-2 , IL-3 and interferon-7 . T H cells of the type 2 class 
(Th2) principally interact with B cells and help them initiate and reinforce clonal 
expansion, enhancing humoral immunity. The principal cytokines produced by T H2 
cells are IL-4, IL-5, IL - 6  and IL-10. However the polarisation of T H1 and T H2 cells
24
may be heterogeneous and these cells maintain their potential to be modified from  
one phenotype to the other (Mocci and Coffman, 1995). Recently, a subset of IL-17  
producing CD4 postive T  cells have been described that develop via a lineage distinct 
from the TH1 and T H2 cell lineages (Harrington et al., 2005). This functionally distinct 
T h lineage of cells, that have been termed as TH17 cells, develop from naive T  cells 
via cytokine signals such as IL - 6  together with transforming growth factor-beta (TGF- 
6 ) and have been shown to have a crucial role in the induction of autoimmune tissue 
injury (Bettelli et al., 2006, Weaver et al., 2006).
Tc cells are responsible for the destruction of cells that have become infected by 
viruses or other intracellular pathogens. Like B cells, T  cells also bear a receptor that 
recognises a specific antigen. However, the T  cell receptor is unique in that it will 
only bind antigen when presented on the surface of another cell in association with a 
membrane protein termed the major histocompatability complex (MHC). There are 
two different classes of MHC that differ subtly in structure and function: MHC class I 
and class I I .  MHC class I molecules are expressed by nearly all nucleated cells and 
recognise peptides processed from pathogens that replicate in the cytosol, principally 
viruses and some bacteria. These pathogens may only be destroyed by killing the 
cells containing them and the CD8  co-receptor helps Tc cells recognise peptide:MHC  
class I complexes on the surface of these infected cells. By contrast MHC class I I  is 
expressed primarily on cells of the immune system and binds peptides derived from 
intracellular vesicles. An antigen presented in association with MHC class I I  will bind 
to and activate TH cells. This may in turn result in a number of possibilities all aimed 
at amplifying the immune response to the invading antigen. Typical antigen  
presenting cells are macrophages, dendritic cells and B cells. An activated TH cell 
may in turn activate the infected macrophage to fuse its lysozomes with the vesicles 
containing the parasite, thus destroying it. External antigen internalised by a B cell 
via binding to its immunoglobulin receptor may trigger activation and clonal 
expansion of the cell (Janeway et al., 2004, Morrow et al., 1999, Roitt et al., 2001).
1.1.1.3 Recognition of pathogens by the innate immune system: Toll-like 
receptors
A significant advance over the past decade has been the realisation that the innate 
immune system, a universal and evolutionary ancient system, is more than just a 
simple mechanical or chemical barrier to infection (Janeway and Medzhitov, 2002). 
Once infection has breached these barriers the innate system has numerous
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im portant functions such as opsonisation, activation of the com plem ent and 
coagulation cascades, phagocytosis, activation of proinflam m atory signalling 
cascades and apoptosis (Janssens and Beyaert, 2003). It  is through these important 
functions that the adaptive immune response is activated and shaped. In order to 
achieve these functions the innate system must have a mechanism for distinguishing 
potentially harmful non-self from self. In contrast to the clonotypic, highly specific, 
receptors of the adaptive immune response present on T  and B cells, the innate 
immune system uses a set of recognition molecules called pattern recognition 
receptors. These receptors bind conserved molecular structures found in large 
groups of pathogens (Janeway and Medzhitov, 2002). In Drosophila, which lack an 
adaptive immune system, a Toll receptor has a central role in the defensive response 
to infection by gram positive bacteria and fungi (Hoffmann, 2003). In mammals the 
identification of proteins similar to Toll, termed Toll-like receptors (TLRs) have been 
identified. TLRs appear to be the most important of the pattern recognition receptors 
in mammals and 10 types have been described in humans (Janssens and Beyaert, 
2003, Kawai and Akira, 2005). To date the ligands to eight out of 10 TLRs have been 
described and enable these TLRs to discriminate an array of protozoan, fungal, 
bacterial and viral invaders (Yamamoto et al., 2004, Kirk and Bazan, 2005). The 
intracellular portion of a TLR has marked homology to the IL-1 receptor and is thus 
termed Toll/IL-1 (T IR ) domain. All ten TLRs signal alarm to the cell via a core nuclear 
factor (NF)-KB pathway utilising the adapter myeloid differentiation protein (MyD8 8 ) 
for most TLRs and /  or the TRIF /  TRAM adapter proteins for TLR 3 and 4 (Kawai and 
Akira, 2005). These peripatetic adapter proteins associate with the activated  
intracellular T IR  domain, in turn recruiting members of the IL-1 receptor associated 
kinase (IRAK) family (IRAK-1 and 4) leading to the activation of the NF-KB signalling 
cascade. Activated NF-KB then enters the nucleus and activates proinflammatory 
genes coding for proinflammatory cytokines, interferons and adhesion molecules 
(Kawai and Akira, 2005, Yamamoto et al., 2004).
1.1.2 Antibodies in the immune system: structure and function
Antibodies are collectively term ed immunoglobulins. These are a group of 
glycoprotein molecules present in the serum and tissues of all mammals. Some are 
carried on the surface of B cells, others are free in the blood or lymphoid circulation. 
They are constructed from four polypeptide chains. Two 50 kilodalton (kDa) chains 
are termed heavy chains each of which contains four domains, three constant (CH) 
and one variable (VH). The two smaller 25kDa chains are termed light chains and
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contain two domains each, one constant CL and one variable VL region. Intra and 
interchain disulphide and covalent bonds serve to combine each unit to make up the 
immunoglobulin. There are only two types of light chains termed lambda (>.) and 
kappa (k ) and no functional differences have been found between them. By contrast, 
there are five distinct forms of Ch regions (ja, 6 , 7 , a , and e) referred to as isotypes. 
These do determ ine functional activity of the antibody and are term ed  
immunoglobulin M (IgM ), IgD, IgG, IgA and IgE. IgG is the most abundant isotype in 
the plasma. Functional properties of each isotype are conferred by the carboxyl (C) 
terminal half of the heavy chain termed the fragment crystalline (Fc) portion. This is 
formed from the Ch portion of the heavy chain and regulates the effector functions of 
the antibody that include binding to cell surface Fc receptors and complement 
fixation leading to elimination of the bound antigen (Morrow et al., 1999, Janeway et 
al., 2004).
In contrast to the CH and CL regions that are highly conserved, the VH and VL regions 
contain great variation in amino acid sequence with short segments of hypervariable 
looping regions. This portion of the antibody is termed the fragment antigen binding 
(F (ab )) portion. I t  is responsible for conferring the antigen specificity of each 
antibody. Three hypervariable loops from the VH region and three hypervariable 
loops from the VL region come together to form the unique antigen binding site 
(Chothia et al., 1989). These hypervariable loops combine to form a surface 
complementary to the antigen and hence they are also termed complementarity 
determining regions (CDRs). The CDRs are separated within the VH and VL chains by 
more conserved regions termed framework regions (FRs) and these serve a more 
structural role (Wu and Kabat, 1970). The number of different antibody specificities 
available in an individual, otherwise known as the antibody repertoire, is in region of 
1011. This enormous diversity is generated by multiple mechanisms. The genes 
coding for different heavy and light chains come together in antibody producing cells 
and the antibodies produced by these cells derived from an inherited gene will bear 
the germ-line sequence. A large number of antibody genes use DNA rearrangement 
to create the antibody repertoire of an individual. However, this diversity is markedly 
enhanced by the presence of somatic mutation, whereby a limited number of 
inherited genes undergo multiple random mutations (Tonegawa, 1983).
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1.1.3 Autoimmunity and autoantibodies
The huge potential diversity of reactivity means there is also the potential to create 
self-reactive lymphocytes. A variety of mechanisms exist both in the thymus and in 
the periphery to ensure that self-reactive T  cells are deleted or removed. When there 
is a persistence of self-reactive lymphocytes then this indicates a breakdown in 
tolerance to self and forms the basis for the development of autoimmunity.
Autoimmune disease may be grouped into organ specific and non-organ specific /  
systemic autoimmune diseases. In organ specific autoimmune disease the condition 
tends to have a single or small number of autoreactive antibodies targeting a single 
or limited number of organ systems. Examples include anti-basement membrane 
antibodies targeted to the basement membrane of the kidneys and lungs causing 
Goodpasture's syndrome, or the anti-acetylcholine receptor antibodies associated 
with myasthenia gravis. The non-organ specific /  systemic autoimmune diseases 
mostly comprise of the connective tissue diseases and autoimmune arthropathies. 
SLE and the APS are typical examples of systemic autoimmune diseases that target 
multiple organs or systems (Roitt et al., 2 0 0 1 ).
However, the presence of auto reactive antibodies may be a physiological rather than 
a pathological phenomenon. Natural autoantibodies of low affinity to self-reactive 
antigens may be detected in normal healthy individuals (Baumgarth et al., 2005). 
These antibodies are produced by long-lived B -l lymphocytes that are positively 
selected by interacting with self. This is in contrast to the more ubiquitous B-2 
lymphocyte population, which produce high affinity antibodies, generate memory 
cells and are negatively selected when self is encountered (Baumgarth et al., 2005). 
The precise functions of natural autoantibodies are unknown but they are often of 
the IgM isotype and are sometimes able to bind more than one self or foreign 
antigen. The repertoire is remarkably stable between species, due in part to the fact 
that most natural antibodies use germ-line encoded VH and VL genes (Baumgarth et 
al., 2005).
Autoantibodies associated with SLE and APS however, tend to be of the IgG isotype 
and of high-affinity binding. Furthermore, most of these pathogenic autoantibodies 
use non-germ line encoded VH and VL genes, due to the presence of somatic 
mutations (Rahman et al., 2001, Giles et al., 2003b).
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1.1.4 Structural nature of proteins, antigens and antigenic determinants
The term antigen was originally used for any molecule that was able to produce an 
antibody response from a B cell (antibody generator). However, the term antigen is 
now used more generically to determine any molecule recognised by key elements of 
the adaptive immune response, which includes both T  and B cells (Roitt et al., 2001). 
Antigens that bind antibodies in humans and provoke an immune reaction tend to be 
proteins in the vast majority of cases, however polysaccharide coats of pathogens, 
nucleic acids and lipids may also occasionally be antigenic. The site on the antigenic 
protein that antibodies recognise is termed the antigenic determinant or epitope. 
Before considering the nature of antigenic determinants the general principles 
governing basic protein structure will be discussed.
Proteins consist of polypeptide chains, which are formed from individual amino acids 
linked by covalent peptide bonds (Stryer, 1988). Peptides are built from a repertoire 
of 20 amino acids and each protein has its own defined amino acid sequence. 
Frederick Sanger in 1953 demonstrated this for the first time when the amino acid 
sequence of the protein hormone insulin was first published (Sanger and Thompson, 
1953a, Sanger and Thompson, 1953b). Amino acids are designated by either a three 
letter abbreviation or a one letter symbol as shown in appendix I. They consist of an 
amino group, a carboxyl group, a hydrogen atom and a distinctive R group all 
bonded to a central carbon atom. It  is the nature of the R side chain that defines the 
type and ultimately the functional properties of each amino acid. The simplest one is 
glycine with just a single hydrogen atom as the side chain. Others have sulphur 
atoms such as cysteine, others an aromatic ring and others hydrocarbons up to three 
or four carbons long. At neutral pH amino acids may be either hydrophobic (non­
polar) or hydrophilic (polar). All hydrophobic amino acids have a net neutral charge 
and these tend to be amino acids with long hydrocarbon side chains e.g. valine and 
leucine. Hydrophilic amino acids may have neutral, positive (basic) or negative 
(acidic) net electrical charges.
A striking feature of proteins is that they have a well-defined three-dimensional or 
tertiary structure and the conformation of a protein is the major determinant of its 
functional properties. There are a number of different factors that determine the final 
structure of a protein. Polypeptides often fold in to a regular a-helical repeating 
structure. These helical structures have 3.6 residues per turn such that amino acids 
spaced three and four apart in the linear sequence come into very close
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approximation in an a-helix. Such a-helical coils form the main structural motif for 
many proteins such as haemoglobin. Alternatively peptides may be arranged into 
parallel flat 6 pleated sheets. The a-helix and 13-sheet describe determinants of the 
secondary structure of proteins, but what elements determine the tertiary structure? 
These are primarily dictated by non-covalent molecular interactions and are mediated 
by hydrophobic properties of the non-polar amino acids and by three types of forces: 
electrostatic bonds, hydrogen bonds and van der Waal forces (Stryer, 1988). The 
strength of the non-covalent bond is critically dependent on distance. Electrostatic 
bonds may occur between positive and negative charges and the force is 
proportional to distance (d) between them (1 /d 2). However, for van der Waal forces 
groups must come into closer approximation for these forces to be significant (1 /d 7). 
The distance required for optimal hydrogen bond formation is longer than for 
electrostatic forces. These bonds are vitally important in the formation of a  and 8 
polypeptide units due to the formation of hydrogen bonds between the amino and 
carboxyl groups of adjacent units. However side chains of 11 amino acids may also 
participate in either receiving or donating one or more hydrogen bonds. The effect of 
hydrophobic side chains on the overall structure of amino acids is also very 
important. A polypeptide chain will fold spontaneously such that the hydrophobic 
side chains are buried deep in the protein whilst the polar, charged chains remain on 
the surface. The segments of main chains may be buried deep in the protein due to 
the formation of hydrogen bonds between the amino and carboxyl groups, which if 
left unpaired would markedly prefer water to a non-polar environment. This type of 
paring may be neatly established in an a  helical coil or f3 pleated sheet and the 
protein structure further stabilised by the formation of van der Waal forces between 
tightly approximating groups. Finally, the presence of a sulphur atom side-chain in 
cysteine allows for the formation of strong covalent disulphide bonds between 
cysteine residues located at different points in the primary structure, creating loops 
in the tertiary structure. Disulphide bonds can also link different polypeptide chains 
together and hence be integral to protein quaternary structures as seen with 
immunoglobulins (Stryer, 1988).
The tertiary structure of a given native protein antigen may allow multiple epitopes 
from different segments of the protein to come into close approximation and form 
the binding site for antibodies. These epitopes are term ed discontinuous or 
conformational epitopes. Hence the effect of denaturing these antigenic proteins is to 
markedly reduce or abolish binding of antibody due to loss of conformation. In
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contrast antibodies that bind linear or non-conformational epitopes will bind 
denatured antigen (Janeway et al., 2004, Roitt et al., 2001). Structural studies of the 
influenza derived protein neuraminidase complexed with monoclonal F(ab) provides a 
typical example of antibody binding non-conformational epitopes. The antibody 
binding site of this complex is comprised of 33 residues derived from eight chain 
segments of neuraminidase coming together to form the epitope (Tulip et al., 1992).
1.1.5 Nature of the antigen : antibody interaction
There exists a huge diversity of antibody repertoire as discussed. However, in order 
for this diversity to be of biological benefit, a high degree of specificity regarding the 
interaction between antibody and its corresponding antigen must exist.
Early investigations regarding the nature of the antigen : antibody interaction were 
limited in that only small molecules known as haptens were investigated as the 
binding antigen and not whole native protein. This is because potential sources of 
monoclonal antibody were limited and came from tumour cells producing antibody of 
unknown specificities. Hence only small compounds could practically be screened for 
binding to antibodies of unknown specificities. These initial structural studies of 
hapten ligands such as vitamin K or phosphorylcholine binding to antibody revealed 
that small antigens lie in a cleft made from the CDRs of both VH and VL. Small 
antigens such as these however may not come in to close contact with all CDRs as in 
the case of phosphorylcholine, which interacts with all three CDRs of the VH but only 
CDR3 of the VL (Davies et al., 1990, Janeway et al., 2004). Native protein antigens 
however are much larger than hapten molecules and often cannot be accommodated 
within the narrow cleft that haptens lie in. There have been few detailed X-ray 
crystallographic structural studies of antigenic proteins complexed with antibody. The 
two most common antigens studied have been the antigenic proteins hen egg white 
lysozyme (Amit et al., 1986, Sheriff et al., 1987) and influenza derived neuraminidase 
(Tulip et al., 1992) complexed with their corresponding monoclonal F(ab). These 
studies demonstrate that larger antigens typically make contact with all six CDRs. 
The surface area of the interaction is typically in the region of 700 angstroms (A )  
(Janeway et al., 2004).
Binding of an antibody to an antigen may be disrupted chemically by altering pH, 
adding detergents or inducing high salt concentrations. This implies that the nature 
of the interaction is non-covalent. Non-covalent forces between residues within a 
protein are essential for defining the tertiary structures of proteins. However, they
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are also very important in defining the interaction between residues forming the 
epitopes of antigens and the paratopes of antibodies. However, in order for residues 
to come into close approximation and form non-covalent bonds there must be a 
good fit between the surface of the antigens and the surface of antibodies. As 
discussed the antibody has a surface complementary to the binding antigen. For 
example, the F(ab) of antibody to lysozyme shows marked complimentarity, with 17 
amino acid residues on the antibody making contact with 16 residues on the 
lysozyme molecule (Amit et al., 1986). A good fit between the antigenic epitope and 
the antibody creates the opportunity for the formation of hydrogen bonds and 
electrostatic attractive forces between residues. The formation of van der Waal 
forces requires close juxtaposition of residues and the hydrophobic non-polar 
residues may also attract by their mutual properties of repelling water. The strength 
of this bond between antibody and antigen is termed affinity (Roitt et al., 2001).
This thesis describes the molecular study and manipulation of a native peptide 
antigen which binds a group of autoantibodies termed aPL. These are the key 
pathogenic autoantibodies associated with the autoimmune disorder APS and are 
also seen frequently in patients with SLE. I will now discuss the clinical syndrome of 
the APS.
1.2 THE ANTIPHOSPHOLIPID SYNDROME
1.2.1 Definition of the APS
There is no standardised simple definition of the APS. The essential clinical features 
characterising APS are of arterial and venous thrombosis, thrombocytopaenia, livedo 
reticularis or recurrent foetal loss. These clinical events typically occur in association 
with a group of circulating autoantibodies directed against phospholipid (PL) or PL 
binding cofactor proteins, the most important and best characterised being B2GPI 
(Harris et al., 1983, Hughes, 1983, Asherson et al., 1989). Though these are a 
heterogeneous group of antibodies, in routine, clinical practice they are detected by 
an enzyme linked immunosorbent assay (ELISA) directed against the anionic PL 
cardiolipin (CL). These aPL are also responsible for the paradoxical lupus 
anticoagulant (LA) effect, a test which detects an inhibitor of phospholipid dependent 
coagulation.
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1.2.2 Historical review of aPL and the APS
The term APS was first coined relatively recently by Harris et al in an abstract 
submitted to the British Society of Rheumatology in 1987 (Harris et al., 1987a). 
Initial experiments leading up to the discovery of aPL were centred around the 
development of assays for syphilis. In 1906 a reagin test developed by Wasserman, 
and coined the Wasserman reaction, identified sera from patients infected with 
syphilis that reacted with syphilitic tissues (Wasserman et al., 1906). It  was initially 
thought that infected serum was reacting with antigens derived from Treponem a  
pallidum present in the syphilitic tissues. However, it was realised that infected sera 
must be reacting with a native antigen as the same effect was seen when non­
infected normal human or mammalian tissue was used (Landsteiner et al., 1907). It  
was another 34 years before Pangborn et al in 1941 identified the antigenic 
component of the reagin test as being CL, sourced in these experiments from bovine 
hearts (Pangborn, 1941, Pangborn, 1942).
Subsequently the combination of CL, lecithin and cholesterol formed the basis of the 
test for syphilis known as the venereal disease research laboratory (VDRL) test. 
However, it was realised with the development of more specific tests, such as the 
Treponema pallidum immobilisation test, that the Wasserman reaction and VDRL test 
could produce false positive results for syphilis in non-infected individuals. In 1952 
Moore and Mohr identified two circumstances in which false positive results for 
syphilis using the reagin test could be observed (Moore and Mohr, 1952). Transient 
false positives were seen in patients following an acute viral infection or post 
vaccination. Persistent false positive tests (more than six months) were observed in 
individuals with autoimmune disorders such as SLE, rheumatoid arthritis and 
Sjogren's syndrome (Moore and Mohr, 1952).
Also in 1952 Conley and Hartman were the first to describe a 'circulating  
anticoagulant' which caused prolongation of the prothrombin tim e in the serum of 
two patients with SLE who also had a false positive serological test for syphilis 
(Conley and Hartman, 1952). Subsequent studies in the mid to late 1950s 
demonstrated that this anticoagulant factor was in fact attributable to the biological 
false positive test result for syphilis in patients with SLE (Lee and Sanders, 1955, 
Laurell and Nilsson, 1957) though it was not until 1972 that the term 'lupus 
anticoagulant' was suggested by Feinstein and Rapaport (Feinstein and Rapaport, 
1972). At the time it was puzzling to investigators in the field that this anticoagulant
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entity, associated with SLE and the prolongation of all coagulation tests involving the 
use of lipid, was not accompanied by a tendency to bleed in the patient (Shapiro, 
2005). Bowie and colleagues from the Mayo clinic in 1963 were the first to describe 
the paradoxical association of the presence of serum with this anticoagulant effect 
and the increased tendency to thrombose rather than bleed (Bowie et al., 1963). 
Interestingly however, it was Laurell and Nilsson in 1957 who first suggested the 
possible association of the anticoagulant phenomenon with a syndrome of recurrent 
miscarriages and also suggested that the prolonged tests might be associated with 
inhibitory effects against PL (Laurell and Nilsson, 1957). The mechanism of the LA 
was first published in 1980, when Thiagarajan et al described the properties of a 
purified IgM antibody from serum with marked LA activity. This purified IgM was 
found to inhibit PL dependent coagulation tests, but only in the presence of anionic 
PL, and not when neutral phosphatidylcholine or phosphatidylethanolamine were 
used as the lipid source (Thiagarajan et al., 1980). The first description of a method 
for measuring LA was published in 1986 and used a variation on the 'Stypven Time', 
a test making use of Russell Viper Venom and hence termed the dilute Russell Viper 
venom test (dR W T) (Thiagarajan et al., 1986).
The possible association of LA activity with recurrent foetal loss was noted first in 
1957, but it was not until the early 1980s' that multiple studies described the triple 
association of LA, recurrent foetal loss and prothrombotic tendencies (Soulier and 
Boffa, 1980, Carreras et al., 1981a, Carreras et al., 1981b). Hughes and colleagues 
at St Thomas's Hospital (London, UK) first described the association of cerebral 
thrombosis with recurrent miscarriage and LA in an editorial in the British Medical 
Journal in 1983 and suggested the presence of a distinct syndrome (Hughes, 1983). 
It  was in Hughes's unit in the same year that Harris et al described a solid-phase 
radioimmunoassay for the detection of aPL reacting against CL as the target antigen 
(Harris et al., 1983). Subsequently, an assay for the detection of anticardiolipin 
antibodies (aCL) was described in 1985 (Loizou et al., 1985). A year later the term  
anticardiolipin syndrome was introduced by Hughes et al (Hughes et al., 1986) and 
was subsequently renamed the APS by the same group in 1987 (Harris et al., 
1987a).
The aCL test required the presence of bovine or human serum to detect binding of 
aCL to CL coated on a plate. This led to a major discovery reported in 1990 by three 
independent laboratories that reactivity to CL was dependant upon the serum co­
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factor 62GPI otherwise known as apolipoprotein H (Galli et al., 1990, Matsuura et al., 
1990) (McNeil et al., 1990b). This co-factor of 50kDa in size and then of unknown 
function was found to bind anionic PL. B2GPI and its role in APS is described in detail 
in section 1.6. Although other co-factors have also been found to bind aPL such as 
protein C (Oosting et al., 1993), protein S (Oosting et al., 1993) and prothrombin 
(Bevers et al., 1991), B2GPI remains the clinically most relevant and best studied.
1.2.3 Classification of the APS
The existence of APS without the presence of lupus or other autoimmune disease 
was first noted by Asherson in 1988, who coined the term "primary" APS (PAPS) and 
proposed classification criteria (Asherson, 1988). A year later three studies describing 
the clinical and serological features of series of patients with PAPS or APS and SLE 
were described (Asherson et al., 1989, Alarcon-Segovia et al., 1989, Alarcon-Segovia 
and Sanchez-Guerrero, 1989, Mackworth-Young et al., 1989). With subsequent 
larger studies of up to 1000 patients with APS it became apparent that in fact PAPS 
possibly constitutes the majority of patients with APS, accounting for just over 50%  
(Cervera et al., 2002).
Early attempts to establish classification criteria were made by many groups, with the 
consequent lack of absolute consensus (Hughes et al., 1986, Harris et al., 1987a, 
Asherson, 1988, Alarcon-Segovia and Sanchez-Guerrero, 1989, Alarcon-Segovia et 
al., 1989). The first attempt to form an international consensus for the classification 
of APS came in October 1998 during the Eighth International Symposium of the APS 
in Sapporo, Japan (Wilson et al., 1999). These preliminary criteria, also known as the 
Sapporo criteria, state that the diagnosis of APS should be made when one or more 
clinical outcome occurs in conjunction with specific laboratory criteria. The clinical 
outcomes include vascular thrombosis (arterial or venous) or pregnancy morbidity, 
either recurrent early (less than 10 weeks) foetal loss or pre-term birth (less than 34 
weeks) due to placental insufficiency or miscarriage. Laboratory criteria constitute a 
positive LA and /  or moderate to high IgG or IgM aCL titres on two or more 
occasions at least six weeks apart (Wilson et al., 1999). Validation studies by 
Lockshin et al showed that these criteria had high specificity of 0 .98 but were 
relatively less sensitive at 0.71 (Lockshin et al., 2000). The criteria were an important 
tool in facilitating research studies, but there were some important manifestations of 
APS that were not covered and accounted for many of the false negative patients 
identified in the validation studies (Lockshin et al., 2000). These include non- 
thrombotic, non-pregnancy related clinical features such as livedo reticularis,
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thrombocytopaenia or patients with anti-B2GPI antibodies, who constitute 3 -10%  of 
patients with APS but have consistently negative aCL and LA tests (Lee et al., 2003, 
Nash et al., 2004, Ebeling et al., 2003). Also, it was not entirely clear what 
constitutes a 'moderate' titre of aCL. These points have been addressed and the 
preliminary Sapporo criteria have been updated recently by a further international 
consensus statement agreed upon at a dedicated workshop convened before the 
Eleventh International Congress on APS in Sydney in 2004 (Miyakis et al., 2006). 
These classification criteria are summarised in table 1. The updated criteria differ 
from the Sapporo criteria, in that additional factors contributing to thrombosis should 
be assessed and that APS patients be stratified according to the presence or absence 
of risk factors contributing to thrombosis. These risk factors may be either inherited 
or acquired and include age (more than 55 years in men and 65 years in women), 
any of the established acquired risk factors for cardiovascular disease, inherited 
throm bophilia, oral contraceptive use, nephrotic syndrom e, m alignancy, 
immobilisation and surgery (Miyakis et al., 2006). The rationale behind this inclusion 
originates from concerns that the association of age and of commonly occurring risk 
factors for thrombosis and cardiovascular disease may cause classification bias. 
However, greater changes were made to the laboratory criteria required to make the 
diagnosis. A clear threshold for a positive result for aCL of more than 40 GPL and 
MPL units was given (see section 1.2.4 for standardisation of units). The committee 
further stated that APS should not be diagnosed if more than five years elapse 
between a positive clinical event and a positive serological result. The interval 
required for two positive successive results was increased from six to 12 weeks 
though this was due more to expert opinion rather than evidence based on previous 
validation studies (Miyakis et al., 2006). The most significant change was the 
inclusion of anti-82GPI testing, either IgG or IgM isotype, which should be positive 
(more than 99th percentile) on two or more occasions at least 12 weeks apart. 
Finally, the statem ent was made that the traditional terms of 'prim ary' and 
'secondary' APS should be abandoned, and that APS with or without the coexistence 
of SLE or other autoimmune disease be simply documented. Classification of the 
Catastrophic APS (CAPS) was outside the remit of these criteria. (CAPS is described 
in section 1.2.8 and preliminary classification criteria summarised in table 1.1).
It  is recognised that patients may have clinical features of APS other than those 
detailed in the criteria. For example, a retrospective Greek study of 81 patients with 
SLE who had a renal biopsy found evidence of APS nephropathy i.e. thrombotic
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microangiopathy in one third of aPL positive patients who did not meet the Sapporo 
classification criteria for APS (Tektonidou et al., 2004). The committee considered 
patients with throm bocytopaenia, livedo reticularis, cardiac valve disease, 
nephropathy and non-thrombotic neurological disease and proposed the terms aPL- 
associated thrombocytopaenia, aPL-associated livedo reticularis, aPL-associated 
cardiac valve disease and aPL-associated nephropathy. Pre-defined inclusion criteria 
were outlined for each group. (Miyakis et al., 2006). These distinct aPL-associated 
non-APS group of patients tend to present the greatest management dilemmas. The 
definition of an 'aPL-associated' condition should help in focussing prospective 
research studies designed to dissect the best treatment regimens for these groups of 
patients and also help stratify risk for the development of APS.
The updated criteria are likely to be an improvement over the Sapporo criteria of 
1999 and future validation studies may confirm this. What was not addressed in the 
updated criteria was how to classify patients that have characteristic clinical features 
of the APS but w ithout evidence of aCL, anti-62GPI antibodies or LA using 
conventional assays tested repeatedly. The term 'seronegative APS' has been 
proposed by Hughes and Khamashta (St. Thomas' Hospital, London) to describe such 
groups of patients (Hughes and Khamashta, 2003). I t  is likely that the standard 
assays do not detect all aPL, given their marked heterogeneity. For example, the aCL 
assay utilises a bovine source for (32GPI, and the human 62GPI assay detects binding 
of aPL to 02GPI coated on a plastic surface, rather than PL as occurs physiologically. 
Furthermore, there may be many other co-factors involved in haemostasis that may 
be important antigenic targets for aPL. Given these potential factors perhaps it is 
unsurprising that not all patients with APS have detectable aPL as assessed using 
conventional assays.
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CLINICAL CRITERIA
1. Vascular thrombosis: One or more episodes of arterial, venous or small vessel
thrombosis in any tissue or organ
2. Pregnancy morbidity:
a) One or more unexplained death of a morphologically normal foetus at 
or beyond the 10th week gestation
b) One or more premature births of a morphologically normal neonate 
before the 34th week of gestation because of i) eclampsia or severe 
pre-eclampsia or ii) recognised features of placental insufficiency
c) Three or more unexplained consecutive spontaneous abortions before 
the 10th week of gestation, with maternal anatomic or hormonal 
abnormalities and paternal /  maternal chromosomal abnormalities 
excluded
LABORATORY CRITERIA
1. LA present in plasma on two or more occasions at least 12 weeks apart, 
detected according to the guidelines of the International Society on Thrombosis and 
Haemostasis (Brandt et al., 1995)
2. aCL antibody IgG or IgM isotype, present in medium to high titre (i.e. more 
than 40 GPL or MPL units) on two or more occasions at least 12 weeks apart, as 
measure by standard ELISA
3^  Anit-62GPI antibody IgG or IgM isotype (more than 99th percentile) on two or
more occasions, at least 12 weeks apart, measured by a standardised ELISA,
according to recommended procedures (Reber et al., 2004)
1 - -    - - - — ---
Table 1.1 Updated classification criteria for definite APS. Definite APS is 
considered to be present if at least one clinical and one of the laboratory defined 
criteria are met within five years of each other.
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1.2.4 Standardisation of aPL assays
The association of aPL with thrombotic events or pregnancy morbidity underpins the 
diagnosis of APS. However, epidemiological studies designed to demonstrate these 
associations show seemingly heterogeneous results and consequently draw  
conclusions that differ from one another. These discrepancies may be due to a 
variety of factors specifically relating to patient inclusion /  exclusion criteria, 
diagnostic criteria for a clinical event, clinical end-points, assay method employed to 
detect aPL and pre-defined cut-off points for determining a positive result. The final 
point is likely to be a major contributing factor towards the heterogeneity between 
studies observed.
IgG and IgM aCL are expressed in international standardised units as GPL and MPL 
units respectively. These standardised units are derived using standardised anti-IgG  
aCL and anti-IgM aCL calibrators distributed from the aPL standardisation laboratory 
in Galveston, (Texas, USA) (Harris and Pierangeli, 2002). The first International aCL 
workshop in 1986 defined GPL and MPL units as binding observed with lp g  of affinity 
purified polyclonal IgG and IgM that was distributed to participating laboratories 
(Harris et al., 1987b). Secondary standards were ultimately calibrated against the 
primary standards. Hence, different batches of calibrators will contain heterogeneous 
polyclonal aPL from different batches of patients. This has led to suggestions that 
these calibrators may not necessarily behave in a homogenous fashion when assayed 
at different dilutions or using different kits (Wong, 2004). This is underlined by the 
observation of considerable inter-laboratory variability (Harris and Pierangeli, 2002) 
even when using the same batch of calibrators. In one inter-laboratory study 12 
serum samples were tested for both IgG and IgM aCL using the same assay in 56 
laboratories. General consensus defined as an inter-laboratory agreement of more 
than 90%  was achieved in 10 (42% ) of the 24 cases only (Favaloro and Silvestrini,
2002). There is also a high degree of variability between different commercial kits for 
aCL detection when assessed within the same laboratory, with lower variability seen 
with different commercial anti-(32GPI kits (Audrain et al., 2004). For the reasons 
stated, the European Antiphospholipid forum have validated the efficacy of two other 
calibrators named HCAL (IgG ) and EY2C9 (IgM ) and claim less inter-laboratory 
variation than when using the standard aCL calibrators (Tincani et al., 2001). These 
calibrators are derived from a monoclonal anti-62GPI antibody developed for use as a 
standard in assays to detect B2GPI dependent aCL and an ti-82GPI antibodies 
(Ichikawa et al., 1999, Ichikawa et al., 1994). It  is unlikely that these standards will
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displace the currently accepted international calibrators in use for detecting aCL, 
however the European Antiphospholipid Forum did suggest th a t they be 
intermittently used as external controls two to three times a year in laboratories that 
undertake routing aCL titre estimations (Tincani et al., 2004). Given the current 
absence of an internationally accepted anti-82GPI calibrator, the same European 
group proposed the use of HCAL and EY2C9 humanised monoclonals as calibrators 
for the anti-82GPI assay to validate comparisons between different assay systems 
(Reber et al., 2004). Internationally accepted criteria for testing LA were proposed in 
1995 by the International Society for Thrombosis and Haemostasis (Brandt et al.,
1995).
1.2.5 Epidemiology of APS and of aPL as a risk for thrombosis
As discussed in the previous section, there are some limitations in comparing 
different epidemiological studies due to lack of uniformity in assay methods and until 
relatively recently, lack of agreed classification criteria for APS. Furthermore, many 
studies investigating the prevalence of aPL in a given patient population presenting 
with thromboembolic events or pregnancy morbidity cannot be extended to form  
conclusions as to the prevalence of APS in these groups. This is because the majority 
of studies have estimated aCL or LA only once and not serially as required by the 
original Sapporo and updated classification criteria (Miyakis et al., 2006).
It  is recognised that there is a relatively high prevalence of aPL and even LA in the 
general population though the majority do not have APS (Petri, 2000). Estimates for 
aCL vary from 1% (Pattison et al., 1993) to 5 .6%  (Shi et al., 1990) and for LA from 
1.2%  (Pattison et al., 1993) to 3 .8%  (Infante-Rivard et al., 1991). However these 
are estimates derived from the general adult population. For those above 48 years of 
age the frequency of aCL (both 82GPI dependent and independent) goes up and 
approximates up to 26%  (Brey et al., 2001). The frequency of anti-82GPI antibodies 
in the healthy population has been little studied. The largest case control study 
investigating the frequency of anti-82GPI antibodies in patients presenting with 
stroke or myocardial infarction tested the serum of 1360 age matched (between ages 
48 and 70 years of age) healthy controls. The frequency of 82GPI dependent IgG aCL 
was 12.1%  and anti-82GPI positivity 1.9%  in this normal group (Brey et al., 2001).
Multiple prospective studies have demonstrated a statistically significant association 
between the presence of aCL and LA and the occurrence of venous thrombosis 
(Finazzi et al., 1996, Schulman et al., 1998, Galli, 2004). Furthermore, this risk is
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enhanced if patients have additional risk factors for the development of venous 
thrombosis (Kassis et al., 2004, Hudson et al., 2003). Ginsburg et al performed a 
case-control sub-study as part of the Physicians Health Study and found a statistical 
association between aCL and venous thrombosis. LA unfortunately was not measured 
and methods for diagnosing thrombosis were not stated (Ginsburg et al., 1992). In 
another case-control study of 256 patients with venous thromboembolism there was 
a statistically significant association with the presence of LA but not of aCL as 
compared to the non-thrombotic arm (Ginsberg et al., 1995). However a weakness 
of this study was that the mean age of patients enrolled was 55 years of age, thus 
accounting for the high prevalence of aCL in the non-thrombotic arm. Given this the 
significance of aCL positivity in those over the age of 50 years is uncertain. The 
presence of anti-B2GPI antibody positivity and the risk of developing venous 
thrombosis was extensively reviewed in a meta-analysis by Galli et al (Galli et al.,
2003). Of the 21 studies identified 12 showed a statistical association with venous 
thrombosis. The most likely reason accounting for this heterogeneity is that these 
studies employed 'hom e-m ade' anti-B2GPI detection assays with varying protocols 
and varying cut-off points defined. Most of the studies were performed between 
1993 and 1998 prior to the publication of the 1999 Sapporo classification criteria.
If  a patient is aCL or LA positive what is the risk of developing a second thrombotic 
episode after cessation of anticoagulation? A study by Schulman et al has addressed 
this question (Schulman et al., 1998). During four-year follow-up of 412 patients post 
six months anticoagulation after a first venous thrombotic episode, 29%  with aCL 
developed a further episode as compared to 14%  without aCL (p = 0 .0 0 1 2 ). This 
positive association was seen despite a number of shortcomings in this study. 
Abnormal aCL was defined as any value above 5 GPL units and the number of 
patients who had significantly positive aCL (i.e. more than 40 GPL units) was only 
eight, of whom three developed a recurrence. The study did not estimate LA or 
attempt to define anti-B2GPI reactivity.
Differentiating between B2GPI dependent and independent aCL reactivity has been 
employed by Brey et al in identifying risk factors for developing arterial thrombosis 
(Brey et al., 2001). In a large case-control study of 374 men presenting with 
myocardial infarction and 259 with stroke, as compared to an age matched control 
group of 1360 men, there was a significantly greater incidence of B2GPI dependent 
IgG aCL in the group with arterial thromboses. However, a relatively low cut-off
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value of 23 GPL units was used and LA activity was not estimated. Other studies 
have also demonstrated an association between aCL and stroke (1993, Tuhrim et al., 
1999) and myocardial infarction (Vaarala et al., 1995) whilst a few have failed to 
demonstrate an association with stroke (Ginsburg et al., 1992, Ahmed et al., 2000) 
or ischaemic heart disease (Phadke et al., 1993). Part of the reason may be due to 
small cohort numbers included in these studies and the fact that these conditions 
occur with high frequency in an elderly population who generally have a higher 
incidence of aCL. This may account for the stronger association of stroke with aCL 
and LA seen in patients under the age of 50 years (de Jong et al., 1993, Brey et al., 
1990, Tietjen et al., 1993). Also others have demonstrated that aCL in excess of 100 
GPL units constitutes an independent risk factor for stroke (Verro et al., 1998). Bas 
de Laat et al identified 58 blood samples from 198 patients with autoimmune disease 
that all had LA activity but only half the samples exhibited (32GPI dependency. The 
presence of LA activity associated with B2GPI dependency had a very strong 
association with thrombosis (odds ratio 42.3; 95%  confidence interval, 194.3-9 .9 ) 
whereas the 82GPI independent samples with LA activity had no association (de Laat 
et al., 2004).
The prevalence of APS in the general population is unknown. One editorial has 
suggested that as 2 % -5 %  of the population have experienced a deep venous 
thrombosis (Coon et al., 1973) and that primary APS may account for 15-20%  of all 
deep venous thrombotic (Ginsburg et al., 1992) episodes, then the prevalence of APS 
in the population is likely to be as high as 0 .3%  to 1% (Roubey, 2004). However, 
caution should be exercised when drawing conclusions from different studies 
investigating different population groups. Without formal epidemiological studies 
designed to address this question the true figure of APS within the population 
remains unknown.
In the largest survey of APS patients to date compiled by the Euro-Phospholipid 
Project Group the clinical features of 1000 patients with APS were analysed (Cervera 
et al., 2002). Of these APS patients, 53.1%  had APS alone, 36%  also had SLE, 5%  a 
lupus like disease, 5 .9%  other autoimmune diseases (such as Sjogren's syndrome- 
2.2%  or rheumatoid arthritis-1 .8% ) and 1% the catastrophic form of APS known as 
CAPS (see section 1.2.8). Ratio of females to males is high at 5:1 in all APS patients 
with 7:1 in those with APS and SLE as compared to 3.5:1 in those with APS alone. 
The presence of aPL as defined by the Sapporo criteria (Wilson et al., 1999) were:
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aCL in 87.9% , LA in 53.6%  and antinuclear antibodies (ANA) in 59 .7%  (Cervera et 
al., 2002). One study comparing 30 male versus 38 female patients with APS and no 
other autoimmune disease found stroke to be significantly more prevalent in females 
(Jara et al., 2005).
In patients with SLE, the frequency of LA has been estimated to be between 11%  
(Wong et al., 1991) and 30%  (Cervera et al., 1990). The frequency of aCL has been 
estimated to be approximately 20-35%  (Radway-Bright et al., 2000, Kutteh et al., 
1993, Cervera et al., 1993) and the frequency of APS also around 10%  (UCH cohort 
of 450 patients, via personal communication with Professor Isenberg). In a cohort of 
380 patients (Hopkins Lupus Cohort) followed up for a mean of 12.3 years, dual 
positivity for LA and aCL was predictive of both venous and arterial thrombosis, 
whilst LA only was predictive of myocardial infarction and neither were predictive of 
atherosclerosis (Petri, 2004). Anti-I32GPI antibodies in patients with SLE or other 
autoimmune diseases have also been shown to predict thrombosis, especially if 
patients are also LA positive (de Laat et al., 2004) and may help stratify risk in SLE 
patients with LA and no history of a thrombotic event (Zoghlami-Rintelen et al., 
2005). In women with SLE, the presence of aCL and LA is associated with increased 
risk of pregnancy loss (Kutteh et al., 1993).
1.2.6 Thromboembolic and cardiovascular manifestations of the APS
Thrombosis of one or more vessels is the most frequent clinical manifestation of the 
APS. Thrombosis may occur in a vessel of any size in either the arterial or venous 
circulation in the absence of vascular anomalies. Some authors have proposed that 
APS is unique in predisposing to both arterial and venous thrombosis (Kandiah et al.,
1998). Even inherited thrombophilic disorders tend to be associated with either 
arterial thrombosis as seen in homocystinuria or venous thrombosis as seen in Factor 
V Leiden, Protein C or S deficiencies (Kandiah et al., 1998). The presenting clinical 
features of vascular thrombosis that may occur in the APS are listed in table 1.2 A) 
and 1.2 B). The most common clinical manifestation is venous thrombosis, notably 
deep venous thrombosis of the legs occurring in 29-55%  of APS patients (Asherson 
et al., 1989, Vianna et al., 1994, Cervera et al., 2002). Pulmonary embolism occurs in 
approximately 20%  (Cervera et al., 2002). Arterial thromboses are also commonly 
seen but less frequently. Stroke is the most frequently observed arterial 
manifestation accounting for up to 50%  of arterial occlusions (Asherson et al., 1989) 
and affecting 20%  of patients with APS (Cervera et al., 2002). APS is the commonest 
cause of thrombotic stroke presenting in patients under the age of 50 (Petri, 2000).
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Myocardial infarction appears in approximately 5%  of APS patients and constitutes 
the presenting clinical event for APS in half of these cases (Cervera et al., 2002).
The association of APS with atherosclerotic disease however remains contentious 
(Vlachoyiannopoulos and Samarkos, 2004) whereas it has been clearly established in 
the case of SLE (Manzi et al., 1997, Manzi et al., 1999). Studies reported from the 
Hopkins Lupus Cohort demonstrate that patients with SLE and LA, as compared to 
patients with SLE and no LA activity, have an increased probability of having a 
myocardial infarction but not of developing atherosclerotic plaques as assessed using 
carotid doppler studies (Petri, 2004). However, not all SLE patients with LA have or 
go on to develop APS. Furthermore, given the high propensity of atherosclerosis in 
patients with SLE, it may be difficult to definitively demonstrate an independent 
predisposition to atherosclerosis in a subset of SLE patients who also have APS. In 
contrast, other studies have demonstrated an increased prevalence of atherosclerosis 
in patients with primary APS using carotid doppler studies (Medina et al, 2003) and 
by measuring the ankle-brachilal index in these patients as compared to an age and 
sex matched healthy control goup in both sets of studies (Baron et al., 2005, 
Christodoulou et al., 2006). Hence current balance of evidence favours the increased 
predisposition of atherosclerosis in APS.
1.2.7 Obstetric manifestations of the APS
Early criteria proposed for the diagnosis of APS used terms such as recurrent 'foetal 
loss' (Harris, 1987) or recurrent 'spontaneous abortions' (Khamashta and Hughes, 
1993) to describe the main obstetric condition. However, this nomenclature was 
confusing as at that time the classification of pregnancy loss was defined as an 
abortion if the event occurred prior to 20 weeks gestation and termed stillbirth or 
foetal loss after this period (Derksen et al., 2004). Subsequently, it was recognised 
that there exists the embryonic period prior to 10 weeks gestation and the foetal 
period that extends beyond 10 weeks (Derksen et al., 2004). There are multiple 
obstetric manifestations seen in the APS, with most outlined in the Sapporo 
classification criteria (Wilson et al., 1999) and remain unchanged in the updated 
criteria proposed in Sydney in 2004 (see table 1.1) (Miyakis et al., 2006). These are 
highlighted in tables 1.2 A) and 1.3.
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ORGAN SYSTEM CLINICAL MANIFESTATIONS OBSERVED IN THE APS 
DUE TO ARTERIAL OR SMALL VESSEL THROMBOSIS
CARDIAC angina, acute coronary syndrome, myocardial infarction, 
coronary bypass rethrombosis, intram ural throm bus, 
peripheral vascular disease
CEREBROVASULAR Stroke, transient ischaemic attack, multi-infarct dementia, 
amaurosis fugax
CUTANEOUS Leg ulcers, pseudovasculitic lesions, digital gangrene
ENDOCRINE Addison's syndrome due to adrenal infarction
GASTROINTESTINAL Oesophageal or mesenteric ischaemia, bowel infarction, 
splenic infarction, pancreatic infarction
OBSTETRIC Uteroplacental insufficiency causing miscarriage or pre-term  
birth (before 34 weeks gestation)
OPTHALMOLOGICAL Retinal artery thrombosis
PULMONARY Pulmonary artery thrombosis
RENAL Renal artery thrombosis, renal small vessel thrombosis 
causing: acute/sub-acute/chronic renal failure, hypertension, 
nephritic syndrome
Table 1.2 A)
ORGAN SYSTEM CLINICAL MANIFESTATIONS OBSERVED IN THE APS 
DUE TO VENOUS THROMBOSIS
CEREBROVASULAR Dural sinus thrombosis
CUTANEOUS Superficial thrombophlebitis
GASTROINTESTINAL Budd-Chiari syndrome (hepatic vein thrombosis)
LIMB VESSELS Deep venous thrombosis
OPTHALMOLOGICAL Retinal vein thrombosis
PULMONARY Pulmonary embolism
RENAL Renal vein thrombosis
Table 1.2 B)
Table 1.2 Clinical manifestations of the APS.
Table 1.2 A), arterial and small vessel thrombotic lesion; 1.2 B), venous thrombotic 
lesions.
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ORGAN SYSTEM CLINICAL MANIFESTATIONS OBSERVED IN THE 
APS DUE TO NON-THROMBOTIC DISEASE
CARDIAC Cardiac valve vegetations (sterile), diffuse valve 
thickening, 'pseudoinfective' endocarditis
CUTANEOUS Livedo reticularis, splinter haemorrhages
EAR, NOSE AND THROAT Perforation of nasal septum
GASTROINTESTINAL Pancreatitis, ascities
HAEMATOLOGICAL Thrombocytopaenia, haemolytic anaemia, haemolytic 
uraemic syndrome
MUSCULOSKELETAL Avascular osteonecrosis, atraumatic metatarsal stress 
fracture, bone marrow necrosis, algodystrophy
NEUROLOGICAL Epilepsy, dementia, transverse myelitis, encephalopathy, 
migraines, mononeuritis multiplex, chorea
OBSTETRIC Pre-eclampsia, eclampsia, HELLP syndrome (haemolysis, 
elevated liver enzymes, low platelet count), intrauterine 
growth retardation
PULMONARY Pulmonary hypertension, alveolar haemorrhage, acute 
respiratory distress syndrome
RENAL Hypertension, nephrotic syndrome, haematuria, renal 
artery stenosis, focal cortical atrophy
Table 1.3 Non-thrombotic manifestations of the APS.
46
In APS, pre-term labour (prior to 34 weeks gestation) is often due to hypertension 
associated disease such as pre-eclampsia or uteroplacental insufficiency. This feature 
has been included in the table 1.2 A) describing arterial thrombotic manifestations of 
the APS, however as will be discussed in section 1.3 relating to the pathogenesis of 
this condition, there is accumulating evidence supporting the concept that 
uteroplacental insufficiency in APS may be an inflammatory rather than thrombotic 
phenomenon predominantly.
1.2.8 Catastrophic antiphospholipid syndrome (CAPS)
This is a subset of the APS that is estimated to affect approximately 1% of patients 
suffering from this condition (Cervera et al., 2002). Its mode and pattern of 
presentation differs significantly from the classical picture of APS in that severe, 
acute multi-organ dysfunction occurs in the acute setting and is predominated by 
small vessel ischaemia and thrombosis (Erkan et al., 2003). The 'catastrophic' nature 
of presentation led Asherson in 1992 to coin the syndrome as such in his initial 
description (Asherson, 1992). Recently the clinical outcomes of 250 patients with 
CAPS have been described (Bucciarelli et al., 2006b). Based on this largest series to 
date, recovery occurred in 56% and death in 44%. The most common cause of 
death was cerebral pathology (thrombotic stroke, cerebral haemorrhage and 
encephalopathy) followed by cardiac disease. Typical clinical features include 
malignant hypertension, acute respiratory distress syndrome, disseminated 
intravascular coagulation, microangiopathic haemolytic anaemia, schistocytes on the 
blood film and thrombocytopaenia (Erkan et al., 2003). Rather than pulmonary 
embolism being the dominant pulmonary lesion as seen in APS, acute respiratory 
distress syndrome is seen more frequently in CAPS affecting approximately 20% of 
patients diagnosed (Bucciarelli et al., 2006a). There are many similarities between 
CAPS and thrombotic thrombocytopaenic purpura (TTP) though key differences do 
exist (Cerveny and Sawitzke, 1999). TTP is more likely if there is a history of a viral 
prodrome, schistocytes on the peripheral blood smear, fever, profound rather than 
moderate thrombocytopaenia, less severe renal impairment, purpura and histological 
evidence of platelet thrombi. Though none of these distinctions are absolute, it is 
important to make the distinction as anticoagulation in CAPS is an important part of 
treatment, whereas in TTP anticoagulation is inappropriate (Cerveny and Sawitzke,
1999). Clearly physicians managing patients with autoimmune disease need to have 
a high degree of awareness for this potentially devastating but very rare condition, 
which can present acutely, mimic other conditions such as TTP and have a high 
mortality rate. In order to focus research on this small but important subset of
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patients affected by the APS an international registry for CAPS patients has been 
established by the European Forum on aPL (Erkan et al., 2003). Furthermore, 
preliminary criteria for the diagnosis of definite and probable CAPS were proposed 
and accepted in Taormina, Sicily at the 10th International Congress on aPL (Asherson 
et al., 2003). These criteria are summarised in table 1.4.
1.2.9 ‘Primary’ and ‘secondary’ APS: is there a true distinction?
This terminology is only relevant if there is a true clinical distinction between the 
two, either in terms of presentation, diagnosis, serology or management. A relatively 
large proportion of patients with APS also have SLE as discussed. It is this 
concordance that led to suggestions that the APS be classified as 'secondary' in the 
presence of SLE, and 'primary' in the absence of any other autoimmune disease 
(Mackworth-Young et al., 1989, Vianna et al., 1994). Precedents for such 
classifications in autoimmune rheumatic disease exist such as Sjogren's syndrome 
which may be classified as 'primary' or 'secondary' when associated with any other 
autoimmune disease (Baurmash, 2004).
The name 'secondary APS' implies that SLE is the primary disease and the 
development of APS occurs as a 'secondary' phenomenon to this. However, it is 
recognised that a small group of patients with APS alone go on to develop clinical 
features of SLE, estimated by one study to be approximately 8% (Gomez-Puerta et 
al., 2005) though found to be ~1% within the UCH cohort of 450 SLE patients (via 
personal communication with Professor Isenberg). Some studies suggest that the 
presence of anti-nucleosome antibodies (Abraham Simon et al., 2004) or 
hypocomplementaemia (Ramos-Casals et al., 2004) in patients with APS may predict 
the development of SLE in these patients. It is unknown if APS and SLE are two 
different diseases coinciding in the same individual, if underlying SLE offers a setting 
for the development of APS, or if APS and SLE represent two elements of the same 
process. Harris and Pierangeli have postulated that APS and SLE are not part of the 
same disorder but rather represent a super family of systemic autoimmune diseases 
(Harris and Pierangeli, 2004). One study of 130 patients with SLE has showed that 
aCL positivity may precede the onset of more severe SLE, as well as SLE complicated 
by features of the APS such as pregnancy loss or thrombosis (McClain et al., 2004).
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1. Evidence of involvement of >3 organs, systems, and/or tissues*
2. Development of manifestations simultaneously or in <1 week
3. Confirmation by histopathology of small vessel occlusion in at least 1
organ/tissuet
4. Laboratory confirmation of the presence of aPL (LA and/or aCL and/or anti-
62GPI antibodies)
DEFINITE CAPS: All 4 criteria
PROBABLE CAPS:
• All 4 criteria, except for the involvement of only 2 organs, systems, and/or 
tissues
• All 4 criteria, except for the absence of laboratory confirmation of the 
presence of aPL at least 6 weeks after a first positive result (due to the early 
death of patients never tested for a PL before the onset of CAPS)
• 1, 2, and 4
• 1, 3, and 4, plus the development of a third event in >1 week but <1 month, 
despite anticoagulation treatment
Table 1.4 Preliminary criteria for the classification of CAPS
♦Usually clinical evidence of vessel occlusion, confirmed by imaging techniques when 
appropriate. Renal involvement is defined by a 50% rise in serum creatinine, severe 
hypertension (>180/100 mm/Hg), and/or proteinuria (>500 mg/24 hours). 
tSignificant histopathological evidence of thrombus must be present, though 
vasculitis may coexist occasionally.
Adapted from Asherson et al (2003) (Asherson et al., 2003).
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There appears to be no difference in terms of clinical manifestations, complications, 
prognosis or frequency of aCL between those with APS alone and those with APS and 
SLE (Vianna et al., 1994, Harris and Pierangeli, 2004, Male et al., 2005). Genetic 
studies may be another means by which a distinction between the 'primary' and 
'secondary' forms of APS may be drawn. One study has found a more frequent 
positive family history of autoimmune disease in patients with APS and SLE as 
compared to patients with APS alone. However, this was a relatively small study of 
109 patients and HLA typing was not performed. Crucially, any potential genetic 
differences between 'primary' and 'secondary' may be due to genetic differences 
between APS and SLE. A difference between 'secondary' APS and SLE without APS 
would need to be demonstrated and at present no such evidence exists.
It would appear that there is no clear value in characterising APS into either a 
primary or secondary group. There is no evidence that such classification is helpful in 
aiding diagnosis, management or follow-up. Furthermore, the implication of the term 
'secondary' APS is that this disease is a secondary phenomenon to the 'primary' 
disease of SLE. Moreover, we know that APS may co-exist with autoimmune 
conditions other than SLE. The recently updated classification criteria for the APS call 
for the terms primary and secondary APS to be abandoned (Miyakis et al., 2006). 
This consensus statement advised on simply using the term APS in the presence or 
absence of SLE. This will be the preferred terminology used for the purposes of this 
thesis.
1.2.10 Management and prognosis of the APS
The management of the APS will be discussed in terms of five main categories: 
secondary prophylaxis of thrombosis, secondary prophylaxis of pregnancy morbidity, 
primary prophylaxis, treatment of non-thrombotic manifestations of APS and 
management of CAPS.
1.2.10.1 Secondary prophylaxis o f venous and arterial thrombosis
The only treatment to have shown any proven benefit for preventing recurrent 
venous or arterial thrombosis in patients diagnosed with the APS is oral 
anticoagulation. What is less certain is the intensity and duration of this 
anticoagulation. This is an important question as the cumulative incidence of a major 
haemorrhage occurring with oral anticoagulation within a 12-month period is 
estimated to be between 7% and 12% (McMahan et al., 1998, Landefeld and 
Goldman, 1989).
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Regarding the duration of oral anticoagulation, early retrospective studies have 
shown high recurrence rates of thrombosis after discontinuation of oral 
anticoagulation. These range from 52-68% of patients developing another 
thrombotic event over a period of 5-6.4 years post discontinuation of warfarin 
(Khamashta et al., 1995, Krnic-Barrie et al., 1997, Rosove and Brewer, 1992). In 
prospective studies aPL positive patients had a higher risk of a recurrent venous 
thrombosis as compared to aPL-negative patients after discontinuation of oral 
anticoagulation originally lasting for only six months (Schulman et al., 1998). 
Regarding secondary prophylaxis of venous thrombosis, the weight of evidence 
seems to favour oral anticoagulation for longer than six months, but crucially there 
have been no prospective risk/benefit studies designed to study the consequences of 
continuing therapy for longer than six months in patients with APS presenting with 
one venous thrombosis and no other risk factors. Given this lack of evidence the 
British Society of Haematology guidelines state that oral anticoagulation is prescribed 
only for three to six months in this scenario (Greaves et al., 2000). However, a low 
threshold for instigating longer periods of anticoagulation is required, particularly if 
other risk factors for thrombosis exist (Meroni et al., 2003, Erkan and Lockshin, 
2004).
Early retrospective studies of oral anticoagulation for the secondary prevention of 
venous thromboembolism recommended a target international normalised ratio (INR) 
of >3.0. This high intensity regimen seemed to demonstrate reduced recurrent 
venous thromboembolism as compared to lower intensity regimens (Khamashta et 
al., 1995, Krnic-Barrie et al., 1997, Derksen et al., 1993). Nevertheless, some 
retrospective (Rosove and Brewer, 1992), and importantly prospective studies, have 
demonstrated that aiming for a relatively low target intensity INR of 2.0-3.0 is also 
effective (Ginsberg et al., 1995). Two randomised prospective studies each with 
approximately 100 APS patients enrolled have compared high intensity (target INR 
3.1-4.0) to lower intensity (target INR 2.0-3.0) anticoagulation and found no 
difference in thrombotic recurrences (Crowther et al., 2003, Finazzi et al., 2005). 
However, it should be noted that the study by Crowther et al was flawed as the 
majority of patients in the high intensity arm who suffered events (four out of six) 
had an INR below 2.0 (Crowther et al., 2003). Furthermore, the study by Finazzi et al 
does not state the INR of the patients in the high intensity arm at the time of the 
thrombotic event (Finazzi et al., 2005). Given the evidence to date, it would seem
51
sensible to propose that for a single venous thromboembolic event (either deep 
venous thrombosis or pulmonary embolism) the initial target should be an INR of 
2.5. Higher intensity oral anticoagulation (target INR of 3.5) should be the target 
when there are additional risk factors or if there has been further thromboembolic 
events despite oral anticoagulation at lower intensity regimens.
The case for high versus low intensity oral anticoagulation in preventing recurrent 
arterial thrombosis is even less well established (Gatenby, 2004, Ruiz-Irastorza and 
Khamashta, 2005). Two early retrospective studies of 70 patients (Rosove and 
Brewer, 1992) and 147 patients (Khamashta et al., 1995) with APS, of which 
approximately 45% had arterial thromboses, have suggested that prolonged 
treatment with high intensity warfarin (target INR>3.0) is required to minimise the 
chance of re-thrombosis. Ruiz-Irastorza et al retrospectively studied 66 patients with 
APS who were managed to a target INR 3.5. The actual INR was frequently below 
3.0 and episodes of life-threatening bleeds were estimated at six per 100 patient 
years with no fatalities. Approximately half had a history of thrombotic stroke and 
four had a recurrent arterial thrombosis, all of whom had an INR of between 2.1 and 
2.6 (Ruiz-Irastorza et al., 2002). There have been two prospective comparison 
studies comparing high versus low intensity anticoagulation with warfarin, neither of 
which found a difference in the recurrence rate of arterial thrombosis. Both these 
studies included patients with mostly venous thrombosis (70% of patients enrolled in 
each study) and crucially excluded patients who had had a recent stroke or who had 
developed a thrombotic event whilst on anticoagulation, thus potentially biasing the 
results towards a relatively low-risk group of APS patients (Crowther et al., 2003, 
Finazzi et al., 2005). Derksen et al reported the results of prospective long-term 
follow-up of eight women with APS presenting with stroke who were only treated 
with anti-platelet therapy. After a median follow up of 8.9 years two developed a 
further stroke and it was concluded that the chances of a recurrence was as one 
would expect for aPL negative patients and that aspirin alone may be sufficient in 
treating this group of patients (Derksen et al., 2003). However, this study had an 
extremely low cohort number and did not have a warfarin treatment arm for 
comparison. The Antiphospholipid Antibodies and Stroke Study (APASS., 1993) took 
advantage of the randomised Warfarin versus Aspirin Recurrent Stroke Study and 
determined the aCL and LA activity of 1770 patients. It found similar end-points for 
the aPL positive versus aPL negative patients and concluded that aPL did not confer 
important knowledge for prognosis or treatment of patients with a recently
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diagnosed ischaemic stroke and that warfarin was not associated with fewer 
thrombotic strokes as compared to aspirin in aPL positive patients (Levine et al., 
2004). However, there are some potential flaws in this large study. Importantly this 
was a sub-group analysis of a study that was not designed to assess the outcomes 
outlined in the APASS study. Also the majority of patients were elderly (mean 62 
years) and had aPL tested only once, with the titres in the majority falling in the low 
category (less than 40 GPL or MPL units). Thus, most of the patients did not have 
APS and furthermore could not be generalised to younger patients with APS. Hence 
upon critically reviewing this study, its relevance to the management of APS is 
questionable. It would appear that on balance evidence favours the use of long-term 
anticoagulation with warfarin. The current British Society of Haematology guidelines 
recommend long-term anticoagulation aiming for an INR 2.5 and if recurrence of 
arterial thrombosis /  stroke occurs, to then increase the target to an INR of 3.5 
(Greaves et al., 2000). Whether adding in aspirin to warfarin confers any additional 
benefit versus risk is unknown. The increased risk of haemorrhage if aspirin is co­
administered with warfarin in non-APS groups of patients has been established 
(Meade and Miller, 1995). At present there exists no data for the long-term use of 
heparin or fondaparinux (Factor X inhibitor) for the secondary prevention of 
thrombosis.
1.2.10.2 Management o f pregnant patients with the APS
Early, small, open-labelled studies recommended the use of prednisolone in 
combination with aspirin (Lubbe et al., 1983, Kwak et al., 1994) or other 
immunomodulatory treatment such as immunosuppressive agents (Gatenby et al., 
1989) or intravenous immunoglobulins (Many et al., 1992). However larger, 
randomised controlled trials have shown no benefit in using corticosteroids, which 
were associated with significantly more maternal morbidity and more pre-term 
deliveries (Silver et al., 1993, Cowchock et al., 1992, Laskin et al., 1997). Hence the 
use of prednisolone in treating or preventing pregnancy morbidity in APS patients 
has been abandoned.
Three randomised trials have compared the efficacy of a combination of heparin and 
low dose aspirin to aspirin alone (Rai et al., 1997, Farquharson et al., 2002, Kutteh,
1996). One study also evaluated the outcome of pregnancies comparing aspirin 
combined with varying doses of heparin (Kutteh and Ermel, 1996). In these studies 
heparin was started either at the time of a positive pregnancy test (Kutteh, 1996, 
Kutteh and Ermel, 1996), when foetal heart activity was first confirmed (Rai et al.,
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1997) or before 12 weeks gestation (Farquharson et al., 2002). Two of the three 
studies comparing the combination of aspirin and heparin to aspirin alone found that 
the combination arm had significantly higher live-birth rates. The rates were 71% 
and 80% in the combination arm as compared 42% and 44% in the aspirin-only arm 
for each respective study (Rai et a I., 1997, Kutteh, 1996). The other prospective 
study by Farquharson et al revealed no additional benefit in adding heparin to aspirin 
(Farquharson et al., 2002). However, an aCL level of greater than 9 GPL units and 5 
MPL units was deemed sufficient for entry. Hence, the majority of women included in 
this study did not fulfil the criteria for classification of APS published while the trial 
was being conducted between 1997 and 2000 (Wilson et al., 1999). In the study 
comparing varying doses of heparin in combination with aspirin, high and low doses 
of unfractionated heparin were associated with similar live-birth rates (Kutteh and 
Ermel, 1996). The long-term use of heparin raises potential concerns regarding bone 
loss over and above that seen in normal pregnancy. One study to address this 
question assessed 55 pregnant patients with APS on heparin and found no significant 
differences in their bone density within six months prior to conception and in the 
post partum period as compared to 20 non-APS pregnant control patients not on 
heparin (Carlin et al., 2004).
The balance of evidence favours the use of low molecular weight heparin and aspirin 
to be started once a patient with APS has a confirmed positive pregnancy test. Given 
that prothrombotic risk extends into the post-partum period, it would seem prudent 
to continue this regime up to six weeks post partum. This is the current management 
protocol recommended by the American College of Rheumatology (Derksen et al.,
2004). However, guidelines for the management of pregnant patients fulfilling the 
classification criteria for APS have also been published under the auspices of the 
British Society of Haematology (Greaves et al., 2000) and do not concur with the 
those of the rheumatologists, stating that patients with APS who become pregnant 
should add heparin to aspirin once foetal heartbeat has been established and that 
heparin be discontinued at 34 weeks gestation. It would appear that some consensus 
between the haematological and rheumatological community is required. Until then it 
would seem prudent for rheumatologists, obstetricians and perhaps haematologists 
with an interest to agree local guidelines and co-manage this important group of 
patients, ideally in dedicated combined clinics.
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1.2.10.3 Primary prophylaxis ofaPL positive patients without APS
Ginsberg et al's study of aCL in the Physicians' Health Study cohort was the first to 
publish data regarding aspirin prophylaxis. This study demonstrated that moderate to 
high titres of aCL were associated with increased risk of venous thrombosis, which 
was unaffected by treatment with low dose aspirin (Ginsburg et al., 1992). However, 
it has since been recognised that the study was underpowered to detect the 
expected effect of aspirin prophylaxis (Alarcon-Segovia et al., 2003a). A retrospective 
cross-sectional study by Erkan et al compared the records of 77 patients with APS 
with those of 56 patients without APS but with aPL. When examining the six month 
period prior to thrombosis (for the thrombosis group) or prior to the last clinic visit 
for the asymptomatic group, the use of aspirin was significantly associated with 
asymptomatic status (Erkan et al., 2002). A consensus report has advocated the use 
of low dose aspirin prophylaxis in patients with moderate to high aPL but no clinical 
evidence of APS, though it conceded that prospective randomised trials were 
necessary to confirm that this was appropriate (Alarcon-Segovia et al., 2003a). Again 
advice by the haematologists differs in that prophylaxis in this group is not indicated, 
though a low-threshold for prophylaxis in the setting of additional risk factors should 
be maintained (Greaves et al., 2000). However, it is worth noting that these 
guidelines were issued two years prior to the publication of Erkan et al's study (Erkan 
et al., 2002). The use of aspirin in pregnancy as primary prophylaxis is more 
controversial. Currently accepted practice is that healthy women with no more than 
two embryonic losses and absence of foetal loss should not be advised to undergo 
aPL testing. The rationale being that if there is aPL positivity in this setting, there 
exists no evidence for improved outcomes with aspirin prophylaxis. However, close 
maternal-foetal monitoring is advised throughout pregnancy and the post-partum 
period (Derksen et al., 2004). Therefore, given the lack of evidence for or against, 
one cannot conclude with certainty that not treating pregnant patients with 
persistently positive aPL but no history thrombosis or miscarriage with aspirin is 
correct.
1.2.10.4 Management o f non thrombotic manifestations o f the APS
There are a number of manifestations for the APS which are not associated with 
thrombosis and for which oral anticoagulation is generally not helpful. However, data 
on how best to manage these manifestations is lacking and mostly limited to 
retrospective studies of generally small cohorts or case reports. Refractory 
thrombocytopaenia has been shown to respond transiently to intravenous
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immunoglobulin therapy (Sturfelt et al., 1990, Sherer et al., 2000). Splenectomy in 
this group of patients may give good long-term responses (Hakim et al., 1998, 
Galindo et al., 1999). Intravenous immunoglobulins have also been successfully 
employed to treat autoimmune haemolytic anaemia associated with APS in one case 
report (Vandenberghe et al., 1996). For non-vascular manifestations such as non- 
ischaemic related epilepsy and chorea, very little evidence exists. Chorea has been 
associated with immune mediated excitatory effects of aPL causing striatal 
hypermetabolism as opposed to ischaemia as assessed by positron emission 
tomography imaging (Sunden-Cullberg et al., 1998, Furie et al., 1994). This may 
explain the reversibility that has been observed in a few cases treated with 
immunosuppressive therapy such as prednisolone in a patient with SLE and APS (Van 
Horn et al., 1996) and methotrexate in a patient with chorea and LA activity and high 
IgG-aCL titres with no other clinical features of either APS or SLE (Paus et al., 2001).
1.2.10.5 Management o f CAPS
The management of CAPS is extremely challenging. The optimal treatment for this
rare condition is unknown, it may be difficult to distinguish it from other acute
conditions such as TTP or systemic vasculitis and multiple simultaneous organ failure
is the typical presentation, necessitating prompt diagnosis and instigation of therapy.
Patients may present with a mixture of haemorrhage (induced by profound
thrombocytopaenia and malignant hypertension for example) and multi-organ failure
due to small vessel thrombosis, presenting difficult treatment dilemmas (Boura et al.,
2005). Consensus guidelines for the management of CAPS have been produced
though the authors acknowledge that these guidelines do not represent standardised
treatment due to lack of prospective trial data (Asherson et al., 2003). Management
of CAPS should have three broad aims: to treat any precipitating factors such as
infection promptly, to prevent ongoing thrombotic events and to suppress the
excessive 'cytokine' storm. Hence, treatment typically involves anticoagulation with
intravenous heparin followed by oral anticoagulation, plasma exchange, intravenous
immunoglobulins and if associated with a lupus flare cyclophosphamide (Asherson et
al., 2003). Other options that have been used on an empirical basis include
prostacyclin, defibrotide, danazol, cyclosporine, azathioprine, and splenectomy
(Asherson et al., 1998, Asherson et al., 2001) though these treatments have been
mostly used in single cases and are hence of doubtful benefit (Erkan et al., 2003). A
recent study of 250 patients with CAPS suggests that a higher recovery rate is
associated with combined treatment of anticoagulants, corticosteroids and plasma
exchange and that concomitant treatment with cyclophosphamide yielded no added
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benefit (Bucciarelli et al., 2006b). Monitoring and active management should occur in 
an intensive care setting once the diagnosis is made with facilities for mechanical 
ventilation and renal replacement therapy readily available (Erkan et al., 2003).
1.2.11 Prognosis in APS
In patients who develop a venous thrombosis and are then anticoagulated for six 
months only, re-thrombosis within a four-year follow-up period occurs in 29% of aPL 
positive patients as compared to 19% of aPL negative patients (p=0.001). This study 
by Schulman et al also demonstrated an increased mortality rate related to 
thromboembolic causes of 7% in the aPL positive group versus 2.2% in those that 
tested negative for aPL (p=0.002) (Schulman et al., 1998). A retrospective study of 
52 patients with aCL, of whom 31 had APS, followed-up for 10 years revealed that 
nine (29%) of the patients with APS had a recurrent thrombosis and 10% of all 
patients died, despite all receiving either anticoagulant or antiplatelet therapy (Shah 
et al., 1998). A prospective five-year follow-up study of APS patients revealed similar 
re-thrombosis rates of 27%, with a mortality rate of 5.4% again despite anti­
thrombotic therapy. This study by Turiel et al also confirmed that an IgG aCL of more 
than 40 GPL units was an independent risk factor, with 43.3% of patients with aCL 
titres in excess of 40 GPL units developing a recurrent thrombotic event as compared 
to 7.7% in patients who had titres below this level (Turiel et al., 2005).
In summary, upon critically reviewing the evidence there are limited treatment 
options with proven efficacy available to the clinician in managing patients with APS. 
Oral anticoagulation for the secondary prophylaxis of thrombosis is beneficial, but 
may be associated with hazards such as haemorrhage with some uncertainties 
surrounding the target intensities and duration of treatment. The treatment of 
pregnant APS patients is established, but the place for primary prophylaxis with 
aspirin in aPL positive patients remains unproven, with these uncertainties 
particularly underlined in pregnant aPL positive patients. What is clear is that there 
remains an unmet need to develop safer, targeted and arguably more effective 
therapies for APS.
1.3 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Approximately 45% of patients with APS also have another autoimmune disease. 
This disease is SLE in approximately 80% of these cases (Cervera et al., 2002) and 
hence this syndrome will be described, albeit briefly.
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SLE is a complex, multi-systemic autoimmune rheumatic disease characterised by 
widespread inflammation and mostly affecting young women. Classification criteria 
by Tan et al were published in 1982 (Tan et al., 1982) and subsequently revised in 
1997 to include a 'positive finding of aPL' (Hochberg, 1997). Undoubtedly, these 
criteria have been an important research tool used in multiple studies designed to 
assess the efficacy of various treatment pathways for SLE. However, due to the fact 
that SLE can mimic so many other conditions they are also commonly used in routine 
practice when diagnosis is in doubt. The criteria are summarised in table 1.5 listing 
11 criteria, of which at least four are required to make the diagnosis of SLE.
1.3.1 Aetiology, epidemiology and natural course for SLE
The precise aetiology of SLE remains uncertain other than there is clear evidence of 
dysregulation of the immune response in affected individuals. This includes the 
production of pathogenic autoantibodies, produced by hyperactive B cells, 
characteristically targeted to nuclear antigens such as nucleosomes. This occurs in 
the context of impaired cell mediated immunity with a predominance of circulating 
Th2 cytokines. One currently popular theory proposed by Walport, amongst others 
and known as the 'waste disposal' hypothesis, suggests that tolerance to these 
ubiquitous autoantigens is broken due to the defective clearance of apoptotic cellular 
debris and immune complexes. Prolonged exposure to these autoantigens in 
genetically and perhaps hormonally susceptible individuals may trigger an 
autoimmune response to these autoantigens and lead to SLE (Walport, 2000). 
Surface blebs on apoptoptic cells have been shown by Rosen and colleagues to 
cluster and expose autoantigens such as DNA, Ro, La, RNP as well as anionic PL 
(Rosen et al, 1994., Rosen et al., 1996). These cells are normally cleared by tingible 
body macrophages within the germinal centres of secondary lymphoid organs, thus 
avoiding contact of nuclear remenants with the immune system and preveting the 
productions and affinity maturation of autoantibodies to nuclear material. Hermann 
and colleagues have shown that in patients with SLE, the number of these tingible 
body macrophages within the germinal centre of lymph nodes is reduced. This 
results in the accumulation of apoptotic cells exposing nuclear autoantigens which 
bind to follicular dendritic cells and may provide the survival signals for autoreactive 
B cells (Baumann et al., 2002). The most recent developments reviewing the likely 
pathogenesis of SLE have been summarised in a report covering the content of the 
6th European Lupus meeting in March 2005, London, UK (Ioannou et al., 2005).
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SLE is found worldwide with an increased preponderance in black females in the UK 
and USA. The female to male ratio approximates to 10:1 with the majority 
developing disease between the ages of 15 and 40 years of age. However, there is a 
subgroup of patients that develop SLE beyond the age of 50 years and the ratio 
drops in this group to 4:1, affecting approximately 10-15% of patients (Morrow et 
al., 1999). The prevalence rates per 100,000 in the UK for Caucasian, Asian and 
Black women with SLE are 36.2, 90.6 and 206 respectively (Johnson et al., 1995).
Four decades ago SLE was deemed to be a serious and frequently fatal disease with 
mortality rates estimated to be around 50% at five years. Since then there has been 
a marked improvement in survival with current estimates of standardised mortality 
ratio observed here at the Centre of Rheumatology, UCH to be approximately 4.0 
(Moss et al., 2002). This reflects the easier identification of milder cases, the 
widespread availability of ANA and anti-double stranded (ds) DNA antibody 
estimations, the introduction of corticosteroids, immunosuppressive drugs, renal 
replacement therapy and renal transplantation. However 10% to 20% will succumb 
to either the disease, a side-effect of its treatment or both within 10 years of follow- 
up (Isenberg and Horsfall, 1998). The causes of death vary with disease duration 
showing a bimodal pattern of distribution. Early deaths within two years of diagnosis 
have a tendency to be related to SLE disease activity or infection, however deaths 
beyond two years of diagnosis tend to be due to atherosclerotic disease, cancer or 
infection (Abu-Shakra et al., 1995). The presence of APS has been shown to be an 
independent predictor of irrevsible organ damage and mortality in SLE patients (Ruiz- 
Irastorza et al., 2004).
1.3.2 Clinical features of SLE
Non-specific symptoms are common in SLE. These include fatigue, fever, anorexia, 
weight loss and lymphadenopathy. Fatigue is often extremely severe and many 
patients find this the most disabling symptom of their SLE (Morrow et al., 1999). The 
most frequent symptom involving the musculoskeletal system is arthralgia, affecting 
approximately 90% of patients with SLE. However, overt arthritis with deformities is 
only present in approximately 5% (Morrow et al., 1999). The arthropathy is 
characteristically non-erosive and extreme deformities have a tendency to be 
correctable, otherwise known as Jaccoud's arthropathy (Spronk et al., 1992). 
Myalgia, muscle weakness and tenderness have been reported in up to 60% of 
patients, though only around 5% have a true myositis overlap condition (Isenberg 
and Snaith, 1981).
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MANIFESTATION DEFINITION/ CHARACTERISTICS
Malar rash Erythematous rash over malar area, sparing nasolabial folds
Discoid rash
Photosensitivity
Oral ulcers Usually painless and observed by physician
Arthritis Non-erosive, involving two or more joints
Serositis Pleuritis: pleural rub, history of pleural pain or pleural effusion 
AND /  OR
Pericarditis: evidence on echocardiogram or the presence of a 
pericardial rub
Renal disorder Persistent proteinuria (>0.5g/24 hours or >3+ on dipstick if 
quantification unavailable) OR cellular casts on microscopy
Neurological
disorder
Seizures OR psychosis (unprovoked)
Haemolytic
disorder
Haemolytic anaemia OR leucopaenia (<4,000/mm3 on >2 
occasions) OR lymphopaenia (< 1,500/mm3 on >2 occasions) 
OR thrombocytopaenia (<100,000/ mm3)
ANA Raised titre at any point
Immunological
disorder
Raised anti-native DNA antibody OR 
Presence of anti-Sm antibody OR
Positive aPL (based on either an abnormal serum level of IgG 
or IgM aCL or positive LA or false positive test result for 
Syphilis sustained for at least six months)
Table 1.5 Updated classification criteria for the diagnosis of SLE
Adapted from Tan et al (Tan et al., 1982) and Hochberg et al (Hochberg, 1997). Out 
of the 11 criteria four are required, either serially or simultaneously, to make the 
diagnosis of SLE.
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The classic butterfly rash is present in approximately one third of lupus patients 
though 85% will have skin involvement (Pistiner et al., 1991). Other dermatological 
lesions include maculopapular discoid lesions, alopecia (often diffuse and non­
scarring), vasculitic lesions, mucosal ulcers, bullous lesions and nasal ulceration. 
Many of these lupus rashes are exacerbated by ultraviolet light (UV), with 
photosensitivity being more common among Caucasian patients (Morrow et al.,
1999).
The most common pulmonary manifestation is pleuritic chest pain due to pleurisy, 
affecting approximately 40% of patients with SLE at some time. Lung parenchymal 
involvement has been reported in up to 18% of patients and includes interstitial 
fibrosis, pulmonary vasculitis and interstitial pneumonitis (Haupt et al., 1981). 
Pulmonary hypertension or pulmonary embolism occurs with greater frequency in 
SLE patients and aPL, in these circumstances, may be a contributing factor (Morrow 
et al., 1999).
Pericardial disease is the most frequent cardiac involvement and may be often 
clinically silent, with necropsy studies reporting that 66% of patients with SLE may 
be affected (Mandell, 1987). Clinical myocarditis is less common and affects 15% of 
patients. The classic Libman and Sacks endocarditis described in 1924 (Libman and 
Sacks, 1924), which is also seen in the APS (Hojnik et al., 1996), may be identified in 
up to 50% of autopsy cases but is often of no clinical significance (Morrow et al.,
1999). There has been increasing recognition over the past two decades of the 
presence of accelerated atherosclerosis in patients with SLE. Women between the 
ages of 35 and 44 years exhibit rates of myocardial infarction that are up to 50-fold 
higher than that seen in age matched women without SLE (Manzi et al., 1997) with 
40% of women with SLE having objective evidence of carotid atherosclerotic plaques 
as assessed by carotid doppler studies (Manzi et al., 1999).
Abdominal pain has been reported in up to 40% of patients. Common causes of an 
acute abdomen are vasculitis or thrombosis causing bowel perforation or bowel /  
organ infarction. Diagnosis of an acute abdomen may be difficult due to the masking 
of traditional signs of peritonitis by immunosuppressive therapy (Sultan et al., 1999). 
The nervous system, both peripheral and central, may be affected in a multitude of 
ways. Migraine affects approximately 30% of lupus patients (Isenberg et al., 1982) 
and seizures may occur in up to 20% (Isenberg and Horsfall, 1998). Peripheral
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neuropathy, usually sensory, may affect 10% of patients. Cognitive dysfunction is 
observed in approximately 21% of patients as compared to 4% affected in an age 
matched disease (rheumatoid arthritis) and heaithy control group (Hanly et al.,
1993). Patients with lupus suffering from neuropsychiatric symptoms tend to have 
persistently elevated IgG aCL (Menon et al., 1999).
A high proportion of lupus patients also have haematological abnormalities. A 
normochromic normocytic anaemia is present in up to 70% of patients with lupus 
with a Coombs positive haemolytic anaemia affecting approximately 10%. 
Leucopaenia and lymphopaenia as defined in table 1.5 affects approximately 45-65% 
and 80% of lupus patients respectively. Chronic thrombocytopaenia as defined in 
table 1.5 may affect 20% of lupus patients (Morrow et al., 1999).
Renal disease until recently in many published series was the commonest cause of 
death (Isenberg and Horsfall, 1998). Given that symptoms only occur late on In the 
course of renal involvement once irreversible damage has occurred, a proactive 
approach for detecting early signs of renal involvement is required. Thus patients 
should have regular estimations of blood pressure, serum creatinine and urinary 
protein. The World Health Organisation has subdivided renal lupus in to five classes 
based on histological changes seen on renal biopsy and these have subsequently 
been revised under the auspices of the International Society of Nephrologists 
(Weening et al., 2004). Renal abnormalities may be further scored according to the 
degree for underlying activity and damage, which may be helpful in predicting 
prognosis and guiding treatment pathways (McLaughlin et al., 1991).
1.3.3 Autoantibodies and role of complement in SLE
The clinical diversity of SLE is matched by the diverse autoantibody profiles observed 
in patients with lupus and these autoanitbodies with those also seen in APS are 
summarised in table 1.6. Antibodies to nuclear cellular components are the most 
frequently observed group and the common ones detected are ANA, anti-dsDNA, 
anti-nucleosome antibodies and antibodies to extractable nuclear antigens such as 
anti-Ro (SS-A), anti-La (SS-B), anti-ribonucleoprotein (RNP), anti-Sm antibodies and 
anti-histone antibodies. Antibodies to cell membrane components are also seen such 
as aPL, anti-erythrocyte and anti-platelet antibodies as well as antibodies to 
circulating proteins such as anti-62GPI, anti-Clq and anti-IgG antibodies (rheumatoid 
factor) (Morrow et al., 1999).
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The most sensitive test for SLE is the ANA, which is positive in 95% or more of 
patients. Anti-dsDNA antibodies are less sensitive, detected in approximately 70% of 
patients with SLE in a cohort of 450 SLE patients followed up at the Centre of 
Rheumatology, UCH (personal communication from Professor D Isenberg, see table 
1.6). However, they are specific to SLE and rarely seen in patients with other disease 
or in healthy individuals (Isenberg et al., 1985). These antibodies generally correlate 
with renal damage and have been shown to deposit in the renal tissue of SLE 
patients (Hahn, 1998). However, as seen with aCL, these antibodies are 
heterogeneous in nature and not all are pathogenic. Patients may have high titres 
and not have renal disease for example and not all anti-dsDNA antibodies tested in 
animal models cause tissue damage (Ehrenstein et al., 1995).
Antibody Specificty %  Prevalence in SLE patients
ANA 96
dsDNA 69
*Nucleosome 78
*Histone 50-80
Sm 14
RNP 28
Ro 37
La 13
*Clq 90
Fc IgG (Rheumatoid factor) 26
*Cardiolipin - IgG 24
*Cardiolipin - IgM 9
♦Lupus anticogulant 16
**62GPI 33
Table 1.6 Key autoantibodies detected in patients with SLE and APS. %
prevalence figures are based on the first ~470 patients with SLE under long-term 
follow-up at the Centre of Rheumatology, SLE clinic, Univerisity College London 
Hospital (via personal communication with Professor Isenberg). *autoantibodies also 
associated with APS. $ anti-nucleosome (Ghillani-Dalbin et al.. 2003); t  anti-histone 
(Egner, 2000); % anti-C1q (Sjoholm et al.. 1997); ( t  anti-U 2GPI (Loizou et al., 2000).
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The complement system, primarily via the classical pathway, is involved in the 
sequence of inflammatory events seen in SLE. Early reacting components of the 
classical pathway, Cl (and its subcomponents Clq and Cls), C4, C2 and C3 are 
frequently reduced in active disease. Inherited deficiencies in these components 
predipose to the development of SLE and these patients do not tend to have 
autoantibodies to dsDNA (Morrow et al., 1999). Clq knockout mice develop 
glomerulonephritis with the presence of glomerular apoptotic bodies (Botto et al., 
1998). In vitro experiments have shown that clearance of apoptotic cells is 
dependent upon the presence of Clq which binds these cells via IgM (Quartier et al.,
2004). Anti-Clq antibodies are also strongly associated with the presence of lupus 
nephritis and induce disease in the context of immune complex deposition (Trouw et 
al., 2004).
1.3.4 Management of SLE
Successful therapy of SLE depends upon treating symptoms and the underlying 
inflammation, involving both pharmacological and non-pharmacological approaches 
(Ioannou and Isenberg, 2002). Patient education is essential, with emphasis on 
wearing UV protection and addressing traditional cardiovascular risk factors such as 
smoking and hypercholesterolemia, given the marked propensity for accelerated 
atherosclerosis and cardiovascular morbidity in lupus patients (Manzi et al., 1997). 
Adequate contraception is vital when patients are taking potent cytotoxic agents. 
Infection is one of the commonest causes of death and patients should have all 
appropriate vaccinations including influenza and pneumococcal vaccines. Live 
vaccines should be avoided in patients taking immunosuppression or prednisolone of 
more than 10 mg/day (Ioannou and Isenberg, 1999).
Patients should be stratified according to severity of disease and pharmacological 
treatment tailored accordingly. Patients with mild disease may be maintained on a 
combination of non-steroidal anti-inflammatory drugs (NSAIDs) and antimalarials 
such as hydroxychloroquine. Low dose oral corticosteroid (less than 7.5mg/day of 
prednisolone) or intermittent intramuscular corticosteroid injections may also be 
necessary. Addressing potential side-effects such as NSAID induced peptic ulceration 
or corticosteroid induced bone loss proactively with appropriate gastroprotection and 
bone protection is essential (Ioannou and Isenberg, 2002). More severe disease 
often associated with one or more major organ dysfunction that may occur over a 
relative short period of time requires prompt and more intense immunosuppression.
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The ultimate aim is to prevent or minimise major organ damage. Higher doses of 
prednisolone (more than 7.5mg/day) in combination with cytotoxic agents are used. 
Drugs most frequently employed are oral azathioprine and cyclophosphamide. For 
the treatment of lupus nephritis a group from the National Institute of Health (NIH) 
in Bethesda, USA have shown in early studies that intravenous monthly pulses of 
cyclophosphamide for six months followed by three monthly pulses for two years has 
superior efficacy and toxicity profiles as compared to intravenous methylprednisolone 
(Boumpas et al., 1992). More recently mycophenolate mofetil has been compared to 
the NIH regimen of pulsed cyclophosphamide and appears to be equally effective 
with fewer side effects (Chan et al., 2000, Ginzler et al., 2005).
1.3.5 Can novel therapeutic candidates for SLE be applied to the APS?
The treatment for SLE up until now has relied on the use of broad-spectrum 
cytotoxic agents. Though this has improved mortality rates in SLE over the past four 
decades current conventional treatment regimens still rely on the use of toxic 
chemotherapeutic agents that favour the development of infection, which remains a 
major cause of morbidity and mortality (Moss et al., 2002). Similar dilemmas exist for 
the treatment of the APS with oral anticoagulation. This may need to be taken 
indefinitely, often at high intensity regimens and in combination with anti-platelet 
agents as reviewed in section 1.2.10. Though this has improved the treatment of the 
APS there exists the inherent problem of haemorrhage and the need to monitor 
therapy closely to ensure that the level of anticoagulation keeps within the desired 
therapeutic window. For both SLE and APS there remains an unmet need for therapy 
that is targeted and safer. This may only be developed through understanding the 
underlying pathogenesis. The past five years has seen the emergence of a number of 
novel therapeutic candidates for the treatment of SLE, many of which have 
demonstrated superior efficacy and safety profiles as compared to current 
treatments in the setting of clinical trials. SLE is characterised by dysregulation of the 
immune system with circulating pathogenic autoantibodies. The pathogenesis of APS 
will be discussed in the following section, however there is sufficient clinical evidence 
to imply that aPL are pathogenic and promote thrombosis (section 1.2.5). Given that 
SLE and the APS may be part of the same 'superfamily' of autoimmune disease, as 
has been proposed recently (Harris and Pierangeli, 2004), which of these novel 
candidates for the treatment of SLE may also be beneficial in treating APS? Rather 
than discuss an exhaustive list of numerous current therapies in development for the 
treatment of SLE, I will only focus on the key candidates for which published clinical 
trial data exist and which may conceivably be applied to APS based on our current
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understanding of this condition. These trials were designed to study the effects on 
SLE and hence there exist no trial data on the effects of therapy on subgroups of 
patients who may also have had APS.
UP394, also known as abetimus (Riquent®), is composed of four double-stranded 
oligodeoxynucleotides attached to a central branched platform. This drug irreversibly 
binds and cross-links anti-dsDNA B cell receptors on the cell surface, preventing 
them from receiving T cell help and thus causing them to selectively die (a process 
termed anergy), hence acting as a toleragen. This treatment was shown to be 
effective in treating lupus nephritis if patients had high affinity anti-dsDNA antibodies 
and had a good safety profile (Furie et al., 2001, Alarcon-Segovia et al., 2003b). 
Though abetimus is unlikely to be of benefit for the APS, the same principle of using 
peptide therapy composed of an aPL antigenic target for use as a toleragen may 
have therapeutic potential (Cockerill et al., 2003). The same company that developed 
LJP394 has pursued this concept and developed a compound named LJP1082 which 
tolerises B cells that produce antibodies to the N-terminal domain of B2GPI. This 
novel compound is in early clinical trial development (Horizon et al., 2003).
Another treatment that has proved effective for treating SLE also targets B cells by 
depleting them, but not in an antigen specific way. An anti-CD20 monoclonal 
antibody (mAb) named rituximab, originally used for the treatment of non-Hodgkin's 
lymphoma and then successfully extended for use in refractory rheumatoid arthritis 
(Edwards et al., 2004), has been used to treat patients with severe SLE refractory to 
all other standard therapies (Leandro et al., 2005). The majority of patients had a 
sustained beneficial response to just two infusions, with significant reduction in anti- 
dsDNA levels seen as well as a favourable safety profile. CD20 as well as CD19 is 
highly expressed on pre-B lymphocytes as well as on resting and activated B 
lymphocytes, hence rituximab depletes these cells. Not all antibodies are depleted 
and some antibodies such as protective anti-pneumococcal or anti-tetanus toxoid 
antibodies curiously remain unchanged (Cambridge et al., 2003). I have 
demonstrated in a small study that the levels of aCL are significantly depleted in 
patients with SLE when treated with rituximab (Ioannou et al., 2006a). The 
possibility of using rituximab for treating APS in cases refractory to oral 
anticoagulation in order to deplete pathogenic aPL may be an option for clinicians to 
consider. One recent report described the use of this rationale to treat three patients 
with refractory APS, one of whom had CAPS. A good response was observed in all
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three patients treated with rituximab (Rubenstein et al., 2006). One other case 
report describes the successful use of rituximab to treat refractory 
thrombocytopaenia associated with APS in one patient with no other autoimmune 
disease. Levels of IgM aCL and anti-B2GPI antibodies that were positive pre-B cell 
depletion, became undetectable post-depletion (Trappe et al., 2006). Clearly further 
studies are required to assess the benefits and risks of such an approach. Depleting 
B cells may also be achieved by targeting a factor called B lymphocyte stimulator 
(BLyS) that enhances B cell proliferation and IgG production (Moore et al., 1999). 
BLyS levels have been shown to correlate with disease activity and anti-dsDNA 
production (Stohl et al., 2003). A human monoclonal anti-BLyS antibody named 
LymphoStat B has been developed that blocks the effects of BLyS in cynomolgus 
monkeys (Baker et al., 2003) and may be entering clinical-trial phase for SLE 
imminently. A factor such as this may conceivably deplete pathogenic aPL producing 
B cells.
Autologous stem cell transplantation for severe, refractory SLE has been employed 
with varying success. Studies in these groups of patients have demonstrated that this 
therapy induces long-term remission in the majority of patients receiving this 
aggressive therapy (Burt and Traynor, 2003, Traynor et al., 2000), though the 
treatment itself is associated with a mortality rate of approximately 7% (Tyndall et 
al., 1999). One recent study treated 46 patients with SLE, of whom 22 had APS 
refractory to oral anticoagulation. Post-transplantation, the majority of patients with 
a previously positive aPL (LA, aCL IgG or IgM - between 70-90%) became negative 
for a median follow-up of 15 months. 82% of patients had anticoagulation 
discontinued for a median of four months after transplantation, with 78% remaining 
thrombosis free for a median of 15 months post transplantation (Statkute et al.,
2005).
There are other targets that have been investigated for the treatment of SLE with 
varying success. Examples include amelioration of T cell co-stimulation by using a 
CD-40 ligand mAb (IDEC-131 (Kalunian et al., 2002)) or by targeting interleukin-10 
(IL-10) by using an anti-IL-10 mAb (Llorente et al., 2000). The rapid developments 
in a number of possible therapeutic options for SLE have arisen through 
understanding the underlying pathogenesis, and through rapid developments in 
biotechnology facilitating the development of this knowledge and the production of 
agents designed to target very specific components of the immune system. There
67
exists considerable epidemiological evidence implying that aPL may be pathogenic 
and enhance the risk of thrombosis (section 1.2.5). However, association does not 
necessarily define causation. The following section will discuss the aetiology of aPL 
and evidence from in vivo animal experiments supporting the thrombogenic potential 
of these antibodies.
1.4 ANTIPHOSPHOLIPID ANTIBODIES (aPL)
1.4.1 Development of aPL -  genetics versus environment
The precise aetiology of aPL is unknown at present. What is likely, is that APS will 
arise in an individual who may be genetically predisposed to developing this 
autoimmune disease and who is exposed to certain antigenic stimulation. Family and 
population studies have attempted to address the degree to which genetic 
predisposition may be an aetiological factor, particularly by looking for associations 
with human leukocyte antigen (HLA) alleles.
A report in 1980 by Exner et al was the first to suggest a familial association, which 
described the presence of LA in two pairs of siblings (Exner et al., 1980). Subsequent 
family studies have demonstrated an increased frequency of aCL (Mackworth-Young 
et al., 1987) and APS (Radway-Bright et al., 2000) in first-degree family members of 
affected individuals, particularly if the affected patient has an additional autoimmune 
disease (Weber et al., 2000). LA associated with DR4 or DR7 haplotypes has been 
described by a number of investigators (Bussel et al., 1983, Rouget et al., 1982, 
Mackie et al., 1987). Dagenais et al found the haplotype A30; Cw3; B60; DR4; 
DRw53; DQw3 to be associated with aCL in an English Canadian family, some of 
whom had evidence of SLE and thrombotic disease and others who had aCL, but no 
evidence of APS. However, an HLA identical individual had no evidence of aCL 
(Dagenais et al., 1992). May et al also identified the haplotype DR4; DRw53; DQw3 
in a set of twins and their mother who had SLE and APS, however two other HLA 
identical siblings who had lived all their lives in the same environment as their 
mother and twin siblings had no evidence of aPL or any other clinical /  serological 
abnormality (May et al., 1993). These family studies indicate that HLA contribution 
may be an important but not sole determinant of aPL production or expression of the 
APS clinical phenotype.
With population studies it would be of interest to compare HLA associations between 
patients with APS and evidence of another autoimmune disease such as lupus, those
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that have APS alone and those that have lupus, but no evidence of aPL or APS. This 
would help resolve the debate as to whether 'primary' or 'secondary' APS are distinct 
entities or not. Few studies have included cohort numbers of each group that are 
large enough to make such meaningful comparisons and none have demonstrated 
any significant differences between the two APS groups (Domenico Sebastiani et al., 
2003). One study found that patients with APS and SLE had an increased frequency 
of HLA-DRB1*03 as compared to patients with APS alone. However, as the authors 
conceded, this haplotype is associated with SLE rather than specifically seen in 
patients with SLE and APS (Freitas et al., 2004).
Population studies on patients with APS as the only autoimmune disease have been 
relatively few. Asherson et al reported on 13 patients form the UK with APS and 
examined class II and class II I genes of the MHC and found differences in the HLA 
class II region of DR4 and DRw53 in line with the family studies, whereas DR3 was 
absent (Asherson et al., 1992). Similar associations have been found in a small 
cohort of Spanish patients with APS and no other autoimmune disease (Camps et al.,
1995). In a British study the haplotype DQBl*0604/5/6/7/9-DQAl*0102-DRBl*1302 
was associated in 53 patients with APS and anti-B2GPI antibodies (Caliz et al., 2001). 
Studies on a small sample of Mexican patients with APS alone found an increase in 
the haplotypes HLA-DR5 (Vargas-Alarcon et al., 1995).
There have been many more studies investigating patients with SLE and aPL though 
in the majority of these studies it is unclear if patients with aPL studied had APS. 
Comparing different studies reveals a number of inconsistent associations, though it 
should be underlined many are from varying geographical areas with a mix of ethnic 
groups. As seen in studies in patients with APS, the presence of aPL in patients with 
SLE from Australia and the UK has been shown to be associated with an increased 
frequency of HLA-DR4 (McHugh and Maddison, 1989) and DRw53 (McNeil et al., 
1990a). Also HLA-DR7 has been observed with increased frequency in patients with 
SLE and aPL from Northern Italy (Savi et al., 1988) and one large multicentre 
European study found all three of these haplotypes were observed with increased 
frequency (Hartung et al., 1992). In contrast no association with HLA-DR or DQ 
alleles in aCL positive patients with SLE was observed in a group of Caucasian and 
Black Americans (Gulko et al., 1993). Given that aPL are heterogeneous in nature, 
studies have investigated the possibility of genetic susceptibilities for the presence of 
different types of aPL. One very large multi-centre European study of 577 patients
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with SLE found an association of aCL with the haplotype HLA-DRB1*04, -DRB1*07, - 
DQA1*0201, -DQA1*0301, -0(261*0302, -DPB1*1501, -DPB1*2301/ -DRB3*0301 
whereas in the same population anti-B2GPI antibodies were associated with 
-DQB1*0302, -DPB1*0301/ -DPB1*1901. No evidence of association with alleles at 
the DRB4 locus (DRw53) was found with DR4 associated in patients from Spain and 
Italy (Sebastiani et al., 2003). However, it was not stated in this study whether the 
aCL group of patients were differentiated into B2GPI dependent or independent 
groups, making interpretation of such results difficult. Arnett et al performed a study 
analysing the association of anti-B2GPI antibodies on three ethnic groups of patients 
with SLE in America. They found that HLA-DR4 haplotypes were strongly associated 
with anti-B2GPI antibodies with White and Mexican Americans and less so in Black 
Americans (Arnett et al., 1999).
It is difficult to draw definitive conclusions regarding the genetic susceptibility to 
develop APS. It is likely that some genetic predisposition to developing aPL exists, 
but at present it is not accurately defined. To add a further layer of complexity it is 
possible that genes outside the MHC region may contribute to the development of 
APS such as polymorphisms in the antigenic protein for example. Polymorphisms in 
the C-terminal domain V (DV) of B2GPI (valine instead of leucine at position 247) 
correlate with the production of anti-B2GPI antibodies in patients with APS (Hirose et 
al., 1999, Yasuda et al., 2005) (see section 1.6.2). Additional genetic factors in 
patients with APS may also confer thrombotic risk such as deficiencies in factor V 
Leiden (Letsas et al., 2005), protein C or protein S (Parke et al., 1992). Future 
studies aimed at genome wide linkage analyses may help assess genetic risk more 
precisely.
Regarding environmental triggers, infection with a variety of foreign antigens have 
been linked to the development of aPL and APS. Numerous infections have been 
linked to the development of aPL as reviewed by Cervera and Asherson (Cervera and 
Asherson, 2005). Examples include viruses (such as hepatitis C, human 
immunodeficiency virus (HIV), Epstein-Barr virus or cytomegalovirus (CMV)), 
bacterial infection (tuberculosis, leprosy, salmonella, Coxiella burnetti), spirochaetes 
(Treponema pallidum) and parasitic infections (malaria, toxoplasmosis). However, in 
the vast majority of cases the induction of aPL in response to infection is transient 
and does not result in the development of APS. Some have proposed that aPL may 
arise through the process of molecular mimicry. For example, peptides that share
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peptide sequence homology with bacterial antigens (Pierangeli et al., 2004a) have 
been shown to bind and inhibit the thrombogenic effects of human aPL. Mice 
immunised with a CMV derived peptide (Gharavi et al., 2002) or whole bacteria such 
as Haemophilus influenza (Blank et al., 2002) produce aPL that demonstrate 
pathogenic properties in vivo in a mouse model of thrombosis. The development of 
CAPS has been linked with bacterial infection (Cervera et al., 2004). However, this 
association does not necessarily mean this is due to molecular mimicry. One 
possibility is that a systemic infection results in pathophysiological processes such as 
activation of ECs or exposure of anionic PL on the surface of activated platelets, for 
example that may lower the threshold at which circulating anti-l32GPI antibodies 
promote pathogenicity. Drugs such as phenytoin, propranolol, hydralazine and 
cocaine have also been linked to the development of aPL, but not APS (Robertson 
and Greaves, 2006).
1.4.2 Distinguishing between pathogenic and non-pathogenic aPL
As discussed in the previous section, the majority of aPL that arise from various 
infections do not give rise to the expression of APS in affected patients. The 
prevalence of aPL in the healthy population is estimated at between 1% to 5% 
(Pattison et al., 1993, Shi et al., 1990), yet there exists substantial epidemiological 
evidence that the presence of aPL promotes thrombotic risk in some people (see 
section 1.2.5). Hence, it is likely that aPL are very heterogeneous in nature, with 
some promoting pathogenesis and others not. The nature of aPL that promote 
thrombosis as opposed to those found in people with no history of thrombosis tend 
to be of the IgG isotype, have specificity for negatively charged PL and bind anionic 
PL only in the presence of 62GPI.
1.4.3 Evidence from animal studies for aPL promoting thrombosis
The association of aPL as a risk factor for thrombosis, as described in various clinical 
studies, does not necessarily mean that aPL themselves are thrombogenic. The most 
persuasive evidence supporting the thrombogenic potential of aPL comes from in 
vivo studies in mice. Two main methods have been employed to induce APS clinical 
manifestations in mice. One method has been by observing the pro-thrombotic 
effects of injecting purified aPL derived from humans with APS into mice, otherwise 
known as passive transfer. Another method is to take immune naive mice, induce 
aPL production and observe the effects. This has been achieved by immunising mice 
with either aPL or an autoantigen (such a 62GPI or a peptide mimicking part of this 
protein) to provoke an antibody response.
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Mouse models of thrombosis are few. Pierangeli et al demonstrated that when the 
femoral vein of a healthy mouse is subjected to a pinch stimulus, the size and 
longevity of the resultant thrombus is significantly enhanced if the mouse is pre­
infused with polyclonal IgG derived from APS patients, as compared to control IgG 
(Pierangeli et al., 1994). Further studies using the femoral vein pinch model 
identified four out of seven monoclonal aPL derived from two patients with APS as 
having the potential to enhance thrombus formation (Pierangeli et al., 2000). In 
these studies, after the size of the resultant thrombus had been estimated, the 
cremaster muscle of the anesthetised mouse was transilluminated under a 
microscope in order to observe in vivo leukocyte adhesion to blood vessel walls. This 
was confirmed for three out of the four monoclonal aPL that promoted thrombosis. 
Increased leukocyte adhesion in vivo was also observed when mice are given 
intra peritonea I injections of affinity purified aPL isolated from patients with APS 
(Pierangeli et al., 1999). Olee et al generated two monoclonal aPL derived from one 
patient with APS. Both bound CL in a foGPI dependent manner, however only one 
had an in vivo thrombogenic effect using the femoral vein pinch model (Olee et al.,
1996). The in vivo experiments described using this model highlight the 
heterogeneous nature of aPL in terms of promoting thrombosis. Blank et al 
demonstrated in 1991 that the passive transfer of either polyclonal or monoclonal 
aPL derived from a patient with APS into pregnant ICR mice was associated with 
lower fecundity rate, increased rates of foetal resorption and lower mean weights of 
embryos and placenta, mimicking the obstetric features of APS seen in humans 
(Blank et al., 1991). This effect was not observed on infusing pregnant mice with 
murine or human IgG lacking CL binding. Similarly pregnant BALB/c mice injected 
with monoclonal human B2GPI dependent aPL resulted in a significantly higher rate 
of foetal resorption and lower embryo and placental weight as compared to mice 
injected with a non-CL binding mAb (Ikematsu et al., 1998).
Given that around 30% of patients with SLE also have aPL with around half of them 
developing features of APS, it may be that some animal models of autoimmune 
prone disease mimicking lupus could also develop APS features. One such model was 
described in the NZWxBXSB Fi strain. These mice develop a lupus-like syndrome with 
features of APS characterised by thrombocytopaenia, coronary vascular disease, 
nephritis, vascular disease, foetal resorption and skin changes (Hang et al., 1981, 
Hashimoto et al., 1992). These mice also develop aCL, which recognise murine and
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human 62GPI and increase in titre with age (Monestier et al., 1996). Another lupus- 
prone strain of mouse known as the MRL/lpr strain has a recessive 
lymphoproliferative gene (Ipr) encoding for defective Fas, thus leading to defective 
Fas mediated apoptosis. These mice have been shown to have high levels of IgG aCL 
and clinical features characteristic of APS, such as poor pregnancy outcome, 
thrombocytopaenia (Gharavi et al., 1989) and histological evidence of cerebral 
thrombosis (Smith et al., 1990). Interestingly, a recent model described by Rauch 
and colleagues demonstrates the production of autoantibodies to SLE autoantigens 
with evidence of glomerulonephritis in mice in response to immunisation with human 
I32GPI in the presence of lipopolysaccharide (LPS) (Levine et al., 2006).
In 1992 Gharavi et al induced aPL production in mice following immunisation with 
purified human I32GPI (Gharavi et al., 1992). These mice developed 
thrombocytopaenia and when mated had a high foetal resorption rate (Blank et al.,
1994). Pierangeli et al in the femoral vein pinch model observed larger and more 
persistent thrombus formation in mice immunised with G2GPI as compared to those 
immunised with human serum albumin as a negative control (Pierangeli et al., 1996). 
Thrombogenic aPL may also be generated by immunising mice with a peptide 
derived from the CMV virus (TIFI peptide) (Gharavi et al., 2002) or with a peptide 
bearing sequence homology to the C-terminal PL binding region of B2GPI (Gharavi et 
al., 1999). These experiments and their relevance to the pathogenesis of APS will be 
discussed in greater detail in section 1.5.
Active induction of APS has also been achieved through utilising the idiotypic 
network. Naive BALB/c mice immunised with aPL leads to the generation of 
antibodies directed against the immunising antibody (anti-idiotype). The animal 
subsequently develops autoantibodies against this anti-idiotype antibody (anti-anti­
idiotype), which may have similar binding characteristics to the original immunising 
antibody. Bakimer et al immunised mice with a monoclonal human IgM aPL and 
observed the development of prolonged partial thromboplastin time and pregnancy 
morbidity. However, the monoclonal aPL was generated from the lymphocytes of a 
healthy subject who had been immunised with diphtheria and tetanus toxoid, raising 
potential questions as to the relevance of the findings to APS (Bakimer et al., 1992). 
A study by Cohen et al took purified IgG and IgM aPL derived from a patient with 
APS and used these antibodies as the immunising agents. The original IgG aPL was 
monospecific for binding CL (in the presence of 32GPI) binding at high titres, but the
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IgM aPL bound CL with low affinity and also bound other antigens such as histones 
and dsDNA. Mice immunised with the CL specific IgG aPL developed prolonged 
partial thromboplastin time, thrombocytopaenia and severe pregnancy morbidity. 
Mice immunised with polyspecific IgM aPL had much milder evidence of pregnancy 
morbidity and no other detectable clinical abnormalities (Cohen et al., 1993). 
However, it should be noted that other groups have failed to reproduce these 
experiments (Isenberg et al., 1991). In another mouse model of atherosclerosis (low 
density lipoprotein (LDL) receptor knockout mice) immunising these mice with 
human aCL accelerates atherosclerosis (George et al., 1997).
Experiments using mouse models of APS, reviewed by Radway-Bright and Isenberg 
(Radway-Bright et al., 1999), support the argument that aPL have thrombogenic 
potential. However, not one animal model encompasses all the multisystemic 
features of the clinical syndrome as seen in humans. Furthermore, it is apparent that 
different antibodies from the same or different patients have varying effects in these 
models. It is likely that this is a function of both the heterogeneous nature of the 
antibodies and also the models studied. The characterisation of chimpanzee I32GPI 
coupled with the observation of elevated anti-G2GPI antibodies in these animals holds 
the possibility of primate models for investigating the APS (Sanghera et al., 2001).
Having discussed the evidence implicating a causal pathogenic effect of aPL, I will 
now explore potential mechanisms by which aPL may promote thrombosis and 
pregnancy morbidity.
1.5 UNDERLYING MECHANISMS OF PATHOGENICITY IN THE 
APS
APS has a varied clinical phenotype and aPL, as discussed in the sections above, are 
a heterogeneous group of antibodies even within the same individual. Furthermore, 
when one considers the likely targets of aPL, PL and PL membranes are involved in 
numerous biological processes and the physiological function of 62GPI as yet, has not 
been fully elucidated (reviewed in section 1.6). For these reasons, multiple 
mechanisms through which aPL promote thrombosis have been proposed with no 
one satisfactory unifying hypothesis. As an overview, the key mechanisms proposed 
revolve around aPL effects on coagulation (particularly inhibition of fibrinolytic 
pathways), cell mediated effects (endothelial cells (ECs), platelets and placental 
trophoblasts) and mechanisms involved in the pathogenesis of atherosclerosis. Which
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is the dominant one of these and whether thrombotic or inflammatory mechanisms 
predominate as yet has not been established.
1.5.1 Effects of aPL on the coagulation pathways
Pro-coagulant and 'anti-coagulant' /  fibrinolytic pathways are finely balanced and 
complex biological processes. The coagulation cascade, ultimately resulting in the 
formation of fibrin as the key component of a thrombus, consists of an intrinsic and 
extrinsic pathway. However, this complex coagulation cascade with the potential to 
form large amounts of fibrin rapidly is regulated by the anticoagulant and fibrinolytic 
pathways with some factors such as thrombin being a key component of both. The 
two pathways of coagulation and fibrinolysis are schematically represented in figure
1.1 A) and 1.1 B). Pathology arises when there is a disturbance in the balance 
between these two pathways. There is evidence that aPL can upset this balance 
favouring a pro-thrombotic phenotype in vivo. This is achieved through aPL 
promoting components of the coagulation pathway and inhibiting key regulatory 
components of the fibrinolytic /  'anticoagulant' pathway. The ability of aPL to 
enhance the production of procoagulant factors may also occur indirectly through cell 
mediated processes that will be discussed in section 1.5.2.
1.5.1.1 Direct effects o f aPL on factors that promote coagulation
Both the extrinsic and intrinsic pathways converge to activate factor X and result in 
the conversion of prothrombin to active thrombin (figure 1.1 A). The presence of 
anti-prothrombin (anti-PT) aPL in vitro would be likely to have an anticoagulant 
effect as observed in the LA test and first demonstrated by Bajaj et al in 1983 (Bajaj 
et al., 1983). However, the presence of these antibodies in vivo and the association 
with thrombosis has not been definitively established in the literature. Some studies 
report no association with anti-PT antibodies and the presence of thrombosis in 
patients with APS (Atsumi et al., 2000, Forastiero et al., 1997, Pengo et al., 1996) 
whilst other studies do report an association (Bertolaccini et al., 1998, Nojima et al., 
2001). The most likely reason accounting for this discrepancy could lie in the assay 
methods employed. Anti-PT antibodies are heterogeneous in nature with some 
exhibiting different binding abilities depending on different detection methods 
employed (Galli et al., 1997). If instead of coating PT on a plate, this antigen is 
coated on an anionic lipid surface such as phosphatidylserine (PS), then serum levels 
of aPL that bind this PS-PT complex have been found to significantly correlate with 
LA activity and also correlate with the clinical features of APS (Atsumi et al., 2000).
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Some advocate that the PS-PT assay be explored as a potential candidate for 
inclusion in the laboratory classification criteria for APS though further validation 
studies are required (Atsumi et al., 2004). However, it remains unclear how aPL 
binding to cryptic epitopes exposed on PT when bound to anionic PL enhance 
thrombosis rather than inhibit it. Inhibition is what one would intuitively expect and 
what is seen in vitro. One possible mechanism could be that pathogenic antibodies 
that bind cryptic epitopes on PT may also bind thrombin (given that it is derived from 
PT) and protect it from deactivation. Support for this hypothesis comes from the 
observation of a strong association between anti-PT and anti-thrombin antibodies 
seen in patients with APS, which have been shown in vitro to inhibit the deactivation 
of thrombin by antithrombin II I (Hwang et al., 2001).
1.5.1.2 Inhibition of the protein C, thrombomodulin and fibrinolytic pathway.
Protein C is an endogenous vitamin K serine protease that has important 
antithrombotic mechanisms via an important feedback mechanism for controlling 
thrombin formation. As shown in figure 1.1 B), this protein is activated when 
thrombin binds thrombomodulin on the surface of ECs (Esmon, 2000). Protein C then 
catalyses the degradation of factors Va and Villa in the presence of protein S, hence 
leading to reduced thrombin production. This pathway has been identified as a target 
for aPL in the APS by numerous studies. The degradation of factor V by protein C has 
been shown in vitro to be inhibited by aPL derived from the serum of patients with 
APS (Oosting et al., 1993, Marciniak and Romond, 1989, Borrell et al., 1992). An 
inhibitory effect on the protein C/protein S complex by aPL has also been 
demonstrated (Malia et al., 1990) and the inhibitory effects of protein C mediated 
factor V degradation has been shown to be PL dependent, namely 
phosphatidylethanolamine (Smirnov et al., 1995). This particular PL in the oxidised 
form has been found to significantly enhance the function of activated protein C 
(Safa et al., 2001). There are elevated levels of oxidised PL in the serum of patients 
with APS (Pratico et al., 1999) and PL in the oxidised state has been shown to exhibit 
greater binding to aPL as compared to aPL binding PL in the reduced state (Horkko 
et al., 1996). Anti-B2GPI antibodies have been shown to bind 62GPI when anchored 
to oxidised PL (Horkko et al., 1997). A recent study by Safa et al demonstrated using 
in vitro studies that monoclonal anti-B2GPI, raised from mice immunised with this 
protein, had the effect of blocking PL oxidation dependent enhancement of activated 
protein C (Safa et al., 2005). If such a process occurs in vivo, then the protective 
effects of oxidised PL would be abrogated by aPL, leading to reduced activated 
protein C function and hence a hypercoagulable state.
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Activated protein C can also inhibit the activity of plasminogen activator inhibitor 
(PAI) (van Hinsbergh et al., 1985). This ultimately leads to elevated levels of tissue 
plasminogen activator (tPA) resulting in the activation of plasmin and consequently 
fibrinolysis (figure 1.1 B). Hence, aPL inhibition of protein C activity may also 
promote thrombosis via inhibition of the fibrinolytic pathway. Data supporting the 
role of PAI and tPA in the APS remains uncertain with conflicting and confusing 
reports. One small study of 23 patients with SLE found elevated levels of PAI antigen 
and tPA in patients who had a history of thrombosis or pregnancy morbidity (Violi et 
al., 1990). Whether these patients had APS or not was not clarified. A study by 
Cugno et al demonstrated significantly elevated levels of antibodies to tPA in 14 out 
of 91 patients with APS as compared to the none out of 23 SLE or 3 out of 91 
healthy control subjects studied. The two samples of IgG that were the best binders 
to tPA were shown to interact with the catalytic domain of tPA (Cugno et al., 2004). 
However, other studies have failed to demonstrate any significant differences 
between SLE disease control and aPL positive patients (Keeling et al., 1991) or APS 
patients (Mackworth-Young et al., 1995) with respect to levels of tPA and PAI. Again, 
as seen with the studies investigating binding of aPL to prothrombin, one reason for 
these discrepancies seen may be due to the assays employed. A recent study by Lu 
et al demonstrated significant binding of monoclonal and polyclonal IgG aPL to tPA 
only when associated with fibrin. The authors postulated that tPA when bound to 
fibrin exposes aPL binding epitopes (Lu et al., 2005).
The activation of protein C by thrombomodulin may also be another target for aPL 
though again there are conflicting reports in the literature. aPL derived from patients 
with positive LA activity have been shown to inhibit the activity of thrombomodulin 
(Freyssinet et al., 1986, Cariou et al., 1988). However, other groups have failed to 
show evidence of aPL binding thrombomodulin (Keeling et al., 1993, Watson and 
Schorer, 1991) and it remains uncertain whether this is an important pathway in the 
pathogenesis of the APS.
An inherited deficiency of protein C results in recurrent thrombotic disease (Griffin et 
al., 1981). There have been a few case reports of patients with APS that have 
protein C or S deficiencies (Parke et al., 1992). However, one study of 74 patients 
with SLE found no association with these deficiencies and the occurrence of 
thrombosis (Hasselaar et al., 1989). These inherited deficiencies are typically
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associated with venous rather than arterial thrombosis. The clinical pattern of APS is, 
however different, and is one of both arterial and venous thrombosis in addition to 
pregnancy morbidity. Despite the wealth of evidence described above, this 
incongruence makes aPL disruption of the protein C pathway difficult to accept as 
the dominant mechanism in inducing disease.
1.5.1.3 Effects of aPL on annexin V
This protein has potent anticoagulant activity by virtue of its high affinity for anionic 
PL surfaces. It is shaped like a concave disk and aggregates on the surface of PL 
membranes forming a crystal lattice that has the effect of displacing and blocking 
accessibility of PL by coagulation factors (Reutelingsperger et al., 1988). It is 
produced by ECs and is also likely to be an important natural anticoagulant in 
pregnancy as it is produced by placental precursor cells, trophoblasts, and is 
essential for the maintenance of placental integrity (Wang et al., 1999). Annexin V 
may be displaced from PL by aPL from patients with APS. This has been shown with 
both polyclonal (Rand et al., 1998) and monoclonal IgG aPL (Rand et al., 2003). This 
effect is not observed when using aPL derived from patients with syphilis (Wu et al.,
2006) or patients with aPL and no history of thrombosis or pregnancy morbidity 
(Rand et al., 2004). Anti-annexin V antibodies are observed in 35-50% of patients 
with APS, but do not predict risk of thrombosis or pregnancy morbidity (de Laat et 
al., 2006a, Arnold et al., 2001, Ogawa et al., 2000). However, one polymorphism in 
annexin V (Cys to Thr at position 1) is an independent risk factor for pregnancy 
morbidity, which is an observation independent from APS (de Laat et al., 2006a). 
The levels of annexin V production by cells within the vascular and placental beds 
may be reduced by aPL induced cell mediated effects and this is discussed further in 
sections 1.5.2 and 1.5.3 respectively. However, uncertainties exist regarding the 
contribution of annexin V as an anticoagulant shield in vivo given the observation 
that annexin V deficient mice have no evidence of an increased propensity for 
thrombosis or pregnancy morbidity (Brachvogel et al., 2003).
1.5.2 Cell mediated effects of aPL
1.5.2.1 aPL induced activation of endothelial cells
The endothelium, previously thought to represent a 'passive' barrier between blood 
and tissues, is now known to be a dynamic and heterogeneous organ that plays an 
active role in the regulation of inflammatory responses, haemostasis and vessel tone 
(Ones et al., 1998). In 1995 two studies described the ability of polyclonal IgG aPL
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to activate cultured human ECs by upregulating adhesion molecules (Simantov et al.,
1995) and that this process was dependent upon the presence of serum containing 
the cofactor 62GPI (Del Papa et al., 1995). These findings have been confirmed and 
extended to monoclonal aPL by other groups and the most common adhesion 
molecules upregulated by aPL and detected as part of the proinflammatory 
phenotype include E-selectin, vascular cell adhesion molecule-1 (VCAM-1), 
intracellular adhesion molecule-1 (ICAM-1) and P-selectin (George et al., 1998c, 
Pierangeli et al., 1999). Levels of soluble ICAM-1 and VCAM-1 in the plasma of 
patients with APS and thrombosis are elevated (Kaplanski et al., 2000, Stale et al., 
2005). Pierangeli et al demonstrated in vivo activation of ECs by aPL by direct 
visualisation of the adherence of leukocytes to the inner walls of venules within the 
cremaster muscle in anaesthetised mice (Pierangeli et al., 2000). This aPL induced 
leukocyte adherence was significantly reduced in ICAM-1 deficient mice and 
completely abrogated in mice deficient in both ICAM-1 and P-selectin. Infusion of an 
anti-VCAM-1 antibody also reversed the aPL induced leukocyte vessel wall 
adherence. The normal mice in these experiments developed enhanced thrombus 
formation when infused with aPL, which again was reversed in ICAM-1/P-selectin 
deficient mice and in mice infused with anti-VCAM-1 antibody. (Pierangeli et al., 
2001). Similar inhibition of in vivo leukocyte vessel wall adherence accompanied by 
reduced thrombus formation was observed in C3 and C5 deficient mice, suggesting 
that an intact complement pathway is necessary for aPL induced EC activation and 
thrombosis (Pierangeli et al., 2005). IgG aPL have also been shown in one study to 
induce production of monocyte chemoattractant protein-1 when incubated with 
human ECs (Cho et al., 2002). These studies confirm that aPL bind to ECs and induce 
a proinflammatory and proadhesive phenotype.
ECs are integral to the function of normal vessel tone. These cells are capable of 
producing a number of factors that may either cause vasoconstriction, such as 
endothelin-1 or platelet activating factor, or vasodilatation such as prostacyclin or 
nitric oxide (NO) (Ones et al., 1998). In fact, the first report of aPL having a 
potential effect on ECs was made by Carreras et al on detecting reduced levels of 
prostacyclin in a woman with circulating LA (Carreras et al., 1981a). One study has 
demonstrated elevated levels of endothelin-1 in patients with APS and a history of 
arterial thrombosis (Atsumi et al., 1998). However, there are other conflicting studies 
that have not shown elevated levels of endothelin-1 or of other adhesion molecules 
in the serum of APS patients (Williams et al., 2000). One method of assessing EC
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dysfunction is by measuring the degree of brachial artery vasodilatation that may be 
induced by increased blood flow-shear (known as flow-mediated vasodilatation) or 
glycerol trinitrate (Vogel, 2001). A study of 25 APS patients versus 25 age and sex 
matched control subjects found reduced flow-mediated and nitrate induced brachial 
artery vasodilatation in the APS group. In addition these APS patients had elevated 
levels of soluble VCAM-1 and ICAM-1 (Stale et al., 2005). Delgado-Alves et al 
demonstrated increased production of inducible NO synthase (iNOS) in response to a 
monoclonal aPL (IS4) in an ex vivo and in vivo rat model of NO production. This was 
coupled with down-regulation of the physiological endothelial NOS (eNOS), resulting 
in a phenotype consistent with oxidative stress (Delgado Alves et al., 2006). 
Prolonged exposure to IS4 in mice resulted in overall reduced production of NO 
(Delgado Alves et al., 2005).
1.5.2.2 Tissue factor in the APS
Tissue factor (TF) is a glycoprotein responsible for being the major initiator of the 
extrinsic coagulation cascade, often at a site of vascular injury, and is an essential 
cofactor for factor Vila to efficiently cleave factor X to its active form Xa (see figure
1.1 A). Functional TF is expressed on the surfaces of ECs, monocytes, leukocytes and 
other cells in contact with free-flowing blood in response to stimulation with a variety 
of agents including P-selectin, chemokines, LPS and inflammatory cytokines such as 
IL-1 and tumour necrosis factor-a (TNF-a) (Wolberg and Roubey, 2004b). Most 
studies investigating the role of TF in the pathogenesis of the APS have focussed on 
experiments using monocytes. Numerous groups have found that APS derived 
serum, plasma, monoclonal and purified polyclonal aPL had the effect of enhancing 
TF expression and procoagulant activity on normal monocytes (Kornberg et al., 1994, 
Schved et al., 1992, Amengual et al., 1998, Reverter et al., 1998). APL induction of 
TF expression may be achieved using the F(ab)2 portion of monoclonal aPL 
suggesting that this process is not Fc mediated (Schved et al., 1992). Circulating 
levels of TF are significantly greater in patients with aPL and APS as compared to 
patients with aPL and leprosy without clinical features of APS (Forastiero et al., 
2005).
Non-functional TF is produced by many cell types in an encrypted form, thought to
be due to dimerisation of TF molecules (Bach and Moldow, 1997). Rapid dissociation
of these dimers into the active or de-encrypted form of TF is a method of producing
significant amounts of active TF very rapidly. There is no change in the number of TF
molecules and very little delay that would otherwise be observed if increased TF
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activity in response to stimulants was due solely to cellular up-regulation of TF. 
Stimulants that have been found to cause de-encryption of TF are calcium ionophore, 
hydrogen peroxide and freeze/thaw cycles (Wolberg and Roubey, 2004b). Anionic PL 
expression may also lead to changes in the TF molecule (Wolberg et al., 1999). 
Current evidence points towards aPL causing increased TF activity by the more 
gradual process via inducing increased cellular expression of TF, rather than by 
causing de-encryption of inactive TF. Ex vivo monocytes derived from patients with 
APS and thrombosis, grown in tissue culture, were found to express elevated levels 
of TF (Cuadrado et al., 1997) and have increased levels of TF messenger ribonucleic 
acid (mRNA) as compared to monocytes grown from patients with APS and no 
thrombosis, thrombosis and no APS and healthy control subjects (Dobado-Berrios et 
al., 1999). A later study by Wolberg and Roubey found no evidence of increased TF 
de-encryption when culturing non-stimulated monocytes with B2GPI and affinity 
purified anti-62GPI antibodies, whereas significant activation of TF was observed 
upon adding calcium ionophore (Wolberg and Roubey, 2004a).
Tissue factor pathway inhibitor (TFPI) complexes with factor Xa and acts as a 
regulator of the TF/VIIa complex (see figure 1.1 A). Reduced levels or activity of the 
TFPI regulator would be expected to cause an enhanced thrombotic tendency. One 
study demonstrated an increase in TF stimulated factor Xa generation in plasma 
when incubated in the presence of anti-l32GPI antibodies. The authors postulated 
that this was indirect evidence of suppression of TFPI-dependent inhibition of TF 
(Salemink et al., 2000). Functional anti-TFPI antibodies have been identified in a 
small subgroup of patients with APS (Adams et al., 2001) and have been found to be 
associated with arterial thrombosis and stroke (Forastiero et al., 2003).
1.5.2.3 Platelet pathology in APS
These cells adhere and aggregate at a site of injury very rapidly, forming a platelet
plug. Platelets may be activated by a number of platelet or EC derived activating
factors such as P-selectin, which may also subsequently bind to and cause activation
of the complement system (Del Conde et al., 2005). Activated platelets express
anionic PL on their surface, providing a surface through which PL dependent
coagulation reactions may occur (see figure 1A) (Heemskerk et al., 2002). Clearly
platelets play a central role in coagulation yet their role in the pathogenesis in APS is
not as well characterised as that of the ECs. Joseph et al analysed the degree of
activation of platelets derived from 20 patients with APS and compared the results to
platelets derived from patients with SLE, but no APS and healthy subjects. Only
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platelets derived from the APS group demonstrated significant activation as assessed 
by detecting CD63 expression and conformational change in glycoprotein Ilb-IIIa  
(GPIIb-IIIa) by binding to a specific monoclonal antibody named PAC-1 that 
recognises this protein (Joseph et al., 2001). Monoclonal anti-B2GPI antibodies have 
been shown to enhance adherence of platelets to vascular subendothelium as shown 
in an in vitro model of platelet activation (Font et al., 2002). Robbins et al 
demonstrated that aPL induced activation of platelets, as assessed by measuring 
thromboxane A2 production, is dependent upon the presence of B2GPI (Robbins et 
al., 1998). Pre-incubating platelets with agonists of cyclic-adenosine monophosphate 
(cAMP) has the effect of reducing aPL/B2GPI induced thromboxane A2 production 
(Opara et al., 2003).
Convincing evidence for platelets having a direct role in the pathogenesis of APS 
comes from a study by Lutters et al which describes the use of an in vitro flow 
system in which whole blood from healthy donors is passed over collagen. Increased 
platelet deposition on the collagen surface was observed when anti-B2GPI antibodies 
were added. Also dimers of B2GPI, which have been shown in previous studies to 
exhibit LA activity (Lutters et al., 2001), had the same effect of enhancing platelet 
adherence to collagen. Co-immunoprecipitation revealed that dimeric 62GPI 
interacted with apolipoprotein E receptor 2 (apo ER2), a member of the LDL receptor 
family present on platelets (Lutters et al., 2003). Pierangeli et al demonstrated that 
mice infused with a monoclonal antibody against GPIIb-IIIa or mice deficient in this 
glycoprotein receptor do not develop enhanced thrombus formation on infusion of 
aPL (Pierangeli et al., 2004b). Similar results were observed in a hamster model of 
photochemical induced thrombosis. A human monoclonal anti-B2GPI antibody with 
cross reactivity to hamster B2GPI caused enhanced formation of platelet rich 
thrombus in the carotid artery of an anaesthetised hamster (Jankowski et al., 2003).
A recent study has shown that 82GPI dependent aPL crosslink B2GPI bound to the 
surface of human platelets via the cell surface receptor GP Iba-IX-V complex (Shi et 
al., 2006). Activation of platelets by aPL in the presence of B2GPI is inhibited by anti- 
GPIba monoclonal antibodies and B2GPI was shown to bind GPIba in vitro. Given 
that ECs are also capable of expressing this surface receptor complex (Beacham et 
al., 1997, Beacham et al., 1999) this may provide a unifying mechanism through 
which B2GPI dependent aPL activate ECs and platelets and promote a thrombophilic
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phenotype. Whether placental trophoblasts also express this cell surface glycoprotein 
receptor is currently unknown.
The mechanism of thrombocytopaenia in patients with APS who do not have SLE is 
less clear. It tends to be mild and does not usually lead to problems of bleeding. It 
may be due to increased consumption though this has not been demonstrated. 
Antibodies to platelet glycoproteins have been demonstrated in patients with APS 
and thrombocytopaenia and may be involved (Galli et al., 1994, Godeau et al.,
1997). An interesting observation made recently in one study was that patients 
suffering from SLE and /  or APS with LA activity also had a tendency to have 
prolonged bleeding times, even in the absence of thrombocytopaenia or any drugs 
that could affect platelet function. The authors went on to assess platelet function 
using in vitro systems and also assess levels of von Willebrand factor, which were 
normal (Urbanus et al., 2004). This paradoxical finding of a prolonged bleeding time 
in patients with a probable tendency to develop thrombosis (much like LA activity) 
could not be explained and it is likely that aPL have complex effects on haemostasis 
and platelet function.
1.5.2A  Activation of autoreactive CD4+ positive T cells
The production of aPL by activated B cells is dependent on T cell help. Autoreactive 
CD4+ T cells specific for B2GPI were found in eight out of 18 patients with APS, but 
not found in healthy controls (Visvanathan and McNeil, 1999). Hattori et al identified 
B2GPI specific T cell clones derived from all 12 APS patients with anti-B2GPI 
antibodies tested. However, I32GPI reactive CD4+ T cell clones were also identified in 
12 out of 25 patients who did not have APS and were either patients with SLE or 
healthy controls (Hattori et al., 2000). All B2GPI reactive T cell clones would only 
react to reduced and not to native B2GPI. The authors postulated that this was due 
to B2GPI reactive T cell clones recognising cryptic epitopes exposed on reduced I32GPI 
and hidden when in the native state. This work was then extended in an attempt to 
identify the dominant peptide region of 82GPI responsible for activation of B2GPI 
autoreactive T cells. A total of 14 B2GPI reactive T cell clones were generated from 
three APS patients and were shown to react to a peptide encompassing residues 276 
to 290 within DV (Arai et al., 2001). This is the PL binding region within DV (section 
1.6.4). This led to experiments demonstrating that macrophages or dendritic cells 
pulsed with PL bound G2GPI induce a response of T cell clones specific for the B2GPI 
derived 276-290 peptide. This effect was not observed when macrophages were 
pulsed with native B2GPI not bound to PL or to PL alone, suggesting that processing
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and antigen presentation of 62GPI bound to PL is essential for 62GPI autoreactive T 
cell activation (Kuwana et al., 2005).
1.5.2.5 Intracellular signalling pathways in the APS
There is a relatively large wealth of knowledge on the functional outcomes of cells 
when stimulated by aPL, but relatively little work up until recently has been done on 
dissecting the intracellular signalling events. The past five years has seen 
considerable advancement of our knowledge in this area in the APS. The three 
groups of cell types in which aPL induced intracellular signalling pathways have been 
described are ECs, platelets and monocytes.
Meroni et al stimulated human umbilical vein ECs (HUVECs) with polyclonal and 
monoclonal anti-(32GPI antibodies and demonstrated expression of adhesion 
molecules coupled with activation of NF-KB, as observed when cells were stimulated 
with TNFa used as a positive control (Meroni et al., 2001). Shortly after this report, a 
study from Dunoyoer-Geindre et al confirmed the same findings. This study 
correlated aPL induction of TF and adhesion molecules by ECs with NF-KB 
translocation from the cytoplasm to the nucleus, but found that the observed 
response was not as rapid or pronounced as that seen when cells were stimulated 
with TNFa (Dunoyer-Geindre et al., 2002). This would suggest that the upstream 
pathways from aPL and TNFa cellular activation leading to NF-KB activation are not 
the same. A further study by Meroni's group dissected this out further (Raschi et al., 
2003). TRAF and MyD88 are adapter proteins that associate with the intracellular 
(TIR) domain of an activated TLR to phosphorylate IRAK leading to the activation of 
the NF-KB signalling cascade (see section 1.1.1.3). TRAF-2 is employed in TNFa 
signalling pathways whereas TRAF-6 is critical to IL-1 and LPS signalling pathways 
along with MyD88 (Muzio et al., 1998). Raschi et al used ECs transfected with 
negative dominants of TRAF-2/-6 or MyD88 and found that incubation with 
monoclonal and polyclonal anti-(32GPI antibodies induced a signalling cascade 
comparable to that activated by LPS or IL-1. Assessment of the IRAK 
phosphorylation time kinetic suggested that aPL activate ECs through TLR-4 involved 
in the LPS pathway (Raschi et al., 2003). Another study demonstrated that aPL 
induction of TF production in ECs is dependent upon phosphorylation of the LPS 
induced kinase p38 mitogen activated protein kinase (MAPK), upstream of NF-KB 
activation (Vega-Ostertag et al., 2005). One hypothesis is that there exists molecular 
mimicry between TLR-4 binding ligands and B2GPI. As briefly discussed in section
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1.4.1, viral and bacterial derived peptides that constitute the natural ligands for TLRs 
bind anti-62GPI antibodies. It is possible that aPL bind to TLR-4 and B2GPI on the cell 
surface, resulting in cross-linking of this complex and cellular activation. The co­
receptor annexin II may also be involved as aPL have been shown to cross-link 
annexin II via bound (32GPI (Zhang and McCrae, 2005). As this protein does not 
display an intracellular domain, however, TLR-4 is required to effect cellular 
activation. A polymorphism in the tlr-4 gene associated with a blunted LPS response 
is seen less frequently in patients with APS as compared to healthy subjects 
(Pierangeli et al., 2005b). However, direct binding of aPL to TLR has as yet not been 
demonstrated and only inferred (Raschi et al., 2003). Furthermore, contamination 
with LPS, the natural ligand for TLR-4, may occur at levels of LPS minute enough to 
escape detection by conventional LPS assay systems (Rifkin et al., 2005).
Less is known about the intracellular events in platelets and monocytes that occur 
following activation by aPL. One study treated platelets with low dose thrombin and 
IgG aPL, both whole IgG and their F(ab)2 fragments. A significant increase in the 
phosphorylation of p38 MAPK (as seen in ECs), but not ERK-1/2 MAPKs was seen in 
the aPL treated platelets. Downstream to phosphorylation of p38 MAPK in platelets, 
there is calcium dependent phosphorylation of the enzyme phospholipase A2 (cPLA2) 
which catalyses the formation of thromboxane A2 from acetylsalicylic acid. 
Phosphorylation of cPLA2 induced by aPL was also demonstrated and a specific 
inhibitor of this prevented aPL induced thromboxane A2 production (Vega-Ostertag et 
al., 2004). A recent study has shown that platelet activation of 62GPI dependent aPL 
via the GPIba surface receptor induces activation of the PI3K /  AKT pathway 
downstream of GPIba activation (Shi et al., 2006). This is also the pathway activated 
by von Willebrand factor induced platelet activation (Jackson et al., 1994), which is 
an important pathway for the induction of platelet adhesion integrins crucial for 
mediating platelet to platelet /  vessel interactions (Chen et al., 2004). 
Phosphorylation of p38 MAPK also occurs in monocytes when stimulated with aPL. 
Bohgaki et al demonstrated that monocytes incubated with a monoclonal I32GPI 
dependent aPL induced mRNA expression of TF, which was dependent upon p38 
MAPK activation. NF-KB nuclear translocation was shown to occur downstream to 
p38 MAPK phosphorylation (Bohgaki et al., 2004). A subsequent study by Lopez- 
Pedrera et al confirmed these findings in monocytes with polyclonal IgG anti-B2GPI 
antibodies and also demonstrated the simultaneous activation of another MAPK 
cascade, namely the ERK/MAP pathway (Lopez-Pedrera et al., 2006). This pathway
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specifically phosphorylates and transactivates transcription factors such as Elk-1 
which then regulates expression of genes such as TF (Chang et al., 2003).
1.5.3 Mechanism for pregnancy morbidity, the complement pathway and 
cytokines
The mechanisms for pregnancy morbidity in APS are complex. Direct evidence for 
aPL having a pathogenic effect comes from studies on pregnant mouse models (as 
reviewed in section 1.4.3) and are supported by the strong association of aPL and 
adverse foetal outcomes in patients with APS (section 1.2.5). 6 2GPI dependent aPL 
have also been shown to bind to human trophoblast cells in vitro (Di Simone et al.,
2000). No evidence for thrombosis has been observed in the foetuses of pregnant 
mothers with APS, and aPL causing uteroplacental insufficiency is the most common 
cause. There are no pathognomonic histological changes seen in the placental beds 
of APS patients who have associated pregnancy morbidity. Characteristic histological 
features as reviewed by Gharavi et al include hyperplastic vessels, vasculopathy of 
uterine arteries (spiral arteries) with fibrinoid necrosis and infiltration of lipid-laden 
macrophages accompanied by areas of placental infarction (Gharavi et al., 2001). 
Worse outcomes tend to occur when multifocal areas of uteroplacental thrombosis 
are observed. One mechanism by which aPL may lead to a hypercoagulable state in 
the uteroplacental bed may be via annexin V (see section 1.5.1.3). Annexin V is 
expressed at high levels on the surface of trophoblastic cells. Decreased annexin V 
has been found on the villi of APS placenta (Rand et al., 1994) and aPL have been 
shown to reduce annexin V expression on cultured trophoblasts and placental villi 
(Rand et al., 1997, Vogt et al., 1997). However, the precise role of annexin V in the 
pathogenesis of the APS remains uncertain with the observation that annexin V 
deficient mice do not have an increased propensity for thrombosis or pregnancy 
morbidity (Brachvogel et al., 2003).
Hyperplasia of vessels with infiltration of inflammatory cells and low grade
vasculopathy rather than profound vasculopathy and thrombosis seem to be the
dominant lesions seen in affected placentas from patients with APS (Stone et al.,
2005). The gross histological changes in the placental beds of patients with APS are
almost indistinguishable from those changes seen in the placentas derived from
patients with pre-eclampsia and no evidence of aPL /  APS (Gharavi et al., 2001).
Hence, it seems likely that aPL may mediate uteroplacental pathogenesis through
other non-thrombotic mechanisms. Within the last several years, two lines of
evidence exist for aPL having an autoimmune inflammatory effect on the
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uteroplacental bed. There is emerging evidence of oxidative stress being important in 
contributing to placental insufficiency seen in conditions such as pre-eclampsia 
leading to foetal growth retardation (Roberts and Hubei, 2004). LDL may be oxidised 
by cells such as the trophoblast at the maternal-foetal interface (Bonet et al., 1998) 
and this can inhibit trophoblast invasion seen in vitro. aPL have been found to 
interact with oxidised LDL and may mediate placental injury through oxidative 
damage of the placental vascular endothelium (Hasunuma et al., 1997, Horkko et al.,
1996). However, there is lack of direct evidence of aPL effecting oxidative damage at 
the maternal-foetal interface. LDL-receptor deficient mice have been studied to 
investigate pro-atherogenic effects of aPL (George et al., 1998a). It would be of 
interest to study the effects of aPL induced pregnancy morbidity in this strain of 
mice.
A second mechanism for which more convincing evidence exists is the role of 
complement. A fully active complement system at the foetal-maternal interface is 
essential to the progression of normal pregnancy as reviewed by Girardi et al (Girardi 
et al., 2006). However, this needs to be controlled by complement regulatory 
proteins such as decay-accelerating factor (DAF, also known as CD55), CD59 and 
complement receptor 1-related protein y (Crry). Deficiency of complement regulatory 
proteins in utero, such as Crry, leads to progressive embryonic lethality (Xu et al.,
2000). Salmon and colleagues demonstrated that pregnancy morbidity observed in 
mice upon passive transfer of IgG aPL can be abrogated with C3 inhibitors such as 
Crry or inhibitors of C5 activation. Furthermore, mice deficient in either C3 or C5 did 
not have a tendency to develop aPL induced pregnancy morbidity (Holers et al., 
2002, Girardi et al., 2003). The therapy for pregnant patients with APS is heparin 
(section 1 .2 .1 0 .2 ) and the ability of heparin to inhibit complement has been known 
for many years (Weiler et al., 1978). Heparin given to mice can prevent aPL induced 
pregnancy morbidity and is associated with reduced complement activation. No 
protection with oral anticoagulation such as a thrombin inhibitor (hirudin) or a factor 
Xa inhibitor (fondaparinux) was observed in these mice (Girardi et al., 2004). 
Complement has also been implicated in the production of thrombosis in APS. 
Passive transfer of IgG with anti-f^GPI activity promoted the development of 
thrombosis in rats, which was not observed upon the passive transfer of IgG 
depleted of 8 2GPI binding antibodies. Histological examination of the mesenteric 
vasculature of aPL treated rats revealed co-localisation of C3 and C9. Rats deficient
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in C6  or pre-treated with anti-C5 antibody were protected from anti-B2GPI induced 
thrombosis (Fischetti et al., 2005).
There exists convincing evidence as detailed above that complement plays an 
important role in the pathogenesis of APS. However, there are some inconsistencies 
that warrant discussion. A study by Jankowski et al demonstrated in a hamster 
model of carotid artery thrombosis that passive transfer of F(ab) 2 antibodies capable 
of binding B2GPI promoted thrombosis to a similar degree as when transferring 
whole IgG aPL (Jankowski et al., 2003). Other studies have also demonstrated the 
ability of F(ab) 2 aPL fragments to cause activation of platelets (Lutters et al., 2003, 
Robbins et al., 1998). F(ab) 2 fragments are unable to fix complement, which is 
dependent on the presence of the Fc portion of antibody. Hence, it seems likely that 
aPL induce thrombosis through mechanisms other than fixing complement. One 
possibility is that platelet activation is known to cause activation of the complement 
cascade, possibly via the production of P-selectin (Del Conde et al., 2005)
Cytokine abnormalities have also been implicated in the pathogenesis of foetal loss. 
Mice deficient in C3 or C5 and protected from aPL induced foetal loss also have 
reduced serum levels of circulating TNFa. TNFa release occurs downstream to 
complement activation and blockade of TNFa in pregnant mice prevents aPL induced 
morbidity, providing a potential target for therapeutic intervention (Berman et al., 
2005). Normal placental development has been shown to be promoted by cytokines 
IL-3 and granulocyte macrophage colony stimulating factor (GM-CSF). Levels of IL-3 
in normal pregnant women peak at delivery and sharply fall upon delivery of the 
placenta (Fishman et al., 1992b). Pregnant BALB/c mice immunised with a human 
monoclonal aPL develop foetal loss and have reduced levels of IL-3 and GM-CSF 
(Fishman et al., 1992a). Passive transfer of aPL into ICR pregnant mice causes foetal 
resorption, which can be prevented if IL-3 is co-administered (Fishman et al., 1993). 
Levels of IL-3 are reduced in pregnant patients with APS (Shoenfeld et al., 1998, 
Fishman et al., 1996). Fishman et al also showed that monocytes cultured in vitro 
can be stimulated to produce IL-3 if they are incubated with low dose aspirin while 
higher doses of aspirin failed to induce IL-3 production. The authors suggested that 
low-dose aspirin protection in pregnant patients with APS could in part be related to 
effects on IL-3 production (Fishman et al., 1996).
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1.5.4 Atherosclerosis and aPL
The risk of aPL promoting atherosclerosis is contentious. Current clinical and 
epidemiological studies support the theory that aPL enhance the risk of developing 
arterial thrombosis in the presence of atherosclerosis or other traditional risk factors, 
but do not cause progression of atherosclerosis per se (discussed section 1.2.6). The 
balance of evidence investigating the pathogenic role of aPL in atherosclerotic plaque 
development is equally contentious.
Evidence of pathogenic mechanisms by which a PL may promote atherogenesis have 
been explored by multiple groups. 6 2GPI is found in atherosclerotic plaque lesions 
(George et al., 1999). Immunisation of atherosclerosis-prone mice with 6 2GPI 
accelerates plaque formation, and transfer of 8 2GPI-reactive lymphocytes in LDL 
deficient mice promotes the development of precursor lesions to atherosclerosis such 
as fatty streaks (George et al., 2000). LDL-receptor deficient mice immunised with 
6 2GPI also develop early atherosclerotic lesions (George et al., 1998a). There is some 
controversy as to whether patients with APS have anti-oxidised LDL antibodies that 
cross-react with I32GPI (Vaarala et al., 1993, Tinahones et al., 1998). A ligand that 
binds 6 2GPI derived from oxidised LDL has been isolated by one group. Liposomes 
that contain this ligand are taken up by macrophages in vitro and this process is 
enhanced in the presence of 6 2GPI (Kobayashi et al., 2001). Pathogenesis may also 
be mediated by aPL targeting protective elements of atherogenesis. High-density 
lipoprotein (HDL) inhibits the oxidation of LDL and apolipoprotein A-I (apo A-I) 
stabilises paraoxonase, an antioxidant enzyme within the HDL particle. Patients with 
APS have been shown to exhibit elevated levels of antibodies to HDL and apo A-I 
that can cross-react with CL (Delgado Alves et al., 2003). Levels of anti-HDL 
antibodies have an inverse correlation to levels of paraoxonase activity in patients 
with APS (Delgado Alves et al., 2002).
Whether aPL promotes atherogenesis remains unclear as there is evidence to 
suggest that antibodies to oxidised-LDL may have a protective role. 
Hypercholesterolaemic rabbits immunised with oxidised LDL exhibit reduced 
atherosclerotic development (Ameli et al., 1996). Mice deficient in apo ER2 or LDL 
receptors immunised with oxidised LDL produce anti-oxidised LDL antibodies that 
also seem to have a protective role in atherosclerotic plaque development (George et 
al., 1998b, Zhou et al., 2001). This protective immunity is reduced if mice are
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depleted of B cells (Caligiuri et al., 2002). Passive infusion of aPL also reduces the 
development of atherosclerosis in LDL deficient mice (Nicolo et al., 2003).
It seems likely that given the heterogeneity of aPL, there exist populations of aPL 
which have either protective or harmful effects upon the development of 
atherosclerosis. Identifying epitopes recognised by the protective group of antibodies 
may aid the development of future therapies.
1.5.5 Lessons from pathogenic mechanisms: current and future 
therapies
A host of pathogenic mechanisms have been described accounting for the 
pathogenic effects of aPL. Given the ubiquitous and heterogeneous nature of PL 
matched by the heterogeneity of aPL, it is perhaps unsurprising that there exist 
many different complex mechanisms by which aPL can effect pathogenicity as 
described above. What has become apparent is that current therapies may work 
through mechanisms that were not anticipated when these therapies were first used 
in APS. Heparin used in pregnancy may primarily work by inhibiting complement 
rather than through a direct anti-thrombin II I  effect (Girardi et al., 2004). Aspirin 
may work through multiple mechanisms. As well as an antiplatelet effect, low-dose 
aspirin may stimulate the production of IL-3 that may have a protective role in 
pregnancy (Fishman et al., 1996). More recently aspirin has been shown to inhibit 
aPL activation of ECs in vitro (Dunoyer-Geindre et al., 2004), which could be 
mediated through aspirin inhibition of NF-KB activation (Kopp and Ghosh, 1994, 
Weber et al., 1995). Other newer oral anticoagulants may have some benefit over 
warfarin. Ximelagatran is an oral thrombin inhibitor, as effective as warfarin given in 
a fixed dose with the advantage of not requiring monitoring (Gustafsson and Elg,
2003). However, there are some concerns regarding liver toxicity and the drug at 
present is not licensed in the UK or the USA.
A number of therapies for SLE may be applicable to APS as discussed in section 
1.3.5. TNFa blockade, an established treatment for rheumatoid arthritis, has been 
shown to prevent aPL induced pregnancy morbidity in mice and may represent a 
future therapeutic agent (Berman et al., 2005). Though current licence guidance in 
the UK prohibits the use of TNFa blockade in pregnant women, emerging post­
surveillance data suggests that continuing TNFa blockade therapy during pregnancy 
may not be associated with an adverse outcome (Salmon and Alpert, 2006).
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Hydroxychloroquine, used frequently to treat patients with either SLE or rheumatoid 
arthritis, has anticoagulant properties that may make it useful in the treatment of 
APS. Patients with APS and SLE taking hydroxychloroquine have a reduced risk of 
developing thrombosis (Erkan et al., 2002). This drug when administered to mice 
reduced aPL induced thrombus size and may also inhibit activation of platelets In 
vitro (Edwards et al., 1997, Espinola et al., 2002). The anti-thrombotic and anti­
inflammatory effects of hydroxychloroquine may occur through the interference with 
TLR-mediated cell activation (Rutz et al., 2004) and inhibition of LPS induced MAPK 
signalling (Weber et al., 2002).
Statins are potent inhibitors of cholesterol synthesis and act by inhibiting 3-hydroxy- 
3methylglutaryl-coenzyme A (HMG-CoA) reductase. Large clinical trials of statin 
therapy have shown beneficial effects in terms of primary and secondary prevention 
of cardiovascular related morbidity and mortality (4S., 1994, Furberg et al., 1994, 
Hebert et al., 1997). Experimental evidence suggests that the beneficial effects of 
statins may extend beyond lowering of cholesterol. Their effects include decreasing 
expression of adhesion molecules in monocytes and inhibiting leukocyte-endothelial 
interactions (Niwa et al., 1996, Weitz-Schmidt et al., 2001), down-regulating 
proinflammatory cytokines in ECs (Inoue et al., 2000), enhancing fibrinolysis (Essig 
et al., 1998, Bourcier and Libby, 2000), inhibition of TF expression by monocytes 
(Aikawa et al., 2001, Colli et al., 1997) and inhibition of platelet activation (Huhle et 
al., 1999). Statins have been shown to inhibit aPL induced activation of ECs in vitro, 
as assessed by adhesion molecule expression and activation by NF-KB (Meroni et al.,
2001). Upon passive transfer of aPL in Pierangeli's mouse model of thrombosis, 
fluvastatin reduces aPL induced thrombus size and leukocyte adherence to the 
cremaster muscle blood vessel walls in vivo (Ferrara et al., 2003).
The universal link in the majority of pathogenic mechanisms described is the 
interaction of aPL with antigen to effect the observed response. As described aPL 
from patients with APS bind PL via PL binding cofactors, of which 8 2GPI seems to be 
the most clinically relevant and consequently most studied (reviewed section 1.2.5). 
Understanding how aPL interact with B2GPI at the molecular level could facilitate the 
development of therapies designed to interfere with this interaction. Having 
discussed the clinical features of APS, the characterisation of aPL and the different 
pathogenic mechanisms that arise in APS, I will now discuss in more detail the I32GPI
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protein and current knowledge base addressing the likely nature of the interaction 
between this protein and aPL at the molecular level.
1.6 CHARACTERISATION OF B2GPI IN APS
1.6.1 Molecular structure and function of fi2GPI
6 2GPI was first described in 1961 as a component of the beta-globulin fraction of 
human serum (Schultze et al., 1961). The gene encoding 6 2GPI maps to 
chromosome 17q23-24 (Steinkasserer et al., 1992) and the promoter has recently 
been characterised (Wang and Chiang, 2004). This protein has also been termed 
apolipoprotein H as approximately 40% is bound to lipoprotein, though it bears no 
structural similarity to other apolipoproteins (Lee et al., 1983). The major source of 
production of this glycoprotein is the liver, although mRNA coding for I32GPI has also 
been found in ECs, intestinal epithelial cells, trophoblasts, neurons and astrocytes 
(Caronti et al., 1999, Averna et al., 1997, Chamley et al., 1997). It is synthesised as 
a single polypeptide chain and consists of 326 amino acids with a calculated 
molecular weight of 37.1 kDa. However, the protein has four N-linked carbohydrate 
side chains that account for approximately 2 0 % (w/w) of the total molecular mass. 
Hence, the actual molecular weight of reduced 6 2GPI as assessed using protein gel 
electrophoresis is approximately 50kDa (Lozier et al., 1984). This non-complement 
protein belongs to the complement control protein (CCP) superfamily (Reid and Day, 
1989) that also includes molecules such as complement receptor 1 and 2 (Fearon, 
1979), IL-2 receptor or DAF (Nicholson-Weller et al., 1982). It consists of five short 
CCP repeating domains also termed 'sushi' domains. Of the five CCP domains (DI to 
DV) making up 6 2GPI, four consist of approximately 60 amino acids each. Within 
each of these four domains there are four cysteine residues forming two disulphide 
bonds that contribute to a 'loop-back' structure, with sequence homology between 
the domains ranging from 20% to 40%. Dili and DIV are the only domains to have 
three and one carbohydrate side chains respectively. The fifth C-terminal domain 
(DV) is aberrant, consisting of 82 amino acids due to a six-residue insertion and a 
19-residue C-terminal extension cross-linked by an additional disulphide bond 
(described in more detail in section 1.6.4). Two independent groups have studied the 
crystal structure of B2GPI describing it as having a fishhook like appearance 
(Schwarzenbacher et al., 1999, Bouma et al., 1999). A schematic representation of 
I32GPI binding to PL is shown in figure 1.2.
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Figure 1.2 Schematic representation of ft2GPI binding PL. Domains I-V are 
shown. N-linked carbohydrate chains are shown in green.
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B2GPI exhibits a high degree of conservation among mammals. Human, bovine, 
canine and mouse proteins all have five domains with 60% to 80% homology in the 
amino acid sequence, with DV being the most conserved domain (Steinkasserer et 
al., 1991, Sheng et al., 1997, Gao et al., 1993). Chimpanzee B2GPI has a 99.4% 
amino acid sequence homology with human B2GPI and even shares common 
polymorphisms (Sanghera et al., 2001). 8 2GPI is one of the most abundant proteins 
in the human serum with a mean level of 2 0 0 pg/ml, second only to fibrinogen 
among proteins involved in clotting. Given these observations it is perhaps 
reasonable to presume that 6 2GPI possesses important homeostatic functions, 
though at present it's physiological function has not been fully characterised and 
seems likely to be complex. Data from early in vitro studies demonstrate the ability 
of 6 2GPI to bind structures or surfaces coated with negatively charged 
macromolecules such as anionic PL, heparin, DNA and mitochondria (Schousboe, 
1979, Wurm, 1984, Polz et al., 1980, Kroll et al., 1976). Specifically relating to the 
coagulation pathways, 8 2GPI has been shown to inhibit activation of the intrinsic 
coagulation cascade (Schousboe, 1985), inhibit activation of factor XII (Schousboe 
and Rasmussen, 1995), reduce platelet prothrombinase activity (Nimpf et al., 1986), 
inhibit ADP mediated platelet aggregation (Nimpf et al., 1987) and aid clearance of 
oxidised LDL (Hasunuma et al., 1997).
More recently B2GPI has been shown to bind factor XI and inhibit its activation by 
thrombin and factor Xlla. This process was shown to be regulated by plasmin, which 
'clips' 6 2GPI at a plasmin cleavage site located in DV rendering the protein unable to 
bind factor XI (Shi et al., 2004). This is further complicated by the recent observation 
that B2GPI may act as a co-factor in promoting tPA induced plasminogen activation 
to plasmin, thus promoting the fibrinolytic pathway (see figure 1.1 B) (Lopez-Lira et 
al., 2006). B2GPI has also been shown to promote the clearance of apoptotic bodies 
(Pittoni et al., 2000) and liposomes (Chonn et al., 1995) in vivo. In the liver where 
the bulk of B2GPI is synthesised, it is emerging that it plays an important role in the 
survival of hepatocytes through as yet uncharacterised mechanisms (Averna et al., 
2004).
Clearly the functions of B2GPI are broad, complex and not fully elucidated. The 
balance favours this protein functioning as a natural occurring anticoagulant in both 
health and disease.
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1.6.2 Effects of polymorphisms or deficiencies of &2 GPI: clues to 
function and pathogenicity
Given the ubiquitous nature of this protein and varied functions described, one would 
intuitively expect the absence of functional 6 2GPI to have considerable adverse 
physiological consequences. Curiously, epidemiological genetic studies on humans 
have found that a deficiency of 6 2GPI is not a major risk factor for either thrombosis 
or bleeding (Bancsi et al., 1992, Hoeg et al., 1985). 6 2GPI deficiency, defined 
arbitrarily as 77% less than the mean of the study population, was found to occur in 
approximately 7%, corresponding to the approximate frequency of heterozygous 
deficiency (Yasuda et al., 2000, Bancsi et al., 1992). In contrast a total lack of 6 2GPI 
is uncommon and occurs in approximately 0.3% of individuals (Hoeg et al., 1985). 
One study identified one man homozygous for 6 2GPI deficiency with a history of 
venous thrombosis. This was inherited in an autosomal dominant pattern and he had 
one brother who was also homozygous deficient for B2GPI who had no history of 
thrombosis aged 35 years (Bancsi et al., 1992). One Japanese study of two families 
with complete 6 2GPI deficiency (due to a single nucleotide deletion resulting in a 
frameshift in the B2GPI gene) found all affected members apparently healthy. 
Curiously, one family with 6 2GPI deficiency had elevated levels of LDL though the 
relevance of deficient B2GPI is questionable as the other B2GPI deficient family had 
normal levels (Yasuda et al., 2000). It may be that there are enough 'biological 
buffers' for reduced levels of B2GPI to be tolerated by individuals for normal 
physiological functioning. The effects of being homozygous for 6 2GPI deficiency as 
yet, have not been fully elucidated in humans as it occurs in the population at a very 
low frequency. Studies in B2GPI gene knockout mice show no clinical evidence of 
thromboses with this genotype. These mice, however do exhibit diminished rates of 
thrombin generation compared to B2GPI replete (+/+) mice (Sheng et al., 2001b). 
Pregnant null mutant mice (B2GPI /‘) had a modest reduction of 18% in number of 
viable implantation sites and reduced foetal /  placental weights. Interestingly, the 
B2GPT/' mice were protected from the more severe rates of foetal loss observed on 
passive transfer of B2GPI binding aPL (Robertson et al., 2004). It may be that 
individuals can tolerate diminished levels of B2GPI, however the presence of B2GPI in 
combination with aPL leads to disease.
Other single nucleotide polymorphisms (SNPs) have been identified in this protein, 
but few have functional effects. In total four SNPs have been identified at the DNA 
level that result in amino acid substitutions, one located in the region coding for DII
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(Ser to Asn at position codon 8 8 ) and the other three are located in DV (Val to Leu at 
codon 247, Cys to Gly at codon 306, Trp to Ser at codon 316) (Sanghera et al., 
1997a, Steinkasserer et al., 1993). The SNP at position 316 located in DV has been 
shown to disrupt the binding of 6 2GPI to PL with functional consequences (Mehdi et 
al., 2000). The presence of the B2GPI allele Val at 247 instead of Leu is seen more 
frequently than expected in patients with aPL and APS in the British, Mexican and 
Asian populations that have been studied (Atsumi et al., 1999, Prieto et al., 2003, 
Yasuda et al., 2005). One study of 140 patients presenting with cerebral 
haemorrhage in China detected the B2GPI allele Asn 8 8  to be associated with an 
increased frequency of cerebral haemorrhage as compared to the allele Ser 8 8  and 
attributed this finding to the generation of hypertension seen in patients with this 
SNP (Xia et al., 2004). However, dissecting genetic predisposition may be very 
complex. A recent paper has identified 142 SNPs located In the non-coding regions of 
the 20.3 kb B2GPI gene, which may occur in areas that affect gene regulation and 
ultimately function (Chen and Kamboh, 2006).
1.6.3 Do aPL bind cryptic or non-cryptic epitopes on 6 2 OPI?
Several groups have found that B2GPI coated on an irradiated plate will bind 
monoclonal aPL (Matsuura et al., 1994) or polyclonal aPL (Chamley et al., 1999), but 
not when B2GPI is coated on polystyrene plates, even at high densities. The authors 
postulated that this effect was due to conformational change of 6 2GPI upon binding 
an irradiated plate facilitating aPL binding. Indirect methods to detect structural 
changes in B2GPI have been used such as infrared spectroscopy (Borchman et al.,
1995), spectrophotometry to produce circular dichroism (Subang et al., 2000) and 
microcalorimetry (Hammel et al., 2001), which infers an alteration in structure of 
B2GPI upon binding PL. Hammel et al used X-ray scatter to infer an S-shaped 
structure of B2GPI in the fluid phase, as opposed to the fishhook structures of the 
published crystal. The authors postulated that DII and Dili were flexible and could 
be rotated. Modelling studies, in which these domains were rotated, revealed a 
change from the fishhook shape to that of the S-shape (Hammel et al., 2002).
There is also evidence to support that aPL binding to 6 2GPI may be dependent upon 
the density of B2GPI coated on a plate or PL, rather than the exposure of cryptic 
epitopes. Roubey et al demonstrated that aPL binds B2GPI coated on irradiated plates 
only at a density that exceeds that which may be coated on non-irradiated plates 
(Roubey et al., 1995). A variant of B2GPI that spontaneously dimerises has been 
produced using an insect cell expression system. This variant was shown to bind aPL
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more effectively than wild-type B2GPI suggesting divalent binding (Sheng et al., 
1998). Divalent binding has also been suggested by other work demonstrating that 
divalent and not univalent aPL F(ab) 2 bind B2GPI. Using surface plasmon resonance, 
molar ratios of monoclonal aPL binding to B2GPI immobilised on a chip approximated 
to 0.5, suggesting divalent binding (Regnault et al., 1999). In a more recent study, 
flow cytometry studies of 6 2GPI binding platelets expressing anionic PL found that 
B2GPI at physiological ionic strengths demonstrates poor binding to platelets, 
however at low ionic strengths or in the presence of bivalent F(ab)2, this binding was 
greatly enhanced. The same effects were not observed with univalent F(ab) 
fragments (Bevers et al., 2005).
There is thus conflicting evidence for and against the presence of a cryptic epitope 
and this on going debate has been reviewed by Giles et al (Giles et al., 2003c). Given 
the heterogeneity of aPL, it is possible that some recognise cryptic epitopes and 
others bind 6 2GPI in a divalent fashion. Another possibility could be that both occur. 
Divalent binding of B2GPI by aPL is necessary for cell activation, and this binding may 
be facilitated by alteration in conformation of 8 2GPI upon binding PL. Two recent 
studies from de Groot's group support this theory. In one study the recombinant 
variant of B2GPI that dimerises was shown to bind apo ER2 (family member of LDL 
receptors) on the surface of platelets and cause spontaneous activation of these cells 
even in the absence of aPL, which were required to activate platelets in the same 
manner when native B2GPI was used (van Lummel et al., 2005). In another study 
two populations of anti-B2GPI antibodies were identified. One termed type A were 
derived from patients with thrombosis and were capable of binding G2GPI only if 
coated onto anionic PL and not in the fluid phase. The other population type B were 
derived from patients with no history of thrombosis /  APS and were capable of 
binding 8 2GPI in both solid and fluid phase. Type A antibodies could, however, bind 
B2GPI in the fluid phase upon deglycosylation of this protein. These studies support 
the theory that B2GPI binds anionic PL and exposes epitopes due to displacement of 
carbohydrate side changes, which then allows aPL to bind clustered B2GPI facilitating 
dimerisation and effecting cell activation.
The location of immunodominant epitopes that are recognised by pathogenic aPL on 
the surface of B2GPI has been debated in the literature. Various groups have 
implicated a number of different domains as harbouring these epitopes. Each domain
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will be discussed in turn and the evidence supporting each as containing aPL binding 
epitopes critically analysed.
1.6.4 DV of &2GPI: anchor to phospholipid
The 6 2GPI protein contains two highly conserved cationic regions rich in positively 
charged amino acids, one in DI and the largest in the C-terminal DV. A 2000 A large 
patch of 14 positively charged amino acids between 274-Glu and 288-Cys within DV 
(12 Lys, one Arg and one His residue) provides the electrostatic interactions with the 
anionic head groups of PL. The area where cationic charge is particularly 
concentrated is between residues 282 and 287 (282-Lys-Asn-Lys-Glu-Lys-Lys-287 -  
KNKEKK). This is stabilised by a hydrophobic loop located between residues 311-Ser 
and 317-Lys that inserts into PL and is schematically represented in figure 1.2 
(Schwarzenbacher et al., 1999, Bouma et al., 1999). Hunt et al demonstrated that a 
peptide sequence spanning the area 274-Glu to 288-Cys could inhibit binding of 
8 2 GPI to CL, and the inhibitory activity of this peptide was restricted to the 
particularly Lys rich region KNKEKK. Peptides that span other areas of DV had no 
such inhibitory effects (Hunt and Krilis, 1994). Further mutational studies by Sheng 
et al showed that altering Lys residues in the region 282 to 287 had the effect of 
reducing binding of B2GPI to CL. Reduction in binding was proportional to a number 
of Lys residues altered in this area (Sheng et al., 1996). The C-terminal end of the 
hydrophobic loop also constitutes a plasmin cleavage site and is a target in vivo. 
Plasmin cleavage of 6 2GPI between residues 317-Lys and 318-Thr has the effect of 
impairing the ability of this protein to bind PL. 6 2GPI cleaved in this manner has been 
termed in the literature as 'nicked' or 'clipped' (Hunt et al., 1993, Ohkura et al.,
1998). Clipping 6 2GPI also impairs the ability of this protein to bind factor XI (Shi et 
al., 2004) and heparin, with heparin enhancing the ability of plasmin to clip 6 2GPI 
(Guerin et al., 2002). There are two polymorphisms within 6 2GPI at positions within 
or adjacent to the PL binding site. One at codon 316 is a substitution mutation of Trp 
to Ser located within the hydrophobic loop and another at codon 306 is a substitution 
of Cys for Gly, which disrupts the disulphide bond with 281-Cys, located within the 
cationic region. 6 2 GPI purified from individuals homozygous for 316-Ser/316-Ser or 
compound heterozygote 316-Ser/306-Gly failed to bind PL (Sanghera et al., 1997b). 
Introducing these mutations into the native cDNA sequence of the 6 2GPI gene and 
expressing recombinant mutagenised 8 2GPI had the same effect (Mehdi et al., 2000).
Work by Gharavi et al has implicated DV as being important for aPL binding. Mice 
immunised with whole 6 2 GPI develop aPL (Gharavi et al., 1992). Further work
99
demonstrated that a synthetic peptide named GDKV spanning 274-Gly to 288-Cys of 
DV could also induce aPL when used to immunise mice. The GDKV induced aPL 
enhanced thrombus formation in vivo and induced activation of ECs (Gharavi et al.,
1999). A peptide derived from CMV named TIFI that is capable of binding PL has also 
been shown to induce thrombogenic aPL formation in mice (Gharavi et al., 2002).
Studying the crystal structure of 6 2GPI reveals the presence of the hydrophobic loop 
adjacent to the region homologous to the GDKV peptide used by Gharavi and 
colleagues. Given that this region is so closely applied to PL, it is unlikely that the 
majority of important aPL binding epitopes are contained within this domain. Also, 
given that the domains share up to 40% homology, it is possible that the GDKV 
peptide shares homology to other areas of 6 2GPI, which may be more amenable to 
aPL binding.
1.6.5 Dill and DIV of B2GPI: evidence for and against aPL binding
The production of mutants of 6 2GPI with one or more domains deleted has helped 
elucidate which domains harbour important antibody binding epitopes. These domain 
deletion mutants of B2GPI were produced using baculovirus to infect insect cells 
Spodoptera frigiperda (Sf9) as the expression host (Igarashi et al., 1996). Igarashi et 
al (Igarashi et al., 1996) and George et al (George et al., 1998d) demonstrated that 
a mutant 6 2GPI containing only the first four domains (DI-DIV), thus lacking DV, 
failed to bind CL. One would expect this, given the evidence described in the section 
above. This 6 2GPI mutant I-IV bound a murine anti-6 2GPI antibody WB-CAL-1 better 
than whole 6 2GPI and mutant domain I- III (mutant B2GPI that lacked both DIV and 
DV) both in solid and fluid phase assays. Cof-21 is a mouse mAb directed against 
DIV. The authors demonstrated that human aPL could compete with binding of Cof- 
21 to B2GPI coated on a plate, but not with other mAbs that recognise epitopes 
present in DIV to DV (George et al., 1998d). The conclusions drawn were that DIV 
most likely contains the crucial aPL binding epitopes. However, these studies would 
have been more compelling if binding to DIV alone had been demonstrated.
Koike et al produced four mutants of whole 6 2GPI with incorporated single point 
mutations within DIV. These mutant forms of B2GPI exhibited reduced binding in the 
solid phase to 24 out of 30 polyclonal aPL samples derived from patients with APS 
(Koike et al., 2000). However, these mutant forms of 6 2GPI have subsequently been 
shown to bind aPL in the fluid phase (Iverson et al., 2002a). It therefore seems more 
likely that the mutations introduced within DIV by Koike et al produce a
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conformational change resulting in either reduced binding of protein to the ELISA 
plate, or reduced exposure of the true epitopes to some aPL when this protein is 
bound to the plate. This theory is supported when one looks at the mutations 
incorporated. Three of the four mutants targeted negatively charged amino acids 
(193-Asp, 222-Asp, 228-Glu) mutating them to neutral Val. This would be likely to 
disrupt electrostatic bonds within the protein resulting in conformational change. 
Also, six out of 30 aPL samples tested, in fact, exhibited enhanced binding to the 
mutant forms of B2GPI, suggesting that the conformational change favoured the 
exposure of epitopes recognised by these aPL (Koike et al., 2000).
Blank et al identified two peptides that bind human anti-8 2GPI mAbs ILA-3 and H-3 
by screening hexapeptide phage display libraries. Both of these monoclonal aPL have 
been shown to exhibit thrombogenic pathogenicity in mice. The peptide that bound 
ILA-3 had sequence homology to a region located in Dili and that which bound H-3 
had sequence homology to a region within DIV. The hexapeptides expressed, 
demonstrated low affinity binding to the mAb aPL tested and they were lengthened 
to 208-KDKATFGCHDGC-219 named peptide B (region in DIV) and 131- 
CATLRVYKGG-140 and named peptide C (region in D ili). Both these peptides 
inhibited their corresponding antibody from activating human ECs in vitro and also 
prevented the induction of foetal loss in pregnant BALB/c mice on infusion of ILA-3 
and H-3 in vivo (Blank et al., 1999). These peptides were subsequently tested for 
binding to human polyclonal aPL derived from patients with APS. Binding at low to 
moderate levels was observed in only nine out of 43 samples tested, with high 
binding observed in only one patient sample. A subsequent multicentre study by 
Shoenfeld et al went on to characterise the binding of six peptides, two of which 
constituted peptide B (DIV region) and peptide C (D ili region), and another three 
(including the GDKV peptide) that have been shown to bind PL (DV cationic region). 
The ability of these peptides coated on a plate to bind sera derived from a total of 
295 APS patients was tested. Binding levels three standard deviations (SDs) above a 
mean obtained by testing 1 0 0  healthy controls was considered positive. 
Approximately 85% of aPL samples bound at least one peptide. However, no 
individual peptide bound more than 50% of samples and no other irrelevant peptide 
was used as a negative control. In addition, it was unclear if standards were used for 
each individual plate to take account of interplate variability and binding to pure IgG 
aPL in the fluid phase was not tested (Shoenfeld et al., 2003).
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On studying the crystal structure of B2GPI, bound to Dili and DIV are a total of four 
carbohydrate molecules (Schwarzenbacher et al., 1999) (figure 1.2). It is likely that 
these large sugar molecules would shield aPL from interacting with any epitopes that 
may be located within DIV. Recombinant whole B2GPI expressed from insect cells has 
a molecular weight of 43 kDa, as opposed to 50 kDa as observed when reduced 
6 2GPI purified from humans is run on an electrophoretic protein gel (Igarashi et al., 
1996). This discrepancy is likely to be due to inefficient glycosylation of proteins by 
insect cells as compared to mammalian cells. In theory less or altered glycosylation 
present in recombinant B2GPI expressed by insect cells could expose epitopes that 
would otherwise be hidden in native protein. On critically reviewing the evidence and 
from studying the structure of 6 2GPI, support favouring the presence of crucial aPL 
binding epitopes located in DIV or D ili is on the whole weak. It is more likely that 
biologically important epitopes bind other more amenable domains.
1.6.6 Dl of &2GPI: evidence of aPL binding
Iverson et al studied the binding of B2GPI domain deleted mutants produced using 
the insect cell expression system developed by Igarashi et al (Igarashi et al., 1996). 
Mutants of B2GPI containing the N-terminal domain (DI) combined with other 
domains bound polyclonal IgG aPL derived from 11 patients with APS in both solid 
and fluid phase assays. However, domain deleted mutants of B2GPI that lacked DI 
exhibited very low or no evidence of binding to aPL. The B2GPI mutants that lacked 
DI were mutants with DII to DIV, Dili and DIV and DIV alone. If DIV was important 
in conferring binding to aPL as suggested by two other studies discussed in the 
section above (Igarashi et al., 1996, George et al., 1998d), then one would have 
expected these mutants to also bind aPL. The data by Iverson et al supports the 
theory that aPL binding epitopes are located within DI rather than DIV. This is 
underlined by the observation that binding of aPL to DI alone was demonstrated 
(Iverson et al., 1998b).
Further evidence exists from numerous other groups supporting DI as containing the 
probable immunodominant aPL binding epitopes. Reddel et al also tested binding of 
27 serum samples from patients with APS against binding to a domain deletion 
mutant lacking DV (DI-IV) and one lacking DI (DII-V). All serum samples tested 
bound DI-IV mutants to a level comparable with wild-type 6 2GPI, whilst all showed 
significantly reduced binding to the DII-V mutants (Reddel et al., 2000). Surface 
plasmon resonance has been employed to study the binding of 106 APS serum 
samples to native B2GPI and various domain deletion mutants (II-IV ) of B2GPI
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immobilised on a chip. For those mutants lacking DI, a significant reduction in 
binding was observed, with almost half of the total APS patient serum samples 
showing almost complete loss of binding to the domain deletion mutants lacking DI 
(McNeeley et al., 2001). Incubation of soluble 6 2 GPI with staphylococcal V8 in 
another study resulted in a 50% reduction in binding to aPL serum samples derived 
from 15 APS patients. A cleavage site for this enzyme resides within DI (Guerin et 
al., 2000). Sheng et al characterised the LA activity of a panel of monoclonal aPL 
derived from either human patients with APS or mice immunised with 6 2GPI or NZW 
x BXSB mice with an APS /  lupus like syndrome. Monoclonal aPL that bind DI cause 
considerable prolongation of the dRWT and kaolin clotting time, thus exhibiting LA 
activity. Monoclonal aPL binding to Dili exhibited less LA activity, with no effect on 
kaolin clotting time whilst monoclonal aPL that bound DIV or DV had no LA activity 
(Sheng et al., 2001a). Another more recent study by de Laat et al has demonstrated 
that a sub-set of anti-B2GPI antibodies derived from patients with thrombosis bind DI 
and do not bind a variety of domain deletion mutants lacking DI. However, anti- 
B2GPI antibodies derived from patients with no history of thrombosis do bind other 
domain deletion mutants that lack DI (de Laat et al., 2005). This study suggests that 
aPL that bind DI are more likely to be pathogenic as compared to aPL that bind 
epitopes located within other domains of B2GPI.
1.6.7 Candidate epitopes within DI
The evidence for DI harbouring immunodominant binding epitopes for the majority 
of pathogenic aPL is compelling. This is underlined by the fact that DI is the most 
exposed of all the domains within B2GPI, as it is at the N-terminal and lacks 
glycosylation (figure 1.2), thus making it more amenable to aPL targeting. But which 
region of DI do the majority of aPL bind? Current evidence addressing this will be 
discussed and critiqued in some depth.
1.6.7.1 Clues from antigen mutational, binding and structural studies
One may argue that the differing effects of binding from one domain deletion mutant 
of B2GPI to the next may potentially be attributed to changes in conformation of 
whole protein introduced by virtue of the lack of one or more domains. In theory this 
could either expose neo-epitopes or result in the shielding of true epitopes present in 
the native protein. To account for this whole B2GPI has been produced by Iverson 
and colleagues with single point mutations incorporated within DI in an attempt to 
define further the precise immunodominant aPL binding epitopes. Phage-displayed 
peptide libraries were screened in which peptide fragments of DI were expressed as
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a fusion with the protein pill. The mutations were created by error-prone PCR such 
that an average of one mutation in DI was generated within each phage clone. A 
phage micropan assay was used to screen individual phage for the ability to bind 
affinity purified aPL from APS patients. Based on this system phages with 
substitution mutations covering half of the DI molecule were identified. Ten with 
variable effects on binding to aPL were chosen and these mutations were 
incorporated into whole B2GPI and whole protein expressed in insect cells (Iverson et 
al., 2002b). Reddel et al studied two of these B2GPI single point mutants, with one 
mutant substituting a Gly to Glu residue at position 40 (G40E) and the other Arg to 
Gly at position 43 (R43G). Binding was tested to 27 serum samples from patients 
with APS. A moderate decrease in binding was observed in 10 out of 27 serum 
samples to G40E and seven out of 27 to R43G. Also noted was significantly enhanced 
binding of one serum sample to R43G as compared to wild-type 8 2 GPI. The mutant 
B2GPI with the Thr to Ala substitution at 50 (T50A) reduced binding to seven 
samples, but also significantly enhanced binding to seven other APS serum samples. 
These results suggested that G40 and R43 within DI could be important in conferring 
binding to aPL and also underlined the heterogeneic nature of these antibodies. 
Iverson et al went on to test G40E, R43G, T50A as well as another seven mutants of 
B2GPI with single point substitution mutations located within DI. All 10 mutants 
bound equally well in both solid and fluid phase assays to three murine mAb anti-DI 
antibodies that recognise conformationally restricted epitopes, suggesting that the 
incorporated mutations did not introduce significant conformational change within 
the protein structure. Binding to B2GPI affinity purified IgG aPL in the fluid phase was 
significantly reduced for mutants G40E and R43G and largely unchanged for the 
other mutants. Binding in the solid phase was less consistent and was reduced by 
more than 50% to only four out of eight aPL for G40E and five out of eight for R43G, 
with many other mutants such as D8 A, K33E, M42K and M42V curiously resulting in 
enhanced binding to the majority of affinity purified aPL as compared to wild-type 
B2GPI (Iverson et al., 2002b). A recent study demonstrated that anti-B2GPI 
antibodies that do not bind 8 2 GPI mutants G40E or R43G, are more likely to have LA 
activity and be derived from patients with a history of thrombosis as compared to 
anti-B2GPI antibodies that bind these mutants (de Laat et al., 2005).
These results prompted the authors Iverson et al to suggest that "the charged 
surface patch defined by residues 40-43 contributes to a dominant target epitope" 
for aPL binding DI (Iverson et al., 2002b). It seems likely that this region is indeed
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important however, there remain a number of unanswered questions arising from 
these very important mutational binding studies. One criticism could be that the 
nature of the mutations incorporated were as a result of a random process through 
error prone PCR, and not through a hypothesis driven approach derived from 
structural or binding analyses of the protein. For example, the effects of the charge 
altering G40E mutation could be due to the fact that this residue is adjacent to Arg 
39. On studying a computer model of 6 2 GPI using Swiss-Model software (Guex and 
Peitsch, 1997, Peitsch, 1996) and the crystal structure of 6 2GPI (Schwarzenbacher et 
al., 1999) the residue Arg-39 has over 50% of its surface area exposed for potential 
interaction with other amino acids. This is more than any other residue within DI of 
6 2 GPI. Only half of the residues within DI were studied by Iverson's group and hence 
the effects of mutating R39 residue may not have been characterised. If aPL do 
recognise this linear epitope as suggested by the authors, then it is surprising that 
many do not bind to denatured I32GPI (Sheng et al., 2001b). Also, incubation of 
soluble I32GPI with staphylococcal V8 results in reduced binding to aPL. This enzyme 
cleaves DI at position 20, hence one may expect to see binding largely unaffected if 
linear epitopes residing further along the protein from this region were dominant 
(Guerin et al., 2000). All these observations suggest that other regions of DI are also 
important and that aPL binding to DI may be more complex.
The binding abilities of a peptide (peptide A) that bears sequence homology to the 
N-terminal half of the D I-II interlinker region have been tested (table 1.6). This 
peptide prevented foetal loss induction by aPL in mice in vivo and activation of ECs in 
vitro by affinity purified aPL (Blank et al., 1999, Shoenfeld et al., 2003). Pierangeli et 
al demonstrated the ability of peptide A to inhibit aPL-mediated thrombosis in mice. 
A scrambled peptide used as a negative control had no such inhibitory effect 
(Pierangeli et al., 2004a). If the region 40-43 is dominant then one may reasonably 
expect peptide A not to have a significant aPL inhibitory effect in vivo. On studying 
the crystal structure of 6 2 GPI, the region 40-43 comes into close approximation with 
the DI-II interlinker region (57-67) (Schwarzenbacher et al., 1999). It may be that 
aPL recognise discontinuous epitopes, or that mutations within the 40-43 region may 
disrupt the exposure of important epitopes elsewhere. The observation that a 
peptide homologous to the D I-II interlinker region binds aPL may in fact provide an 
explanation why some groups have published studies suggesting that DIV harbours 
aPL binding epitopes. (Igarashi et al., 1996, George et al., 1998d). Though possible, 
it is unlikely that aPL recognise completely different epitopes within the same
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protein. It is more likely that aPL recognise homologous regions within B2GPI that 
may contain only slight differences in peptide sequences, and that DI has been 
identified as the domain containing the immunodominant epitopes given its 
accessibility. This theory of epitope spreading is supported by the fact that different 
domains within 8 2GPI have 20% to 40% homology. The D I-II interlinker region is 
homologous in amino acid sequence to the DIII-IV interlinker region, with no such 
homology existing between the other interlinker regions (Steinkasserer et al., 1991) 
(table 1.6). In theory epitopes within the DIII-IV interlinker region of a B2GPI mutant 
protein expressed by insect cells may have greater exposure than is present in native 
protein due to suboptimal glycosylation that occurs in the expression of heterologous 
protein by these cells. Thus epitopes present in DI homologous to epitopes exposed 
within other domains such as DIV may also bind aPL, perhaps accounting for the 
ongoing debate as to which domain binds the majority of aPL.
Another unanswered question from the Iverson et al study was the observation that 
the mutations D8 A, K33E, M42K and M42V resulted in enhanced binding to seven out 
of eight B2GPI affinity purified aPL tested as compared to wild-type B2GPI (Iverson et 
al., 2002b). This finding was not discussed but is of importance as a peptide that can 
bind the majority of aPL better than native B2GPI may be of therapeutic potential. 
Hence, further studies investigating the possibility of producing such peptides are 
warranted and are feasible given these observations.
Protein region Peptide sequence
Domain I-II interlinker (57-68) NTLKCTPRVCPF
Domain II- II interlinker (113-124) PELPVCAPIICP
Domain III-IV  interlinker (174-188) NWTKLPECREVKCPF
Domain IV-V interlinker (235-248) WSAM PSCKASCKLP
Synthetic peptide A NTLKTPRVGGC
Table 1.7 Amino acid sequences of domain interlinker regions within &2GPI
Homologous amino acid sequence between DI-II interlinker, DIII-IV interlinker and 
synthetic peptide A (Blank et al., 1999) is underlined.
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1.6.7.2 Clues from aPL mutational binding studies
Investigations studying the consequences of alterations within aPL to binding CL or 
whole B2GPI may also be of some use in terms of inferring which aspects of the 
antigen may be important. Dr Ian Giles in our laboratory has performed such studies 
on IS4. This is a monoclonal human aPL which binds anionic PL and B2GPI and has 
proven thrombogenicity in mice in vivo (Pierangeli et al., 2000). Sequence analysis of 
IS4 and other human monoclonal aPL have revealed an accumulation of positively 
charged Arg and Lys residues in their antigen binding CDRs. These residues have 
arisen through somatic mutation and are present in numbers greater than one would 
expect by chance, inferring the presence of antigen driven preferential selection 
(Giles et al., 2003b). A mammalian expression system for aPL has been developed in 
this unit to produce whole antibodies with the VH of one antibody paired up with the 
VL of a different antibody. This development has been achieved through a transient 
expression system using COS-7 cells and more recently via a stable system using 
Chinese Hamster Ovary (CHO) cells (Lambrianides et al., 2004). These studies have 
demonstrated that IS4VH rather than IS4VL was dominant in conferring binding to CL 
(Giles et al., 2003a). Subsequently, mutational studies identified two adjacent Arg 
residues at positions 100 and lOOg in IS4Vh/CDR3 as having a major influence on 
binding to CL (Giles et al., 2005). Arg residues may interact with other amino acids 
either through the donation of H-bonds or given their positive charge through 
electrostatic interactions with negative charged residues (Stryer, 1988). On studying 
the amino acid sequence of DI of B2GPI, this domain is unique in that it contains two 
groups of clustered negatively charged residues - two Asp (D) residues at position 8  
and 9 and three Glu (E) residues at position 23, 26 an 27. DIV also contains three E 
residues in a cluster and two D residues that are not adjacent to each other 
(Steinkasserer et al., 1991). Thus, one possibility is that positively charged Arg 
residues on aPL could form important electrostatic interactions with negatively 
charged epitopes exposed on DI.
1.6.7.3 Conclusion on likely epitopes
In conclusion, it is likely that the region identified by Iverson et al (40-43) is 
important. However, more detailed mutational studies need to be undertaken, 
particularly of charged residues lying adjacent to this region such as Arg 39 to define 
this area more thoroughly. Furthermore, one needs to rationalise how this fits in with 
the observations that the D I-II interlinker region is important, given the aPL 
inhibitory effects of peptide A homologous to this region. Crystal structure analysis
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and computer modelling studies could help in identifying which regions lie adjacent 
to the region 39-43 and the interlinker region. Site-directed mutagenesis of DI could 
target these regions, and the negatively charged epitopes, to investigate what 
effects charge altering or charge conserving mutations would have on binding aPL. 
Also the observations that some mutations could enhance binding to affinity purified 
aPL over wild-type 6 2GPI merit further exploration given the therapeutic implications 
of such peptides. A study by de Laat et al suggests that carbohydrate molecules from 
other domains restrict access to DI when 8 2GPI is in the fluid phase, but on binding 
to anionic PL a conformational change in the position of carbohydrate residues opens 
up dominant epitopes within DI (de Laat et al., 2006b). A system of expressing and 
mutating non-glycosylated DI would aid in addressing the uncertainties surrounding 
the nature of these dominant epitopes. Such a platform of production could also be 
used to investigate the degree to which different mutations within DI could not only 
reduce but also enhance binding to aPL, which could aid in the eventual development 
of therapeutic blocking peptides or peptide mimetic agents. An expression system in 
Escherichia coli (E.coli) could offer such a platform of DI production, given the 
relative ease and efficiency of established prokaryotic expression systems. Other 
groups such as Iverson, Linnik and colleagues have attempted to establish such a 
system of DI production but have been unsuccessful (via personal communication). 
The following section will discuss recombinant protein biotechnology more broadly, 
with particular emphasis on prokaryotic platforms of protein production.
1.7 PRODUCTION OF RECOMBINANT PROTEINS
The rapid advancement in recombinant protein biotechnology over the last 10-20 
years has seen a very diverse spectrum of proteins, peptides, monoclonal antibodies 
and antibody fragments produced for almost equally diverse purposes. In some 
applications a large array of proteins /  antibodies are needed in relatively small 
quantities for scientific purposes such as verification of the identity of a protein or 
cloned gene, or studies on the function and structure of a protein. The high end of 
the spectrum involves the production of human therapeutic proteins that are 
required in quantities approaching the metric ton scale, whilst posing extreme 
demands in terms of product quality and safety. One report states that biotech drugs 
accounted for more than 35% of the 37 substances launched in 2001 (Tang et al., 
2004). Most of these are antibodies and examples of successful drugs launched are 
remicade (Infliximab®), etanercept (Enbrel®), adalimumab (Humira®) and rituximab 
(Mabthera®) that have revolutionised the treatment of rheumatoid arthritis and other
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inflammatory diseases (Maini et al., 1999, Moreland et al., 1999, Weinblatt et al., 
2003, Edwards et al., 2004). The majority of therapeutic proteins have been 
produced in either mammalian cell-culture systems, with CHO cells representing the 
most common system, or in E.coli (Chu and Robinson, 2001, Swartz, 2001).
1.7.1 Production of eukaryotic proteins in prokaryotic cells
E.coli is the most frequently used prokaryotic expression host for the production of 
heterologous proteins. This popularity is by virtue of its efficiency, cost-effectiveness 
and potential for high-level production as an expression host (Hannig and Makrides, 
1998). E.coli was the first host to produce a recombinant DNA pharmaceutical, 
enabling the approval of Eli Lilly's recombinant human insulin in 1982 (Kroeff et al., 
1989). The success of this and subsequently bovine growth hormone, produced also 
in E.coli, was due to the cost-efficient, highly effective and scaleable process of 
protein production that E.coli offers (Swartz, 2001). The disadvantages however, are 
that some eukaryotic proteins may be toxic to E.coli, there may be a tendency for 
proteins to not fold correctly and form inclusion bodies and proteins which require 
significant post-translational modifications, such as the addition of carbohydrate 
molecules cannot be achieved in E.coli.
Even with eukaryotic proteins that do not require glycosylation, there is no guarantee 
that a recombinant gene product will accumulate in E.coli at high levels in a full- 
length and biologically active form. Strategies for achieving these goals are focussed 
on optimising essential components of the expression vector, consideration of codon 
usage, choice of cellular compartment for protein expression, minimising proteolysis 
and the use of fusion proteins.
1.7.1.1 Expression o f target protein by E.coli
Optimal design of the expression vector is crucial to the successful induction of 
target protein expression by E.coli. Factors to consider in the choice of expression 
vector include the type of promoter, incorporation of additional sequences (such as a 
leader sequence, fusion or tagged sequences), selective antibiotic resistance, plasmid 
copy number, restriction sites available within the multiple cloning site, nature of the 
inducing agent and the degree to which basal production of target protein can be 
regulated. Figure 1.3 schematically represents a typical example of target gene 
transcription and regulation, with transcription driven by the 17 promoter using a 
pET plasmid (Studier and Moffatt, 1986). The RNA polymerase specific for the T7 
promoter is T7 RNA polymerase. Hence, the E.coli cell must have a gene encoding
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for this polymerase otherwise expression of target gene cannot take place. If the cell 
has a chromosomal copy of the T7 RNA polymerase gene, then production of this 
polymerase specific for the T7 promoter can initiate transcription at this site on the 
plasmid. Transcription of the target gene by T7 polymerase will continue until a 
specific terminator sequence known as the transcription terminator (TT) is 
encountered downstream of the target gene. Translation of the mRNA sequence then 
requires a Shine-Dalgarno sequence followed by an initiation codon, which is most 
commonly AUG. Translation of the target gene mRNA occurs and is terminated upon 
encountering a stop codon such a UAA, UGA or UAG.
This process of protein expression must be tightly controlled, particularly if the target 
protein is toxic to E.coli. If a toxic protein is produced even at low levels prior to 
induction, the bacterial cells will not have the opportunity to replicate to a sufficient 
density to produce any significant amount of product. This process may be regulated 
by the production of factors either at the chromosomal level or plasmid level. The 
most common regulator employed is the production of a lac repressor by the lacl 
gene (Deuschle et al., 1986). A chromosomal copy of this gene can regulate the 
production of the transcribing RNA polymerase. For example, a chromosomal copy of 
the lacl gene results in the production of the lac repressor, which then binds at a 
lacilV5 operator sequence present within the promoter upstream to the T7 RNA 
polymerase gene. On encountering lactulose, or more usually an analogue of 
lactulose with a longer cell half life such as ispopropyl-B-D-thiogalactopyranoside 
(IPTG), this binds the lac repressor, freeing up the lacilVS promoter to enable host 
E.coli RNA polymerase to drive the production of T7 RNA polymerase and hence 
transcription of target gene. This process may be further regulated if a lac operator 
sequence is present immediately downstream of the promoter sequence within the 
plasmid. The plasmid must then also contain a copy of the lacl gene. Additional 
repression by lac at this T7/ac promoter would then also inhibit transcription of the 
target gene by any T7 RNA polymerase that may have 'leaked' out (Studier and 
Moffatt, 1986). The addition of IPTG binds the lac repressor preventing inhibition by 
the operator at both the chromosomal and plasmid levels, switching on or 'inducing' 
target protein production (see figure 1.3). The choice of promoter is governed by 
several criteria. It should be capable of induction in a simple manner, such as the 
addition of an inducing agent, like IPTG for example. However, for large-scale 
production of therapeutic proteins IPTG is not suitable given cost and toxicity 
(Hannig and Makrides, 1998). The introduction of a lacl thermosensitive repressor
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provides a convenient alternative for the large-scale production of therapeutic 
proteins by E.coli (Adari et al., 1995, Hasan and Szybalski, 1995). The promoter 
should also exhibit minimal level of basal production and ideally be repressible. 
Importantly it should be a strong promoter and be capable of protein production, 
ideally in excess of 10% to 30% of total cellular protein (Hannig and Makrides, 
1998). Contaminant E.coli or cells that lose plasmid will replicate rapidly and 
subsequently overgrow within the culture flask, inhibiting protein expression and 
growth of cells harbouring plasmid. The presence of an antibiotic resistance gene 
allows the supplementation of growth media with the relevant antibiotic killing cells 
lacking this gene. The addition of protein 'tags' such as hexahistidine (hise) tags or 
glutathione S-transferase may aid subsequent purification of target protein using 
chromatography columns that bind the incorporated tag.
1.7.1.2 Consideration o f codon usage
Different cell species derived from primates to yeast cells to prokaryotic cells each 
use a specific subset of the 61 available amino acid codons for the production of 
mRNA molecules (Wada et al., 1992, Lloyd and Sharp, 1992, Zhang et al., 1991). 
The appearance of rare codons within E.coli correlates with low levels of cognate 
tRNA species. There are approximately 20 codons that occur with a frequency of less 
than 10 per 1000 codons in E.coli, the least frequent being Arg coding codons 
AGG/AGA occurring 1.4 per 1000 codons (Kane, 1995) and the presence of many of 
these codons in a gene leads to reduced protein synthesis and cell growth (Zahn, 
1996).
Hence target genes that contain many of these codons that are rarely used by E.coli
will express at low levels. This is particularly evident if these codons occur in clusters
of two to five codons in length (Kane, 1995). Broadly two strategies have been
employed to minimise the effects of preferential codon usage by E.coli. One method
is by modifying the codons within the target gene to alter them to 'major' ones that
occur with greater frequency (Hu et al., 1996, Hua et al., 1994, Martin et al., 1995).
Another method could be to expand the intracellular pool of tRNA by co-expressing
genes that encode for such minor codons such as the argil (dna Y) gene that
encodes the minor tRNA-Arg (AGG/AGA) (Brinkmann et al., 1989). This expansion
may be achieved by using commercially available E.coli strains that contain an extra
plasmid for the minor tRNAs. Although these strains may be efficient in producing
large amounts of some proteins (Kleber-Janke and Becker, 2000), the commercially
available plasmids at present only encode for up to six rare tRNAs. Hence one may
i l l
still expect translational problems if the eukaryotic sequence contains clusters of 
minor codons not supplied by these plasmids. This may explain why the former 
method of codon optimisation within the target gene is used more frequently (Kane, 
1995).
Exoli nucleus Exoli cytoplasm Growth media
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Figure 1.3 Schematic representation of expression vector and elements of 
regulation. Abbreviations: E.coli, Escherichia coir, 17 RNA poly gene, 17 RNA 
polymerase; SD, Shine-Delgarno; RBS, ribosomal binding site; TT, transcription 
terminator; ori, origin of replication; IPTG, ispopropyl-B-D-thiogalactopyranoside.
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1.7.1.3 Choice o f cellular compartment
The three compartments where expressed proteins may be targeted are the 
cytoplasm, the periplasm and the culture medium. Each has its set of advantages 
and disadvantages.
Expressing protein within the cytoplasm has the advantage of requiring simpler 
plasmid constructs as additional leader sequences do not have to be incorporated. 
Also, given that this is the largest cellular compartment, there is potential for higher 
protein yields. Insoluble aggregates of protein termed inclusion bodies are a frequent 
consequence of cytoplasmic protein expression. Multiple cysteine and proline 
residues, hydrophilicity and total number of residues are the major physiochemical 
parameters that correlate with inclusion body formation (Wilkinson and Harrison, 
1991). This may be an advantage as inclusion bodies are protected from protease 
degradation, easily recoverable and inactive so cannot harm host. However, the 
resolubilisation process of inclusion bodies is time consuming and expensive and 
precludes large-scale production (Georgiou and Valax, 1996). Strategies such as 
expressing at lower temperatures or co-expressing a variety of different molecular 
chaperones may improve yields of soluble target protein (Walton and Sousa, 2004, 
Ullers et al., 2004, Won et al., 2004). Proteolytic enzymes within the cytoplasm may 
degrade soluble protein. This has led to the development of strains deficient in 
proteases such as the B strains of E.coli (e.g. BL21, B834 and BLR strains) (Grodberg 
and Dunn, 1988). Purification of protein from the cytoplasm may be relatively more 
difficult compared to other compartments given that the cytoplasm harbours 
approximately 96% of cellular total protein. The environment of the bacterial 
cytoplasm is a reducing one that does not favour the formation of disulphide bonds. 
This is due to the presence of thioredoxin and glutaredoxin groups of reducing 
enzymes within the cytoplasm (Prinz et al., 1997). Mutant strains of E.coli are 
commercially available that lack these reducing enzymes and can enhance 
cytoplasmic disulphide bond formation and improve yields of soluble of target protein 
(Bessette et al., 1999).
Expressing in the smaller outer compartment of the bacterial cells, the periplasm 
holds a number of advantages over cytoplasmic expression. Periplasmic protein may 
be recovered whilst maintaining the integrity of the inner cell wall. Given the smaller 
pool of proteins within the periplasm this facilitates the isolation of purified target 
protein. The periplasm also lacks reducing enzymes and contains disulphide
113
isomerase enzymes, facilitating the formation of disulphide bonds. This has facilitated 
the expression of immunologically active anti-dsDNA F(ab) 2 fragments purified from 
the periplasm of E.coli, which requires the formation of five disulphide bonds within 
each fragment (Kumar et al., 2000, Kumar et al., 2001). Disulphide isomerase 
enzymes are exclusively periplasmic and are termed the Dsb group of enzymes 
(Bardwell et al., 1991). Further enhancement of periplasmic recombinant protein 
folding may be achieved by the overexpression of Dsb enzymes or by fusing target 
protein with DsbA (Hiniker and Bardwell, 2003). This strategy has facilitated the 
expression of recombinant tPA used for the treatment of acute myocardial infarction. 
This 527 amino acid protein contains 35 cysteine residues that participate in the 
formation of 17 disulphide bonds (Qiu et al., 1998). The disadvantage of periplasmic 
expression is that an N-terminal leader sequence needs to be included. This is 
necessary to transport protein from the cytoplasm to the periplasm. However, during 
the translocation process the leader sequence is cleaved by signal peptidase, and the 
cleaved leader sequence is then degraded by the enzyme signal peptide peptidase 
(Weihofen et al., 2002). Hence, target protein has a free N-terminus.
Finally, secretion of target protein into the extracellular culture media may be 
desirable. This compartment has the lowest level of proteolytic activity of all 
compartments and lowest number of contaminating proteins, thus facilitating 
purification. However, expressed protein needs to cross two membrane barriers. This 
translocation process is a highly specific one, particularly through the outer 
membrane where membrane translocation steps governing protein secretion are 
complex. Hence, this method has proved difficult generally producing low yields and 
is unsuitable for commercial production of recombinant protein (Swartz, 2001). To 
establish recombinant protein secretion three strategies have been employed. One is 
the utilisation of existing pathways for secreted proteins. For example, the kil gene 
mediates controlled export of periplasmic proteins and may be incorporated within 
an expression plasmid with some success, particularly if Klebsiella planticola is the 
expression host (Miksch et al., 1997). The second, is the use of signal sequences and 
translocator peptide sequences present at the carboxyl terminal of proteins secreted 
by E.coli, such as hemolysin. Hemolysin has a carboxyl HlyA signal sequence and 
HlyB and D translocator peptide sequences. These latter two peptide sequences may 
be employed to secrete other proteins if co expressed with the outer membrane 
protein TolC (Tzschaschel et al., 1996). Finally, mutant strains of E.coli have been 
engineered that lack the ability to synthesise an outer membrane and are termed L-
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form strains. Thus, proteins targeted to the periplasm are released directly into the 
culture media (Gumpert and Hoischen, 1998, Rippmann et al., 1998).
1.7.2 Production of proteins using mammalian cells
Expressing eukaryotic proteins within mammalian host cells has the advantage of 
generating protein that has all the post-translational modifications included such as 
the addition of carbohydrate molecules. Mammalian cells also tend to recognise the 
same processing signals found in the original organism. In transient mammalian 
expression systems, only a fraction of the plasmid DNA delivered to the cell is 
incorporated into the host nucleus for transcription, with eventual export of mRNA to 
the host cytoplasm for protein production. In these systems gene expression from 
non-integrated plasmid DNA takes place. This non-integrated foreign DNA is 
degraded by nucleases or diluted by cell division and after approximately seven days 
its presence is no longer detected. Hence the disadvantages are of relatively low 
yields within a transient culture system, making it unsuitable for large-scale 
production of recombinant protein. However, transient expression systems are less 
time and labour intensive relative to stable mammalian systems, facilitating the 
production of high numbers of proteins for screening purposes. COS-7 cells derived 
from monkey kidney cell lines are often used as transient expression hosts and have 
been used to produce whole monoclonal native and mutant aPL in our unit (Giles et 
al., 2003a) as well as anti-ds DNA antibodies (Rahman et al., 1998). Some transient 
hosts such as the HEK293-EBNA cell line derived from human embryonic kidney cells 
have been cultured in bioreactor volumes of 1-3 litres to produce protein yields of a 
recombinant IgGl antibody of 10-20mg/L of culture (Meissner et al., 2001).
In contrast stable expression occurs when the transgene spontaneously integrates 
with the host genome and replicates in synchrony with the cells. Cells containing 
integrated DNA are few and must be amplified by selection for drug resistance or 
identified as a result of phenotypic identification. This system requires several weeks 
to establish. However, the resulting cell lines form a stable source of protein 
production and hence larger quantities of recombinant protein yield may be 
obtained, making it the preferred method of protein production for biotech 
companies producing therapeutic recombinant proteins. The CHO and NSo murine 
myeloma cell lines have established themselves as the predominant lines of choice 
for mammalian expression. The advantages that a stable mammalian expression 
system offers over a transient system were the reasons why a system for expressing 
monoclonal aPL within CHO cells was developed within our unit (Lambrianides et al.,
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2004). Biotech companies employ CHO cell lines to produce therapeutics such as 
etanercept and rituximab and NSo murine myeloma cell lines are used to produce 
infliximab (Chu and Robinson, 2001).
1.7.3 Advantages and disadvantages of other expression systems
Yeast cells are simple eukaryotic cells with a subcellular organisation that enables 
them to carry out some post-translational folding and modifications required for 
eukaryotic human proteins. Advantages over mammalian cells are that relatively 
simple transformation and fermentation conditions are required and they may be 
grown to high densities, facilitating high yields of protein. They may also be induced 
to secrete certain proteins into the growth medium for harvesting, such as the 
hepatitis B vaccine (McAleer et al., 1984). Disadvantages include less rapid growth as 
compared to prokaryotic cells and potentially less control over gene expression. 
Disadvantages over mammalian and insect cell systems are that there is incomplete 
glycosylation and occasionally refolding of protein may be required. The most 
frequently used strains of yeast are Saccharomyces cerevisiae and Pichia pastoris 
(Eckart and Bussineau, 1996, Buckholz and Gleeson, 1991).
Insect cells may be used as the expression host for eukaryotic proteins through the 
incorporation of genes into baculovirus vectors. Sf9 cell lines are the most frequently 
used lines (Altmann et al., 1999) and therapeutics such as the hepatitis C vaccine 
may be expressed using insect cells (Baumert et al., 1998). Advantages are that 
these cells are capable of more complex post-translational modification of protein, 
leading to correct folding of protein more frequently than both E.coli and Yeast 
systems. Cell growth is also marginally more rapid than mammalian cells. 
Disadvantages are that cell growth is significantly slower than both Yeast and E.coli 
systems. Expressed eukaryotic glycosylated proteins within insect cells are also often 
of lower molecular weight than native protein when run on an electrophoretic protein 
gel. This is most often due to proteolytic processing and incomplete glycosylation. 
Insect cells are only capable of simple glycosylation of proteins, lacking the ability to 
add sialic acid residues and form complex mammalian glycoproteins, which often 
consist of intricate scafolds of N-linked acetylglucosamine, mannose, galactose, sialic 
acid and fucose residues (Altmann et al., 1999). These are likely to play a significant 
functional role as knock-out mice unable to synthesise complex N-glycans die in 
utero (Ioffe and Stanley, 1994, Metzler et al., 1994).
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Spirin et al demonstrated that proteins may be synthesised using an E.coli based cell 
free system through an in vitro coupled transcription and translation process. E.coli 
cells are grown and lysed and the cell extract prepared. A feeding buffer composed 
of amino acids, ATP and GTP is added and protein synthesis is initiated upon adding 
template DNA. Protein may be synthesised for up to 40 hours in this continuous 
translation system (Spirin et al., 1988). The method was modified by Kigawa et al to 
produce up to 6 mg/ml yields of recombinant chloramphenicol acetyl transferase 
(Kigawa et al., 1999). Recent advances in cell-free systems allow for the production 
of proteins directly from PCR products using a hollow-fibre membrane bioreactor 
(Nakano et al., 1999). This would enhance proteomic studies for high-throughput 
screening studies (Swartz, 2001). Wheat germ extract may also be used and can 
result in yields sufficient for nuclear magnetic resonance (NMR) spectroscopy 
structural studies (Vinarov et al., 2004). The disadvantages are that proteins are less 
likely to fold correctly and no post-translational modifications can take place, 
minimising the use of this system for creating bioactive proteins.
1.8 PRODUCTION OF RECOMBINANT B2GPI
1.8.1 Established systems of recombinant &2GPI expression
The vast majority of structural and functional studies of recombinant B2GPI over the 
past 10 years have been achieved by cloning cDNA sequence into a baculovirus 
which is then used to infect Sf9 insect cells as the expression host (Igarashi et al.,
1996). Multiple groups have used this platform of production to perform structural 
and functional studies on 8 2GPI by expressing amounts sufficient to perform 
crystallographic studies (Schwarzenbacher et al., 1999, Bouma et al., 1999) and also 
produce mutants with one or more domain deleted to observe effects on binding to 
aPL (section 1.6). The yield from this production system is typically 2mg/L of 
supernatant (via personal communications with Dr M. Iverson, La Jolla 
Pharmaceuticals, San Diego, CA, USA). However, protein electrophoretic analysis of 
recombinant B2GPI expressed by insect cells reveals a band of 43 kDa as opposed to 
50 kDa when native 6 2GPI is run on a protein gel (Igarashi et al., 1996). This size 
discrepancy between insect-driven recombinant proteins and authentic protein is a 
frequent occurrence and a major reason is due to a reduction in the amount and 
complexity of glycosylation residues by insect cells as compared to mammalian cells 
(as discussed in section 1.7.3.) (Altmann et al., 1999). If such a recombinant protein 
is used to study immunogenic determinants on epitopes that may otherwise be 
surrounded by carbohydrate molecules on the native protein, then it becomes
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difficult to draw meaningful conclusions. This applies to Dili and DIV of B2GPI, which 
have N-linked glycosylated molecules and have been cited by some groups as 
containing the immunodominant binding epitopes (Igarashi et al., 1996, George et 
al., 1998d).
There is one early study from Kouts et al that describes the production of 
recombinant 6 2GPI using CHO mammalian cells (Kouts et al., 1993). It is unclear 
from reading the methods what yields were obtained from this system. Purified 
protein run on a protein gel and transferred on to a membrane for western blot 
analysis revealed two bands, one at 61 kDa and the other at 50-53 kDa level. In 
contrast to expression by insect cells, both bands are higher than the observed 
weight of 50 kDa for native B2GPI. Digestion by N-glycosidase which cleaves off all 
N-glycosylated molecules revealed a single diffuse band at 36-42 kDa as observed 
with native deglycosylated protein. This demonstrates that oligosaccharide 
processing amongst mammalian cells can be species and cell type dependent 
(Goochee et al., 1991) and may explain why this expression method does not seem 
to have been pursued by this or other groups.
1.8.2 Challenges in establishing expression of DI of &2GPI in E.coli
E.coli would be an inappropriate expression host for whole B2GPI due to the absence 
of glycosylation. Whole B2GPI has 38 cysteine residues forming 11 disulphide bonds 
that could potentially hamper protein folding in E.coli. However, this in itself would 
not preclude E.coli expression as bioactive tPA, which has 17 disulphide bonds may 
be expressed in the periplasm of E.coli when the periplasmic disulphide isomerase 
enzyme DsbA is co-overexpressed (Qiu et al., 1998). In fact the absence of 
glycosylation of protein by E.coli has been cited as an advantage given the 
consequent prolonged half-life of non-glycosylated rtPA in vivo, which is used as a 
thrombolytic drug in the treatment of acute myocardial infarction (Mattes, 2001). 
The bulk of evidence as discussed in section 1.6.6 supports DI as containing the 
immunodominant aPL binding epitopes and expressing this protein and multiple 
mutants could enhance our understanding of how this interacts with aPL and 
importantly, may facilitate the development of mutant peptides of DI that could have 
enhanced binding as compared to native protein. Given that this domain is not 
glycosylated in native protein and only has two disulphide bonds, expression may be 
possible in E.coli. This system is potentially the least labour intensive and time 
consuming of all the expression systems, genetic manipulation is relatively 
straightforward and there are multiple methods by which gene expression can be
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controlled (Swartz, 2001). However, expressed protein would need to be transported 
to the periplasmic compartment by an appropriate leader sequence to facilitate 
correct folding. Fusion with DsbA may also enhance correct folding (Hiniker and 
Bardwell, 2003). The signal peptide is likely to be cleaved off by signal peptidase 
resulting in an authentic N-terminus (Hannig and Makrides, 1998). Osmotic shock 
breaks down the outer cell wall whilst retaining the integrity of the inner cell wall, 
resulting in the release of the relatively small pool of periplasmic proteins in to the 
media facilitating purification (Hannig and Makrides, 1998).
Another potential obstacle for expressing DI in E.coli is the observed set of codon 
preferences of E.coli that differs from the set of codons preferred by eukaryotic cells 
(section 1.7.1.2) (Kane, 1995). On studying the native cDNA sequence of DI, of the 
61 codons 26 (43%) occur in E.coli at a frequency of less than 1% (Steinkasserer et 
al., 1991, Kane, 1995). These rare codons often occur in clusters of two to five 
codons in length. Hence one may expect translational problems in E.coli with an 
abundant mRNA species containing as excess of rare tRNA codons.
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1.9 AIMS OF THESIS
1. To establish an expression system of DI of B2GPI using E.coli as the 
expression host. This system should be reliable, efficient and produce 
sufficient amounts of purified DI to use in direct and inhibition binding 
assays.
2. To characterise the binding of recombinant DI produced by E.coli to both
monoclonal and polyclonal IgG aPL derived from patients with APS
3. To use this platform of production to create multiple mutants of DI.
Analyses of binding and structural studies will be used to generate 
hypotheses as to the site and nature of the mutations that are likely to 
cause the greatest effects on binding.
4. To explore the possibility of creating mutant DI peptides which bind aPL
better than native protein.
5. To determine effects of these mutations upon binding to monoclonal and
polyclonal human aPL in both solid and fluid phase assays and compare 
binding to wild-type recombinant DI.
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CHAPTER 2
MATERIALS, METHODOLOGICAL PRINCIPLES AND DETAILS
OF PROCEDURES
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OVERVIEW OF CHAPTER 2
This thesis represents the first reported successful attempt to express DI of human 
G2GPI in E.coli, express multiple variants of this protein and characterise the binding 
properties of the wild-type and mutant recombinant DI proteins to human antibodies 
relevant to the pathogenesis of APS.
The first part of this chapter, after listing the general materials used, describes in 
detail the cloning techniques necessary to produce a construct containing an insert 
encoding DI of human B2GPI. The rationale for producing a custom made gene 
encoding DI for use in a prokaryotic expression system is explained. A list of the 
mutant variants of DI that were made is also described and the techniques used to 
make these are outlined.
The second part then describes the methodological principles and design of the 
protocol for expressing wild-type and variant DI in E.coli. This is followed by a 
description of the target protein purification process, methods for target protein 
identification and assessment of quantity and purity.
The final part focuses on describing the principles and techniques of all the direct 
and inhibition assays that were performed in order to characterise the binding 
properties of the purified recombinant proteins.
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2.1 Chemicals, general materials and equipment
2.1.1 Chemicals
BDH, Lutterworth, Leicestershire, UK supplied all chemicals used in this project with 
the following exceptions:
Absolute alcohol & propran-2-ol (Hayman Ltd, Witham, Essex, UK)
5-bromo-4-chloro-3-indolyl-8-D-galactopyranoside in dimethylformamide (Xgal),
IPTG (Insight Biotechnology, Wembley, UK)
All solid chemicals were dissolved in ddH20, adjusted to correct pH with 0.1M HCI, 
glacial acetic acid, 5M KOH or 0.1M NaOH and autoclaved or filter sterilised with
0.22pm syringe driven filter units (Millipore, Bedford, MA, USA) unless otherwise 
stated. NaOH and KOH were not autoclaved. Ethidium bromide was stored in a light­
tight container at room temperature (RT).
2.1.2 General materials and equipment
15ml and 50ml sterile tubes 
Bijou tubes
1.5ml and 0.5ml microfuge tubes 
1.5ml thin-walled microfuge tubes 
Centrifuges
Sorvall Biofuge Pico (and refrigerated version), 
Sorvall RT-7 Plus,
RC26 Plus 
PCR Cycler Machine 
Spectrophotometer 
Microdensitometer (GS-800)
# 91015T, Helena Biosciences, Sunderland, UK
# 39740, Bibby Sterilin Ltd, Staffordshire, UK 
Anachem, Luton, Bedfordshire, UK 
Eppendorf AC, Hamburg, Germany
Kendro Lab Products Ltd, Hertfordshire, UK
Eppendorf Mastercycler, Hamburg, Germany 
BioRad laboratories, CA, USA 
BioRad laboratories, CA, USA
2.1.3 Enzymes
Nco I 
Xhol 
Bgl II
T4 DNA Ligase 
PfuTurbo® DNA Polymerase
Vent DNA Polymerase
# R6513, Promega, Southampton, UK
# R6161, Promega
# R6081, Promega
# M1801, Promega
(Quikchange™ Site-directed mutagenesis kit, 
Stratagene, CA, USA)
(New England Biolabs (NEB), Herts, UK)
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rEnterokinase Novagen, Nottingham, UK
All enzymes and reaction buffers were stored at -20°C.
2.1.4 Reaction buffers
a) lOx PfuTurbo D N A  polymerase reaction buffer in Quikchange™ Site-
directed mutagenesis kit (Stratagene, C A , U S A ) and lOx Vent D N A  
polymerase reaction buffer (NEB, Herts, U K )
- lOOmM KCl
- lOOmM (N H 4)2S 0 4
- 200m M  Tris-HCl, pH 8.8
- 20m M  M g S 0 4
- 1% Triton® X -100
1 mg/ml nuclease-free bovine serum albumin (BSA)
b) lOx D N A  ligase buffer (Promega, Southampton, U K )
- 300m M Tris-HCl
- lOOmM M gC l2
lOOmM dithiothreitol (D T T )  
lOmM adenosine triphosphate (A TP)
c) lOx Promega Buffer D  -  for restriction enzymes Nco I and Xho I
- 60m M  Tris-HCl, pH 7.9
- 1.5M NaCl
- 60m M  M gC l2
- lOmM D T T
A ll reaction buffers were stored at -20°C .
2.1.5 General buffers and solutions
a) Phosphate buffered saline (PBS) pH 7.4. One PBS tablet (Invitrogen, Paisley, 
U K ) was added per 500ml ddH20  and autoclaved. To make PBS/0.1% Tween, 
lm l “Tween 20” detergent was added to 1L PBS.
b) Tris-ED TA (TE  buffer), pH 7.5
- lOmM Tris-HCl, pH 7.5
- Im M E D T A
2.1.6 Specific buffers and solutions
a) Agarose gel electrophoresis
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Agarose and low melting point agarose were supplied by Gibco BRL, Life 
Technologies, Paisley, Scotland, UK.
Molecular weight markers:
lOObp DNA MW marker (Promega, Southampton, UK)
1Kb DNA MW marker (Invitrogen, Paisley, UK)
Lambda/Hind I I I  DNA marker (Promega, Southampton, UK)
Tris Acetate EDTA (TAE buffer):
A stock of solution of 50 times working strength TAE buffer was made by dissolving 
the following components in 1L of ddH20: 
o 242g/L Tris base 
o 57.1ml glacial acetic acid 
o 100ml 0.5M EDTA (pH 8.0)
Dilution to a working strength gave a final concentration of 40mM Tris acetate and 
ImM EDTA.
Loading Buffer:
The following components were added to 8.45ml autoclaved ddH20  
o 25mg xylene cyanole
o 1.5g Ficoll 400 (Pharmacia Biotech, Uppsala, Sweden)
b) Plasmid DNA purification from bacterial cultures
The following buffers were supplied with Qiagen (Crawley, West Sussex, U K )  
plasmid purification kit:
o Buffer P I (resuspension buffer) 50m M  Tris-Cl (pH 8.0)
lOmM E D TA  
100//g/ml RNase A  
200m M  NaOH  
1% SDS
3.0 m M  potassium acetate, 
pH 5.5
10 m M  Tris-HCl (pH 8.5)
o Buffer P2 (lysis buffer)
o Buffer N3 (neutralisation buffer)
o Buffer EB (elution buffer)
c) His6-tagged protein purification buffers
The following buffers were supplied with Novagen (Nottingham, U K ) his6-tagged 
protein purification kits:
o 8x binding buffer 40m M  imidazole
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o 8x charge buffer 
o 4x elute buffer
4 M  NaCl
160mM Tris-HCl (pH 7.9) 
400m M  N iS 0 4 
4 M  imidazole 
2M  NaCl
80m M Tris-HCl (pH 7.9)
d) Buffers fo r production o f “ super’ competent D H 5 a  and B L 21(D E 3) E.coli 
cells:
o Transformation Buffer 1
o Transformation Buffer 2
lOmM MES, pH 5.8 
lOOmM RbCl2 
lOmM CaCl2 
50m M  M nC l2 
lOmM PIPES, pH 6.5 
75m M  CaCl2 
lOmM RbCl2 
15% v/v glycerol
e) ELISA reagents and buffers
BSA # A7030, Sigma.
# 18885, Sigma.
# C1649, Sigma.
# P7769, Sigma. 
Scipac (Kent, UK)
# 15029, Sigma
# A3150, Sigma
# 104-105, Sigma
Goat anti-human IgG (Fc fragment specific)
CL
Phosphatidylserine (PS)
6 2GPI
Purified human IgGx
Goat anti-human IgG„ alkaline phosphatase conjugate 
p nitrophenyl phosphate tablets
Sample, enzyme and conjugate (SEC) dilution buffer 
o lOOmM Tris-HCl (pH 7.0) 
o lOOmM Sodium Chloride 
o 0.02% Tween-20 
o 0.2% BSA 
Bicarbonate buffer (BIC) (pH 9.6) 
o 0.5M Sodium bicarbonate 
o 0.05M Sodium dihydrogencarbonate
f) Western blot reagents 
Perfect Protein™ Western Markers Novagen, Nottingham, UK
HisTag® Monoclonal Antibody Novagen, Nottingham, UK
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Horse radish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulins (P 
0447) Dako, Glostrup, Denmark
Anti-human IgG (y-chain specific) peroxidase conjugate (A 8419) Sigma, Poole, UK
g) IgG purification buffers 
IgG binding buffer 0.02M Sodium phosphate buffer pH 7
57.7% Na2 HP04 + 42.3 NaH2 P04  
IgG elution buffer 0.1M glycine.HCI, pH 2.7
2.2 Bacterial strains
E.coli of strain DH5a were supplied by Gibco, Paisley, UK
E.coli of strain BL21(DE3) and BL21 were supplied by Invitrogen, Paisley, UK
E.coli of strain W3110 were supplied by CellTech, Slough, UK
2.3 Antibiotic and growth media
Media were made in ddH20 and sterilised by autoclaving.
a) Luria-Bertani (LB) medium:
o 1% (w/v) Bacto-tryptone (Duchefa, Haarlem, The Netherlands) 
o 0.5% (w/v) Bacto-yeast extract (Duchefa) 
o 1% (w/v) NaCl 
Adjusted to pH 7.0 with NaOH.
For LB agar plates 1.5% (w /v) agar (Duchefa) was added to LB medium.
b) NZY+Broth:
o 1% (w/v) NZ amine (casein hydrolysate), (Sigma) 
o 5% (w/v) Bacto-yeast extract (Duchefa) 
o 5% (w/v) NaCl
This was made up to 1L with ddH20, pH adjusted to 7.5 using N aO H and then 
autoclaved. Filter sterilised 1.5% 1M M gC l2, 1.25% 1M  M g S 0 4 and 1% 2M  
Glucose solution were added to the media prior to use.
c) "Terrific" Broth (TB):
o 1.2% (w/v) Bacto-tryptone (Duchefa) 
o 2.4% (w/v) Bacto-yeast (Duchefa) 
o 0.4% Glycerol
In a separate flask TB  Salts were prepared, 1M K H 2P 0 4, monobasic and 1M  
K 2H P 0 4, dibasic.
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TB  and TB  Salts were autoclaved separately and then combined in ratio of 
1TB: 10 TB Salts. To this filter sterilised 1% (w /v) glucose was added.
Where antibiotics were added to media and LB agar plates, final concentrations were 
of 50/<g/ml ampicillin or 60/<g/ml kanamycin. Filter sterilised stock solutions of 
ampicillin at 50mg/ml and kanamycin 60mg/ml in ddH20 were kept in light-tight 
containers at -20°C .
2.4 Monoclonal antibodies (mAb)
2.4.1 Human monoclonal aPL -  binding characteristics
IS4, B3 and UK-4 are all human IgG monoclonal antibodies produced from 
lymphocytes of three different patients. IS4 was derived from a patient with SLE/APS 
by Epstein-Barr virus transformation of peripheral blood mononuclear cells and fusion 
with human-mouse heterohybridoma K6H6/B5 cell line (Zhu et al., 1999). This was 
produced and kindly donated by Dr. P Chen, Department of Medicine, Division of 
Rheumatology, University of California at Los Angeles, LA, USA. B3 (Ehrenstein et al., 
1993) and UK-4 (Menon et al., 1997) were isolated by fusion of peripheral blood 
lymphocytes from patients with cells of the mouse human heteromyeloma line CB- 
F7. B3 binds CL, single stranded (ss)DNA, dsDNA and histones (Ehrenstein et al., 
1993, Kalsi et al., 1996). UK-4 binds negatively charged (but not neutral) PL in the 
absence of 6 2 GPI (Menon et al., 1997). IS4 binds to CL only in the presence of 
bovine and human B2GPI and to human foGPI alone (Zhu et al., 1999).
A system of production of monoclonal human IgG molecules has been established in 
our unit in which the heavy chain (VH) is derived from the cloned cDNA of one 
human mAb and the light chain (Vl) from another (Rahman et al., 1998, Giles et al., 
2003a). A stable expression system in CHO cells has been established to express 
three mAb variants - IS4Vh/IS4Vl, IS4Vh/B3Vl and IS4Vh/UK-4Vl (Giles et al., 2003a).
2.4.2 Murine monoclonal antibodies
6C4C10 and mAb-16 are anti-DI antibodies produced from mice immunised with 
recombinant DI of human 6 2GPI (Iverson et al., 2002b). These antibodies recognise 
conformational (but not linear) epitopes on DI and binding to whole B2GPI has been 
shown to be unaffected by 10 different single-point mutations within DI (Iverson et 
al., 2002b). Both these antibodies were kind gifts from Drs' Mike Iverson and Matt 
Linnik, La Jolla Pharmaceuticals (UP), San Diego, USA.
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2.5 Human polyclonal IgG
IgG was purified from serum collected from four groups of subjects: PAPS, APS and 
SLE, SLE with no clinical evidence of APS and finally healthy volunteers. 10-15mls of 
blood was collected in EDTA tubes, spun for 10 minutes at lOOOg and serum 
collected and stored at -20°C pending IgG purification. Collection of samples was 
approved by the Joint UCL/UCLH Committees of Ethics of Human Research.
Purification of IgG from serum was performed using Protein G coated beads (Sigma, 
Poole, UK). Protein G 'slurry' was centrifuged at 200g for five minutes. Supernatant 
was then discarded and the beads washed with PBS and then centrifuged at 200g for 
five minutes. After three washes with PBS, serum was added to give 1:2 ratio of 
serum:beads. IgG binding buffer to give 2:1 ratio of IgG binding buffer:serum was 
also added and incubated at RT for two hours on a mixing table. The sample was 
then centrifuged at 200g and supernatant stored at -80°C as IgG free human serum. 
The IgG-coated Protein G beads were washed three times with IgG binding buffer 
and elution of IgG performed by adding 2ml of IgG elution buffer per 0.5ml serum. 
The sample was mixed for one minute and centrifuged. Supernatant was transferred 
as purified IgG and pH balanced with 1M Tris.HCI, pH 9.0. The elution step was 
repeated a second time.
2.6 Plasmids
The plasmid pRSET-b (Invitrogen, Paisley, UK) was used as the initial cloning vector. 
pET-20b (figure 2.1), pET-26b (figure 2.2) and pET-39b (figure 2.3) (Novagen, 
Nottingham, UK) were used as both cloning and expression vectors.
2.7 Minipreparation of plasmid DNA from E.coli
DH5a-strain E.coli containing recombinant plasmid was stored in media containing 
15% (v/v) glycerol at -80°C. Under sterile conditions a wire loop was used to streak 
the glycerol-stored cultures onto an LB agar plate supplemented with the appropriate 
antibiotic and incubated at 37°C overnight in a dry incubator. 5mls LB medium 
supplemented with the appropriate antibiotic in a 50ml falcon tube were inoculated 
with a colony and incubated at 37°C in a shaking incubator overnight. An 
uninoculated sample was also cultured overnight as a control to check that irrelevant 
bacteria had not contaminated the LB medium.
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Plasmid DNA was extracted from overnight E.coli cultures using the QIAGEN 
QIAprep® Miniprep kit (Crawley, West Sussex, UK) according to the manufacturer's 
instructions. A bacterial pellet was obtained by centrifugation at 1864g for 10 
minutes at 4°C and dried by inversion. The pellet was resuspended in 250pl of buffer 
PI and transferred to a 0.5ml microfuge tube. Then 250pl of buffer P2 were added 
and the tube inverted six times. Following this 350pl of buffer N3 were added, mixed 
by inversion and then centrifuged for 10 minutes. All subsequent centrifugation steps 
were carried out at 13000 rpm in a microcentrifuge for one minute at RT. 
Supernatant from this step was decanted into a QIAprep spin column and 
centrifuged. DNA bound to the QIAprep spin column was washed by adding 0.75ml 
buffer PE and centrifuged. Flow through was discarded and the column centrifuged. 
After placing the QIAprep spin column in a clean 1.5ml microfuge tube recombinant 
DNA was eluted by adding 50pl of autoclaved water to the centre of each QIAprep 
column, which was left to stand for one minute before being centrifuged. Eluted DNA 
was then stored at -20°C.
2.8 Restriction digest of DNA
Plasmid DNA constructs or purified PCR products were digested with two different 
restriction enzymes, either Bgl II, Nco I or Xho I. Typically lpg of plasmid DNA and 
1 0  units of restriction enzyme were incubated in a total volume of 2 0 pl for one hour 
with buffer D, at 37°C. The recipe for a typical small-scale digest would be as 
follows:
Plasmid DNA 5pl (lpg DNA)
Enzyme lpl (lOu/pl)
lOx Buffer D 2pl
ddH20 to 20pl
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Xhol
Nco I
Nde 1
MCS
fl origin pel B
T7p
pET-20b
3716 bp
ori
Figure 2.1 Plasmid map of expression vector pET-20b
Abbreviations: T7p -  T7 promoter; pel B -  pel B leader sequence; MCS -  multiple
cloning site; His6 -  hexa-histidine tag; Ap -  ampicillin resistance gene; ori - pBR322 
origin. The sequence is numbered by the pBR322 convention, so the T7 expression 
region is reversed on the circular map
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Xho
Nco I
MCSfi origin
Kan
pET-26b
5360 bp lacl
on
Figure 2.2 Plasmid map of expression vector pET-26b
Abbreviations: T7p -  T7 promoter; lac I - lac I coding sequence; pel B -  pel B leader 
sequence; MCS -  multiple cloning site; His6 -  hexa-histidine tag; Kan -  kanamycin 
resistance gene; ori - pBR322 origin. The sequence is numbered by the pBR322 
convention, so the T7 expression region is reversed on the circular map.
132
Xhol
Nco 1
MCS
fl origin His 6
Kan
T7p
pET-39b
6106 bp
on lac I
Figure 2.3 Plasmid map of expression vector pET-39b
Abbreviations: T7p -  T7 promoter; lac I  - lac I  coding sequence; DsbA gene (DsbA 
leader sequence 408-465); MCS -  multiple cloning site; His-6 -  hexa-histidine tag; 
Kan -  kanamycin resistance gene; ori - pBR322 origin. The sequence is numbered by 
the pBR322 convention, so the T7 expression region is reversed on the circular map.
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2.9 Separation of DNA fragments by agarose gel 
electrophoresis
In order to separate the DNA fragments resulting from the above restriction digests, 
the products were run on a 1-2% agarose gel. For a 1% agarose gel, 100ml of TAE 
buffer was added to lg of low melting point agarose and heated in a microwave until 
the agarose had dissolved. Once cooled to hand hot, 2pl of lOmg/ml ethidium 
bromide was added. Ethidium bromide molecules intercalate between base pairs in 
the DNA double helix rendering it fluorescent when viewed under UV light.
The open ends of a gel tray (Bio-Rad) were closed off with tape and the agarose 
solution poured in. Plastic combs were then placed in the gel tray to create wells in 
the agarose as it solidified. Once the gel had set, the comb and tape were removed 
and the gel tray placed in an electrophoresis tank (Bio-Rad) to which 800mls of TAE 
buffer was added.
To each 12pl of sample to be loaded onto the gel, 2pl of loading buffer were added. 
This buffer contains Ficoll which increases the density of the sample, ensuring the 
DNA in each sample sinks evenly into the well. The buffer also colours the sample 
with the dye (xylene cyanole) that moves towards the anode at a predictable rate, 
allowing progress through the gel to be monitored. Between 10 and 50pl of each 
sample were added to each well and a voltage of 100 volts applied for one hour. The 
gel was then removed from the tank and examined under UV light. The size of the 
bands in the gel were estimated by comparison with a standard DNA molecular 
weight marker loaded into another well in the same gel. Photographs of the gel were 
taken using the Genesnap programme (Syngene, Cambridge, UK) and printed onto 
paper.
2.10 Quantification of dsDNA concentration
dsDNA concentrations were quantified by running linearised DNA samples alongside 
molecular weight markers of known DNA concentration on an agarose gel and 
comparing the intensity of the bands.
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2.11 Purification of DNA from agarose gels
PCR samples and digested DNA fragments were purified from agarose gels using the 
QIAquick gel extraction kit (Qiagen, Crawley, West Sussex, UK). An excised band of 
DNA weighing up to 400mg was placed in a 1.5ml microfuge tube and 1ml of buffer 
QG added. The mixture was then incubated at 55°C for 10 minutes until all agarose 
had dissolved. Then lpl of isopropranol per lmg of initial agarose gel dissolved was 
added and the tube inverted 1 0  times to mix. 800pl of this solution were then added 
to a spin column placed in a collection tube and centrifuged at 13000 rpm for 10 
seconds. Flow through was discarded from the collection tube and the procedure 
repeated until all of the initial mixture had been passed through the spin column. A 
further 500pl of buffer QG was added to each spin column and centrifuged at 13000 
rpm for 10 seconds. After discarding the flow through, 750pl of buffer, PE were 
added and centrifuged as above, flow through discarded and centrifuged again. Each 
column was then placed into a fresh 1.5ml microfuge tube and elution of DNA from 
each column performed by addition of 50pl of solution EB, allowing the column to 
stand for one minute followed by centrifugation as above. The product was then 
stored at -20°C.
2.12 Synthesis of synthetic DI gene using recursive PCR
The advantages of synthesising a gene encoding for DI of B2GPI rather than using 
cloned cDNA is that codons preferred by bacteria can be used, thus potentially 
increasing yield of expressed target protein by E.coli. Furthermore, convenient 
restriction sites can be incorporated to aid genetic manipulation. DI and 11 DI 
mutants (E23S, Mut 23-26-27, Mut 8-9-23-26-27, R39S, R39K, G40E, G40S, R43G, 
R43K, DI ext, II- III)  were made using recursive PCR (Prodromou and Pearl, 1992).
2.12.1 Design of primers for recursive PCR
Design of the synthetic gene was performed using Juniper computer software, a kind 
gift from Dr. Chris Richardson and Professor Laurence Pearl, Institute of Cancer 
Research, London, UK. The amino acid sequence of DI of human B2GPI with an Omp 
A sequence at the N-terminal was entered into Juniper along with the desired 
flanking restriction sites. Juniper then designed a gene encoding this recombinant 
protein, but altered the codon usage, such that codons preferred by E.coli were used 
rather than those preferred by eukaryotic cells. Juniper then designed six 60mer 
oligonucleotide primers that together cover the length of this 270bp gene. The 
primers overlapped sequentially with each other by 17 nucleotides and were used in
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a recursive PCR reaction to produce the desired synthetic gene optimised for E.coli. 
Thus, each primer effectively acted as a template (at the 3' end) and primer (at the 
5' end). The principles of recursive PCR are schematically represented in figure 2.4.
1 1 1
1 1
I/2/3/4 3/4/5A
1
Figure 2.4. Schematic diagram of DI gene synthesis using recursive PCR.
Oligonucleotides are numbered 1-6.
2.12.2 Recursive PCR
2 0 pmol of each outer primer and two pmol of each internal primer were used in a 
reaction containing 2U of Vent DNA polymerase (NEB, Herts, UK) and 25mM of 2'- 
deoxynucleoside 5'- triphosphates (dNTPs') in lOOpI of lOx supplied buffer and 
ddH20. Cycling parameters were as follows:
Initial denaturation of 94°C for eight minutes
Then 30 cycles as follows: Denaturation - 94°C for two minutes
Annealing - 57°C for one minute
Extension - 72°C for one minute
Final extension - 72°C for 10 minutes
The reaction was then kept at 4°C until the samples were removed. The PCR 
samples were run on a 2 % agarose gel, the amplified gene excised and purified from 
the agarose gel. The purified recombinant gene was then digested with Bgl II  and 
Nco I restriction enzymes and ligated (section 2.13) into the cloning vector pRSETb. 
Plasmid DNA of the pRSETb construct containing the recombinant DI insert was 
precipitated as described in section 2.16 and sent for automated sequencing.
2.13 Ligation of amplified DNA from recursive PCR into 
pRSETb
Gel purified, digested PCR products from step 2.12 were ligated into 50ng of
pRSETb. Ranges from 3:1 to 1:3 insert:vector molar ratios were used. To lOpI of
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insert:pRSETb mix, 2pl of lOx ligase buffer, 7.4pl autoclaved ddH20 and 0.6pl (3U/pl) 
T4 DNA ligase were added. Samples were incubated for three hours at RT or at 4°C 
overnight. The ligation product was used to transform competent DH5a cells (section
2.14 and 2.15).
2.14 Production of competent DH5a and BL21(DE3) E.coli 
cells
DH5a or BL21(DE3) cells picked from a discrete colony upon an LB agar plate were 
grown overnight in lOmls of LB medium at 37°C in a shaking incubator (220rpm). 
The following morning lOOpI of this culture was added to 100ml sterile LB in a sterile 
2.5L flask and returned to the shaking incubator for three hours. When swirling 
clouds of bacteria were just visible the culture was removed from the incubator and 
divided into two 50ml falcon tubes, placed on ice for five minutes and then 
centrifuged at 1864g for 10 minutes at 4°C. Supernatant was discarded from each 
tube and the pellet resuspended in 2 0 mls ice-cold transformation buffer 1  and 
incubated on ice for five minutes. Each tube was again centrifuged at 1864g for 10 
minutes at 4°C and the supernatant discarded. Each pellet was then resuspended in 
lml of transformation buffer 2 and incubated on ice for 15 minutes. lOOpI of this 
suspension was then aliquoted into pre-chilled 1.5ml microfuge tubes and stored at 
-80°C or used directly for transformations.
2.15 Transformations of competent E.coli cells
5pl of ligation mixture were added to lOOpI of competent E.coli cells and incubated 
on ice for 30 minutes. A heat shock at 42°C for 60 seconds was then applied, 
following which the cells were incubated in 800pl of LB at 37°C for one hour. The cell 
suspension was then centrifuged at 700g for 10 minutes at RT, most of the 
supernatant poured off and the pellet resuspended in the remaining supernatant. 
This suspension was then spread on an LB agar plate containing the appropriate 
antibiotic. After drying on the bench for 15 minutes the plates were then incubated 
at 37°C overnight. The following day antibiotic resistant clones were picked, grown 
in 5ml LB with appropriate antibiotic and miniprep plasmid DNA produced as in 
section 2.7.
2.16 Ethanol precipitation of plasmid DNA
In the presence of salt (monovalent cations such as Na+) and at a temperature of 
-20°C or less, absolute ethanol efficiently precipitates nucleic acids. Therefore 0.1
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volume of 3M Sodium Acetate, pH 5.2 and 2.5 volumes of 100% ethanol were added 
to the DNA preparation in a 1.5ml microfuge tube. This was placed in a -80°C  
freezer for one hour to precipitate the DNA.
To collect the precipitate, the precipitation was firstly spun in a microfuge for 10 
minutes at 13000 rpm at 4°C. The supernatant was discarded and the pellet washed 
with 1ml 70% ethanol and centrifuged again as above. The 70% ethanol was then 
decanted and the sample left to dry under a lamp for one hour.
Dried precipitated plasmid DNA was sent for automated sequencing to MWG-Biotech, 
Ebensburg, Germany.
2.17 Production of DI mutants
DI mutants with single or multiple amino acid mutations were made using either site 
directed mutagenesis, or recursive PCR with the primers designed by Juniper (see 
section 2.12) and subsequently ligated into pET-26b as above. In total 16 constructs 
of DI mutants with single or multiple amino acid substitutions were made. Details of 
the amino acids targeted and the designated names given to each mutation are 
shown in Table 2.1.
2.17.1 Computer modelling of DI and DI mutants
Swiss-Model is a fully automated protein homology modelling server freely available 
on the internet via http://swissmodel.expasv.org website. Via the validated 
programme Swiss-Pdb Viewer (GlaxoSmithKline R&D and Swiss Institute of 
Bioinformatics), an accurate 3-dimensional template of a protein sequence can be 
made, and several proteins can be superimposed in order to deduce the effects of 
altering single amino acids on H-bond formation and overall conformation (Peitsch, 
1996, Guex and Peitsch, 1997). This programme was used to minimise the 
probability of the desired mutations causing -
i. significant conformational change
ii. hydrogen bond or salt-bridge formation with neighbouring amino acids
iii. large alterations in surface exposure of the epitopes of interest.
138
Mutation designated name Amino acids substituted
D8 S Asp at 8  to Ser
D9G Asp at 9 to Gly
Mut 8+9 Both Asp at 8+9 to Ser at 8  and Gly at 9
E23S Glu at 23 to Ser
E26S Glu at 26 to Ser
E27S Glu at 27 to Ser
Mut 23-26-27 All three Glu at 23, 26 and 27 to Ser
Mut 8-9-23-26-27 Mutations of both Mut 8+9 and Mut 23-26-27
R39K Arg at 39 to Lys
R39S Arg at 39 to Ser
G40E Gly at 40 to Glu
G40S Gly at 40 to Ser
R43G Arg at 43 to Gly
R43S Arg at 43 to Ser
DI ext Insertion of PRVCPF from position 61 to complete the 
DI-II interlinker
D II-III Interlinker D II-III (RPIELPVCA at positions 53-61) 
substituted for wild-type interlinker (WPINTLKCT)
Table 2.1 DI mutations -  designated names and positions of amino acids 
targeted
2.17.2 Site directed mutagenesis
The QuickChange site-directed mutagenesis kit (Stratagene) was found to be a 
convenient method to produce single amino acid substations. Five constructs 
encoding for mutant DI cloned into pET-26b were made - D8 S, D9G, Mut 8+9, E26S 
and E27S. The basic procedure requires a dsDNA vector containing an insert of 
interest and the design of two specific oligonucleotide primers containing the desired 
mutation. The oligonucleotide primers, each complimentary to opposite strands of 
the vector, are extended during temperature cycling by PfuTurbo DNA polymerase. 
This enzyme has a 6 -fold higher fidelity in DNA synthesis than Taq DNA polymerase 
and hence has a low potential for generating further mutations during PCR. 
Incorporation of the oligonucleotide primers generates a mutated plasmid. Following 
PCR, the product is treated with Dpn I, an endonuclease specific for methylated DNA
139
produced by DH5a E.coli, which thus digests the parental DNA template but not the 
mutated plasmid. Vector DNA containing the desired mutation(s) is then transformed 
into XL-Blue supercompetent cells. Mutagenic oligonucleotide primers were designed 
according to manufacturers specifications. Primer length was between 25 and 45 
bases with melting temperatures (Tm) > 78°C. The formula used to calculate Tm is 
shown in Table 2.2 (A) and the specific primers used in Table 2.2 (B).
Purified pET-26b was obtained as described in section 2.7. A series of PCR reactions 
were then set up containing 5ng, lOng, 20ng and 50ng concentrations of plasmid 
DNA with the appropriate mutagenic primers (see Table 2.2 (B)), and the reaction 
solutions provided in the QuickChange site-directed mutagenesis kit (Stratagene) of 
plasmid DNA was mixed with 5pl lOx reaction buffer, lpl of dNTP mix, 5pl forward 
primer (125ng), 5pl reverse primer (125ng), lpl PfuTurbo DNA polymerase (2.5 
units/pl) and autoclaved ddH20 to a final volume of 50pl. As negative control no 
plasmid DNA was added to one reaction mixture. Each mixture was then taken, pulse 
spun, and placed into a PCR machine programmed according to the manufacturers 
instructions with the extension time of each reaction calculated at one minute per kb 
of plasmid length. Cycling parameters were as follows:
Initial denaturation at 95°C for 30 seconds
Then 12 cycles as follows -
Denaturation - 95°C for 30 seconds
Annealing - 55°C (for D8 S, D9G) for one minute
- 57°C (for Mut 8+9, E26S, E27S) for one minute 
Extension - 6 8 °C for one minute per kb plasmid for sample reactions and
six minutes for control reaction.
The reaction was then held at 4°C until the samples were removed.
Once the PCR step had been carried out the methylated template DNA containing the 
undesired sequence was digested by the addition of lpl (10U) of Dpn I endonuclease 
restriction enzyme directly to each amplification reaction. The sample was mixed 
gently by pipetting up and down several times, after which it was pulse spun and 
incubated at 37°C for one hour. A separate 50pl aliquot of XL-Blue supercompetent 
cells was then transformed with lpl of the Dpn I treated DNA from each control, 
sample reaction and transformational control plasmid (pUC-19) supplied by 
Stratagene.
140
A) Tm = 81.5 + 0.41(%GC) -  675/N - %mismatch 
Where -  N is the primer length in bases 
Values for % GC and % mismatch are whole numbers 
%GC = the percentage of GC bases in the primer sequence 
% mismatch = the number of deletions /  primer sequence xlOO
B)
PRIMER SEQUENCE
1 . Forward
2 . Back
3. Forward
4. Back
5. Forward
6 . Back
7. Forward
8 . Back
9. Forward
1 0 . Back
S'GGTCGTACCTGCCCGAAACCGKCGACCTGCCGTTCrCCS' 
5,GGAGAACGGCAGGTCGfiACGGTTTCGGGCAGGTACGACC3, 
5 'CGTACCTGCCCGAAACCGG ACGSICTGCCGTTCTCCACC3' 
5'GGTGGAGAACGGCAGACCGTCCGGTTTCGGGCAGGTACG3' 
5'CGTACCTGCCCGAAACCGICCGfilCTGCCGTTCTCCACC3'
5 'GGTGGAGAACGGCAGACCGfiACGGTTTCGGGCAGGTACG3' 
5'ACCTTCTACGAACCGGGTTCCGAAATCACCTACT CCTGC31 
5'GCAGGAGTAGGTGATTTCGGAACCCGGTTCGTAGAAGGT3' 
5'ACCTTCTACGAACCGGGTGAATCCATCACCTACTCCTGC31 
5' GCAGGAGTAGGTG ATGG ATTCACCCGGTTCGT AG AAG GT51
Table 2.2 Properties and sequences of primers used in site directed 
mutagenesis
A) Formula to calculate melting temperature of mutagenic primers
B) Mutagenic primers with sites for point mutations shown in bold and underlined. All 
primers were used to amplify DI cloned pET-26b and mutate:
Primers 1 and 2 Asp to Ser Codon 8  - D8 S
Asp to Gly Codon 9 - D9G
Asp,Asp to Ser,Gly Codons 8,9 - Mut 8+9
Glu to Ser Codon 26 - E26S
Glu to Ser Codon 27 - E27S
Primers 3 and 4 
Primers 5 and 6  
Primers 7 and 8  
Primers 9 and 10
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This method is very similar to that described in section 2.15 with the following 
exceptions - a heat shock at 42°C of 45 seconds with recovery on ice for a further 
two minutes and 0.5ml of NZY medium preheated to 42°C was added to each 
transformation reaction. Colonies were picked from the sample transformation plates 
and inoculated into 5ml LB cultures containing 60pg/ml kanamycin and kept 
overnight in a 37°C shaking incubator. The following day glycerol stocks were made 
and plasmid DNA purified (see section 2.7). This was sequenced to confirm the 
presence of the desired mutation (see section 2.16).
2.18 Recombinant wild-type and mutant DI protein expression
2.18.1 Optimisation of protein expression protocol
An extensive range of experiments were carried out in an effort to establish and 
optimise the induction and expression protocol of recombinant DI detailed in this 
section below. Specifically expression experiments were performed using the pET- 
20b construct as well as the final expression construct pET-26b, altering media and 
culture volumes, varying culture and induction temperatures, using alternative E.coli 
strains, varying induction duration, inducing in the presence or absence of glucose in 
the culture media and varying levels of the inducing agent IPTG. These experiments 
are discussed in more detail in chapter 3.
2.18.2 Final optimised culture and induction experimental protocol
The final recombinant expression vector pET-26b, containing the DI gene and a 
kanamycin resistance gene, was transferred to the expression strain BL21(DE3) that 
contains a chromosomal copy of the gene for T7 RNA polymerase. Single colonies 
were picked from the transformants, and 5ml cultures of TB with 60pg/ml kanamycin 
in 50ml falcon tubes were inoculated and cultured at 30°C overnight in a shaking 
incubator. Fresh 250ml cultures of pre-warmed TB with 60pg/ml kanamycin were 
then set up using the overnight culture to inoculate the medium to an optical density 
(OD)** of 0.1 and grown at 30°C to an OD6oo of 0.6. Cultures were then induced 
with O.lmM IPTG and allowed to grow for a further four hours at 30°C with shaking. 
O D 6oo was recorded at periodic intervals before and after induction as a measure of 
bacterial growth in the culture.
2.18.3 Preparation of periplasmic fraction
The method for periplasmic extraction of protein from E.coli is based on previously 
published methods by our group for the expression of periplasmic F(ab)s of human
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antibodies in W3110 E.coli (Kumar et al., 2000). Cultures were centrifuged four hours 
post induction at 4000g for 20 minutes at 4°C and the supernatant saved (at 4°C) 
for the detection of any leaked DI protein from cells. The cell pellet was then 
resuspended in ice-cold autoclaved ddH20  (30ml ddH20  per 1L culture) and stirred at 
4°C for 30 minutes. This exposes the cells to osmotic shock, a process that degrades 
the outer-cell membrane releasing periplasmic protein into the medium whilst 
maintaining the integrity of the inner-cell membrane. The sample was then 
centrifuged at 8000g for 20 minutes at 4°C. The supernatant constitutes the 
periplasmic fraction containing recombinant DI, an aliquot of which was stored at 
-20°C for subsequent SDS-PAGE and western blot analysis.
2.19 Recombinant wild-type and mutant DI purification
DI was purified using nickel chromatography by virtue of the incorporated C-terminal 
hiS6-tag, which binds divalent cations such as Ni2+ immobilised on resin. The 
HisBind® purification kit (Novagen, Nottingham, UK) was used. Conditions were 
optimised for DI purification as below.
All purification steps were done on ice. 0.6ml bed volume (BV) of resin was added 
per 1L expression culture to a chromatography column. This was then charged with 
nickel by applying five volumes of lx  charge buffer and equilibrated with three 
volumes of lx binding buffer. The periplasmic extract was then applied to the column 
and subsequently washed successively with 5mM imidazole, then 45mM imidazole 
and DI eluted subsequently with 300mM of imidazole. The wash and elution buffers 
were made up by combining appropriate proportions of lx  binding buffer (5mM 
imidazole) and lx elution buffer (1M imidazole) included in the kit. Imidazole binds 
to nickel cations in preference to a hise-tag and thus displaces bound hiS6-tagged DI. 
All washes and flow-through were collected and stored at -20°C for subsequent 
SDS-PAGE analyses.
DI elution sample was then dialysed against PBS-10% glycerol overnight at 4°C 
using dialysis visking tubing, MWCO-3500, Medicell (London, UK), aliquoted into 1.5 
ml microfuge tubes, snap frozen in liquid nitrogen and stored at -80°C. The purity of 
eluted DI was assessed on SDS-PAGE 15% gels.
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2.20 Protein quantification, detection and characterisation
2.20.1 Total protein quantification
Total protein was quantified by colorimetric detection using the bicinchoninic acid 
(BCA) protein assay kit (Pierce, IL, USA) according to manufacturers instructions. 
The method combines the reduction of Cu2+ to Cu1+ by protein within an alkaline 
medium with the sensitive and colorimetric detection of cuprous cation Cu1+ using a 
reagent containing BCA (Smith et al., 1985). The purple coloured reaction formed by 
the chelation of two molecules of BCA with one cuprous ion exhibits absorbance at 
562nm that is linear with increasing protein concentrations over a range of 80-2,000 
pg/ml. Varying known concentrations of 25pl of a protein standard, BSA (in 0.9% 
saline and 0.05% sodium azide) supplied with the kit, is used to plot a line which is 
then used to quantify the total protein concentration in the 25pl test sample.
2.20.2 SDS-polyacrylamide gel electrophoresis (PAGE)
Each gel consisted of 3mls 5% stacking gel layered on top of 5mls 15% resolving 
gel. The resolving gel was poured and immediately layered with isopropranol. After 
the gel had set, the isopropranol was removed and the stacking gel added to form 
the upper layer. A suitable comb was added prior to the polymerisation of the 
stacking gel. The composition of the resolving and stacking gels is described in table 
2.3.
Total protein samples were separated into polypeptide units by SDS-PAGE according 
to the method of Laemmli, 1970 (Laemmli, 1970). Protein samples were added in a 
1:1 ratio to sample buffer (2% (w/v) SDS, 50mM Tris-HCl, pH 6.8, 0.1% 
bromophenol blue, 10% (w/v) glycerol, lOOmM DTT and denatured at 100°C for 
three minutes immediately before loading on to the gel. 20pl of sample or 5pl of 
molecular weight protein marker (Prestained Protein Marker, Broad Range (NEB, 
Herts, UK) or Rainbow™ Coloured Protein Molecular Weight Markers (Amersham Bio, 
Bucks, UK)) were loaded. SDS-PAGE gels were prepared in a vertical gel, one­
dimensional, electrophoresis system (Gibco-BRL, Paisley, UK) and run in lx running 
buffer (25mM Tris, 250mM glycine and 0.1% (w/v) SDS, pH 8.3) at 40 mA/gel at RT 
until the dye reached the bottom of the plate.
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10 mis 
10% resolving gel
8 mis 
5% stacking gel
ddH20 2.3 mis 5.5 mis
30% acrylamide 
mix1
5.0 mis 1.3 mis
1.5 M Tris, pH 8.8 2.5 ml
1.0 M Tris-HCl, 
pH 6.8
1.0 ml
10% SDS 0.1 ml 0.08 ml
10% APS2 0.1 ml 0.08 ml
TEMED3 0.004 ml 0.008 ml
Table 2.3. Composition of resolving and stacking gels for SDS-PAGE.
^crylamide mix = N,N'-Methylene-bis-acrylamide. 2APS = ammonium persulfate. 
^TEMED = NNNN-tetramethylethalinediamine.
2.20.3 Coomassie stain
This stain was used to visualise the protein bands run on an SDS-PAGE gel. The gel 
was transferred from the electrophoresis apparatus to a plastic container and 
covered with 0.2% Coomassie gel stain (0.2% (w/v) Coomassie, 7.5% acetic acid, 
40% methanol, dH20 to a volume of 1L) for eight minutes. The gel was then 
destained with Coomassie destain (7.5% acetic acid and 5% methanol made up to 
1L with dH20) for three hours. The gel was then dried on a gel dryer at 60-80°C for 
30 minutes and kept as a permanent record.
2.20.4 Transfer of protein to nitrocellulose and western blotting
Protein separated on SDS-PAGE gels were transferred to Hybond C membranes 
(Amersham, Bucks, UK) using a wet-transfer method described by Towbin, 1979 
(Towbin et al., 1979). The gel and the nitrocellulose membrane were pre-soaked in 
transfer buffer (50mM Tris, 180mM glycine, 0.1% (w/v) SDS) and 20% methanol) 
and blotted over one hour at 400mM at RT in a Trans-blot™ Cell (Bio Rad) according 
to manufacturers instructions. An ice-block was placed in the cell to avoid over­
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heating. The membrane was subsequently removed, dried and the protein marker 
used highlighted.
2.20.5 Immunodetection of proteins on western blots
The membrane was blocked in PBS /  0.1% polyxyethylene sorbitan monolaurate 
Tween 20 /  5% (w/v) skimmed milk for one hour at RT on a shaking platform. The 
primary antibody solution (in PBS /  0.1% Tween 20 /  5% milk) was then added and 
incubated for a further one hour, shaking at RT. The unbound primary antibody was 
then rinsed off by two 10 minute washes with PBS /  0.1% Tween 20, and the 
appropriate anti- IgG HRP conjugated secondary antibody (in PBS /  0.1% Tween 20 /  
5% milk) added for one hour, RT on a shaker. Unbound secondary antibody was 
then rinsed off with two washes of 10 minutes with PBS /  0.5% Tween 20. The 
bound HRP was then detected using chemiluminescence (ECL™, Amersham, Bucks, 
UK) and the resultant light emissions exposed to X-ray film from one second to one 
hour, depending on the strength of the signal.
2.20.6 Quantitative western blotting
The concentration of purified target protein was further confirmed using quantitative 
western blotting. This technique was particularly useful for concentrations below 
80pg/ml, which represents the lower sensitivity limit of the BCA protein assay 
(section 2.20.1). A known concentration of hiS6-tagged DI (stock at 500pg/ml) was 
kindly donated by Dr M Iverson. Known serial dilutions were loaded onto a 15% 
SDS-PAGE mini gel (section 2.20.2) and a known dilution of the target protein also 
loaded. The proteins were then transferred onto a nitrocellulose membrane (section 
2.20.4) and probed with an anti-his5 antibody (Novagen). The intensity of signal 
displayed on the film is directly proportional to the amount of protein transferred 
onto the membrane. Digital microdensitometry analysis (GS-800, BioRad Lab, CA, 
USA) of the film produced arbitrary units representative of the intensity of signal. 
These results were used to plot a standard curve of hiS6-tagged DI protein 
concentration versus arbitrary units, against which the concentration of expressed 
target protein could be estimated.
2.21 Functional binding assays -  enzyme linked 
immunosorbent assay (ELISA)
In all the different ELISAs performed, 96 well plates used were supplied by either 
Nunc, VWR International, Leicester, UK (irradiated plates) or Xenopore, NJ, USA 
(nickel-chelate plates). OD was measured by the Genios plate reader (Tecan,
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Reading, UK). Each plate was marked vertically to divide it into two halves; the test 
half and the control half. The 36 wells at the edge of the plate were not used and 
henceforth all descriptions of the plate refer to the inner 60 wells only.
2.21.1 Detection and quantification of total whole IgG molecules
A 'Sandwich' ELISA was used to detect the total whole IgG molecule concentration of 
each human monoclonal or affinity purified polyclonal IgG sample. Goat anti-human 
IgGx (Fc fragment specific) was dissolved in BIC buffer to give a working solution of 
400ng/ml. 50pl of BIC buffer alone was added to the wells in the right (control) half 
of the plate. Each plate was then covered and incubated overnight at 4°C. After this 
the plates were washed three times with PBS /  0.1% Tween 20 and lOOpI of PBS 
containing 2% BSA was added to each well to block non-specific binding of Ig to the 
plastic. The plates were incubated for one hour at 37°C and then washed three times 
with PBS /  0.1% Tween 20.
In order to dilute CHO cell supernatant or affinity purified antibody in SEC buffer 
serially, such that for each well in the test half of the plate there was a well in the 
control half containing the same supernatant at the same dilution, the following 
procedure was performed - 50pl of SEC was added to each well in both halves of the 
plate except the top wells. lOOpI of neat CHO supernatant was added to the top well 
and diluted down the column such that each well contained supernatant at half the 
concentration of the well above. Purified human IgG of known concentration (lOOng 
/  ml) was loaded and diluted serially in the same way upon each plate to allow the 
construction of a standard curve relating OD to IgG concentration. The plates were 
incubated for one hour at 37°C and then washed three times with PBS /  0.1% 
Tween 20.
To detect bound antibody, 50pl goat anti-human k light chain alkaline phosphatase
conjugate (diluted 2500-fold in SEC dilution buffer) was added to the wells and
incubated for one hour at 37°C. After one hour, the plates were washed three times
with PBS /  0.1% Tween 20 and once with BIC buffer. One tablet of p-nitrophenyl
phosphate substrate was dissolved in 5ml BIC buffer supplemented with lOpI of 2mM
MgCI2. 50pl of this solution was added to each well. The plates were then incubated
at 37°C to allow a yellow colour to develop in each well. The OD of the reaction was
read after 60 minutes at 405nm (reference 490nm). The final reading was calculated
by subtracting the OD value of each control well from the OD value of the same
sample in the corresponding test well. This ensured that only the conjugate bound
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directly to IgG in the supernatant that had been captured by the anti-Fc IgG would 
contribute to the result.
The binding of whole IgG molecules in the supernatants to the plate depended on 
the presence of the Fc region whereas detection by the alkaline phosphatase 
conjugate depended on the presence of the K light-chain, therefore this method only 
detected whole IgG* antibodies.
2.21.2 Detection of aPL binding to cardiolipin in solid phase
A polysorb ELISA plate was coated with 50pl of CL (diluted to 2.5pg/ml in ethanol) 
on the test half and 50pl of ethanol on the control half. The plate was then incubated 
overnight at 4°C uncovered. Following that each plate was washed twice with PBS 
and lOOpI of PBS containing 10% foetal calf serum (FCS) (Invitrogen) was added to 
each well to block non-specific binding of IgG to the plate surface. After incubation 
for one hour at RT the plate was washed twice with PBS.
Human polyclonal IgG was diluted in PBS containing 10% FCS to 20pg/ml and 50pl 
added to the test half and the corresponding well in the control half. All patient 
samples were tested in duplicate. IgG derived from a patient with APS whose sera 
was known to bind CL was used as a positive control in each plate tested. This 
positive control (P18) was serially diluted and used as the in-house standard against 
which to measure % binding activity to CL for each IgG sample. The plate was then 
incubated for 90 minutes at RT and washed three times with PBS. Goat anti-human 
IgG alkaline phosphatase conjugate was diluted 1000 fold in PBS containing 10% 
FCS and 50pl of this solution added to each well. After one hour incubation at RT the 
plate was washed three times with PBS and once with BIC buffer. Addition of 
substrate was carried out as in section 2.21.1, the plate incubated at RT and OD 
measurements taken at 30 minutes and one hour.
2.21.3 Detection of aPL binding to phosphatidylserine in solid phase
A polysorb ELISA plate was coated with 50pl of PS (diluted to 50pg/ml in methanol 
and chloroform 4:1) and 50pl of methanol and chloroform alone was added to the 
control half. The plate was then incubated overnight at 4°C uncovered. Following 
this all steps performed subsequently were as those described in the section 2.21.2 
above.
148
2.21.4 Detection of aPL binding to M3PI in solid phase
A maxisorp ELISA plate was coated with 50pl of 82GPI (diluted to lOpg/ml in PBS) on 
wells in the test half and 50pl of PBS alone in the control half. The plate was covered 
and incubated overnight at 4°C. Following that each plate was washed three times 
with PBS and then blocked by adding lOOpI of 0.25% gelatin in PBS. After incubation 
at 37°C for one hour the plate was washed three times with PBS.
Monoclonal antibody samples were serially diluted in 0.1% BSA/PBS and then loaded 
upon each half of the plate, as well as a positive control of serum containing 
polyclonal anti-62GPI antibodies leaving a final volume in each well of 50pl. Affinity 
purified polyclonal IgG samples were diluted to 40pg/ml and 50pl loaded on the test 
side only. IgG derived from a patient with APS whose sera was known to bind B2GPI 
was used as a positive control in each plate tested. This positive control (designated 
sample 'A96*) was serially diluted and used as the in-house standard against which to 
measure % binding activity to B2GPI for each IgG sample. The plate was then 
incubated for two hours at 37°C after which it was washed three times with PBS. 
Goat anti-human IgG alkaline phosphatase conjugate was diluted 1000 fold in PBS 
containing 0.1% BSA/PBS and 50pl of this solution added to each well. A final 
incubation for one hour at 37°C was performed and the plate washed four times with 
PBS and once with BIC buffer. Addition of substrate and incubation were carried out 
as in section 2.21.1 with additional OD measurements taken at 30 minutes.
2.21.5 Detection of aPL binding of polyclonal IgG to pure human B2GPI 
coated on cardiolipin in solid phase
A polysorb ELISA plate was coated with 50pl of CL (diluted to 2.5pg/ml in ethanol) 
on both the test and control half. The plate was incubated overnight at 4°C 
uncovered. Following that each plate was washed twice with PBS and lOOpI of 
0.25% gelatin/PBS was added, incubated at RT for one hour and washed twice with 
PBS. Pure human B2GPI was diluted to lOpg/ml in PBS and 50pl coated on the 
sample side and 50pl per well of PBS alone was added on the control side. The plate 
was incubated at RT for one hour and washed twice with PBS.
Human polyclonal IgG was diluted in PBS containing 0.1% BSA to 40pg/ml and 50gl 
added to the test half and the corresponding well in the control half. All patient 
samples were tested in duplicate. IgG derived from a patient with APS whose sera 
was known to bind B2GPI and DI (designated sample 'A960 was used as a positive
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control in each plate tested. This positive control was serially diluted and used as the 
in-house standard against which to measure % binding activity to 62GPI for each 
patient IgG sample. The plate was then incubated for 90 minutes at RT and washed 
three times with PBS. Goat anti-human IgG alkaline phosphatase conjugate was 
diluted 1000 fold in PBS containing 0.1% BSA and 50pl of this solution added to each 
well. After one hour incubation at RT the plate was washed three times with PBS and 
once with BIC buffer. Addition of substrate was carried out as in section 2.21.1, the 
plates incubated at RT and OD measurements taken at 30 minutes and one hour.
Given that the whole plate was coated with CL and subsequently only one half with
i
whole B2GPI, the net OD represents the difference between binding to 82GPI in the 
presence of CL and to CL alone which is relevant clinically.
2.21.6 Detection of aPL binding to purified recombinant Dl in solid phase
By virtue of the incorporated C-terminal hiS6-tag, a direct ELISA could be performed 
by recombinant DI binding to a nickel-coated microwell plate. This would orientate 
DI correctly and allow binding to various aPL to be assayed (Iverson et al., 1998a).
Initially recombinant hise-tagged DI was diluted to a concentration of 75pg/ml using 
PBS and 50pl added to the wells of a nickel chelate-coated microwell plate. For 
binding assays testing polyclonal IgG patient samples, it became apparent that 
coating the plate with lOpg/ml of DI was sufficient to detect binding and for all the 
polyclonal IgG assays this lower coating concentration was used. The test half was 
coated with DI and the control half with PBS. Plates were incubated at RT for two 
hours and then washed three times with PBS, blocked with lOOpI 0.25% gelatin in 
PBS, incubated for a further one hour at RT and washed three times with PBS.
Affinity purified human polyclonal IgG samples were diluted in SEC to a concentration 
of 20pg/ml. 50pl was added in both the test half and the corresponding well in the 
control half. Each patient sample was tested in duplicate. IgG derived from a patient 
with APS whose sera was known to bind DI (P ll sample) was used as a positive 
control in each plate tested. This positive control was serially diluted and used as the 
in-house standard against which to measure % binding activity to DI for each IgG 
sample. Each monoclonal aPL sample to be tested, either affinity purified antibody or 
derived from CHO supernatant, was serially diluted in SEC. An identical concentration 
of primary antibody was loaded into a well in the test half and a corresponding well 
in the control half of the plate. The total volume in each well was 50pl. The plate
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was then incubated for one hour at 37°C after it was washed three times with PBS. 
Goat anti-human IgG alkaline phosphatase conjugate was diluted 1000 fold in SEC 
buffer and 50pl of this solution added to each well. After one hour at 37°C the plate 
was washed three times with PBS and one time with BIC buffer. Addition of substrate 
was carried out as in section 2.21.1, the plate incubated at RT and OD 
measurements taken at 30 minutes and one hour.
2.21.7 Detection of aPL binding in fluid-phase
2.21.7.1 Inhibition o f aPL binding to DI
A direct binding ELISA carried out as above in section 2.21.6 and was used to 
determine the concentration of affinity purified IS4Vh/IS4Vl required to achieve 
~50% maximum binding. DI or G2GPI as test inhibitors were diluted in SEC at 
concentrations ranging from 0 (i.e. no inhibitor) to 30pM. Affinity purified aPL was 
then added to each sample of inhibitor to achieve final concentration of antibody 
required to achieve 50% maximum binding. The samples were incubated at RT for 
two hours and then tested for binding to DI on an ELISA plate as described in 
section 2.21.6.
The per cent inhibition for each concentration of inhibitor was determined from the 
following formula:
% inhibition = (Ao-A /A o) x 1 0 0 , where Ao is the OD (A) from the well containing no 
inhibitor (corrected for background).
2.21.7.2 Inhibition of aPL binding to B^PI/cardioiipin
A direct ELISA was carried out as in section 2.21.5 and was used to determine 
approximately what concentration of each polyclonal IgG patient sample was 
necessary to achieve 50% maximum binding. This approximated to between 20- 
40pg/ml. DI and mutant DI samples were diluted in 0.1% BSA/PBS to a 
concentration of between 1.25 to 7pM and incubated with the appropriate 
concentration of human IgG aPL at RT for 90 minutes. The samples were then tested 
for binding to (32GPI/CL as in section 2.21.5 and the per cent inhibition calculated as 
is in the section 2.21.7.1 above.
2.22 Statistical analysis
Comparisons between different clinical groups (APS, SLE disease control group and 
healthy controls) for each of the binding assays (DI, B2GPI, PS, CL, B2GPI/CL
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complex) presented in Chapter 4 were made using a paired t-test. A paired t-test 
was also used to compare the binding of DI mutants with wild-type DI in the fluid 
phase (Chapter 6).
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CHAPTER 3
THE DEVELOPMENT OF AN EXPRESSION SYSTEM FOR 
PRODUCING RECOMBINANT DOMAIN I OF HUMAN B2GPI IN
E.COLI
153
OVERVIEW OF CHAPTER 3
This chapter focuses on the steps taken that led to the development of a successful 
and reliable platform of expression of DI of human 62GPI in E.coli. It is broadly 
divided into three main parts:
The first part elucidates the design and production of a synthetic gene encoding for 
DI, which crucially, is optimised for expression in E.coli.
The second part describes the cloning scheme that was undertaken. The first 
plasmid into which the DI synthetic gene was cloned was not the final expression 
construct used. This is because it became apparent that stability of the expression 
construct was dependent on the presence of tight regulation of expression. Thus 
multiple constructs were tested and this is discussed in detail.
The final part illustrates the successful expression and purification of hiS6-tagged DI. 
Evidence is presented which supports the hypothesis that an optimised gene for 
E.coli improved yield of expression. Optimisation experiments using varying 
concentrations of the induction agent highlighted the fact that excessive levels of this 
eukaryotic protein are toxic to E.coli, underlying the need to regulate expression.
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3.1 Production of a synthetic gene encoding for DI of human 
ft2GPI optimised for expression in E.coli
3.1.1 Introduction
The expression of non-glycosylated eukaryotic proteins in bacteria has many 
advantages over other production systems, mostly relating to efficiency, reliability 
and convenience of production. However, the initial steps required in establishing a 
reliable prokaryotic expression protocol for a given eukaryotic protein can be difficult 
(Baneyx, 1999). Clearly an efficient production system for DI of B2GPI would 
facilitate the study of this potentially important antigenic target for aPL. A group in 
La Jolla (California, USA) who express DI using baculovirus to infect insect cells as 
the expression host (Iverson et al., 1998b, Igarashi et al., 1996) find this method 
laborious and time consuming. Consequently they attempted and failed to establish a 
system for expressing DI in E.coli (personal communication with Dr M Linnik, La Jolla 
Pharmaceuticals, CA, USA). I hypothesised that one reason accounting for the 
current absence of an E.coli expression system for DI could be due to the nature of 
the codons in the native gene coding for DI. The native DI gene has 61 codons and 
26 (43%) are used by E.coli at a frequency of less than 1% (Kane, 1995). Optimising 
codon usage to facilitate expression by E.coli has been successfully employed to 
establish the production of many other eukaryotic proteins (Kane, 1995, Hua et al., 
1994, Hu et al., 1996, Martin et al., 1995).
My aim was to produce a gene that coded for DI, but ensure that all codons within 
that gene are those most frequently used by E.coli. I intended to use the system of 
recursive PCR to synthesise this globally optimised gene (Prodromou and Pearl, 
1992). This would involve designing primers that sequentially overlap by 15-20 
nucleotides and cover the length of the DI gene, whilst consulting codon tables to 
ensure optimal ones for E.coli are incorporated. To do this manually is possible but 
likely to be considerably time consuming as the primers would also need to be 
designed to minimise the possibilities of non-specific annealing (Prodromou and 
Pearl, 1992). In order to avoid this delay I collaborated with the group that 
developed recursive PCR, who had also developed a computer programme named 
Juniper, which was written to perform this time-consuming task. Juniper consults 
codon usage tables to ensure good expression, inserts restriction sites where 
appropriate and checks for sequence overlap or complimentarity to avoid non­
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specific priming. It then designs overlapping regions with melting temperatures in a 
specific range to yield an even number of oligonucleotides of similar length suitable 
for recursive PCR. At the time of writing this thesis, Juniper was freely available on 
the internet at following website: http://strubiol.icr.ac.uk/extra/iuniper
Hence the aim of these experiments was to synthesise an artificial gene encoding for 
an N-terminal Omp A leader sequence followed by DI, flanked by Bgl II and Nco I 
restriction sites whilst incorporating codons preferred by prokaryotic expression 
systems.
3.1.2 Results from Juniper
The amino acid sequence of the desired gene was entered into Juniper using FASTA 
format, and the desired flanking restriction sites, preferred oligonucleotide length, 
Tm and codon usage entered. Juniper then designed the gene, flagging all restriction 
sites and designed the overlapping oligonucleotides to the specifications as described 
above (see figure 3.1)
Juniper altered 41 out of the 61 codons (67%) present in the native sequence 
(Steinkasserer et al., 1991) to optimise expression in E.coli (figure 3.2).
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Results from Juniper
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Oligo overlaps:
1 GCGAGAIC TA IG AAAAAAACCGCTA TCGC T A IC G C . G T IGC T C . GGC IGG  
............................................................................................................................................... CCGACC
5 1 r :  rcG C  t a c c g ...........................................................................c c c a a a c c g g a c g a c c
AAAGCGATGGCAACGAGICCGACCAGCArGGACGGGCXXIGGCCTGC IGG
i o i  i g c c g : :crccACGGrrc. rccGCt g a a a a c c  t rc : a c g a a c c g g .............
...................................................................................... ...t t g g a a g a t g c : t g g c c c a c : r
1 5 1  ........................................................ A AA CCG GGTIACC .  r  XCCCGIGG I'GG I'ATGCG
C :  I TAGrGGAIGAGGACG ITTG G C C CA A TCC A AA G G ...........................................
201  t a a a t : c a  rc : g c c  c g c i g a c c g g rc i g  r ..................................................................
......................................... GGCGAC TGCCCAGACACCGGCIAG TIG  TGG GACTT. A
2 5 1  .....................................................
CGTGGATCGGIACCACA
Forward oligos: 5 to 3
1 . GGGAGAl C TAIGAAAAAAACCGC TAl'CG C 1’ATCGC IG  TTGC TCIGGCTGG T T TCGCIACCC
2. C C G A A A C C G G A C G A C C T G C C G rrC rC C A C C G IIG rrC C G C IG A A A A C C l.C T A C G A A C C G C  
.3. AAACCGGGT TA C G TTTCC C G TG G TG G TA.G CC - A A A . TCA.’CTGCCCGC -G A C C G G IC T G I
Reverse oligos: 5' to 3'
1 . g l  • c g  r c c o o  r • t l l g u l a g o  i*a  c o  a l l a o l  l . o a g c a a l g o  r a g c o a a a l l a g c l
2. g g a a a c g t a a c c c g g : t t g c a g c a g t a g g t g a . t t c .T C A C C C G G T T C G -A G A A G G T .t
3. A C A C C A IG G C TA G G IG C A I .  TCAGGGl'G .  TGA.CGGCCACAGACCGGTCAGCCG
Figure 3.1 Results generated by the Juniper programme. Sequence of desired 
gene encoding for an N-terminal Omp A leader sequence followed by DI designed to 
incorporate E.coli preferred codon usage. Overlapping oligonucleotides designed for 
use in a recursive PCR to synthesise the desired gene product and primers required 
listed 5' to 3'.
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GGG ATGAAAAAAACCGCTATCGCAATCGCTGTTGCTCTGGCTGGTTTCGCTACCGTTGCTCAGGCA3GTCGTkCC TGOCCGAAACCGGACGACCTGCCG
CCC TACTTTTTTTGGCGATAGCGTTAGCGACAACGAGACCGACCAAAGCGATGGCAACGAGTCCGAbcAGCAlrG(3ACGGGCTTTGGCCTGCTGGACGGC
B g l l l
F S T V V P L K T F Y E P G E E I T Y S C K P G Y V S R G G M R K F I
FTClrCCkCCGTTGT'lJCCGfcTG^AAfeVCCtrTClTACGAACCGGG'llGAAGAAATCACCTAC rCCTGCAAAZCG
c P L T G L W P I  N T L K C T
,  X  1  X  X 'd V j r / i  X V j l l J L k
TGC
ACG
^GCTGACCGGTJCTGTGGfcCG 
3GCGAC TGGCCAGACACC GGC
ATCAAC
TAGTTG
\CC
PGG
2TGAAA
G A C T T T
rGCACC
fiCGTGG
rAG TGT 
!VTC ACA
G G C C  C A A T G C  A fllAGCC C  A C  C A C  C A T  A C
IGTTACGTTtrCCpGTGGTGGIJATGPGI AAA TTC ATC
^CATTmAaTAG
N c o l
Figure 3.2 Synthetic gene encoding for DI. DI of human 6 2GPI underlined (amino acids) with Omp A leader sequence. Codons 
were chosen for optimal expression in E.coli by Juniper, altering 67%  of the native sequence (boxed codons). Synthetic 
oligonucleotide primers are denoted by grey shading; oligonucleotides of the upper DNA sequence are read 5' to 3' (left to right) and 
the oligonucleotides of the lower DNA sequence are read 3' to 5' (left to right). Flanking restriction sites are denoted in the light grey 
font.
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3.1.3 Amplification of synthetic DI gene using recursive PCR
Initial PCR reactions using the oligonucleotide primers at the recommended Tm of 
55°C yielded primer-dimers and no target gene product. Optimisation of the PCR by 
raising the Tm to 57°C , performing a hot-start and altering the ratio of outer to 
internal primers to 10:1 yielded a band of approximately 270bp consistent with the 
size of the desired gene (figure 3.3)
500bp ------►
300bp ------►
Boxed band excised, 
gel purified and run 
on gel
1 2 3 4 5
Lanes:
1 and 4 lOObp marker
2 10pl recursive PCR mixture using 100:1 outer:internal primer ratio
3 lOpI recursive PCR mixture using 10:1 outer:internal primer ratio
5 gel purified band cut out from lane 3 (boxed area)
Figure 3.3 Results of recursive PCR. Mixtures were run on 2%  agarose gel. Size of 
band in lane 5 consistent with desired 267bp gene. This was confirmed with  
subsequent sequencing of the gene cloned into pRSETb.
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3.2 Cloning scheme for synthetic DI gene: expression is 
critically dependent on tight regulation of expression
3.2.1 Introduction
This section describes the rationale and results of the cloning scheme that led to the 
final expression construct being DI cloned into pFT-26b (Novagen). The DI gene was 
cloned into several expression constructs before this one was made. Each was found 
to be inappropriate for different reasons that are discussed in the respective sections 
below. DI was initially cloned into pRSET-b (Invitrogen), then pET-20b and finally 
into pET-26b (pET series -  Novagen), the eventual expression plasmid used to 
produce recombinant DI and the subsequent mutants.
3.2.2 Ligation of synthetic Omp A-DI gene into pRSET-b expression 
plasmid
The synthetic gene with the Omp A leader sequence followed by the optimised 
sequence encoding for DI was digested using Bgl II and Nco I restriction enzymes. 
The digested gene was then ligated into pRSET-b digested at the same restriction 
sites. A successful ligation was confirmed upon digesting the extracted plasmid DNA 
construct with Bgl I I  and Nco I enzymes and observing two distinct bands on the 
agarose gel. The larger band of 2673bp constitutes digested pRSET-b minus the 
insert and the smaller band of 267bp the synthetic DI gene with an Omp A leader 
sequence as shown in figure 3.4. Between five and 10 colonies were screened for the 
presence of the desired construct. This is because many colonies when grown were 
shown to harbour an empty plasmid indicating unsuccessful ligation or foreign 
plasmids from contaminant E.coli strains as shown in figure 3.4. Similar screening 
principles were observed for subsequent ligations using other expression plasmids. 
The plasmid was sequenced to ensure that PCR errors had not occurred and the 
sequencing plot is shown in figure 3.5.
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1 2 3 X X X 4
Lanes
1 lOObp marker
2 and 3 Bgl I I  /  Nco I  digested pRSET-b and Omp A-DI insert
4 lkb  marker
X lanes with either empty pRSET plasmids or foreign plasmid DNA
Figure 3.4 B g l  I I I N c o  I digests of synthetic DI cloned into pRSET-b. Band  
constituting synthetic gene insert is at 267bp and digested pRSET plasmid minus 
insert at 2673bp (lanes 2 and 3). 1.2%  agarose gel.
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Figure 3.5 Sequencing plot confirms synthetic sequence of Omp A-DI gene 
cloned into pRSET-b. Abbreviations and symbols: HiS6, hexahistidine-tag; SP, signal 
peptidase cleavage site; * ,  stop codon.
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3.2.3 Ligation of synthetic Omp A-DI gene into pET-20b expression 
plasmid
The pRSET plasmid incorporates a hiS6-tag at the N-terminal of the expressed target 
protein as shown in the sequencing plot in figure 3.5. It was realised that the 
process of periplasmic transportation of protein cleaves off the signal peptide by 
signal peptidase. This process would thus render periplasmic target protein without a 
hiS6-tag, which was necessary to facilitate purification.
The plasmid pET-20b (Novagen) was identified that is designed to add a pel B leader 
sequence at the N-terminal of an expressed protein to transport it to the periplasm, 
and also incorporates a hiS6-tag sequence at the C-terminal. This made it suitable for 
expressing periplasmic DI. As shown in the plasmid map of pET-20b in figure 2.1, the 
pel B leader can be removed if the plasmid is digested with Nde I and any other 
enzyme located downstream of pel B in the multiple cloning site. Hence a PCR was 
performed using the Omp A-DI-pRSET construct as the template with primers 
designed to amplify the Omp A-DI synthetic gene whilst simultaneously altering the 
restriction sites to Nde I at the 5' end and Nco I at the 3' end (figure 3.6). This PCR 
product was then digested with Nde I and Nco I restriction enzymes as was the 
native pET-20b plasmid, which in effect removed the pel B leader sequence. The 
Omp A-DI gene was then ligated into pET-20b (figure 3.7) and sequenced to exclude 
PCR errors (figure 3.8). However, on transforming the expression strain BL21(DE3) 
E.coli cells with this construct the cells grew poorly on the plate, which was not 
observed when other host strains such as the cloning host DH5a were transformed. 
In case poor cell growth was a function of the Omp A leader sequence in the 
BL21(DE3) strain, another PCR amplification of DI was performed using the Omp A- 
DI—pET-20b construct as the template. Primers were designed such that only the DI 
gene was amplified without the Omp A sequence, flanked by Nco I restriction site at 
the 5' end and Xho I at the 3' end (figure 3.9). The Nco I /  Xho I digested DI gene 
was then cloned into Nco I /  Xho I digested pET-20b, in effect retaining the pel B 
leader sequence native to the pET-20b plasmid (figure 3.10). This was also 
sequenced to exclude PCR errors (figure 3.11). A schematic representation of the 
cloning steps described in this section are shown in figure 3.12.
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1 2
Lanes:
1 lOObp marker
2 Omp A-DI amplified gene
Figure 3.6 PCR amplification of Omp A-DI gene from the Omp A-DI-pRSET 
construct. 5pl of PCR mix run on a 2% agarose gel. 267bp band consistent with 
amplified gene.
3054bp ----- ► W
1018bp  ^ ►
506bp ------►
1 2 3 4 5 X 6 7
Lanes:
1 kb DNA ladder
2 Omp A-DI gene from recursive PCR mix
3 to 7 Nde I /  Nco I digested pET-20b and Omp A-DI insert
X Lane with either empty pET-20b plasmid or foreign plasmid DNA
Figure 3.7 Nde 11 Nco I digests of synthetic Omp A-DI gene cloned into pET- 
20b. Band constituting synthetic gene insert is at 267bp and digested pET-20b 
plasmid minus insert at 3600bp. 1.2% agarose gel.
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Figure 3.8 Sequencing plot confirms synthetic sequence of Omp A-DI gene 
cloned into pET-20b. Abbreviations and symbols: HiS6, hexahistidine-tag; * ,  stop 
codon.
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Lanes:
1 lOObp marker
2 and 3 DI amplified gene
4 Negative control (PCR minus template DNA)
Figure 3.9 PCR amplification of DI gene from the Omp A-DI-pET-20b construct.
5pl of PCR mix run on a 2%  agarose gel. 201bp band (lanes 2 and 3) consistent with 
amplified recombinant DI gene minus the Omp A leader sequence.
1 2 3 4 X 6  7
Lanes:
1 lOObp marker
2 DI gene from PCR mix
3 and 4 Nco I  /  Xho I digested pET-20b and DI insert
6  and 7 Nde I  /  Xho I  digested pET-20b and Omp A-DI insert
X Lane with empty pET-20b plasmid
Figure 3.10 Nco 11 Xho I digests of synthetic DI gene cloned into pET-20b. Band 
constituting synthetic gene insert is at 201bp and digested pET-20b plasmid minus 
insert at 3600 bp (lanes 3 and 4). D I gene from the PCR mix was run as a 201bp 
marker (lane 2). Omp A-DI cloned into pET-20b was also digested and run on the gel 
to act as a positive control for the Xho I  enzyme and as a marker for the double cut 
pET-20b plasmid (lanes 6  and 7). 2%  agarose gel.
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Figure 3.11 Sequencing plot confirms synthetic sequence of DI gene cloned 
into pET-20b. Site of gene cloned within plasmid results in retention of pel B leader 
sequence native to the pET-20b plasmid. Abbreviations and symbols: HiS6, 
hexahistidine-tag; *, stop codon.
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Synthetic gene produced by recursive PCR
^  BglII Ompyl Recombinant DI
Recombinant DI
Recombmant DI Xho:
Figure 3.12 Cloning scheme of DI into pET-20b plasmids. The final construct 
using pET-20b included the DI insert with an N-terminal pel B leader and a C- 
terminal hise-tag. Abbreviations: Ap, ampicillin, his-6, hexahistidine tag.
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3.2.4 Ligation of synthetic DI gene into pET-26b plasmid - tight 
regulation of expression using the high stringency 17lac promoter
DI cloned into pET-20b with the native pel B leader sequence was then transformed 
into the expression host strain BL21(DE3) E.coli. Poor transformation efficiencies 
were observed, as defined by the number and size of the transformed BL21(DE3) 
E.coli colonies after 24 hours overnight incubation at 37°C. This implied that poor 
growth of transformed BL21(DE3) colonies was not due to using Omp A and 
probably due to the DI gene. I hypothesised that the transformed BL21(DE3) E.coli 
cells in the uninduced state were exposed to a basal level of expressed DI protein 
that was proving toxic to the cells. In an effort to regulate expression further I 
identified a plasmid that has target gene expression driven by the high stringency 
17lac promoter. As discussed in the introduction (section 1.7.1.2 and figure 1.3), this 
promoter possesses a lac binding site that inhibits T7 RNA polymerase from initiating 
transcription of the target gene. This lac repression at the plasmid level within the 
cytoplasm is in addition to lac binding at the promoter driving expression of T7 RNA 
polymerase within the nucleus. This double repression has the effect of allowing 
E.coli to replicate without any or negligible basal production of target protein. The 
pET-26b plasmid as shown in the map in figure 2.3 also incorporates a pel B leader 
sequence and a C-terminal hiS6-tag making it ideal for periplasmic expression of DI. 
Hence the DI gene derived from the PCR in figure 3.9 was digested with Nco I and 
Xho I and ligated into pET-26b digested with these same enzymes. Figure 3.13 
shows the results of the ligation with the smaller band representing the 201bp DI 
gene and the larger band double digested pET-26b. The sequencing plot of figure 
3.14 confirms the absence of PCR errors and that the DI gene was cloned in frame. 
Upon transforming the expression strain BL21(DE3) with pET-26b-DI construct, 
transformation efficiencies were considerably improved, supporting the hypothesis 
that tight regulation of expression is important. The transformation efficiencies for 
each plasmid-DI construct are summarised in table 1.1.
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Lanes:
1 to 9 Nco I  /  Xho I  digested pET-26b and DI insert
10 lOObp marker
Figure 3.13 Nco  11 X h o  I digests of synthetic DI gene cloned into pET-26b. All
nine colonies screened contained the desired construct. Band constituting synthetic
gene insert is at 201bp and digested pET-26b plasmid minus insert at 5500bp. 1.2%
agarose gel.
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Figure 3.14 Sequencing plot confirms correct synthetic sequence of DI cloned 
into pET-26b. Abbreviations and symbols -  rbs, ribosomal binding site; pelB, pelB 
leader sequence; SP, signal peptidase cleavage site; * ,  stop codon.
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PLASMID PROMOTER
Colonies 24 hours post transformation
Colony number Size
pET-20b - native 17 1000 +++
pET-20b - OmpA-DI 17 2 +
pET-20b - DI 17 2 +
pET-26b - native 17lac 1000 +++
pET-26b - DI 17lac 800 +++
pET-39b - native T7lac 1000 +++
pET-39b - DI 17lac 500 +++
Table 3.1 Transformation efficiencies significantly improved upon tightly 
regulating DI production. BL21(DE3) expression strain of E.coli transformed with 
5pl of standard miniprep of plasmid (mean concentration 150pg/ml DNA) diluted 1 in 
100 in dH20. Colonies counted after 24 hour overnight incubation at 37°C. Size of 
colonies defined as: + => small, just visible; ++ => moderate size, easily visible, not 
merging; +++  => fat colonies with many merging on plate. Only pET-26b and pET- 
39b plasmids have expression driven by high stringency T7/ac promoter, hence 
transformation efficiency of native plasmid is maintained when plasmid harbours 
recombinant DI target gene.
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3.2.5 Ligation of the synthetic DI gene into pET-39b plasmid -  
incorporation of DsbA tag.
There was a concern that despite the periplasm favouring the formation of disulphide 
bond formation through its oxidative environment, yields of soluble target protein 
would not be sufficient. The protein DsbA is a member of thioredoxin family. This 
21kDa protein interacts with substrate proteins and oxidises them, thus catalysing 
the formation of disulphide bonds (Hiniker and Bardwell, 2003). To facilitate the 
formation of disulphide bond formation further and potentially improve yield of target 
protein, a construct was made which would encode for a DsbA-tagged DI expression 
product. The synthetic optimised gene encoding for DI was thus ligated into the 
multiple cloning site of the pET-39b plasmid (for plasmid map see figure 2.3). This 
construct encodes for a pel B leader sequence transporting target protein into the 
periplasm, an N-terminal DsbA-tag and a C-terminal hiS6-tag. Expression remains 
tightly regulated through the T7/ac promoter as seen in the pET-26b construct. 
Figure 3.15 shows the results of the ligation with the smaller band representing the 
201bp DI gene and the larger band double digested pET-39b. Given that expression 
is driven by the high stringency T7lac promoter, like pET-26b, DI cloned into pET- 
39b results in good transformation efficiencies upon plasmid insertion into the 
expression strain BL21(DE3) as shown in table 1.1.
The main disadvantage with this construct however is that the expressed product is 
not DI with a free N-terminal. Rather it has the 21kDa DsbA protein attached at the 
N-terminal of DI. In order to attribute binding and biological properties of expressed 
protein to DI alone, DsbA would need to be cleaved off. Thrombin and enterokinase 
sites are incorporated at the C-terminus end of DsbA to facilitate this. These sites 
and the confirmed correct sequence of DI are shown in the sequencing plot figure 
3.16.
Hence DI, which was originally cloned into pET-20b as shown in figure 3.12, was 
subsequently cloned into pET-26b and pET-39b to assess which construct would give 
greatest yield of soluble target protein.
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Lanes:
1 lOObp marker
2 Nco I  /  Xho I digested pET-20b and DI insert
3 and 4 Nco I  /  Xho I digested pET-39b and DI insert
X Foreign /  contaminant plasmid DNA
Figure 3.15 Nco I I Xho I digests of synthetic DI gene cloned into pET-39b. Band 
constituting synthetic DI gene insert is at 201bp and digested pET-39b plasmid 
minus insert at 5995bp in lanes 3 and 4. Lane 2 constitutes digested DI and pET-20b 
minus insert at 3600bp which was used as positive control for the digest. 2%  
agarose gel.
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Figure 3.16 Sequencing plot of DI of human B2GPI cloned into pET-39b.
Abbreviations: * ,  stop codon. Enterokinase cleavage site, thrombin cleavage site and 
the sequence encoding for the C-terminus end of DsbA is shown. The sequence 
reads 3' to 5' (left to right) as the T7 terminator was used as the sequencing primer. 
Given the size of DsbA, using the T7 forward primer for sequencing would have 
yielded a sequencing plot including most of DsbA, but not DI as only approximately 
800 bases are included in any given plot.
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3.3 Successful expression of DI in E.coli
3.3.1 Introduction
The previous section alluded to the likely toxicity that DI demonstrates in E.coli cells, 
necessitating tight regulation of expression. Thus the expression protocol was 
optimised with this in mind. Multiple optimisation experiments were performed 
investigating the effects of different culture and induction temperatures, culture 
media and concentration of inducing agents on target protein production. A summary 
of the key optimisation experiments undertaken and the resultant yields of target 
protein are summarised in table 3.2. Eventually the optimal conditions were found by 
inducing expression at 30°C, using an enriched culture media such as TB and adding 
1% glucose, which has the effect of lowering production of target protein in 
uninduced cells further.
The aim of this section is to demonstrate the efficient production of soluble, correctly 
folded, purified hiS6-tagged DI and show how optimisation of codons to suit 
prokaryotic expression and induction with varying concentrations of the inducing 
agent IPTG improved yield.
3.3.2 Expression and purification of periplasmic his6-tagged DI
The host E.coli cells chosen for expression were of the strain BL21(DE3). These were 
chosen because this is a protease deficient strain, potentially reducing target protein 
degradation. Also this strain contains a chromosomal copy of the T7 RNA polymerase 
gene (X.DE3). The presence of a source of T7 RNA polymerase is crucial given that 
expression is driven by the T7 promoter.
BL21(DE3) cells were transformed with the expression construct DI cloned into pET- 
26b. Harvested induction cultures were exposed to ice-cold ddH20 causing osmotic 
shock. This process lyses the outer membrane releasing periplasmic proteins whilst 
keeping the inner spherocyte intact. The periplasmic fluid then collected as 
supernatant was run on a 15% SDS-PAGE gel, electrophoretically transferred onto a 
nitrocellulose membrane and probed with a murine anti-his5tag-antibody (Novagen). 
Figure 3.17 demonstrates the western blot confirming the presence of a hiS6-tagged 
7kDa protein consistent with expected size of the target protein.
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Medium Culture 
temp C°C)
Induction 
temp (°C)
IPTG
concentration
Glucose Target
protein
yield
LB 37 37 ImM 0 0
LB RT RT ImM 0 0
TB 30 30 ImM 0 +
TB 30 30 ImM 1% ++
TB RT RT ImM 1% ++
TB 30 30 0.4mM 1% +++
TB 30 30 O.lmM 1% ++++
Table 3.2 Summary of key optimisation experiments for expressing 
recombinant DI. Abbreviations: temp, temperature. Target protein yield as assessed 
by western blot of periplasmic fraction: 0 => no detectable target protein; + + + +  => 
saturated band on blot after exposure time of 3 seconds. Constructs used for 
expression were with DI cloned into pET-26b and pET-39b.
178
1 2
Lanes:
1 HiS6-tagged molecular weight marker
2 Periplasmic fraction
Figure 3.17 Western blot of recombinant DI probed with an anti>his tag 
antibody. Periplasmic fraction was transferred onto a nitrocellulose membrane from 
a 15% SDS-PAGE gel and probed with an anti-his5-antibody. The ~7kDa band (lane 
2) is consistent with DI.
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Periplasmic sample was then applied to a column containing resin charged with 
nickel. The washing steps were crucial to obtaining purest product. The purification 
kit recommended a second wash with 30mM imidazole, however this resulted in 
impure target protein on elution. Conversely washing with 60mM imidazole partially 
eluted hiS6-tagged DI as demonstrated by western biot in figure 3.18. Optimal 
washing with 45mM imidazole and elution at 300mM imidazole (rather than the 
recommended 1M elution) proved to be optimal for obtaining purest sample of hise- 
tagged DI, as shown in figure 3.19.
Once purified, the elution sample was then subjected to extensive dialysis overnight 
against 10% glycerol in PBS at 4°C to remove traces of imidazole. Removal of 
imidazole is not only necessary for subsequent direct ELISA binding assays using 
nickel coated microwell plates, it is also required for total target protein 
quantification using the BCA protein assay (Pierce) as imidazole affects the sensitivity 
of this assay. Yields approximated to 750pg of target protein per one litre of 
expression culture, resulting in a working concentration of 150-200pg/ml of purified 
hiS6-tagged DI.
Purified recombinant hiS6-tagged DI was then coated on nickel-chelate coated 
microwell plates and binding confirmed to two murine monoclonal anti-DI antibodies, 
mAb-16 and 6C4C10 which recognise conformationally restricted epitopes (Iverson et 
al., 2002b), as shown in figure 3.20. Hence the correct size of target protein and 
observed binding of these antibodies on both the blot (figure 3.18) and the ELISA 
plate confirm the successful expression of DI, most likely in its correct conformational 
state.
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15kDa
6.5kDa
1 2  3 4
Lanes:
1 Column flow through
2 Wash with 5mM imidazole
3 60mM imidazole - partial elution of hiSe-DI
4 400mM imidazole - partial elution of hiSe-DI
5 1M imidazole - no remaining target protein
Figure 3.18 His6-tagged DI elutes from nickel at low concentrations of 
imidazole. Samples were run on a 15% SDS-PAGE, transferred on to a nitrocellulose 
membrane and probed with the murine monoclonal anti-D I antibody 6C4C10. No 
detectable DI in the flow through suggests that all of the target protein binds nickel. 
DI could be eluted using between 60mM and 400mM of imidazole. Hence using 1M 
of imidazole as recommended by the manufacturers was not necessary as all target 
protein could be eluted at a lower concentration as demonstrated.
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14kDa
7kDa
1 2 3 4 5 6
Lanes:
1 Protein molecular weight marker
2 Periplasmic extract
3 Column flow-through
4 Wash with 5mM imidazole
5 Wash with 45mM imidazole
6 Elution of pure hiSe-DI with 300mM imidazole
Figure 3.19 Coomassie stain of DI purification steps using nickel 
chromatography. Sample analysed by 15% SDS-PAGE. Washing with 5mM and then 
45mM of imidazole and subsequent elution with 300mM imidazole yields an elute 
containing pure target protein.
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Figure 3.20 Murine anti-DI antibodies bind recombinant DI. Direct ELISA 
demonstrating strong binding to recombinant DI by two murine anti-DI monoclonal 
antibodies that bind conformationally restricted epitopes on DI, suggesting that 
expressed target protein is conformationally correct.
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3.3.3 Efficient expression achieved with low levels of IPTG induction
Inducing the expression culture with Im M  and 0.4mM of IPTG resulted in very 
similar reduction of culture growth rate as measured by OD6oo- However inducing at 
O.lmM IPTG resulted in significantly less inhibition of growth as compared to higher 
IPTG induction levels. This observation, that cells grow better under these gentler 
induction conditions, suggests that cells can tolerate a critical level of target protein 
production which if exceeded results in intolerable toxicity (figure 3.21). In parallel to 
this the amount of target protein production is greatest with O.lmM of IPTG and 
least with Im M  IPTG induction as observed on the blot in figure 3.22. No target 
protein is seen with the uninduced control underlining the tight-regulation of 
expression that this system provides.
- ♦ - D I  (U n in d u c e d )  
- • - D I  ( Im M  IP T G )  
- • - D I  (0 .4 m M  IP T G )  
- ■ - D I  (O .lm M  IP T G )
0  2  4  6  8  1 0
Time - hours
Figure 3.21 Growth curves of E.coli expression cultures following induction 
with varying concentrations of IPTG. OD6oo represents the density of bacterial 
growth in the culture media. Samples were induced at OD60o of 0.6. Inducing with 
IPTG at Im M  and 0.4mM IPTG results in marked inhibition of cell growth. DI in the 
figure legend signifies that the bacteria had been transformed with the DI-pET 26b 
construct.
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Figure 3.22 Western blot of expression cultures induced with 1mM, 0.4mM and 
O.lmM IPTG and an uninduced control. Periplasmic extracts (P) and culture 
supernatant (S) samples were analysed using 15% SDS-PAGE and transferred onto a 
membrane. The membrane was probed with 6C4C10, a monoclonal antibody that 
recognises conformationally restricted epitopes. All cultures were performed in 
parallel under identical conditions and equal volumes applied to the protein gel. 
Inducing with O.lmM IPTG yields the greatest amount of target protein.
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3.3.4 Recombinant sequence optimised for E.coli is crucial to successful 
expression of DI
One possible explanation for successful expression of recombinant DI could simply 
be the plasmid used and the specific expression and induction conditions utilised. My 
hypothesis was that E.coli preferential codon usage was crucial to successful 
prokaryotic production of DI in addition to other measures employed. To prove this I 
obtained a cDNA sequence of DI of human B2GPI cloned into a BacPAK™ (Clontech, 
CA, USA) plasmid used for baculovirus expression, a kind gift from Dr. M Iverson, 
UP, CA, USA). Using the published cDNA sequence of human DI (Steinkasserer et 
al., 1991), I designed primers to amplify this sequence in a PCR whilst 
simultaneously incorporating the same flanking restriction sites (Nco I and Xho I) 
present in the optimised synthetic gene. The PCR amplified human DI gene as shown 
in figure 3.23 was then cloned into pET-26b utilising the incorporated Nco I /  Xho I 
flanking restriction sites and sequenced to exclude PCR errors (figure 3.24). Two 
parallel expression and induction cultures were then grown, one containing 
BL21(DE3) transformed with the construct containing the human cDNA sequence of 
DI and one containing the construct harbouring my synthetic gene which had been 
optimised for E.coli. Equal amounts of periplasmic fractions from each were then 
applied to the same 15% SDS-PAGE gel and transferred on to a membrane. Though 
some target protein was seen using the native cDNA sequence, much greater yield of 
target protein was seen when using the optimised sequence as seen figure 3.25.
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1 2 3
Lanes:
1 Human DI amplified gene
2 Negative control (PCR mix minus template DNA)
3 lOObp marker
3.23 PCR amplification of human DI gene. A PCR amplification of the human DI 
gene cloned into BacPAK™ plasmid was undertaken whilst simultaneously 
incorporating Nco I  /  Xho I flanking restriction sites. 5pl of the PCR mix was run on 2 
%  agarose gel and the 2 0 1 bp band is consistent with the target gene.
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Figure 3.24 Sequencing plot of native cDNA sequence of DI cloned into pET 
26b. Abbreviations -  Hum DI, native human cDNA sequence of DI; * , stop codon.
15kDa
2
Figure 3.25 Western blot analysis of recombinant his6-tagged DI probed with an 
anti-his5-antobody. Lane 1, hise-tagged molecular weight protein markers; lane 2, 
DI expressed using native DNA human sequence; lane 3, DI expressed using 
sequence optimised for E.coli. Equal amounts of periplasmic extract were applied to 
lanes 1 and 2  on the protein gel.
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3.3.5 Expression of DI tagged with DsbA at the N-terminal
Though satisfactory yields were eventually obtained using the DI-pET26b construct, I 
also attempted to express recombinant DI tagged with DsbA at the N-terminus by 
cloning my synthetic DI gene into the plasmid pET-39b, which also incorporates a C- 
terminal hiS6-tag. Given that DsbA catalyses the formation of disulphide bonds in the 
periplasm, I hypothesised that this could augment the yield of the target protein. The 
same protocol for expression was used as described above. Figure 3.26 
demonstrates that expression is possible using this construct and, as seen when 
expressing DI with a free N-terminus, greater yield of target protein is observed at 
lower induction concentrations of IPTG. As a control the empty vector of pET-39b 
was used to express DsbA tagged with hiS6 alone. As expected this protein was 
approximately 7kDa smaller than the DsbA-DI expressed protein as seen in figure 
3.26.
It was felt necessary to cleave DI off from DsbA before proceeding onto the planned 
experiments characterising the binding properties of DI. As there was an 
incorporated enterokinase cleavage site conveniently located between the N-termius 
of DI and the C-terminus of DsbA (figure 3.16), this site was specifically targeted. 
The aim would be to cleave DI from DsbA using recombinant enterokinase whilst 
avoiding non-specific protein degradation of target protein. Figure 3.27 demonstrates 
that incubating expressed DsbA-DI with a low concentration of enterokinase resulted 
in non-cleavage, whilst higher concentrations resulted in non-specific protein 
degradation and hence marked loss of target protein with minimal amounts of free 
DI detected. Varying the concentration of enterokinase, temperature and duration of 
enzyme incubation neither improved yield nor efficiency of cleavage. Given that this 
method ultimately led to reduced yields of free DI, for further experiments native DI 
and variants of this protein would be expressed using the pET-26b construct. 
However, DsbA alone, expressed by using the empty pET-39b vector, was purified 
and used as a his-tagged negative control protein for subsequent binding assays 
(figure 3.28).
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Figure 3.26 Expression of DI tagged with DsbA at the N-terminal. Periplasmic 
extract was transferred onto a membrane and probed with an anti-his5 antibody. 
Lane 1, pET-39b empty vector expressing DsbA alone; lane 2, DsbA-DI induction 
with Im M  IPTG; lane 3, induction with 0.5mM IPTG; lane 4, induction with O.lmM  
IPTG.
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Figure 3.27 Western blot demonstrating inefficient cleavage of DI from DsbA 
using enterokinase. The membrane was probed with the anti-DI antibody 6C4C10. 
Lane 1, no enterokinase; lane 2, 2U/pl enterokinase; lane 3, 0.5U/pl enterokinase; 
lane 4, O.lU/pl enterokinase. Low levels of cleaved 7kDa DI seen in lanes 2 and 3 
due to non-specific degradation of protein by higher concentration of enterokinase.
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Figure 3.28 Coomassie stain of purified his-tagged DsbA protein for use as 
negative control. Lane 1, Molecular weight protein marker; lane 2, purified DsbA 
elute.
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3.4 Discussion of results
This chapter describes the results charting the development of an efficient system of 
recombinant DI expression in E.coli. It became apparent through successive 
experiments that efficient expression of DI in E.coli was dependent upon addressing 
certain key factors. These relate to codon usage for E.coli, control of basal 
production of protein, disulphide bond formation and the observation that DI is toxic 
to bacteria. These problems were addressed in turn as detailed in the sections above 
and consequently a novel platform of expression of DI of human B2GPI in E.coli 
developed.
The cDNA sequence of human DI contains clusters of codons used rarely by E.coli 
(Steinkasserer et al., 1991). Of the 61 codons present in the native DI gene, 26 
(43%) are used by E.coli at a frequency of less than 1% (Kane, 1995). These rare 
codons are present in clusters of between two to five codons in length. Hence one 
may expect translational problems in E.coli with an abundant mRNA species 
containing an excess of rare low tRNA codons. Even a single rare codon can have a 
deleterious effect on heterologous protein expression (Hua et al., 1994). Recursive 
PCR has the advantage of being able to design and create a gene to meet a number 
of specifications in one simple PCR reaction (Prodromou and Pearl, 1992). Specifically 
Juniper ensured that all codons incorporated were those seen at relatively high 
frequencies in E.coli. The establishment of other eukaryotic protein expression 
systems in E.coli using the same codon optimisation principles has been described 
before (Hu et al., 1996, Hua et al., 1994, Martin et al., 1995). All these studies 
however, targeted specific areas of the genes of interest, and did not ensure pan­
gene codon optimisation as described in this chapter. One study has reported the 
successful expression of the eukaryotic protein human translation initiation factor 
eIF2 alpha by creating a gene with all codons optimised (Ito and Wagner, 2004). 
However this gene was created in step-wise fashion using successive PCR steps, and 
not in a single reaction using recursive PCR. Other strategies that may be employed 
to address codon optimisation involve expanding the intracellular tRNA pool by co­
expressing genes that encode rare tRNAs such as argU (dnaY) gene that encodes the 
minor tRNA-Arg (AGG/AGA) (Andrews et al., 1996). This may be achieved by using 
commercially available E.coli strains that contain an extra plasmid for the minor 
tRNAs such as E.coli Rosetta (Novagen) or E.coli CodonPlus (Stratagene). Although 
these strains may be efficient in producing large amounts of some eukaryotic
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proteins, the commercially available plasmids only encode for up to six rare tRNAs. 
E.coli uses 18 codons at a frequency of less than 1% (Kane, 1995) so one may still 
expect translational problems if the eukaryotic sequence contains a cluster of minor 
codons not supplied by these plasmids. Synthesis of an artificial gene not only 
ensures the optimisation of all codons, but there is also the added advantage of 
being able to modify the sequence simultaneously to aid subsequent cloning steps, 
periplasmic localisation and to produce genes with mutations at multiple points of 
interest as I have done.
Periplasmic localisation of target protein facilitated the formation of disulphide bonds 
due to the oxidative environment of this compartment in bacteria (Hannig and 
Makrides, 1998). The target protein in the periplasm has a free N-terminal as the pel 
B leader sequence is cleaved by signal peptidase during the translocation process 
and subsequently degraded by cytoplasmic signal peptide peptidase (Weihofen et al., 
2002). Furthermore, release of periplasmic proteins into the osmotic shock fluid 
potentially enhances efficiency of purification due to the significantly smaller pool of 
periplasmic bacterial proteins compared with the cytoplasm (Hannig and Makrides, 
1998). Similar principles have been applied by this laboratory to express human anti- 
dsDNA antibody F(ab) in E.coli successfully (Kumar et al., 2000). Other approaches 
to improve solubility of protein with disulphide bonds could be to co-overexpress 
enzymes that catalyse the formation (DsbA) (Cervera et al., 2002) or isomerisation 
(DsbC) of disulphide bonds in the periplasm (Zapun et al., 1995), over-express 
molecular chaperones such as heat shock proteins, Gro-EL-GroES and trigger factor 
(Ito and Wagner, 2004), or express in E.coli cells with mutations in the thioredoxin 
reductase ( trxB) and glutathione reductase (gor) genes, potentially enhancing 
disulphide bond formation in the cytoplasm (Lobel et al., 2002). However, it 
transpired that these approaches were not necessary as sufficient quantities of 
soluble DI could be obtained from the periplasm.
Toxicity proved to be a major obstacle in terms of establishing efficient expression of 
DI. Tightly regulating expression by utilising the more stringent T7/ac promoter, as 
offered by pET-26b plasmid, partly overcame this problem. Other frequently used 
methods of tightly regulating T7 promoter systems are to express protein in 
BL21(DE3) cells containing the T7 lysozyme producing pLysS and pLysE plasmids 
(Dubendorff and Studier, 1991). This was not appropriate for my project as although 
T7 lysozyme regulates expression by inhibition of RNA polymerase (Huang et al.,
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1999, Zhang and Studier, 1997), it has long been established that it can also cut 
specific bonds in the peptidoglycan layer of the E.coli inner cell wall, thus disrupting 
the periplasmic compartment (Inouye et al., 1973). Gentle induction of expression 
with low concentrations of IPTG was also crucial as inducing with the standard ImM 
concentration resulted in reduced yields implying E.coli cells could tolerate only a 
certain level of DI production. The expression of periplasmic human anti-dsDNA 
F(ab) in E.coli by our laboratory found that greater yields of this protein were seen 
with the ImM of IPTG induction rather than O.lmM, implying that human anti-dsDNA 
F(ab) is less toxic to E.coli than DI of B2GPI (Kumar et al., 2001).
Finally, this expression system lends itself to detailed mutational studies of DI as the 
ease and relatively low cost of E.coli expression systems relative to other hosts 
facilitates the production of a number of DI mutants. However, before embarking on 
the task of producing numerous variants of DI and investigating the effects of 
introducing mutations at specific sites of interest, the binding characteristics of wild- 
type recombinant DI first need to be fully characterised.
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CHAPTER 4
BINDING PROPERTIES OF RECOMBINANT DI OF B2GPI
195
OVERVIEW OF CHAPTER 4
Having developed an efficient system for expressing DI in E.coli, my next aim was to 
establish the binding properties of this purified recombinant protein. This Chapter's 
first focus is on presenting the results of recombinant DI binding assays to 
monoclonal aPL.
The focus then shifts to the assessment of DI binding polyclonal IgG purified from 
APS patient serum samples with two control groups included for comparison 
purposes (autoimmune disease and healthy controls). Patient selection details and 
criteria are presented. Purified IgG from all subjects is assessed for binding to a 
number of clinically relevant antigens such as CL, PS, whole 82GPI as well as 
recombinant DI. Statistical analyses of the binding results aims to detect differences 
between each of the patient groups studied within each of the antigen binding 
assays. Subset analyses are also performed for the APS group to detect if binding to 
DI can predict a specific clinical phenotype. Some IgG aPL exhibited interesting 
binding properties, such as displaying good binding to DI, whilst exhibiting relatively 
poor binding to whole B2GPI. These and other intriguing results are discussed, 
hypotheses for explaining them are put forward and results of experiments testing 
these hypotheses presented. Finally, results confirming the ability of recombinant DI 
to bind polyclonal aPL in the fluid phase are shown.
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4.1 Recombinant DI binds to pathogenic monoclonal human 
aPL in both direct and inhibition assays
4.1.1 Introduction
IS4 is a human monoclonal antibody with proven pathogenicity derived from a 
patient with APS (Zhu et al., 1999). Our group have made two variants of this 
monoclonal aPL, swapping the light chain with that of an anti-DNA antibody B3 and 
another monoclonal aPL UK-4. The light chains are very similar to each other with 
more than 90% sequence identity. Thus the three monoclonal antibodies tested for 
their ability to bind recombinant DI were IS4Vh/B3Vl, IS4Vh/IS 4V l and IS4VH/UK-4VL. 
These have previously been shown to bind CL and 82GPI in the following order of 
descending magnitude: IS4Vh/B3Vl -- IS4Vh/IS 4V l -- IS4VH/UK-4VL (Lambrianides et 
al., 2004). Recently our group has demonstrated, using point mutational studies, that 
non-germ line encoded arginine residues in CDR-3 of the heavy chain of IS4 play a 
critical role in binding to CL (Giles et al., 2005). Three mutants named IS4VHi&ii, 
IS4VHih and IS4VHiv contained mutations of arginine to serine at positions 96, 97 (for 
IS4VHi&ii), 100 (for IS4VHiii) and 100G (for IS4VHiv). These three mutants are 
schematically represented in figure 4.1 and have previously been shown to exhibit 
reduced binding to CL as a consequence of the incorporated mutations (Giles et al., 
2005).
The aim was to demonstrate that DI bound to a plate exhibits binding to these 
monoclonal antibodies in a comparable way to that seen with whole I32GPI and CL. 
The ability of DI to bind affinity purified IS4Vh/IS4Vl in solution was also investigated 
and compared to that of whole 62GPI.
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IS4VH18ui IS4Vl
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IS4Vh„, IS4Vl
1 0 0
IS4VHIv IS4Vl
100G
Figure 4.1 Schem atic of IS4VH point m utations. Yellow shading depicts the
arginine to serine point mutations within each of the IS4VH mutants. Each of the
three IS4VH mutants was paired with native IS4VL.
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4.1.2 Recombinant DI in solid phase binding to native IS4, IS4VH/B3VL, 
IS4Vh/UK-4Vl and variants containing point mutations in IS4V h.
Binding of these monoclonal human aPL variants to whole G2GPI is shown in figures
4.2 and to DI in figure 4.3. Total IgG ELISAs were used to determine the precise 
stock concentrations of purified IgG aPL. The positive control in all ELISAs was a 
patient serum known to contain antibodies reactive to whole foGPI. The same aliquot 
of patient serum was used for all direct binding assays.
As shown in figure 4.2, the strongest binding to whole B2GPI coated on an irradiated 
plate is observed with the monoclonal variant IS4VH/B3VL whilst almost no binding is 
observed with IS4Vh/UK-4Vl. The same order of binding with these three antibodies 
is observed to CL, except that low level (rather than negligible) binding occurs with 
the IS4Vh/UK-4Vl variant (Giles et al., 2005). Figure 4.3 demonstrates that DI also 
exhibits the strongest binding to native IS4 and IS4Vh/B3Vl and the least to 
IS4Vh/UK-4Vl. However, low rather than negligible binding, to IS4VH/UK4-VH is 
observed in line with the binding to CL. The variants of IS4 with point mutations in 
IS4Vh revealed no detectable binding to DI, suggesting that the arginine residues 
exposed on CDR-3 of IS4VH are critical to binding DI of 62GPI.
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Figure 4.2 Binding of IS4VH/light chain variants to B2GPI coated on an irradiated 
plate. Each heavy /  light chain variant was expressed in CHO cells and secreted into 
the supernatant. Strongest binding was seen with IS4VH/B3VL and almost no binding 
was seen with IS4VH/UK-4VL variant.
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Figure 4.3 Binding of IS4VH/light chain variants and IS4VH mutants to Dl coated 
on a nickel plate. Monoclonal antibodies were expressed in CHO cells and secreted 
in the supernatant. The strongest binding to D I was observed with native 
IS4VH/IS4VL and the variant IS4VH/B3VL and least with IS4VH/UK-4VL. The variants of 
native IS4 with the single point mutations in IS4VH (IS4VHi&ii, IS4VHiii and IS4VHiv 
-  see figure 4 .1 ) revealed no detectable binding to D I, suggesting that arginine 
residues exposed on the CDRs of IS4VH are critical to binding to DI.
201
4.1.3 Recom binant DI in the fluid phase binds to affinity purified  
IS4Vh/IS4Vl
Native IS4 was available in an affinity purified form. The ability of D I to bind IS4 in 
the fluid phase and inhibit IS4 binding to DI coated on a plate was ascertained and 
compared to whole B2GPI in the fluid phase. As B2GPI has a molecular weight 
approximately seven times greater than that of DI the concentration of inhibitors are 
expressed in pmol concentration rather than in pg/ml. As shown in figure 4.4, DI is 
capable of binding IS4 in the fluid phase. There is a clear threshold of concentration 
above which DI in solution markedly inhibits binding of IS4 to D I coated on a plate. 
The degree of inhibition of this antibody was greater than that of equivalent pM 
concentrations of whole B2GPI.
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Figure 4.4 Recombinant DI in the fluid phase inhibits native IS4 from binding to 
DI coated on a plate.
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4.2 Demographic data on polyclonal IgG patient samples
Polyclonal IgG was purified from the serum of three sample groups. Serum was 
obtained from the bank of SLE serum samples stored at -20°C or taken prospectively 
from patients /  healthy volunteers after taking informed consent. Ethical approval for 
the sampling and use of serum within this project was granted by the UCL/UCLH 
Joint Research Committee on the 6th March 2003. The three sample groups studied 
were patients with APS, patients with either SLE or another autoimmune disease but 
no APS as disease controls and healthy volunteers. In total, IgG was purified from 
the serum of 54 individuals and the demographic information of these subjects are 
shown in table 4.1. Of the 24 APS patient samples, 18 (75%) had no other 
autoimmune disease whilst 6 (25%) also had SLE. The clinical details of each APS 
patient were recorded and shown in table 4.2 and all fulfilled the preliminary 
diagnostic classification criteria for APS (Wilson et al., 1999). The vast majority had a 
recorded positive IgG aCL (22/24, 91.7%) with a much smaller number also being 
positive for IgM aCL (7/24, 29.2%). None were positive for IgM aCL only. LA was 
positive in 17/24 (70.8%) and 9/24 (37.5%) at one point had a platelet count of less 
than 150xl03/pl. There was a history of at least one miscarriage in 16/18 (88.9%) 
women with a history of pregnancy. 18/24 patients (75%) had a history of one or 
more thrombotic event. The most common venous thrombotic event was deep 
venous thrombosis (7/24, 29.2%) followed by pulmonary embolism (4/24, 16.7%). 
The most common arterial thrombotic event was a stroke (8/24, 33.3%) followed by 
myocardial infarction (2/24, 8.3%). The numbers of patients with a history of both 
arterial and venous thrombosis were 4/24 (16.7%). For the disease control group, of 
the 20 patients included 18 (90%) had SLE, one (5%) had autoimmune thryroid 
disease and one (5%) primary Sjogren's syndrome.
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GROUP n Mean age 
(SD)
Gender Ethnicity
APS 24 45.5 (9.1) F=21 (87.5%) 
M=3 (12.5%)
C= 21 (87.5%) 
B= 3 (12.5%) 
0=  0 (0%)
*SLE /  autoimmune disease 
(no APS)
20 36.4(11.1) F=19 (95%) 
M=1 (5%)
C= 19 (95%) 
B= 1 (5%) 
0=  0 (0%)
Healthy volunteers 10 31.8 (6.6) F=7 (70%) 
M=3 (30%)
C=8 (80%) 
B=1 (10%) 
0=1 (10%)
Table 4.1 Demographic details of subject samples. Age is given as mean in years. 
Abbreviations: F, females; M, males; C, Caucasian; B, black; 0 , other which was 
Latin American. * Among the patients with SLE but no clinical features of APS, 6/20 
(30%) were positive for either IgG aCL +/or IgM aCL +/or lupus anticoagulant.
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Patient
code
+ /-
SLE
ACL LA Low
PI
Miscarriage
number
Thrombotic event(s)
IgG IgM
PI - + - + - Nulligravida MI
P2 - + + + + None PE
P3 - + - - - 3 None
P4 - + - - - 6 PE, Stroke
P5 - + - + - 4 DVT
P6 - + - + + 2 DVT
P7 - + + + - 1 PE, Stroke (x2)
P8 - + - + - 4 None
P9 - + + + - 1 None
P10 - + - + - 2 Stroke (x3)
P13 - + - - + 1 None
P14 - + + + + Nulligravida TIA
P15 - + + + + 1 None
P16 - + + + + N/A Stroke (x2)
P18 - + - + + N/A Stroke
P19 - + - + - Nulligravida DVT (x2), PE, MI
P-H - + - + + N/A DVT, CAPS
P-J - + + + + 2 None
A46 +SLE + - + - 1 DVT
A73 +SLE - - + - 1 Stroke
A90 +SLE + - - - 1 Stroke
A96 +SLE + - - - None DVT, PE
A123 +SLE + - - + 5 DVT
A221 +SLE + - - - 2 Stroke
Table 4.2 Clinical details of APS patients. Abbreviations: Low PI,
thrombocytopaenia; N/A, non-applicable for miscarriages as males; MI, myocardial 
infarction; PE, pulmonary embolism; DVT, deep venous thrombosis; CAPS, 
catastrophic antiphospholipid syndrome; TIA, transient ischemic attack. All patients 
fulfilled the preliminary consensus classification criteria for APS (Wilson et al., 1999). 
Thrombocytopaenia defined as platelet count less than 150xl03/pl.
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4.3 Binding profile of purified IgG to cardiolipin, 
phosphatidylserine and whole M3PI-
Prior to performing binding assays to recombinant DI, I wanted to confirm that the 
binding characteristics of the purified IgG samples were as one would predict for the 
APS and control sample groups. Hence the purified IgG samples were assayed for 
binding to CL (figure 4.4), PS (figure 4.5) and whole B2GPI (figure 4.6). The results 
are expressed as a percentage of binding of an in-house polyclonal IgG standard 
derived from a patient with APS. All individual samples were tested in duplicate and 
the mean OD used to calculate percentage of binding activity. A binding level of 
100% indicates the same level of binding compared to the standard, when used at 
the same IgG concentration on the same plate. A paired two-tailed t-test was used 
to calculate the probability of any difference observed between the groups as being 
statistically significant. For all three antigens, as one would expect, the majority of 
APS samples bound well and significantly better than either of the control groups. 
Figure 4.5 demonstrates a significant difference in binding to CL between the groups 
APS and autoimmune control (p=0.007) and APS and healthy controls (p=0.03). 
However, there was also a significant difference between the autoimmune control 
group and the healthy volunteers (p=0.03), though not as marked. Figure 4.6 
demonstrates that when testing binding to whole 62GPI, there was also a statistically 
significant difference between APS and autoimmune controls (p=0.02), but again 
there was a significant difference between autoimmune controls and healthy controls 
(p=0.0001). The binding to PS was clearly not as sensitive at detecting APS as 
shown in figure 4.7. Though there was a significant difference between the APS 
group and the autoimmune disease control group (p=0.03), there was no difference 
between the APS and healthy control group (p=0.1), most likely due to the 
combination of a low number of healthy volunteer samples studied in contrast to the 
other groups and the relatively low number of APS samples which demonstrated 
binding to PS.
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Figure 4.5 Results of polyclonal IgG samples binding to cardiolipin. APS, n=22; 
SLE/Autoimmune controls, n = 2 0 ; healthy controls, n = 10. **A P S  versus 
SLE/Autoimmune controls, p=0 .007 ; *APS versus healthy controls, p=0 .02 ; 
*SLE/Autoimmune controls versus healthy controls, p=0.03.
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Figure 4.6 Results of polyclonal IgG samples binding to whole R2GPI coated on 
an irradiated plate. APS, n=22; SLE/Autoimmune controls, n=20; healthy controls, 
n=10. *APS versus SLE/Autoimmune controls, p=0.02; *APS versus healthy controls, 
p=0.007; **SLE/Autoimmune controls versus healthy controls, p=0.0001.
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Figure 4.7 Results of polyclonal IgG binding to phosphatidylserine. APS, n=24; 
SLE/Autoimmune controls, n = 20; healthy controls, n = 1 0 . *APS versus 
SLE/Autoimmune controls, p = 0 .0 3 ; APS versus healthy controls, p = 0 .1 ;  
SLE/Autoimmune controls versus healthy controls, p=0.58.
4.4 Recombinant DI binds polyclonal IgG derived from APS 
patients
Having established the binding characteristics of the polyclonal IgG samples to the 
standard antigens used in ELISAs in clinical practice, my aim was to ascertain 
whether these same antibody samples bind recombinant DI in a comparable pattern. 
Again an in-house standard from a patient with APS was identified which bound 
recombinant DI and this was used to calculate the binding activity of the other 
samples. Figure 4.8 demonstrates that the APS samples bound DI significantly better 
than the autoimmune disease control group (p = 0 .0 0 2 ) and the healthy control group 
(p=0.007). However, there was no significant difference between the two control 
groups studied (p=0.24). This is in contrast to the CL and whole 8 2GPI assays which 
did demonstrate a significantly greater difference between the autoimmune disease 
control and healthy control group (figures 4.5 and 4.6).
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Figure 4.8 Results of polyclonal IgG binding recombinant DI expressed from 
E .coli. APS, n=24; SLE/Autoimmune controls, n=20; healthy controls, n=9. *APS 
versus SLE/Autoimmune controls, p=0.002; *APS versus healthy controls, p=0.007; 
SLE/Autoimmune controls versus healthy controls, p=0.24.
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4.5 Comparative sensitivities and specificities for detecting  
clinically relevant IgG
I f  DI of 8 2GPI harbours the epitopes that the majority of pathogenic IgG aPL bind to, 
then one may expect a high degree of sensitivity and specificity in detecting clinically 
relevant IgG upon testing binding to this antigen. Inspecting the above data, it 
seems apparent that there is a large degree of variability between the sensitivity and 
specificity for each antigen test. Table 4.3 details the sensitivity and specificity of 
each antigen test in terms of detecting IgG derived from patients with APS. An 
arbitrary result of 30%  binding of standard was used as a cut off above which a 
result would be defined as positive. The most sensitive test for detecting binding to 
clinically relevant purified IgG was binding to D I, with 62.5%  sensitivity whilst also 
retaining high specificity of 90% . Binding to both CL and PS had marginally higher 
specificities of 96 .7%  but these tests were not as sensitive (45 .5%  and 25%  
respectively). Though binding to 8 2GPI had a moderate sensitivity of 59 .1% , the 
relatively low specificity of 76.7%  was due to the high proportion of patients with 
SLE but without APS testing positive (13/20 -  65% ).
The positive and negative predictive values were also calculated. These tests 
calculate the probability of a subject having APS upon obtaining a positive result for 
the positive predictive value and similarly for the negative predictive value, the 
probability of a subject not having APS upon obtaining a negative result. Binding to 
DI gave the best overall positive and negative predictive values, being the only test 
that gave more than or equal to 75%  for both values (table 4.3).
Direct binding ELISAs testing binding of purified IgG to:
CL 6 2GPI PS DI
Sensitivity 45.5% 59.1% 25% 62.5%
Specificity 96.7% 76.7% 96.7% 90%
+ve predictive value 91% 65% 8 6 % 83.3%
-ve predictive value 70.7% 71.9% 61.7% 75%
Table 4.3 Comparative sensitivities and specificities for each antigen test.
Abbreviations: +ve, positive; -ve, negative; CL, cardiolipin; PS, phosphatidylserine.
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4.6 Correlation analyses of binding studies between DI, 
cardiolipin and whole B2GPI
The aim of this section is to dissect the binding patterns of individual samples more 
thoroughly. It  is of interest to ascertain whether the samples that bind well to 
recombinant DI are the same as those that also demonstrate good binding to CL or 
whole I32GPI. I f  there is good correlation between the different ELISA studies then 
one may hypothesise that the antibodies are binding the same or closely related 
epitopes within each antigen binding assay.
4.6.1 Binding of aPL to DI correlates well with binding to cardiolipin
Given the ubiquitous use of the CL assay in detecting aPL, correlation studies 
between DI and CL were felt to be of relevance as to ascertaining the significance of 
a positive DI binding test. As figure 4.9 demonstrates, there is a moderate to strong 
positive correlation between the aPL that bind CL with those that bind DI (r=0.65).
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Figure 4.9 Correlation scatter plot of purified IgG patient samples binding DI 
against binding to cardiolipin. Linear regression line of best fit is shown in black. 
Boxed values are IgG samples that demonstrate >40%  binding to DI but <20%  
binding to CL. Correlation coefficient r=0.65.
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4.6.2 Identification of polyclonal aPL demonstrating species preference 
for 6 2GPI
Correlating binding of DI with binding to CL highlighted a small group of three aPL 
that bound DI well (more than 40%) but CL relatively poorly (less than 20%). These 
aPL samples have been highlighted in figure 4.9. Two of these samples were from 
PAPS patients (PI and P4) and one from a patient that had SLE and no APS (P ll). 
Given that the CL ELISA is performed using FCS as the source of bovine 62GPI, two 
different hypotheses were put forward that could explain the results described:
• The aPL PI, P4 and P ll may exhibit preferential recognition for human rather 
than bovine B2GPI and thus account for the poor binding to CL but relatively 
good binding to human recombinant DI.
• Recombinant DI alone may result in the exposure of different epitopes that 
are hidden when DI is attached to the rest of the B2GPI bound to CL.
In order to test the hypotheses described above, the CL ELISA for PI, P4 and P ll 
samples was repeated, except that instead of FCS being used as the source of bovine 
82GPI, IgG depleted human serum derived from a healthy volunteer was used thus 
providing a source of human B2GPI. Otherwise the protocol for the CL assay was 
unchanged. Figure 4.10 demonstrates that two of the three samples demonstrate 
undetectable binding to CL with human B2GPI, suggesting that these aPL bind neo­
epitopes exposed on DI supporting the second hypothesis described. However one 
aPL (PI) which demonstrated poor binding to CL with bovine B2GPI demonstrated 
high binding to CL when human serum was used, suggesting that this aPL 
demonstrates species specificity for human B2GPI.
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Figure 4.10 Identification of an aPL with species specificity for human R2GPI.
Abbreviations: FCS, foetal calf serum; HS, IgG deplete human serum. PI 
demonstrates preference for binding to CL in the presence of human serum. P4 and 
P ll exhibit poor binding to CL when both FCS and HS are used.
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4.6.3 Correlation of binding between DI and whole M 5P I
Intriguingly there was a weaker positive correlation between binding to DI and whole 
6 2GPI as compared to CL (r= 0 .2 2 ), figure 4.11. Two aPL were identified that 
demonstrated poor binding to whole 6 2GPI (less than 10% ) but relatively good 
binding to DI (more than 40% ) and these sample are highlighted in figure 4.11.
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Figure 4.11 Correlation scatter plot of purified patient IgG samples binding DI 
against binding to whole 62GPI coated on an irradiated plate. Linear regression 
line of best fit is shown in black. Boxed values are IgG samples that demonstrate 
>40%  binding to DI but <10%  binding to whole B2GPI (P I and P6 ). Correlation 
coefficient r= 0 .2 2 .
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4.7 Identification and characterisation of aPL that bind whole 
&2GPI when bound to phospholipid
One would expect all aPL that bound DI to also bind whole B2GPI. This apparent 
paradox may be explained by two possible hypotheses:
• That aPL may recognise epitopes exposed on recombinant DI that are hidden 
on whole B2GPI when stuck to an irradiated plate, due to the orientation of 
the protein. These epitopes then become exposed due to alteration in 
orientation of protein or due to conformational change in overall structure 
when the normal physiological environment is simulated by B2GPI binding to 
CL.
• The exposure of neo-epitopes exposed on the surface of the DI peptide in 
isolation that are not present when DI is attached to whole 82GPI whether it 
is bound to a plate or CL.
To test the hypotheses above, a modified version of the CL ELISA was performed 
without the presence of any serum (see section 2.21.5). A plate was coated with CL 
and then coated on only one half with pure human B2GPI at the same concentration 
of lOpg/ml as used in the standard B2GPI ELISA. aPL was then added to both the 
B2GPI/CL coated side and the PBS/CL side. Hence a net difference in OD reflects 
binding to either whole 82GPI or a 82GPI/CL complex only. Again an IgG aPL sample 
was identified which exhibited good binding to B2GPI within this modified B2GPI-CL 
ELISA and was used as an arbitrary in-house standard against which the binding 
activity of the other aPL samples was measured.
Figure 4.12 shows that this ELISA is a valid and relevant test for identifying 
pathogenic aPL. The majority of the aPL samples were tested and compared against 
the binding of IgG derived from the two control groups. In line with the standard CL, 
whole B2GPI and DI ELISAs, there was a significant difference between binding of 
IgG from APS patients and autoimmune disease controls (p=0.003) and APS and 
healthy controls (p=0.018). However, unlike the standard CL and whole B2GPI ELISA, 
there was no significant difference between the two control groups (p=0.63) in line 
with the DI ELISA. In fact there was undetectable binding in both control groups 
which underlines the low background of this assay. In line with previous antigen
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tests determining the reliability of defining clinically relevant IgG (table 4 .3 ), an 
arbitrary cut-off of 30%  binding of standard was defined as a positive result. Using 
this the sensitivity of this assay was 50% , specificity 100%, positive predictive value 
100% and negative predictive value 74.3% . Figure 4.13 shows that there is a much 
stronger correlation between this more physiological 6 2GPI/CL ELISA and DI (r=0 .47) 
as compared to the standard 6 2GPI ELISA and DI (figure 4.11, r=0.22).
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Figure 4.12 Results of polyclonal IgG binding human R2GPI coated on 
cardiolipin. APS, n=18; SLE/Autoimmune controls, n=16; healthy controls, n=10.
**APS versus SLE/Autoimmune controls, p=0.003; *APS versus healthy controls, 
p=0.018; SLE/Autoimmune controls versus healthy controls, p=0.63.
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Figure 4.13 Correlation scatter plot of purified patient IgG samples binding DI 
against binding to human li2GPI when coated on cardiolipin. Linear regression 
line of best fit is shown in black. Circled values are IgG samples that demonstrate 
>40%  binding to DI but <10%  binding to whole B2GPI coated on CL (P2, P4, P5 and 
P10). Correlation coefficient r=0.47.
4.7.1 Identification of aPL that preferentially bind B2GPI bound to 
cardiolipin as opposed to an irradiated plate
As illustrated In figure 4.11, two IgG samples demonstrated poor binding to whole 
I32GPI when bound to a plate (P I and P6 ) but bound DI in isolation relatively well. On 
assessing the same two samples for binding to pure human I32GPI bound to CL, both 
revealed strong binding as shown in figure 4.14. These findings would support the 
hypothesis put forward above that G2GPI stuck to a plate causes sub-optimal 
orientation of the protein and hence the loss of some aPL binding epitopes that are 
otherwise exposed when B2GPI is bound to CL.
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Figure 4.14 Identification of aPL that binds recombinant DI, R2GPI bound to 
cardiolipin but not li2GPI bound to a plate. Abbreviations: G2GPI-PLATE, 6 2GPI 
bound to an irradiated plate; I52GPI-CL, B2GPI coated on a CL surface.
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4.8 Subset analyses of aPL samples
For meaningful subset analyses ideally large numbers of patients are required, unless 
the difference between the groups being analysed are marked. This limits the degree 
of subset analysis that may be possible in this study given the sample size of 24.
One possible method of stratifying different groups is to split them into those with a 
history of miscarriage and those who only present with thrombosis. However, once 
males and nulligravida women are excluded, there is only one female with a history 
of thrombosis and no miscarriage making this comparison unfeasible. Another option 
is to compare those presenting with only venous thrombosis + /- miscarriage against 
those who develop only arterial thrombosis +/- miscarriage. Analysing binding to CL, 
whole 62GPI and DI revealed no significant difference between these two groups (CL 
p=0.72, B2GPI p=0.72, DI p=0.69). Figure 4.15 shows the results of comparing the 
two groups for binding to DI. Even though the sample size is low for each group, 
there seems to be no emerging pattern of any one group demonstrating a greater 
bias towards binding DI. However, as emphasised a larger sample size is required 
before definitive conclusions may be made.
When comparing patients with and without LA, again only seven patients do not 
have a positive LA previously recorded, limiting meaningful comparison between 
these two groups. There was however an approximate even split between those APS 
patients that at one time have had a low platelet reading (n=13) and those who 
have consistently had platelet levels above the lower limit of normal (count of 
150x103/ mO (n=10). Figure 4.16 shows the comparison between these two groups 
and binding to DI. There is no discernible difference between the two (p=0.59) with 
similar results attained when comparing the two groups for binding to CL (p=0.38) 
and whole B2GPI (p=0.87).
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Figure 4.15 Comparison of DI binding of aPL derived from patients with venous 
thrombosis only versus those with arterial thrombosis. Each group included 
patients with miscarriage. No significant difference between the venous and arterial 
thrombosis groups was found (p=0.69).
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Figure 4.16 Comparison of DI binding of aPL derived from patients with and 
without thrombocytopaenia. No discernable difference between the two groups 
was found with binding to DI (p=0.59).
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4.9 Binding of recombinant DI to polyclonal aPL samples in 
the fluid phase
The ability of DI to inhibit binding of polyclonal IgG derived from APS patients to 
82GPI coated CL was also tested. Eight samples were chosen that had been shown to 
exhibit strong binding to G2GPI coated CL as well as DI in the solid phase. As shown 
in figure 4.17, DI in the fluid phase was able to inhibit binding of these IgG samples 
to whole human B2GPI coated on a CL surface. Data presented in the final results 
chapter (chapter 6) demonstrates that some of the single point mutants of D I were 
found to exhibit no inhibition to these IgG samples in the fluid phase and hence it 
was not felt necessary to use an additional negative control. The mean inhibition of 
binding by DI was 62.9%  (SD 25.7% ).
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Figure 4.17 Inhibition of IgG binding &2GPI/cardiolipin in the fluid phase by DI.
DI used at 3.25pM concentration was able to inhibit binding of 8 IgG samples to 
human 62GPI coated on a CL surface (mean + /-  SD) 62.9%  + /-  25.7% .
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4.10 Discussion of results
The results presented in this section demonstrate that recombinant DI, produced by 
E.coli utilising the expression platform developed, binds clinically relevant monoclonal 
and polyclonal aPL derived from patients with APS. This supports the theory that DI 
of 62GPI harbours the epitopes that are bound by pathogenic aPL derived from 
patients with APS and furthermore validates analysis of IgG binding to DI in isolation. 
This was an essential pre-requisite prior to embarking upon multiple mutational 
studies of DI. Furthermore, the aPL tested were fully characterised in assays of 
binding to other antigens relevant to APS such as CL, whole B2GPI and PS. The 
binding properties of monoclonal aPL and the multiple monoclonal variants have 
already been fully characterised in our unit by Dr Ian Giles and Nancy Lambrianides 
(Giles et al., 2005). The polyclonal IgG samples, purified from patients with APS, 
autoimmune disease and healthy controls were also tested for binding to these 
antigens prior to testing to DI. By comparing DI binding of aPL to these other 
antigens such as CL and B2GPI, hypotheses were generated regarding the potential 
nature of the aPL-antigen interaction.
There are a number of advantages of testing binding of DI (and subsequent variants 
of this protein) to polyclonal IgG affinity purified from APS patient serum samples. 
Polyclonal IgG is more representative of the heterogenous autoantibody repetoire of 
patients and limiting the binding studies to only B2GPI affinity purified antibodies 
risks the loss of antibodies that may be of clinical relevance, and could potentially 
bind DI in isolation, but not whole 82GPI for example. By testing multiple samples 
derived from APS patients, and through comparing binding to SLE disease and 
healthy control groups, meaningful conclusions may still be drawn. Furthermore, the 
ease and yield of IgG polyclonal purification meant that multiple patient samples 
could be tested to multiple DI variant samples, facilitating subsequent hypothesis led 
epitope mapping studies. This binding data to polyclonal IgG is underlined and 
reinforced by the mAb binding data. It is the intention that once important candidate 
epitopes are identified, further binding studies to whole 62GPI and DI affinity purified 
antibodies will be undertaken.
Statistical comparisons between the different clinical groups were initially made using 
a paired t-test. This makes the assumption that the binding data is normally 
distributed. The data was also re-analysed using the non-parametric Mann-Whitney 
U test and this data is presented in the subsequent published paper presenting the
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bulk of binding data presented in this thesis (Chapters 4 and 6; Ioannou et al., 2007 
-  appendix II  for reference). For all group comparisons, statistical significance (or the 
lack of it) remained unchanged when both parametric and non-parametric statistical 
tests were used, thus not altering the ultimate conclusions drawn.
IS4, derived from a patient with APS, is a relevant monoclonal aPL to study given its 
proven thrombogenic pathogenicity in animal studies (Pierangeli et al., 2000). IS4 
has Arg residues in the heavy chain CDR that have probably arisen through somatic 
mutation (Giles et al., 2003b). When these residues are mutated to neutral serine 
the result is loss of binding to whole B2GPI and CL (Giles et al., 2005). These Arg 
residues also seem to be crucial in conferring binding to DI, consistent with the 
hypothesis that these antibodies bind to similar epitopes on DI in isolation, DI when 
attached to the rest of B2GPI and within the standard CL assay.
Monoclonal aPL are derived from single B cell clones from a single patient. APS is 
characterised by the presence of heterogeneous aPL derived from patients with 
varying clinical phenotypes, a third of whom have SLE (Cervera et al., 2002). Would 
similar results be obtained by testing polyclonal aPL derived from multiple patients 
with APS? Also would DI in isolation open up neo-epitopes that could be recognised 
by non-pathogenic control IgG derived from patients with autoimmune disease other 
than APS or even by healthy volunteers? To answer these questions it was 
imperative that polyclonal IgG derived from multiple patients with APS and controls 
was tested. When testing the purified aPL for binding to CL and whole B2GPI using 
the standard ELISAs, as expected greatest binding was observed in the APS group, 
significantly greater than both the disease and healthy control group. However, there 
was also a significant difference (though not as marked) between the autoimmune 
disease control group and the healthy controls. This was not unexpected with the CL 
ELISA as it is known that around 30% of patients with SLE can develop aCL but only 
about half go on to develop APS (Petri, 2000). However, the observation that there 
may be a group of anti-B2GPI antibodies that may have a poor association with 
pathogenicity is a relatively new finding. Binding to DI predicted pathogenicity at 
least as well as CL and whole B2GPI. However, uniquely there was no significant 
difference between the SLE/autoimmune disease and healthy controls. This binding 
data, from a limited set of samples, would thus suggest that binding to DI of 62GPI 
in isolation is a better predictor of pathogenicity as compared to binding to whole 
B2GPI bound to a plate. It may be that B2GPI bound to a plate exposes domains
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other than DI that are recognised by non-pathogenic aPL. This hypothesis is further 
supported by a recent report from Bas de Laat at al (de Laat et al., 2005). In this 
study 52 samples of anti-B2GPI antibodies have been characterised into two groups. 
One is termed Type A and bind DI only. The other group of aPL is type B and binds 
domains I to V as assessed by testing binding to a combination of domain deletion 
mutants. Types A antibodies have LA activity and are associated with thrombosis and 
type B antibodies have no LA activity and no association with thrombosis. However in 
this study all patients investigated had an autoimmune disease other than APS. The 
data reported in this section are more representative of the APS population with only 
30% having SLE and the rest being patients with APS as their only autoimmune 
disease.
Correlation analyses between different antigens using different ELISA techniques 
need to be interpreted with caution. However I felt it important to perform these 
correlation studies as some insight into the potential nature of the interactions 
between DI, CL and human B2GPI bound to a plate with aPL may be gained. Binding 
of APS derived IgG to DI correlates well with binding to CL, as one would expect 
given that the CL ELISA is a measure not only of aPL binding to CL, but also 
potentially of bovine B2GPI binding. However, there was a small group of three aPL 
samples that bound DI well but CL relatively poorly. One aPL sample, previously 
demonstrating poor binding to CL with bovine serum, became strongly positive when 
human serum was used instead in the CL ELISA, suggesting that this aPL binds 
species specific epitopes on B2GPI present on the human protein but absent on 
bovine B2GPI. However, the other two aPL that bound DI well still bound CL poorly 
even when human serum was used. This highlights the heterogeneous nature of aPL 
and suggests that these aPL recognise epitopes on DI that are hidden on human 
B2GPI when bound to CL. Our unit has recently developed a monoclonal anti-dsDNA 
antibody with a single point mutation in the heavy chain resulting in loss of activity to 
dsDNA, but the emergence of binding to human 62GPI and to recombinant human DI 
but not to bovine whole B2GPI (Lambrianides et al -  Appendix B). The sequence of 
bovine B2GPI has 89% homology to human 62GPI (Gao et al., 1993). In total nine 
amino acids in the sequence of human DI differ from bovine DI. The amino acids are 
{human -*■ Bovine}: {Asp 9 -*• Gin 9}; {Thr 20 — Arg 20}; {Glu 27 Gin 27}; {Thr 
29 -  Val 29}; {Tyr 30 -  Phe 30}; {Lys 33 -  Gin 33}; {lie 42 -  Met 42}; {Lys 44 
-*  Arg 44}; {lie 46 -*  Thr 46}. It is very likely that one or more of these epitopes 
are important in conferring binding to DI for the species specific aPL sample Pla.
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The correlation between the binding of APS derived IgG to DI and binding to human 
B2GPI coated on a plate was not as strong as that between DI and CL. This poor 
correlation was primarily due to a small group of aPL that were poor binders to 
whole B2GPI immobilised on a plate but relatively good DI binders. This phenomenon 
may also be explained by the fact that DI not attached to the rest of B2GPI may 
present neo-epitopes. However, given that whole B2GPI is bound to a plate, one 
other possibility is that B2GPI may undergo a conformational change when bound to 
anionic PL as in the CL assay, and reveal aPL binding epitopes on DI which are also 
exposed when DI is present in isolation. When B2GPI is bound to CL, the previously 
poor B2GPI binders became good binders. Conversely, non-pathogenic samples from 
the autoimmune disease control group that bound B2GPI immobilised on a plate did 
not bind B2GPI immobilised on CL. Data presented in this section from the limited 
number of samples studied suggests that assessing binding of aPL to pure human 
B2GPI bound to CL is a far better predictor of pathogenicity than any of the other 
standard ELISAs tested and this also correlates well with binding to DI. However, this 
ELISA can only detect binding to IgG aPL purified from serum (thus free of native 
B2GPI) and so is not practical for use as a clinical assay. There has been considerable 
debate In the literature as to whether the epitopes on 62GPI that aPL recognise are 
cryptic or not and this has been reviewed by Giles et al (Giles et al., 2003c). The 
suggestion that pathogenic B2GPI antibodies recognise DI of B2GPI only after 
conformational change is supported by a further recent study by Bas de Laat et al 
(de Laat et al., 2006b). In this study pathogenic aPL as opposed to non-pathogenic 
aPL bound 62GPI only if coated on to a negatively charged hydrophilic plate and not 
when coated on a neutral plate or in the fluid phase. Furthermore on removing the 
carbohydrate chains of B2GPI, these pathogenic aPL were then able to bind the non­
glycosylated B2GPI in the fluid phase. The suggestion is that large carbohydrate 
chains from other domains extend up and cover important aPL binding epitopes on 
DI. When B2GPI is then anchored to a negatively charged surface the sugar 
molecules flip down and expose these epitopes. If this is true it may explain the high 
sensitivity of the DI ELISA, given that E.coli expressed DI is not glycosylated. These 
important studies however did not investigate aPL from PAPS patients nor did they 
attempt to mimic the physiological in vivo environment more closely in vitro by 
assessing binding to pure B2GPI anchored to an anionic PL surface such as CL as I 
have done.
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Finally, I have demonstrated that DI binds to aPL in the fluid phase, inhibiting the 
binding of aPL to fcGPI immobilised to CL. This was important to demonstrate as it 
shows that the aPL binding epitopes exposed when DI is anchored to a nickel plate 
are also exposed with DI in the fluid phase. Numerous other studies have also 
demonstrated the ability of DI to bind aPL in the fluid phase (Iverson et al., 1998b, 
Iverson et al., 2002b, de Laat et al., 2005). Generally these studies have 
demonstrated the ability of DI to inhibit aPL binding to whole B2GPI immobilised on 
plastic, but none have demonstrated the ability of DI to inhibit aPL binding to pure 
82GPI immobilised on to CL.
To conclude, the results described in this section confirm that recombinant DI 
produced by this E.coli expression system binds clinically relevant aPL derived from 
APS patients. These data also reinforce the emerging evidence favouring DI as the 
dominant domain for harbouring important immunodominant aPL binding epitopes. 
Comparing the binding patterns of aPL to CL using either bovine or human serum as 
a source of B2GPI, B2GPI immobilised on to a plate and to B2GPI immobilised on CL 
has highlighted the heterogeneous nature of these antibodies. Broadly the 
conclusions are that it is likely that aPL binding epitopes on DI in isolation are 
relevant to pathogenicity, and that these epitopes on the whole B2GPI protein are 
best exposed when this protein is bound to CL. The importance of aPL binding 
epitopes exposed on DI is reinforced by the ability of DI in the fluid phase to inhibit 
aPL binding. The ability of a peptide to inhibit pathogenic aPL from binding native 
antigen may be of potential therapeutic value. However, in preference to a 7kDa DI 
or related peptide of a similar size being given therapeutically, a smaller peptide 
analogue modelled on the fine immunodominant epitopes exposed on the surface of 
DI or even a small molecule mimetic of this peptide analogue would be preferable for 
immunogenic and pharmacokinetic reasons (Tang et al., 2004, Gadek and McDowell, 
2003). In order to ascertain the precise location of these epitopes mutational studies 
of DI need to be under taken. Though there have previously been some reports of 
mutational studies within DI in the context of whole B2GPI (Iverson et al., 2002b, de 
Laat et al., 2005), there have been no published reports of the effects of mutations 
within DI in isolation.
The following section will describe the application of the E.coli expression system to 
produce multiple mutants of DI designed to test specific hypotheses. These 
hypotheses were generated from computer modelling studies of DI, previous
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mutational studies within DI of whole B2GPI (Iverson et al., 2002b, de Laat et al., 
2005) and work from this unit on mutational studies of monoclonal aPL expressed in 
mammalian expression systems (Giles et al., 2005).
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CHAPTER 5
DESIGN AND EXPRESSION OF MULTIPLE RECOMBINANT
MUTANTS OF DI
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OVERVIEW OF CHAPTER 5
Work has been presented demonstrating both the development of an efficient 
expression system for DI in E.coli and the binding properties of this recombinant 
protein. This platform of DI production was then used to create multiple mutants of 
DI.
This chapter will describe the production of 15 of these mutants. The initial focus is 
on describing the rationale behind choosing which specific mutations to incorporate, 
a process facilitated by protein computer modelling studies. Evidence for the 
production of the mutant constructs is shown with sequencing plots confirming the 
correct mutation for each construct. Finally, results for the expression and 
purification of these mutants are demonstrated.
The majority of mutants expressed well, whilst a few had relatively low yields of 
purified target protein. Results of some experiments are shown which suggests 
potential explanations for the differences in yields between some mutants and these 
potential reasons are discussed.
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5.1 Introduction: rationale for choice of regions to target
Each specific mutation chosen was designed to test a hypothesis. Results have been 
presented that demonstrate the importance of Arg residues, exposed on the surface 
of antigen binding regions of monoclonal aPL, in conferring binding not only to CL 
(Giles et al., 2005) and to whole 82GPI, but also to DI alone. It is possible that these 
positively charged residues on aPL are interacting with five negatively charged Asp 
and Glu residues clustered and exposed on the surface of DI. Hence these five 
residues were targeted. Computer modelling studies were used to predict which 
amino acid replacements at those positions would result in least overall 
conformational change of protein. Further evidence supporting the importance of two 
of these residues (Asp 8+9) comes from a study by Vlachoyiannopoulos et al 
(Vlachoyiannopoulos et al., 2004). An eight amino acid peptide derived from the 
region 239-245 of CD40 with 89% sequence homology to the 7-13 N-terminal region 
of DI has been shown to bind anti-62GPI antibodies derived from patients with APS. 
This peptide harbours the neighbouring Asp 8 and 9 residues.
The second area to target was the region Arg at position 39 through to Arg at 
position 43. Iverson et al has reported that the G40E and R43S mutation in the 
context of whole foGPI resulted in marked reduction in binding to the aPL tested 
(Iverson et al., 2002b). I aimed to introduce the same mutations into DI alone and 
also test the hypothesis that the effects on binding may in part be due to the fact 
that these residues lie adjacent to Arg 39, which has over 60% of its surface area 
exposed for potential antibody interaction. Finally I also chose to express DI with the 
whole DI-II interlinker region included. This was to test the hypothesis that this 
region may be important in conferring binding given its marked homology with the 
DIII-IV interlinker region (Steinkasserer et al., 1991) and the findings from some 
groups which suggest that important immunodominant aPL binding epitopes lie in 
DIV (George et al., 1998d, Igarashi et al., 1996). Another reason for targeting this 
region was that a peptide with homology to the DI-II interlinker region has been 
shown to bind aPL and inhibit aPL induced thrombosis in mice (Pierangeii et al., 
2004a). The aim was to create mutations that would have the greatest effects on 
binding. Whilst some were expected to demonstrate reduced binding to aPL, it was 
anticipated that others might show enhanced binding compared to wild-type DI.
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5.2 Design and production of DI mutant constructs
5.2.1 Computer modelling used to design nature of single I multiple 
point substitution mutations
A computer modelling programme, Swiss-Model ( http://swissmodel.exDasv.orQ) . was 
used to build three-dimensional templates of hiS6-tagged DI of human 62GPI. Swiss- 
Model has been validated as an accurate tool to predict protein structure (Peitsch, 
1996, Guex and Peitsch, 1997) and furthermore the predicted structure of wild-type 
DI by this software is identical to the known crystal structure of this protein (Bouma 
et al., 1999, Schwarzenbacher et al., 1999). An example of a template demonstrating 
the location and surface exposure of negatively charged residues within a DI protein, 
tagged at the C-terminal with hiS6, is shown in figure 5.1. Models of mutant DI were 
then made in order to deduce the effects of altering the targeted residues on H-bond 
/  salt-bridge formation with neighbouring amino acids and the degree of surface 
exposure. Though it was anticipated that incorporating a mutation would inevitably 
cause some alteration in overall protein conformation as compared to wild-type, this 
software was used to help identify which mutation would cause least change. For 
example, as predicted by Swiss-Model, Glu 23 has 20% surface accessibility and 
forms H-bonds with Arg 2, Gly 25 and a double H-bond with Glu 26. The aim was 
design a mutation such that the negative charge at position 23 was lost while 
minimising the disruption in overall protein conformation. According to the model 
created by this software, mutating Glu 23 to Ser 23 would result in no change in 
surface accessibility of that residue but the H-bond with Arg 2 would be lost. This 
implies that the conformation is altered such that the residue at position 23 is no 
longer in close approximation with Arg 2 as seen in the wild-type protein. However, 
mutating Glu 23 to Gly 23 results in loss of all four H-bonds with no change in 
surface accessibility. Mutating to Ala 23 results in only loss of only one H-bond with 
Arg 2 as seen with Ser 23, but a reduction in surface accessibility from 20% to 10%. 
Hence the E23S mutation seemed the most appropriate. This systematic approach 
was made to all residues targeted for mutation and the results are shown in table 
5.1. Regarding residues Gly 40 and Arg 43, the mutations were chosen on the basis 
that these were the mutations that Iverson et al (Iverson et al., 2002b) had 
incorporated in the whole 62GPI protein. The effects on conformation were 
nevertheless analysed and the results shown in table 5.2.
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Figure 5.1 Ribbon structure of his6-tagged DI of B2GPI. Molecular conformation of 
protein structure shows that Asp and Glu amino acid residues are located on surface 
exposed areas of the protein. Swiss-Model was used to create this model (Peitsch, 
1996, Guex and Peitsch, 1997).
| Mutation Resultant loss of H-bond or 
salt-bridge with:
Resultant new H-bonds 
or salt-bridge with:
H-bond or salt-bridge 
remaining unchanged
Change in %> amino add surface area exposure 
from wild-type -*  to mutant
D8S None None None 50% -*■ 40%
D9G Ser 13 None None 30% -  25%
Mut 8+9 Asp 9 with Ser 13 None None D 8=50% — 45% 
D 9=30% -  30%
E23S Arg 2 None Gly 25, Glu 26(2x) 20% -*  25%
E26S Lys 19 None Glu 23 (2x), Cys 47 15% -  15%
E27S Thr 29, Lys 44 (2x) None None 20% -  25%
Mut 23-26-27 Ser 23 with Arg 2 
Ser 26 with Lys 19 
Ser 27 with: Thr 29, 
Lys 44 (x2)
None Ser 23 with Ser 26 (x2) 
Ser 23 with Gly 25 
Ser 26 with Cys 47
Glu 23= 20% -  25% 
Glu 26= 15% -  15% 
Glu 27= 20% -  25%
Mut
8-9-23-26-27
Asp 9 with Ser 13 
Ser 23 with Arg 2 
Ser 26 with Lys 19 
Ser 27 with: Thr 29, 
Lys 44 (x2)
None Ser 23 with Ser 26 (x2) 
Ser 23 with Gly 25 
Ser 26 with Cys 47
Asp 8=50% -  40% 
Asp 9=30% -  25% 
Glu 23=20% -  25% 
Glu 26=15% 15% 
Glu 27=20% -  25%
Table 5.1 Results of computer modelling studies targeting negatively charged amino acids. Abbreviations for multiple point mutations: Mut 
8+9, D8-D9 mutated to S8-G9; Mut 23-26-27, E23-E26-E27 mutated to S23-S26-S27; Mut 8-9-23-26-27, D8-D9-E23-E26-E27 mutated to S8-G9-E23- 
S26-S27.
Mutation Resultant loss of H- 
bond or salt-bridge 
with:
Resultant new H- 
bonds or salt- 
bridge with:
H-bond or salt-bridge 
remaining unchanged
Change in %  amino add surface area 
exposure from wild-type ->to mutant
R39K None None Arg 43 60% -> 100%
R39S None None Arg 43 60%->40%
G40E None Gly 41 Ser 38 25% -> 15%
G40S None None Ser 38 25% -> 20%
R43G Arg 39, Thr 57 None Tyr 30, Gly 41 15% -  10%
R43S Arg 39, Gly 41, Thr 57 Gly 46 Tyr 30 15% -> 20%
Table 5.2. Results of computer modelling studies targeting region Arg 39 to Arg 43.
5.2.2 Design of DI interlinker variants
The aim was to produce DI variants designed to test the hypothesis that the DI-II 
interlinker region was important in conferring binding to aPL. To test this hypothesis 
a variant of DI was designed with the remainder of the interlinker region attached on 
the C-terminal. This constitutes the addition of another five amino acids and the aim 
of this variant was to assess if the inclusion of the whole interlinker region enhances 
the binding properties to aPL as compared to DI expressed with only half the 
interlinker included. Another mutant of DI was designed substituting the D II-III 
interlinker region for the DI-II interlinker region hypothesising that this would lead to 
reduced binding. The amino acid sequences of the C-terminal portion of these 
recombinant DI variants are shown in table 5.3. Computer modelling studies of the 
interlinker region were undertaken to assess the degree of surface accessibility of 
each amino and to identify the H-bonds formed between the amino acids in the 
interlinker region and those located in other regions of DI (table 5.4).
5.2.3 Codon design of mutant amino acids
In total 16 mutant /  variant DI constructs were thus planned for synthesis. In order 
to facilitate expression by prokaryotes, codons used frequently by E.coli were chosen 
to encode for the substitution mutations (Kane, 1995). The codons chosen for each 
mutant are shown in table 5.5.
5.2.4 Results of constructs made by site directed mutagenesis
Site-directed mutagenesis was used to make the mutants D8S, D9G, Mut 8+9, E23S 
and E27S. Automated sequencing of these constructs was undertaken to ensure 
absence of PCR errors and confirm correct sequence. The results of the sequencing 
plots are shown in figure 5.2.
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Amino add sequence of C-terminal portion of protein
Wild-type WPINTLKCTHHHHHH
DI ext WPINTLKCTPRVPFHHHHHH
D II-III RPIELPVCAHHHHHH
Table 5.3 Amino acid sequences of hise-tag DI variants investigating the DI-II 
interlinker region. Abbreviations: DI ext, DI with remainder of interlinker region 
included (bold); D II-III, DI with D II-III interlinker substituted for wild-type interlinker 
(underlined). Protein sequences are shown in FASTA format.
Amino add at position: Forms H-bonds with: surface accessibility
Trp 53 Gly 51 15%
Pro 54 Asn 56 20%
lie 55 Thr 57 50%
Asn 56 Pro 54, Thr 57, Leu 58 35%
Thr 57 Arg 43, He 55, Asn 56, 35%
Leu 58 Asn 56, Leu 58, Cys 60 3%
Lys 59 Ser 38 30%
Cys 60 Leu 58 0.5%
Thr 61 Val 64, His 69, His 70 10%
Pro 62 Pro 65, Phe 66, His 70, 
His 71
15%
Arg 63 Phe 66, His 71, His 72 15%
Val 64 Thr 61, His 72 0%
Pro 65 Thr 61, Pro 62, His 67 0%
Phe 66 Pro 62, Arg 63, His 67, 
His 68
20%
Table 5.4 Results of computer modelling studies targeting DI-II interlinker 
region.
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DI mutant Amino acid and codon changes: wild-type-»mutant
D8S D
GAC
D9G D
GAC
S
J£C_
G
GTL
Mut 8+9 D
GAC
D
GAC
S G 
ISC G H
E23S E
GAA
E26S E
GAA
E27S E
GAA
Mut 23+26+27 E
GAA
E E
GAA GAA
Mut
8+9+23+26+27
D D E E E
GAC GAC GAA GAA GAA
S G S
TCC G *  TCC
R39K R
CGT
R39S R
CGT
G40E G
GGT
E
G40S G
GGT
R43G R
COT
G
Jot
R43S R
COT
DI ext* P R V P F
CCG COT GTT CCG TTC
D II - I I I W
TGG
R
J G G .
P I
CCG ATC
IN
AAC
E
T L K C T
ACC CTG AAA TGC ACC
L P V c A
CTG cfc GTT tg| ocr
Table 5.5 Amino acid and corresponding codon changes of DI mutants. The
mutant codons substituted are shown with the altered bases highlighted in red. *  DI 
ext -  as this is not a substitution mutation only the additional amino acids inserted 
into the peptide at the C-terminal are shown with the relevant codons.
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Figure 5.2 Sequencing plots of DI mutants produced by site-directed 
mutagenesis - D8S, D9G, Mut 8+9, E26S and E27S.
Indicates site of mutation.
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5.2.5 Production of synthetic mutant DI genes using recursive PCR
The rationale behind using recursive PCR to create the other DI mutants lay in the 
observation of variable efficiency rates of the site-directed mutagenesis kit 
(Stratagene) as found by myself and other members within our laboratory using it 
for other projects. The DI mutants produced using site-directed mutagenesis 
required considerable optimisation of a number of parameters. Thus although this 
method was initially employed to save time, it proved to be both time and cost 
consuming. The advantages of recursive PCR were that the technique had already 
been optimised for the production of wild-type DI, it was quick and cost-effective 
and, importantly, multiple mutations at different regions of the recombinant gene 
could be incorporated in a single PCR, which is not possible with site-directed 
mutagenesis. Up to three PCRs could be set up simultaneously to synthesise three 
mutant DI genes and the presence of the desired PCR fragment for each reaction 
confirmed on a single agarose gel.
Juniper was used to design the recombinant mutant genes encoding for E23S, Mut 8- 
9-23-26-27, R39K, R39S, G40E, G40S, R43G, R43S, DI ext and D II-III. These genes 
were designed in the same manner as wild-type DI (section 3.1.2). As with the wild- 
type DI recombinant gene, codons optimal for E.coli were incorporated. Juniper 
designed four 60mer overlapping primers spanning the length of the mutant genes 
with flanking Nco I and Xho I restriction sites. The sites of the desired mutations 
were located in non-overlapping regions, hence some primers could be used for 
multiple recombinant mutant DI genes. As an example figure 5.3 shows the results 
from Juniper for the gene E23S detailing the gene and overlapping primers used to 
create this mutant recombinant gene.
The primers for each mutant as designed by Juniper were then used in a recursive 
PCR to create the 201bp recombinant mutant DI genes and these are shown in table 
5.6. The PCR amplification products corresponding to the size of the desired 
synthetic mutant genes are shown in figures 5.4.
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Results from Juniper
I 1 1 G R T C P X F
1 G G G G C C A T G G G T C G T A c C T G C C C G A A A C C G
\ - M c o l
D 0 L P F S T V V P
31 G A C G A c C T G C C G T T C T c c A C C G T T G T T c C G
L K T F Y S F G E B
61 C T G A A A A C C T T C T A c T c c C c G G G T G A A G A A
\ - Xmal
X T Y 5 C X F G Y V
»1 A T C A C C T A C T C e T G c A A A C C G G G T T A C G T T
S ft G G M R K F X C
1 2 1 T C c C G T G C T G c T A T G C G T A A A T T C A T C r G C
\ - D e x 0 3 R
P L T G L W F 1 N T
1 S1 C c G C T G A c C G G T C T G T G G C C G A T C A A c A C c
\« P i n A I
L K C T ! 1 1
181 C r G A A A T G C A C C C T C C A G T G T
\ - S f r 2 7 4 I
Oil go overlaps
D D
1 g g g g c c a t g < j g t c g t a c c t g c c c g a a a c c l £ a ^ c a 3 . t g c c g : t c t c c a c
.....................................................................................................................................GTG
S 1 CGTTGTTCCGCTGAAA  «   . . . CACCTACT
GCAACAAGGGGACTTTTGGAAGATdAG^GGCCc/JL ITC ; J rAGTGGATGA
S  E E
101 CCTGCAAACCGGGTTACGTTTCCCGTGGTGGTATGCGTAAATTCATCTGC 
GGACGTTTGG................................................. . ................................TAAGTAGACG
151 CCGCTGAC................................... .. ...............................................................................
GGCGACTGGCCAGACACCGGCTAGTTGTGGGACTTTACGTGGGAGCTCAC
201 . 
A
Figure 5.3 Results from Juniper demonstrating design of gene for the E23S 
mutation. Restriction sites are highlighted by Juniper. Overlapping primers to use in 
a recursive PCR designed and shown. Site of the E23S mutation is boxed and 
labelled in blue and other negatively charged amino acids boxed and labelled in 
black.
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Primer A Primer C 
5 3' 5 ' ------------------------- ■ — - 3'
3' 5' 3' 5' 
Primer B Primer D
Primer Sequence and mutants used for
D I-F I S.'rGGGGGCAXGGGXCGTACOGGCCGAAAGCGGACGACCTGCGGTTCTGCACCGXTGTTC.CGCTGAAA^ .1 
Primer A for: E23S, Mut 23-26-27, R39K, R39S, G40E, G40S, R43G, R43S, DI ext, DII-III
D8-9-F1 5'-GGGGCCATGGGTCGTACCTGCCCGAAALLG HHhCTGCCGTT CTCCACCGTTGTTCCGCTGAAA-3' 
Primer A for: Mut 8-9-23-26-27
E23-R1 11 J.GU®GTAGGT.GATACCCGGGGAGTAGAAGGn JT.CAGCGGAACAACGGTG:3.’ 
Primer B for: E23S
E23-27-R1 5':GGIKGCABBGTAGGT.GA7TIGriCAC.CCGGGGACTAGAAGGTTITCAGCGGAACAAC.GGIG-.3' 
Primer B for: Mut 23-26-27 and Mut 8-9-23-26-27
DI-R1 5^ GGTJIGCAGGAGTAGGT.GATnCTTCACCCGGTTCGIAGMG.GITITCAGC.GGAA.CAA.CGGTG:3.' 
Primer B for: R39K, R39S, G40E, G40S, R43G, R43S, DI ext, DII-III
DI-F2 5.':CACCTACTCCTGCAAACCGG.GIIACGTITCCC.GI6GTGGTATG.CGIAAATrCATCTGCCCGCTGAC:3' 
Primer C for: E23S, Mut 23-26-27, Mut 8-9-23-26-27, DI ext, DII-III
R39K-F2 5.'^ .CCTACn^ CTGGAAACCGGGIIACG.TTKCMGGTGGTAIGCGTAAATrCAICIGCCCGCIGAC:3]
Primer C for: R39K
R39S-F2 :^CACCTACTCCTGCAAACCGGGTTACGTTTCCMGGTGGTATGCGTAAATTCATCTGCCCGCrGAC-3'
Primer C for: R39S
G40E-F2 5':CACCTACnT^ GCAAACCGGGJIA.CGTTTCCCGI^ BGGTATGCGTAAAnCAICIGCCCG-CIGAC:3'
Primer C for: G40E
G40S-F2 5>CACCTACTCCTGCAAACCGGGTTACGTTTCCCGTBBGGTATGCGTAAATT(^ TCT.GCCCGCTGAC-3'
Primer C for: G40S
R43G 5':C^ CCTACTCCTGCAAACCGG.GIIACGTXTCCC.GIGGrGGTATGJS55XAAATTCATCn'GCCCG.CrGAC:3.'
Primer C for: R43G
R43S 5.':C^ CCrACTCCTGCAAACCGGGTTACGTrrCCC.GIG.GrGGTATGJS3CAAATTCAICTGCCCGCTGAC:3.'
Primer C for: R43S
DI-R2 5.l:ACACTCGAGGGTGCATrr.CAGG.GTGTTGATCG.G.CCACAGACCGGTCAGC.G.GGCA.GATGAAT:3.' 
Primer D for: E23S, Mut 23-26-27, Mut 8-9-23-26-27, R39K, R39S, G40E, G40S, R43G, R43S
DIext-R2* 5>a c a c t c g a g Ig a a c g g a a c a c g c g .g Ig.g t g c a it t c a g g g t g t t g a t c g g c .c a c a g a c c g g ic -.3!
Primer D for: Dl-ext
D II-III-R 2 5>a c a c t c g a g a g c a G ^ C ^ G C A G 7 T Q ^ T !Q ^ Q C T C a g a c c g g t c a g c g g g c a g a t g a a i-3:
Primer D for: DII-III
Table 5.6 Overlapping primers designed by Juniper for the synthesis of mutant 
DI genes in a recursive PCR. All primers read 5' to 3' left to right. The site of the 
mutant codons are highlighted in red. *Boxed codons indicate that addition of five 
amino acids to complete the interlinker region.
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Lanes:
A) 1A = E23S
2A = Mut 23-26-27  
3A = Mut 8-9-23-26-27  
4A =  lOObp marker
B) IB  = R39K 
2B = R39S 
3B = lOObp marker
C) 1C = lOObp marker 
2C = G40E 
3C =  G40S
D) ID  = lOObp marker 
2D = R43G 
3D = R43S
Figure 5.4 Recursive PCR amplification of DI mutants.
The technique of recursive PCR allowed for 2-3 mutants to be produced 
simultaneously. lOpI per lane of each PCR mixture was run on a 1.2%  agarose gel. 
A-D show the individual agarose gels run confirming a band consistent with a 201bp 
mutant DI gene.
5.2.6 Successful synthesis of mutant DI genes is dependent on type of 
DNA polymerase employed in recursive PCR
Attempts made to produce the final two mutant DI genes altering the interlinker 
region (DI ext and D II-III) were initially unsuccessful. This was despite not altering 
the PCR conditions. The only difference from the previous successful recursive PCR 
amplifications was that different batches of the laboratory stock of the DNA 
polymerase Pfu was used rather than the Vent polymerase. Vent DNA polymerase 
was used for all previous recursive PCR amplifications and was also used in the 
original paper describing the technique (Prodromou and Pearl, 1992). Two parallel 
recursive PCR amplifications were set up to produce DI ext and D II-III and both 
were run at the same time in the same PCR cycler. The only difference between the 
two sets was that one had the DNA polymerase Pfu and the other Vent. Figure 5.5 
demonstrates that Vent polymerase is essential for successful amplification of the 
desired synthetic gene when using recursive PCR and that this technique, at least for 
the production of these two particular genes, does not work with Pfu polymerase.
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200bp
5 0 0 b p
1 2 3 4 5 6 7
Lanes: 1 = lOObp marker
2 = DI ext using Pfu
3 = D II- I I I  using Pfu
4 = positive control (201bp) using Pfu
5 = D I I - I I I  (201bp) using Vent
6  = DI ext (213bp) using Vent
7 = Positive control (201bp) using Vent
Figure 5.5 Successful recursive PCR amplification of DI mutants is dependant 
on Vent DNA polymerase. 10pl of PCR mix from each amplification was added to 
the wells. As a positive control primers employed successfully in previous 
experiments (with Vent DNA polymerase) to produce R39K were used. 2%  agarose 
gel.
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5.2.7 Cloning of synthetic mutant DI genes into expression plasmid
The eleven synthetic mutant DI genes produced by recursive PCR as shown in 
figures 5.4 and 5.5 were purified from the PCR mixture. The purified mutant DI 
genes were then digested with Xho I and Nco I restriction enzymes in order for these 
to be ligated into the pET-26b expression plasmid digested at the same sites. 
Successful ligation was confirmed by performing a Xho I /  Nco I digest and observing 
two distinct bands, a large band corresponding to a digested plasmid minus the 
insert (5298 bp) and a smaller band corresponding to the mutant DI gene (201 bp). 
The construct of wild-type DI cloned into pET-26b was digested and run on the gel 
to be used as a positive control for the digest and as a molecular weight marker for 
the mutant digested constructs. Otherwise native digested plasmid or 5pl of PCR mix 
comprising a mutant DI PCR fragment was run to determine the respective levels of 
5298bp and 201bp sizes on the agarose gel. Figure 5.6 shows the gels from the Xho 
I /  Nco I digestion of the mutant constructs E23S, Mut 23-26-27 and Mut 8-9-23-26- 
27, figure 5.7 the digestion of the mutants R39S, R39K, G40E, G40S and figure 5.8 
digests of the mutants R43S, R43G, D II-III and DI ext. The number of colonies 
screened for the presence of the desired ligated construct were between five and 10 
as not all colonies when grown were shown to harbour the desired construct on 
extracting plasmid DNA, with many being either native plasmid or foreign plasmids 
derived from contaminant E.coli strains. This is illustrated in multiple gels. All mutant 
constructs were sequenced to confirm absence of PCR errors as shown in the 
sequencing plots of figure 5.9. The mutant construct Mut 8-9-23-26-27 contained a 
PCR error of a single base deletion resulting in frameshift. Hence the gene was re­
synthesised using recursive PCR, cloned into pET-26b (figure 5.6B) and re-sequenced 
to confirm no errors in the second construct.
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1A 2A 3A
1A
2A
3A
lOObp marker 
E23S gene (PCR mix) 
E23S ♦digested construct
Mut 23-26-27 digested
construct
♦Digested tpositive control
1C to 5C
6 C
Mut 8-9-23-26-27  
♦digested construct 
♦Digested tpositive control
Figure 5.6 Xho 11 Nco I digested mutant constructs of E23S, Mut 23-26-27 and 
Mut 8-9-23-26-27. Gels: A) = E23S digests, B) = Mut 23-26-27 digests and C) = Mut 
8-9-23-26-27 digests. ♦All digests were performed using Xho  I  /  Nco I restriction 
enzymes. tAII positive controls were digested pET-26b with the wild-type DI insert. 
All agarose gels were 1.2% .
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LANES
1A R39K ^digested construct
2A *  Digested + positive control
3A R39K gene (PCR mix)
1A X2A3A
R39S ^digested construct 
G40S ^digested 
*  Digested + positive control
I *
■ m t t ;
d m
1F2F X  ► X3F X X 4F X X 5F
IF  lOObp marker
2F to 4F G40E ^digested construct
5F ^Digested tpositive control
X Unsuccessful ligation or
contaminant
Figure 5.7 Xho 11 Nco I digested mutant constructs of R39K, R39S, G40S and 
G40E. Gels: A) = R39K digests, B) =  R39S and G40S digests and C) = G40E digests. 
*AII digests were performed using Xho  I  /  Nco I  restriction enzymes. +AII positive 
controls were digested pET-26b with the wild-type DI insert or native pET-26b. All 
agarose gels were 1 .2 % .
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LANES
2 0 0 bp ►
1A 2A -►  5A 6A
1A lOObp marker
2A to 5A R43G ^digested construct
6 A *  Digested + positive control
2 0 0 bp ►
IB  lOObp marker
2B to 4B R43S ^digested construct
IB  2B 3B 4B
1C lOObp marker
2C and 3C D IM I I  ^digested construct
4C and 5C DI ext ^digested construct
1C 2C 3C  4 C  5C
Figure 5.8 Xho 11 Nco I digested mutant constructs of R43G, R43S, Dll-Ill and DI 
ext. Gels: A) = R43G digests, B) = R43S digests and C) = D II- I I I  and DI ext digests. 
*AII digests were performed using Xho  I  /  Nco I restriction enzymes. +AII positive 
controls were digested pET-26b with the wild-type DI insert. All agarose gels were 
1.2%.
2 0 0 bpr—►
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Figure 5.9 Sequencing plots of DI mutants synthesised using recursive PCR. All
base sequences underlined represent site of mutation substitution with the exception 
of DI ext, which represents base sequence insertion.
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5.3 Expression and purification of mutant DI proteins
Expression and purification of all 16 mutant DI proteins was performed as per 
expression of wild-type DI. Samples of each elute was run on a 15% SDS-PAGE mini­
gel and the bands visualised using a Coomassie stain. The purified mutant bands are 
shown in figure 5.10. Insufficient yields of the mutants Mut 23-26-27, Mut 8-9-23- 
26-27 and D II - I I I  were obtained to allow visualisation using this technique.
kDa
target protein
1A 2A 3A 4A 5A 6A 7A SA 9A 1QA
target protein
IB 2B 3B 4B 5B 6B 7B SB
target protein
Gel A 1A = MW marker Gel B IB  = MW marker Gel C 1C = MW marker
2A = D9S 2B = R39S 2C =  D II- I I I
3A = D9G 3B = R39K 3C = DI ext
4A = Mut 8+9 4B = G40E
5A = E23S 5B = G40S
6 A =  E26S 6 B = R43S
7A = E27S 7B = R43G
8 A = Mut 23-26-27  
9A = Mut 8-9-23-26-27
8 B = Wild-type DI
10A = Wild-type DI 
Figure 5.10 Protein gels of DI mutants. Gels A-C, 15% SDS-PAGE.
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5.3.1 Western blot analysis of expressed DI mutant proteins
Western blot analysis, probing with an anti-his tag antibody, was used to confirm 
that the purified 7kDa protein indeed contained a his-tag, making it highly likely to 
be the desired target protein. Furthermore, given the sensitivity of this technique, it 
was used to confirm whether any protein had been expressed for the three mutants 
not visualised on the less sensitive Coomassie stained gel (Mut 23-26-27, Mut 8-9- 
23-26-27 and D II-III). Simultaneously, in order to be certain that the protein assay 
represented an accurate measure of the concentration of purified recombinant 
mutant DI protein, these western blots were performed in a quantitative manner. A 
recombinant hiS6-tag DI of known concentration was used as a standard and the 
blots probed with an anti-his tag antibody. Western blots of varying concentrations 
of this standard and appropriate dilutions of expressed mutant proteins, run on the 
same gel, were performed and microdensitometry employed to quantify the intensity 
of each band (results expressed as arbitrary units). Plotting microdensitometry 
arbitrary units against concentration of standard consistently gave a linear standard 
curve, against which the concentration of mutant DI proteins could be estimated. 
Figure 5.11 shows an example of a typical quantitative western blot performed in 
this manner and figure 5.12 shows western blots of all DI mutants purified.
It is apparent in figure 5.12C that the mutant D II-III would not express. The mutant 
with all three Glu residues altered to Ser (Mut 23-26-27) and the mutant with all five 
negatively charged amino-acids altered to Ser /  Gly (Mut 8-9-23-26-27) did express 
but only at very low levels detectable on a western blot probing with an anti-his 
antibody (figure 5.12A). The most likely reason for the low expression levels 
observed for these mutants is due to the effects these mutations may have on the 
overall conformation of the protein as predicted in table 5.1. A marked 
conformational change would potentially lead to mis-folding and affect solubility 
resulting in lower yields. To test this theory, the same membrane as shown in figure 
5.12A was stripped with 0.2M NaOH and re-probed with a monoclonal murine anti-DI 
antibody that recognises conformationally restricted epitopes (figure 5.13). This 
murine antibody bound wild-type and mutants of DI with single and double point 
mutations with bands almost identical to those seen when probing with the anti-his 
tag antibody (figure 5.11A). However, despite a long duration of film exposure, the 
bands for mutants Mut 23-26-27 and Mut 8-9-23-26-27 were not visible, suggesting 
an alteration in conformation to the extent that these mutants no longer bind the 
murine anti-DI antibody tested.
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Lanes 1-4 represents hiS6-tagged DI (500pg/ml neat) run at varying dilutions:
1 = dilution six times - 83pg/ml
2 = dilution eight times - 62.5pg/ml
3 = dilution 12 times - 41.7pg/ml
4 = dilution 16 times - 31.25pg/ml 
Lanes 5-7 represent mutant DI samples:
5 =  Mut 8+9  dilution four times
6  = E23S dilution two times
7 =  Mut 23-26-27 neat
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Figure 5.11 Quantitative western blot using microdensitometry. A) Western blot 
probed with an anti-his tag antibody. Microdensitometry arbitrary units are quantified 
for each band. A standard curve is drawn B), against which the concentration of the 
mutants may be calculated. Mut 8+9  (lane 5) microdensitometry reading was above 
the standard, necessitating the western to be repeated at a higher dilution.
kDa
A)
1A 2A 3A 4-A 5A 6A 7A 8A 9A
Lanes:
1A = Wild-type DI IB  =  R39K 1C = DI ext
2A =  D8 S 2B = R39S 2C = wild-type DI
3A = D9G 3B = G40E 3C = D II- I I I
4A = Mut 8 + 9  4B = G40S
5A = E23S 5B =  R43S
6 A = E26S 6 B =  R43G
7A = E27S
8 A = Mut 23-26-27
9A = Mut 8-9-23-26-27
Figure 5.12 Western blots of DI mutants probing with anti-his tag antibody.
Blots A) to C) were probed with an anti-his5 antibody. Low signals are seen for the 
mutants E26S, Mut 23 -26-27  and Mut 8 -9 -23-26-27  and there was insufficient 
quantities of these proteins for use in binding studies. Complete absence of a signal 
for the D II- I I I  mutant implies lack of any soluble protein.
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kDa
Lanes: 1 = Wild-type DI
2 = D8S
3 = D9G
4 = Mut 8+9
5 = E23S
6 = E26S
7 = E27S
8 =  Mut 23-26-27
9 =  Mut 8-9-23-26-27
Figure 5.13 Western blot of mutants probing with murine anti-DI antibody. The
membrane from figure 5.12A ) was stripped and re-probed with mAb-16, a 
monoclonal murine an ti-D I antibody that recognises conformationally restricted 
epitopes (Iverson et al., 2002b). Loss of signal for the mutants M23-26-27 and M8-9- 
23-26-27 suggest marked conformational change in the structure of these proteins 
relative to wild-type and other single point DI mutants.
I
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5.4 The use of computer modelling to rationalise epitopes 
targeted for mutation
Broadly the three hypotheses formed to define the aPL binding epitopes targeted for 
mutation were: clustered negatively charged epitopes on DI, regions R39 to R43 with 
R39 being particularly important given its greater surface exposure and the D I-II 
interlinker (see section 5.1). However, on reflection it would seem that these 
hypotheses contradict each other. For example, if positively charged Arg residues in 
the VH of aPL are important and bind negatively charged residues on DI then how 
does this hypothesis fit in with the positively charged patch in region 39-44 
(RGGMRK) as also being important. Furthermore, if one or both these regions are 
important then how is it that the DI-II interlinker region may be important and that a 
short peptide, which bears some homology to this region, binds pathogenic aPL in 
the fluid phase (Blank et al., 1999)? It may be that polyclonal aPL being 
heterogeneous in nature bind varying linear regions of DI. Yet denaturing B2GPI 
results in loss of binding to aPL (Sheng et al., 2001b), suggesting that most aPL bind 
non-continuous epitopes. Studying the computer model of DI, which corresponds to 
the known crystal structure of DI within whole 62GPI, offers some rationale that may 
explain these apparent paradoxes. We know that H-bonds, which are stronger than 
Van der Waal forces, form between non-continuous amino-acids within a protein, 
bringing the interacting amino-acids in close proximity to each other, and play an 
important role in defining protein structure (Stryer, 1988). On studying the computer 
model of DI, Ser 13 is situated in very close proximity, just 4A, from the interlinker 
region and Asp 9 forms a H-bond with Ser 13. This has the result of bringing Asp 8 
and 9 residues to within 6A of the interlinker region. Furthermore Arg 39 lies only 5 A 
from the interlinker partly due to a H-bond between Arg 43 and Thr 57 within the 
interlinker region. Thus it is conceivable that these three discontinuous surface 
exposed areas, which lie in close proximity to each other within the tertiary structure 
of the protein as shown in figure 5.14, act together in either binding or stabilising the 
aPL-antigen interaction and that disrupting any of these areas could have an effect 
on binding.
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bFigure 5.14 Computer model of DI of B2GPI and the proposed aPL binding 
epitopes, a, molecular model of DI with the three regions within close proximity to 
each other highlighted, b, molecular surface of DI with electrostatic charge 
highlighted. The considerable surface area exposure of R39 is highlighted.
258
5.5 Discussion of results
The results presented in this chapter demonstrate the successful application of the 
E.coli expression and purification platform, developed as shown in Chapter 3, to 
produce 15 mutants of DI. I felt it was important that there existed a clear rationale 
behind incorporating each specific mutation. A hypothesis existed for targeting the 
residues chosen and detailed computer modelling analyses were undertaken to 
choose the most appropriate mutants and analyse the effects on overall protein 
structure.
Some mutants did not express in sufficient quantities to use in further binding 
studies. These were E26S, Mut 23-26-27 and Mut 8-9-23-26-27. Glu 26 forms a H- 
bond with Cys 47. Cys 47 is integral to the structure of DI as it forms a disulphide 
bond with Cys 4. Hence mutating E26 may destabilise this bond and affect solubility 
of protein and hence yield. The multiple Glu mutants include a mutation at E26 and 
thus as expected these also had poor yields. Destabilising a disulphide bond is likely 
to produce significant structural changes within the protein (Stryer, 1988). This 
would have a detrimental effect on binding to antibodies that recognise 
conformational epitopes on DI as observed. The D II-III mutation would not express 
at all suggesting that this structure was very unstable.
The observation that recursive PCR only works when using Vent DNA polymerase 
and not Pfu is intriguing and I have not been able to find this phenomenon described 
elsewhere in the literature. The technique of recursive PCR is particularly prone to 
PCR errors, which is why Taq DNA polymerase, which has the highest error rate is 
unsuitable and why the authors that described this technique used Vent (Prodromou 
and Pearl, 1992). The thermostable polymerases Vent and Pfu have proofreading 
capabilities and consequently have much lower PCR error rates. The polymerase Pfu 
has the greatest proofreading properties of the three and consequently the error rate 
is 8-10 fold lower than that of the non-proofreading Taq. The error rate for Vent lies 
somewhere in between at approximately 4-5 fold lower than Taq (Cline et al., 1996). 
Given that the primers do not tightly anneal, but rather have overlapping 
complimentary regions, it is possible that the high fidelity Pfu cannot tolerate sub- 
optimal matching of oligonucleotide strands and hence will not amplify DNA under 
these circumstances.
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The areas targeted for mutation on native DI were analysed using the computer 
model of DI, which was identical to the published crystal structure. It was clear that 
these areas lay in close proximity to each other and raised the possibility that they 
could form a discontinuous epitope that the majority of aPL from patients with APS 
bind to. The fact that denatured B2GPI does not bind aPL (Sheng et al., 2001b) 
supports the hypothesis that aPL bind non-continuous rather than linear epitopes in 
this protein. It may be that some changes would reduce binding but it is also 
conceivable that others may have an enhanced binding effect. The assay studies 
presented in the final results chapter aim to test these possibilities
In conclusion, the E.coli platform of DI production was used to produce and purify 
sufficient quantities of 12 mutants of DI for use in binding assays. The site and 
nature of the mutations were chosen as a direct result of generated hypotheses and 
detailed computer modelling studies as used by the well validated Swiss-Model 
software (Peitsch, 1996, Guex and Peitsch, 1997). The data generated from using 
Swiss-Model led to the development of a unifying hypothesis potentially explaining 
how three different areas of DI could all be important in being responsible for 
conferring binding to aPL, given the close approximation these areas have to each 
other. Binding studies presented in the final chapter aim to delineate which region of 
DI has the greatest effect on aPL binding when altered.
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CHAPTER 6
ELUCIDATING THE BINDING CHARACTERISTICS OF 
RECOMBINANT DI MUTANTS
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OVERVIEW OF CHAPTER 6
This final results chapter aims to elucidate the binding characteristics of the purified 
DI mutants expressed by E.coli. The initial focus is on describing the binding data of 
these mutants to a panel of APS derived polyclonal IgG in the solid phase. Binding 
for each mutant is expressed as a percentage of binding to wild-type DI. Binding of 
mutants to a monoclonal aPL (IS4) is also assessed. The results show that some 
mutants bound the polyclonal and monoclonal IgG less well than wild-type DI, as 
predicted by the original hypotheses but others displayed unexpected binding 
characteristics such as enhanced binding. Experiments excluding variability in the 
coating densities of antigen on the plate as a potential cause for these observations 
are presented.
A panel of DI mutants with either reduced or enhanced binding to aPL over wild-type 
DI were then selected for assessment of binding to APS IgG in the fluid phase. 
Inhibition of IgG binding to B2GPI coated on a CL surface was tested. The results 
show that some mutations cause almost complete loss of binding to aPL in the fluid 
phase whilst others cause enhanced binding to the majority of IgG samples in line 
with the solid phase binding data.
Finally, computer modelling studies were employed to help form structural 
hypotheses explaining the observed binding data for some of the DI mutants with 
the greatest effects on binding. These results are then discussed and consequently 
hypotheses are generated that outline the precise nature of the aPL-DI interaction.
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6.1 Direct binding data of recombinant DI mutants to APS 
derived IgG
In line with the DI ELISA outlined in section 2.21.6, plates were coated in duplicate 
with lOpg/mi of wild-type DI and the relevant Di-mutant being investigated on one 
half of the plate and PBS alone on the control half. Binding of either monoclonal IgG 
aPL or polyclonal purified IgG derived from APS patients was then assessed to both 
the wild-type and the mutant DI coated antigens. Net ODs were calculated and 
binding expressed as a percentage of binding to wild-type. Wild-type DI was coated 
on every plate to ensure that inter-plate variability would not be a factor contributing 
to the varying binding levels seen between the different DI mutants. As a negative 
control, a his-tagged irrelevant protein (DsbA) expressed and purified from native 
pET-39b was used and coated on the plate at the same concentration as the other 
DI mutant antigens.
6.1.1 Direct binding of DI mutants to polyclonal purified IgG
In total 12 mutants of DI could be expressed and purified in sufficient quantities for 
investigation in a direct binding assay. Binding was assessed to a panel of 10 IgG 
samples, all derived from patients with APS of whom two also had SLE. All samples 
bound well in direct assays of binding to wild-type DI, CL and B2GPI. As shown in 
figure 6.1, small changes in the DI protein can result in large alterations in binding to 
the majority of APS derived IgG tested as compared to wild-type DI. In the solid 
phase, the mutations with the greatest effect in reducing binding were D8S, D9G and 
the R39S mutation with a mean + /- SD binding as compared to wild-type of 48.7 + /- 
11.5%, 46.6 + /- 8.3% and 53.8 + /- 6.4% respectively. Given that the D8S and D9G 
single point mutants caused reduced binding, surprisingly the double mutant Mut 
8+9, with both these residues mutated, had the opposite effect of enhancing binding 
to the IgG samples tested as compared to wild-type DI (185.7 + /- 31.9%). Another 
unexpected finding was that the mutant E23S also showed enhanced binding 
compared to wild-type DI (182.5 + /- 30.5%). The DI variant with the remainder of 
the interlinker attached (DI ext) as predicted enhanced binding as compared to wild- 
type (188.3 + /- 24.1%). The his-tagged negative control protein revealed very low 
levels of binding.
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Figure 6.1 Direct binding of DI mutants to polyclonal APS derived IgG. The
distribution of binding is shown for each mutant to each APS IgG derived sample 
(n =10 ) as compared to wild-type DI. The mutants with the least binding were D8 S, 
D9G and R39S and those with marked enhanced binding over wild-type were Mut 
8+ 9 , E23S and DI ext. An irrelevant hise-tagged protein (DsbA) coated at lOpg/ml 
was used as a negative control.
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6.1.2 Direct binding of DI mutants to monoclonal human aPL
Binding of the DI mutants in the solid phase was determined to CHO derived IS4. As 
shown in figure 6.2, there were some similarities to the polyclonal IgG data. IS4 
bound least well to the mutants R39S and D9G and had marginally enhanced binding 
to E27S in line with the polyclonal data (figure 6 .1). However, it was clear that 
differences also existed, as no significant enhancement of binding over wild-type DI 
to IS4 was observed with Mut 8+ 9  or DI ext.
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Figure 6.2 Binding of native IS4 to mutant DI in the solid phase. Least binding 
was observed to R39S and strongest to E27S. Error bars represent SD.
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6.1.3 Assessing coating density of mutant antigens
The fact that polyclonal IgG bound some DI mutants better than others in direct 
ELISA could arise from two factors:
a) The mutations could affect the interaction of aPL with DI or
b) The mutations could alter binding of DI to the plate, affecting the
coating density of the antigen.
The fact that the mutant DI proteins bind the plate through a hiS6-tag that is not part 
of the domain itself make explanation b) less likely. To exclude this possibility, the 
density of recombinant human D I and that of two selected mutants that display 
enhanced (Mut 8 + 9 ) or reduced (R39K) binding to purified APS derived IgG was 
measured. To determine the amount of DI bound to the microwells, advantage of 
the fact that each peptide contains a his6-tag was taken. Thus by using an anti-his 
antibody, the relative amounts of each bound peptide on the ELISA plate could be 
measured. As seen in figure 6.3, less than 10%  variation in coating density was 
observed with minimal background binding of the anti-his tag antibody. Therefore 
there was no evidence that mutations altered the coating density on the nickel plate.
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Figure 6.3 Assessing density of antigen coated on the nickel plate. By using an 
anti-his tag antibody, no significant differences in antigen coating densities on the 
plate were observed between the DI mutants. Mean OD + /-  SD shown, (experiment 
planned by myself and performed by Charis Pericleous).
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6.2 DI mutants inhibit binding to APS derived IgG in the fluid 
phase
Results in the solid phase assays suggested that binding to 62GPI coated on CL was a 
more specific assay for detecting pathogenic aPL (section 4.7) than either the 
standard CL ELISA or the standard 62GPI binding ELISA (section 4.5, table 4.3). I 
chose five recombinant DI proteins to inhibit a panel of eight purified IgG samples, 
derived from patients with APS, from binding to B2GPI/CL in this assay. All eight IgG 
samples were known to bind well in this ELISA.
The recombinant DI proteins chosen to test binding in the fluid phase were wild-type 
DI, two that displayed good binding in the direct ELISA (Mut 8+9 and DI ext), a poor 
binder (R39S), and one mutant that had been shown in the context of whole 62GPI 
to cause marked reduction in binding to clinically relevant aPL (G40E) (de Laat et al., 
2005, Iverson et al., 2002b), although my solid phase ELISA had shown the opposite 
effect of this mutation in the context of DI in isolation (figure 6.1). After a series of 
experiments the optimum concentration of inhibitor was found to be 3.25pM.
Figure 6.4 shows the results for the fluid phase differed from those for the solid 
phase. Wild-type DI inhibited binding of the eight IgG samples tested to variable 
extents (mean + /- SD inhibition 62.9 + /- 25.7%) with the binding of two samples 
inhibited by >90% and for another two <35% (this data was also shown in section 
4.9, figure 4.17). Results were much clearer for Mut 8+9, which inhibited binding of 
all IgG samples to 62GPI/CL (lowest level of inhibition was 72.6% [mean + /- SD 
inhibition 83.1 + /- 8.9%]). Therefore the combination of D8S and D9G mutations 
consistently enhanced binding of DI to all APS IgG samples, in both solid and fluid 
phase assays.
In contrast, altering R39 residue (R39S) had the effect of significantly reducing 
binding to the majority of aPL in the fluid phase (14 + /- 18.5%) as compared with 
wild-type DI (p=0.0007). The G40E mutation also showed evidence of overall 
reduced binding to the IgG samples as compared to wild-type DI (44.1 + /- 31.7%), 
but the effect was more variable than that observed with R39S. Although adding the 
remainder of the interlinker region onto the C-terminal of DI had the effect of 
enhancing binding in the solid phase, this effect was not observed in the fluid phase 
(43.3 + /- 26.7%, p=0.16).
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DI Mut 8+9 R39S G40E DI ext
Figure 6.4 Binding of APS derived polyclonal IgG to wild-type DI and mutants 
in the fluid phase. Recombinant DI inhibitors were used at 3.25pM concentration. 
Variable inhibition was observed with wild-type DI. The R39S mutation resulted in 
loss of inhibition to the majority of IgG samples (p=0.0007) whilst the Mut 8+9 
double point mutant caused enhanced binding to the majority of IgG samples in the 
fluid phase and thus a trend towards enhanced inhibition as compared to wild-type 
(p=0.054).
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6.3 Computer models of mutants R39S and Mut 8+9
In the previous chapter (section 5.4, figure 5.14) a computer model of DI shows that 
the epitopes R39-R43, the interlinker region and the D8 and D9 residues lie within 
close proximity to each other according to the tertiary structure of the protein. Swiss- 
Model was then used to predict the changes in the molecular structure of DI that 
would occur upon introducing the mutations tested in the binding assays described 
above. The R39S mutation had a marked effect in reducing binding to the IgG 
samples tested in the solid phase (figure 6.1). This effect was amplified in the fluid 
phase with loss of binding to the majority of IgG samples assayed (figure 6.4). This 
residue has approximately 60% of its area surface exposed. As shown in figure 6.5, 
Swiss-Model predicts that altering R39 to S39 results in the loss of a protruding side- 
chain and a change in electrostatic charge within this area. Thus a marked alteration 
in the surface epitope conformation is seen, with no significant effect on the overall 
protein tertiary structure. This is underlined by the fact that two murine anti-DI 
antibodies that bind conformationally restricted epitopes on DI bind R39S as strongly 
as wild-type DI (figure 6.6), supporting the computer model's prediction that the 
overall tertiary protein structure of DI is maintained.
The unexpected finding of a strong trend towards enhanced binding of Mut 8+9 to 
the majority of APS derived IgG samples tested in both solid and fluid phase assays 
is more difficult to explain. Figure 6.7 shows that the surface accessibility of mutated 
residues does not alter. The distance between D8 and D9 from the interlinker is 6A, 
which does not alter upon mutating these residues to S8 and G9. However, a groove 
does exist in the surface of DI at the site of the D8 and D9 residues that is more 
pronounced upon mutating these to S8 and G9. This is illustrated upon visualising 
the DI and Mut 8+9 models from multiple angles as shown in figure 6.7. 
Furthermore, Mut 8+9 causes a small reduction in binding to the two murine anti-DI 
antibodies (figure 6.6) suggesting some alteration in tertiary protein structure. What 
is clear however, is that this subtle change in protein structure, perhaps combined 
with the alteration in charge within this region of DI, has the effect of dramatically 
altering the binding pattern of DI, enhancing binding to aPL and hence making it 
likely to be an important region of DI that dictates binding to aPL.
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Figure 6.5 Computer model of the DI mutant R39S. Molecular structure for wild- 
type DI (A) and R39S (B). Figure 6.5-A also highlights the position of the interlinker 
region (grey) and the D8 and D9 residues (red). Surface structure with electrostatic 
charge for wild-type DI (C) and R39S (D). The above models show the marked 
change in the local epitope upon mutating R39 to S39 without any other marked 
change in overall protein conformation.
270
160
« 120
GQ 40
Mut 8+9 R39S
□  mAb-16
□  6C4C10
Figure 6.6 Binding of murine anti-DI antibodies to Mut 8+9 and R39S. As
compared to wild-type DI, there was some reduction in binding to Mut 8+9 
suggesting a small alteration in the tertiary structure as a result of this mutation. 
R39S revealed no obvious difference from wild-type DI in binding to these 
antibodies. Error bars represent SD calculated from triplicate wells.
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D 8+D 9
D8+D9 S8+G9
Figure 6.7 Computer model of the DI mutant Mut 8+9. Molecular structures for 
wild-type DI (A and C rotated 180° on its vertical axis) and Mut 8 + 9  (B and D 
rotated 180° on its vertical axis). All four figures also highlight the position of the 
interlinker region (grey) and the R39-R43 residues (blue). Mutating D8 and D9 to S8 
and G9 creates a molecular groove that is better appreciated upon rotating the 
protein 180° on its vertical axis.
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6.4 Discussion of results
The DI mutants created and tested were designed to test three hypotheses 
regarding immunodominant aPL binding epitopes outlined in the previous Chapters. 
The binding data of these mutants supported some of these hypotheses, but also 
yielded other unexpected, yet intriguing findings. In comparing my results with those 
of previous groups it is important to stress that I studied isolated recombinant DI, 
whereas investigators in most previous studies examined whole G2GPI containing 
mutations in DI. However, meaningful comparisons may be made, as I have 
demonstrated that DI in isolation binds clinically relevant IgG in a manner 
comparable to whole B2GPI and CL. Furthermore, it is recognised that as a general 
property of the CCP family of proteins, that B2GPI belongs to, isolated CCP domains 
are representative of their structure and dynamics as observed in the presence of 
neighbouring domains (O'Leary et al., 2004).
Despite this difference in methodology, my results confirmed the previous finding 
that region G40-R43 is likely to be important in binding to aPL, but these mutational 
studies lead to the new idea, and confirmed the hypothesis, that R39 plays a 
particularly important role. Altering R39 to serine had a greater effect on reducing 
binding to APS derived IgG in the fluid phase than the G40E mutation that had 
previously been studied in the context of whole B2GPI (Iverson et al., 2002b, de Laat 
et al., 2005). The R39S change reduced binding to IgG derived from APS patients in 
both the solid phase and fluid phase assays, whereas G40E reduced binding only in 
the fluid phase. Iverson et al studied 10 mutants of whole B2GPI with changes in DI, 
but none of these had changes at R39. Their selection of mutations was not 
hypothesis driven, but was based on an initial screen of a phage peptide display 
library of DI fragments in which mutations had been incorporated by a random 
process through error-prone PCR (Iverson et al., 2002b).
Some evidence for involvement of an epitope in the DI-II interlinker region was 
observed, as the extended DI (DI ext) molecule bound better than wild-type DI in 
the solid phase ELISA. However, these results were not confirmed in the fluid phase. 
It may be that mutations within this area are required in order to observe changes in 
the binding of aPL in the fluid phase. Unfortunately attempts to express a DI mutant 
with the D II-III interlinker substituted for the DI-II interlinker were unsuccessful, 
suggesting that point mutational studies of this region would be necessary. On
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studying the structure of DI, the R43 residue forms a H-bond with both R39 and T57 
located within the interlinker, which are both lost upon altering R43 to G43. Thus it 
would be of interest to target T57 for future mutational studies given the close 
proximity this residue has with the R39-R43 region.
Although the G40E mutation showed poor binding in the fluid phase as compared to 
wild-type DI, enhanced binding of this mutant and R43G was observed in the solid 
phase. The observation that recombinant human DI in isolation may behave 
differently in solid an fluid phase ELISAs is in keeping with previous observations by 
other investigators using whole B2GPI (de Laat et al., 2006b, Giles et al., 2003c, 
Iverson et al., 2002a). It  is interesting to note in Iverson et al's point mutational 
study of DI within whole B2GPI, that the mutants M42K and M42V did show 
enhanced binding to affinity-purified aPL in the solid-phase as compared to wild-type 
B2GPI, but the increase was not as large, or as repeatable, in the fluid phase 
(Iverson et al., 2002b). The authors made no mention of these observations nor 
offered a potential explanation in their discussion. One possible explanation for this 
would be that some mutations in DI alter its ability to bind to the nickel plate, thus 
affecting the density of the antigen available for binding. Such alterations in coating 
density would affect binding to aPL in the solid phase not in the fluid phase ELISA. 
However, this is an unlikely explanation for the results observed in our tests, because 
binding to the plate occurred via a his-tag that was the same in all mutants, and 
because the direct measurements of binding of wild-type DI, Mut 8+9, and R39K 
using an anti-his-tag antibody showed these mutants coated the plate at similar 
densities despite giving widely divergent results in assays of binding to aPL. An 
alternative explanation is that some of the mutations alter the way in which the 
recombinant DI molecules pack together on the plate, thus affecting the way in 
which the epitopes are exposed to aPL. This underlines the importance of carrying 
out both solid and fluid phase ELISAs, because the latter are not affected by these 
plate-based considerations. The fact that the R39S mutant exhibited reduced binding 
to APS derived IgG, in both the solid and fluid phase assays, supports the hypothesis 
that this residue is particularly crucial for conferring binding to aPL due to its 
considerable degree of surface exposure, as shown in the computer models of DI.
Intriguingly, these mutational studies also demonstrate, for the first time, the 
production of a mutagenised variant of DI (Mut 8+9) in which mutations (D8S and 
D9G) are associated with markedly enhanced binding to the majority of APS derived
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IgG tested, in both solid phase and fluid phase assays. This observation of enhanced 
binding upon altering D8 and D9 to S8 and G9, respectively, was unexpected and did 
not concur with my original hypothesis that interactions between the R residues in 
aPL and the D residues on DI contribute to the antigen-antibody interaction in a 
charge dependent manner. One may speculate that the N-terminal region of DI is 
likely to play a complex role in ensuring a stable aPL-DI interaction and altering this 
area seems to have a variable effect on binding, depending on the alteration. This 
complexity is underlined by the fact that the single mutations D8S and D9G both 
reduced binding to aPL even though the combination of D8S and D9G increased 
binding to the same panel of IgG samples. One possibility is that altering both 
residues creates a groove within DI that may favour a tighter fit with the antigen 
binding regions of the majority of aPL, shown in the computer model of figure 6.7. 
Although the cause of the binding properties of Mut 8+9 remains unclear, the fact 
that this product can potentially be expressed and purified from bacteria in large 
quantities and can inhibit binding of polyclonal aPL to whole B2GPI bound to anionic 
PL could have therapeutic implications.
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CHAPTER 7 
OVERVIEW AND IDEAS FOR FUTURE WORK
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7.1 Summary of results
In this thesis work is described that expands our understanding about the precise 
nature of the molecular interaction of autoreactive aPL with their antigenic target DI 
of human I32GPI. These detailed mutational studies support the theory that the 
majority of aPL bind discontinuous epitopes neighbouring R39-R43 located within the 
tertiary structure of DI. Specifically the key achievements in this thesis were:
1. The development of an efficient system for expressing and purifying 
recombinant DI of 62GPI from E.coli cells.
2. The demonstration that recombinant DI expressed from E.coli binds 
clinically relevant monoclonal and polyclonal IgG in both the solid and 
fluid phase.
3. The use of this novel platform of DI production to create multiple mutants 
of DI with single /  double point mutations targeting key areas of interest.
4. Confirmation that the region G40 to R43 is important but also propose the 
new idea that R39 is a particularly crucial residue participating in the aPL- 
DI interaction.
5. Definition of new areas within DI that are also likely to be involved in this 
interaction such as residues D8-D9 and the DI-II interlinker region.
6. The creation of a mutant of DI that binds the majority of clinically 
relevant polyclonal IgG better than wild type DI in both solid and fluid 
phase assays.
7. The use of computer modelling studies to demonstrate the close proximity 
of these discontinuous epitopes and visualise the changes in the 
molecular protein structure upon incorporating the mutations studied
7.2 Inhibiting the biological properties of aPL
Recombinant DI binds clinically relevant IgG in assays of binding in vitro, but does it 
necessarily follow that DI could bind to aPL and inhibit their functional effects in 
terms of promoting a thrombophilic phenotype? Currently one of the best animal 
models in which the thrombogenic effects of aPL have been demonstrated is the in 
vivo model of microcirculation developed by Pierangeli et al (Pierangeli et al., 1994). 
Both polyclonal and monoclonal antibodies including IS4 have been shown to be 
highly thrombogenic and to enhance endothelial activation in this in vivo model 
(Pierangeli et al., 2000, Pierangeli et al., 2001). I have developed a collaboration
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with Professor Pierangeli who was very interested in investigating the ability of E.coli 
expressed DI to inhibit aPL enhancement of thrombosis in her femoral vein pinch 
mouse model. E.coli expressed recombinant wild-type DI was sent to Professor 
Pierangeli to perform these experiments. As a negative control an irrelevant his- 
tagged protein (DsbA) was also expressed and purified. Injecting the peritoneum of 
mice with 500pg of IgG purified from patients with APS enhanced thrombus 
formation and injecting mice with 40pg of the control his-tagged protein 
intravenously, prior to the femoral vein pinch, had no effect on the size of thrombus 
enhanced by aPL. However, if mice were injected with 40pg of recombinant DI, aPL 
enhancement of thrombus was inhibited down to the level of that seen with mice 
injected with control IgG. These data were presented at the American College of 
Rheumatology annual general meeting in 2006 (Ioannou et al., 2006b) and provides 
strong support for the clinical relevance of the binding studies presented in this 
thesis. It would also be of interest to investigate the ability of recombinant wild-type 
DI to inhibit the ability of aPL to activate human ECs and platelets in vitro.
It is intended that the above studies will be extended further to assess the relative 
ability of R39S and Mut 8+9 to inhibit aPL induced thrombus enhancement in mice as 
compared to wild-type DI. Furthermore, it would be of interest to test the abilities of 
these mutants to inhibit aPL induced activation of human ECs and platelets as 
compared to wild-type DI. I have set up a collaboration with Professor Krilis (Sydney, 
Australia) who has the necessary expertise in investigating the effects of aPL upon 
human platelets as well as ECs and I intend to perform such experiments through an 
approved Arthritis Research Campaign (arc) Clinician Scientist Award.
Finally La Jolla Pharmaceuticals have developed a drug called UP 1082, which carries 
the wild-type DI molecule and can bind to Di-binding aPL on the surface of B cells 
(Cockerill et al., 2003, Horizon et al., 2003). Given that there is a lack of T cell 
epitopes, the B cell cannot recruit T cell help and dies. It is conceivable that the 
replacement of DI in this drug with a mutant of DI that binds a greater number of 
clinically relevant aPL (such as the mutant with the D8S/D9G mutations) would 
increase the ability of this drug to bind to and tolerise B cells producing anti-62GPI 
antibodies.
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7.3 Work towards a smaller blocking peptide
This thesis demonstrates that whoie DI and the mutant containing D8S/D9G are 
potent inhibitors of aPL. Particularly given that wild-type DI may inhibit the 
thrombotic effects of aPL in vivo, it raises the possibility as alluded to in the above 
section that such peptides may be used therapeutically to block the pathogenic 
effects of aPL. However, for reasons such as bioavailability, immunogenicity and ease 
of manufacture, smaller peptides containing parts of the DI structure may be better 
therapeutic agents. It is likely that such peptides will need to contain the epitopes 
described in this thesis and this raises issues as to how the peptides will fold and 
how stable they will be. To explore these issues I have set up a collaboration with Dr 
Alethea Tabor (Department of Organic /  Chemical Biology, UCL) and plan to develop 
small peptides modelled on the epitopes described. These peptides could be 
produced through a variety of methods such as the development of mimetopes by 
screening peptide libraries based on the amino acid sequences of interest, or by 
coupling short peptides together again based upon the candidate discontinuous 
epitopes. Such peptides could then be tested in assays of binding and biological 
function and may serve as candidate therapeutic agents if shown to be stable and to 
inhibit the pathogenic effects of aPL. Again this is work I intend to explore in my arc 
funded post-doc studies.
Ultimately, it is envisaged that these ideas for future work, which have directly arisen 
from work described in this thesis, will lead to safer and more effective therapies for 
APS patients than that which is currently available.
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APPENDICES 
APPENDIX A 
ONE AND THREE LETTER CODES FOR AMINO ACIDS
ONE LETTER CODE THREE LETTER CODE AMINO ACID
A Ala Alanine
C Cys Cysteine
D Asp Aspartic Acid
E Glu Glutamic Acid
F Phe Phenylalanine j
G Gly Glycine
H His Histidine
I He Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
W Trp Tryptophan
Y Tyr Tyrosine
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APPENDIX B
ORIGINAL ARTICLES ARISING FROM WORK DESCRIBED IN 
THIS THESIS
Ioannou. Y.. Giles, I., Lambrianides, A., Richardson, C., Pearl, L., Latchman, D. S., 
Isenberg, D. A. and Rahman, A. (2006) A novel expression system of domain 
I of human beta2 glycoprotein I in E.coli. BMC Biotechnology, 6, 8-18.
Ioannou. Y.. Pericleous, C., Giles, I., Latchman, D. S., Isenberg, D. A. and Rahman, 
A. (2007) Binding of antiphospholipid antibodies to discontinuous epitopes on 
domain I of beta2-glycoprotein: mutation studies including R39 to R43. 
Arthritis and Rheumatism, 56, 280-90.
Lambrianides, A., Giles, I., Ioannou. Y.. Mason, L., Latchman, D. S., Manson, J., 
Isenberg, D. A. and Rahman, A. (2007) Arginine mutation alters binding of a 
human monoclonal antibody to antigens to systemic lupus erythematosus and 
the antiphospholipid syndrome. Arthritis and Rheumatism, 56, in press.
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